HEPATOLOGY, October, 2014

Poster Sessions Poster Session 1 Saturday, November 8 POSTER VIEWING: 2:00 - 7:30 PM Hall C Presenters in attendance: 5:30 - 7:00 PM Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Ascites, Renal Dysfunction and Hepatorenal Syndrome 241: Reversal of Hepatorenal Syndrome Type 1 (HRS-1) with Terlipressin plus Albumin versus Placebo plus Albumin - Not All Responses Are Created Equal An Analysis of the REVERSE and OT-0401 Trials

Arun J. Sanyal, Thomas D. Boyer, R Todd Frederick, Fredric Regenstein, Lorenzo Rossaro, Victor Araya, Hugo E. Vargas, K. Rajender Reddy, Khurram Jamil, Stephen Chris Pappas

242: New Multivariate Models to Predict Glomerular Filtration Rate in Patients with Cirrhosis


Ayse L. Mindikoglu, Thomas C. Dowling, Laurence S. Magder, Robert H. Christenson, Matthew R. Weir, Stephen L. Seliger, William R. Hutson, Charles Howell

243: No evidence of reduced mortality due to albumin substitution in HCC-free cirrhotic patients undergoing large volume paracentesis: a systematic review and meta-analysis

Fabian Kütting, Jens Schubert, Jeremy Franklin, Agnes Pelc, Andrea Bowe, Vera Hoffmann, Münevver Demir, Dirk Nierhoff, Ulrich Toex, Hans-Michael Steffen

244: Serum creatinine within 48 hours after hospitalization is a strong predictor of mortality in patients with cirrhosis with complications provided the peak creatinine is above 1.2 mg/dl

Anantha Nuthalapati, Nicholas Schluterman, Deborah Greenberg, Anuj Khanna, Paul J. Thuluvath

245: Unprecipitated acute kidney injury can occur amongst stable patients with cirrhosis and ascites but no other complications

247: Chronic Kidney Disease Epidemiology Collaboration Equation combining Creatinine and Cystatin C is superior to other Creatine- and Cystatin C-based Equations in Assessing Renal Function in Patients with Cirrhosis

Elisabeth Krones, Sabine Zitta, Stefan Neunherz, Katharina Artinger, Tatjana Stojakovic, Gilbert Reibnegger, Franziska Durchschein, Juliana Buchgrabner, Vanessa Stadlbauer, Peter Fickert, Alexander R. Rosenkranz

248: Bile pigment nephropathy and acute tubular necrosis in decompensated cirrhotics and acute on chronic liver failure

Suman Nayak, Rajendra P. Mathur, Sivaramakrishnan Ramanarayanan, Gyan Prakash, Shiv K. Sarin, Chitranshu Vashishtha, Manoj Kumar, Rakhi Maiwall, Ajeet S. Bhadoria

249: Plasma Renin concentration is associated with portal hypertension, liver dysfunction, ascites and hyponatremia and may predict mortality in cirrhosis

Rafael Paternostro, Simona Bota, Philipp Schwabl, Remy Schwarzer, Thomas Reiberger, Mattias Mandorfer, Monika Ferlitsch, Michael Trauner, Markus Peck-Radosavljevic, Arnulf Ferlitsch

250: Alpha-2a Adrenoceptor Subtype Stimulation by Guanfacine Restores Diuretic Efficiency in Experimental Cirrhosis and Refractory Ascites: Comparison with Clonidine Effects

Giovanni Sansoe, Manuela Aragno, Raffaella Mastrocola, Maurizio Parola

251: Albumin Infusions in Patients with Cirrhosis who Present with Acute Kidney Injury and its Effect on Renal Function

Derek J. Feussner, Amy P. Myers, James C. Slaughter, Andrew Scanga

252: Nosocomial spontaneous bacterial peritonitis is associated with increased mortality compared to community-acquired spontaneous bacterial peritonitis

Nicolas M. Intagliata, Zachary Henry, Nitin K. Ahuja, Neeral L. Shah, Curtis K. Argo, Stephen H. Caldwell, Patrick G. Northup

253: Microscopic Urinanalysis May Represent a Sensitive Test for Kidney Injury in Cirrhotic and Cholestatic Patients with Preserved Kidney Function

Florence Wong, Peter Jepsen, Hugh R. Watson, Hendrik V. Vilstrup

Elisabeth Krones, Julia Fritz, Christoph Schwarz, Franziska Durchschein, Kathrin Eller, Gernot Zollner, Werner Ribitsch, Tatjana Stojakovic, Sabine Zitta, Juliana Buchgrabner, Alexander R. Rosenkranz, Peter Fickert

246: Evaluation of serum cystatin C as a marker of early renal impairment in patients with liver cirrhosis

254: Relative Adrenal Insufficiency in Cirrhotic Patients with Ascites

Mahmoud S. Omar, Wael Abdel-Razek, Gamal Abo-Raia, Medhat Assem, Gasser El-Azab

Denotes AASLD Presidential Poster of Distinction

Virendra Singh, Rajiv R. Singh, Rama Walia, Naresh Sachdeva, Ashish Bhalla, Navneet Sharma, Yogesh K. Chawla




Poster Sessions 255: Urinary NGAL Levels Reflect the Therapeutic Effects of norUDCA in Mice with Cholemic Nephropathy

Elisabeth Krones, Dietmar Glaenzer, Franziska Durchschein, Alexander Kirsch, Kathrin Eller, Michael Trauner, Alexander R. Rosenkranz, Peter Fickert

256: Prevalence of hyperdynamic circulation in cirrhosis: lack of association to presence and severity of ascites

Cristina Ripoll, Phillip Hohaus, Marcus Hollenbach, Robin A. Greinert, Alexander Zipprich

257: Outcomes in Patients Receiving Rifaximin along with Systemic Antibiotics for the Inpatient Treatment of Spontaneous Bacterial Peritonitis

266: Response guided ascitic tap in spontaneous bacterial peritonitis predicts outcome

Ashok K. Choudhury, Ankur Jindal, Chandan K. Kedarisetty, Tanmay S. Vyas, Ajeet S. Bhadoria, Shiv K. Sarin

267: Does transjugular intrahepatic portosystemic shunt (TIPS) with covered stents modify the natural course of decompensed cirrhosis?

Xavier Adhoute, Paul Castellani, Guillaume Penaranda, Olivier Monnet, Herve Perrier, Bernard L. Pol, Cyril Muller, Arthur Laquiere, Valerie Oules, Patrick Beaurain, Christian Boustiere, Olivier Bayle, Marc Bourlière

Jennifer D. Twilla, Anuj Sharma, Satheesh Nair, Emily H. Wong, Sanjaya K. Satapathy

Behavioral, Quality of Life, and Practice Issues

258: Clinical Predictors of Morbidity and Mortality in Hospitalized Children with Ascites

268: Factors associated with medication adherence in patients living with cirrhosis

Grace Felix, Thammasin Ingviya, Ann O. Scheimann, Pavis Laengvejkal, Alexandra Vasilescu, Hejab Imteyaz, Eric C. Seaberg, Wikrom Karnsakul

Suzanne Polis, Ling Zhang, Amany Zekry, Ritin Fernandez

259: Beyond Dr. Google: Early results of a personalized weight-tracking smartphone application and alert system for patients with ascites

Rachel A. Annunziato, Samantha G. Lee, Elizabeth Galici, Alexander Newcorn, Ronen Arnon

Chanda Ho, Neil Shah, Nabil Alshurafa, Behnam Shahbazi, Hassan Ghasemzadeh, Norah Terrault

Jonathan Aguirre-Valadez, Haydee Verduzco-Aguirre, Ariadna K. Flores-Balbuena, Octavio R. García-Flores, Ricardo MacíasRodríguez, Cristino Cruz-Rivera, Jose A. Niño-Cruz, Ignacio Garcia, Aldo Torre

261: Predictors for the Development of Cardiac Ascites in Patients Referred for Cardiac Transplantation

Brian Kim, Amy Tan, Berkeley N. Limketkai, Sean Pinney, Thomas D. Schiano

262: Computer-assisted image analysis of fibrosis on liver biopsy : relationship with portal pressure, histology and clinical data Nicolas Goossens, Sophie Restellini, Sophie Clément, Laura Rubbia-Brandt, Laurent Spahr

263: Non-invasive measurement of acute hemodynamic changes using inert gas rebreathing during routine therapeutic paracentesis in tense ascites

Christoph Antoni, Joachim Saur, Thomas Zimmerer, Nenad Suvajac, Julia D. Michels, Matthias Ebert, Frederik Trinkmann

264: PTFE-covered TIPS position relative to the hepatocaval junction and impact on shunt patency

Charles N. Weber, Gregory J. Nadolski, Michael C. Soulen


Poster Viewing: 2:00 – 7:30 PM

270: A single-center report of hepatitis A and hepatitis B vaccination performance in patients with chronic hepatitis C (CHC): A quality improvement project Bobbi Jo Quigley, Matthew Kowgier, Colina Yim

271: Two Types of Fatigue in Subjects with Chronic Liver Disease Can Be Distinguished Through Correlations with Physical Activity and Mental Symptoms

Ali A. Weinstein, Heibatollah Baghi, Carey Escheik, Lynn Gerber, Zobair Younossi

272: Characteristics of Nutritional Intake in End-Stage Liver Disease Secondary to Viral Hepatitis, NASH, and Alcoholic Liver Disease

Anna Marie Hefner, Cynthia D. Connelly, Kathy S. James, Catherine Hill, Preeti Reshamwala, Tarek Hassanein

Cholangiocyte Biology 273: Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis

James H. Tabibian, Steven P. O’Hara, Christy E. Trussoni, Pamela S. Tietz, Patrick L. Splinter, Taofic Mounajjed, Lee R. Hagey, Nicholas F. LaRusso

274: Lipopolysaccharide (LPS)-induced cholangiocyte N-Ras activation requires epidermal growth factor receptor (EGFR) activation

Christy E. Trussoni, Patrick L. Splinter, James H. Tabibian, Steven P. O’Hara

Presenters in Attendance 5:30 – 7:00 PM


260: Determination of renal function through creatinine and cystatin C-dependent formulas in comparison to DTPA-Tc-99 clearance in Mexican cirrhotic patients

269: Children with HCV: The impact of disease and treatment on patients, caregivers and families



HEPATOLOGY, October, 2014

Poster Sessions 275: Ezrin, a membrane cytoskeletal cross-linker is essential for the regulation of biliary flow in mice Ryo Hatano, Kaori Akiyama, Shinji Asano

276: Regulation of cholangiocyte IL-6 release by extracellular adenosine

Elise G. Lavoie, Jessica R. Goree, Michel Fausther, Jonathan A. Dranoff

277: Role of the miR-125b- regulated HDC/histamine/ VEGF axis during the progression of biliary proliferation in the PSC/MDR2-/- mouse model

Yuyan Han, Laura Hargrove, Lindsey Kennedy, Allyson B. Graf, Sharon DeMorrow, Fanyin Meng, Quy P. Nguyen, Victoria Huynh, Heather L. Francis

278: Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis

Christy Trussoni, James H. Tabibian, Steven P. O’Hara, Patrick L. Splinter, Julie Heimbach, Nicholas F. LaRusso

Cholestasis and Autoimmune Liver Disease


279: The Fraction of Bile Ducts Lost in Portal Areas Correlates with Degree of Fibrosis and Alkaline Phosphatase Levels in Patients with Primary Biliary Cirrhosis

Mazen Noureddin, David E. Kleiner, Xiongce Zhao, Jason L. Eccleston, Daniel Woolridge, Nabil Noureddin, T. Jake Liang, Jay H. Hoofnagle, Theo Heller

280: Altered Functional Connections in the Brain of Patients With Primary Biliary Cirrhosis are Associated with Fatigue

Victoria Mosher, Mark G. Swain, Robert P. Myers, Glenda M. MacQueen, Bradley G. Goodyear

281: Sub-stratification of hepatocellular carcinoma risk in men with primary biliary cirrhosis: results of an international multicenter study

Palak J. Trivedi, Willem J. Lammers, Henk R. van Buuren, Annarosa Floreani, Albert Pares, Angela C. Cheung, Cyriel Y. Ponsioen, Christophe Corpechot, Marlyn J. Mayo, Pietro Invernizzi, Pier Maria Battezzati, Frederik Nevens, Andrew Mason, Kris V. Kowdley, Ka-Kit Li, Tony Bruns, Mohamad Imam, Teru Kumagi, Nora Cazzagon, Irene Franceschet, Llorenc Caballeria, Kirsten Boonstra, Raoul Poupon, Ana Lleo, Keith D. Lindor, Harry L. Janssen, Bettina E. Hansen, Gideon Hirschfield

282: A Mouse Model of Fibrous Cholangiopathy

Sumera Rizvi, Anuradha Krishnan, Maria Eugenia Guicciardi, Steven F. Bronk, Gregory J. Gores

283: Increased BMI is associated rapid progression of fibrosis in Primary Sclerosing Cholangitis (PSC) Aliya Gulamhusein, Danielle Reid, Bertus Eksteen

Denotes AASLD Presidential Poster of Distinction

284: Activation of mDCs and CD8+ T cells is associated with PSC-like cholangiopathy induced by small bowel bacterial overgrowth in a mouse model of autoimmune biliary disease

Qingqing Wang, Vijay Saxena, Bin Wang, Lili Miles, Marnie A. Ryan, Jorge A. Bezerra, William M. Ridgway, Jaimie D. Nathan

285: Changes of the hepatic transcriptome in human extrahepatic cholestasis

Frank G. Schaap, Marlon J. Jetten, Marcel H. Herwijnen, Maarten L. Coonen, Jos C. Kleinjans, Peter L. Jansen, Steven Olde Damink

286: High serum levels and liver expression of sclerostin in patients with primary biliary cirrhosis. Association with markers of bone remodeling and severity of cholangitis

Silvia Ruiz-Gaspa, Laia Gifre, Nuria Guañabens, Rosa Miquel, Pilar Peris, Ana Monegal, Albert Pares

287: Contribution of polymorphic LINE-1 retrotransposon insertion in SLCO1B3 gene to susceptibility to drug-induced cholestasis

Tatehiro Kagawa, Kazuya Anzai, Kota Tsuruya, Yoshitaka Arase, Shunji Hirose, Koichi Shiraishi, Tetsuya Mine

288: The role of repeated brush cytology in detecting dysplasia or cholangiocarcinoma in primary sclerosing cholangitis before liver transplantation

Ammar Majeed, Annika Bergquist, Gunnar Söderdahl, Maria Castedal, Karouk Said

289: Contribution of Next Generation Sequencing to the genotyping of patients with hereditary cholestasis and cholelithiasis

Véronique D. Barbu, Isabelle Jéru, Christophe Corpechot, Eric Fernandez, Laure Muller, Fabienne Dufernez, Olivier Chazouillères, Yannick Marie, Zhenyu Xu, Chantal Housset

290: Fenofibrate is Effective adjunctive Therapy in the Treatment of Primary Biliary Cirrhosis: A MetaAnalysis

Alla Grigorian, Houssam E. Mardini, Christophe Corpechot, Raoul Poupon, Cynthia Levy

291: Fenofibrates do not improve transplant-free survival despite biochemical response in patients with primary biliary cirrhosis

Angela C. Cheung, Javier M. Meza-Cardona, Matthew Kowgier, E. Jenny Heathcote, Harry L. Janssen, Jordan J. Feld

292: Assessment of Environmental Exposures among 1000 North American Primary Sclerosing Cholangitis Patients with and without Inflammatory Bowel Disease

John E. Eaton, Brian D. Juran, Elizabeth J. Atkinson, Erik M. Schlicht, Xiao Xie, Mariza de Andrade, Craig Lammert, Velimir A. Luketic, Joseph A. Odin, Ayman A. Koteish, Kris V. Kowdley, Kapil B. Chopra, Gideon M. Hirschfield, Naga P. Chalasani, Konstantinos Lazaridis




Poster Sessions 293: Efficacy Trial of All-trans Retinoic Acid (ATRA) in combination with Ursodeoxycholic Acid (UDCA) in Primary Sclerosing Cholangitis (PSC)

David N. Assis, Osama Abdelghany, Shi-Ying Cai, Andrea A. Gossard, John E. Eaton, Jill C. Keach, Yanhong Deng, Stephenson W. Nkinin, Kenneth D R. Setchell, Maria Ciarleglio, Keith D. Lindor, James L. Boyer

294: Galectin-3 Plays a Role in Primary Biliary Cirrhosis by Mediating Inflammasome Signaling

Jijing Tian, Tzu-I Chao, Yu Sasaki, Fu-Tong Liu, M. Eric Gershwin, Natalie Torok, Joy Jiang

295: An International Phase 3 Study of the FXR Agonist Obeticholic Acid in PBC Patients: Effects on Markers of Cholestasis Associated with Clinical Outcomes and Hepatocellular Damage

Frederik Nevens, Pietro Andreone, Giuseppe Mazzella, Simone I. Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost Drenth, Paul J. Pockros, Jaroslaw Regula, Michael Trauner, Annarosa Floreani, Simon Hohenester, Velimir A. Luketic, Mitchell L. Shiffman, Karel J. van Erpecum, Victor Vargas, Catherine Vincent, Bettina E. Hansen, Roya Hooshmand-Rad, Shawn Sheeron, David Shapiro

296: Noninvasive testing are poor surrogate markers for fibrosis staging and liver-related outcomes in patients with primary biliary cirrhosis who do not respond to ursodeoxycholic acid

Angela C. Cheung, Javier M. Meza-Cardona, Matthew Kowgier, Harry L. Janssen, Jordan J. Feld

Elisabeth M. de Vries, Joanne Verheij, Stefan G. Hubscher, Mariska M. Leeflang, Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen

298: Relation of gallbladder enlargement with bile acid homeostasis and colorectal malignancy in primary sclerosing cholangitis

Mourad Aissou, Lionel Arrivé, Dominique Rainteau, Sara Lemoinne, Astrid Donald D. Kemgang Fankem, Delphine Firrincieli, Nicolas Chignard, Christophe Corpechot, Olivier Chazouillères, Chantal Housset

299: Do patients with “early” PBC benefit from UDCA treatment? -results from the nationwide cohort study in Japan-

Atsushi Tanaka, Junko Hirohara, Yasuni Nakanuma, Hirohito Tsubouchi, Hajime Takikawa

300: A possible involvement of endoplasmic reticulum stress in the process of biliary epithelial autophagy and senescence in primary biliary cirrhosis

Motoko Sasaki, Masami Miyakoshi, Yasunori Sato, Yasuni Nakanuma

301: Younger patients presenting with Primary Biliary Cirrhosis are more likely to have cognitive impairment

Jun Zhang, Weici Zhang, Patrick S. Leung, Christopher L. Bowlus, Sandeep S. Dhaliwal, Ross L. Coppel, Aftab A. Ansari, Guo-Xiang Yang, Jinjun Wang, Thomas P. Kenny, Xiao-Song He, M. Eric Gershwin

303: Risk stratification in primary biliary cirrhosis using the UK-PBC Research Cohort

Marco Carbone, Stephen Sharp, Michael A. Heneghan, James Neuberger, Gideon M. Hirschfield, Andrew K. Burroughs, Andrew Bathgate, Mervyn H. Davies, Carolyn Adgey, Paul Trembling, Kate D. Williamson, Laura Griffiths, Teegan R. Lim, Nick Wareham, David E. Jones, Graeme J. Alexander, Richard N. Sandford, Heather J. Cordell, George F. Mells

304: NGM282 is a Potent Modulator of Bile Acid Synthesis in Humans via Suppression of CYP7A1 Activity

Stephen Rossi, Michael Elliott, Kenneth D. Setchell, Stephenson W. Nkinin, Jian Luo, Lei Ling, Krishna P. Allamneni, Hui Tian, Alex M. DePaoli

305: Obeticholic Acid in PBC Patients: The Utility of Titration Based on Therapeutic Response and Tolerability

Christopher L. Bowlus, Paul J. Pockros, Joost Drenth, Annarosa Floreani, Catherine Vincent, Velimir A. Luketic, Karel J. van Erpecum, Victor Vargas, Mitchell L. Shiffman, Frederik Nevens, Richard Pencek, Roya Hooshmand-Rad, David Shapiro

306: Clinical Course And Outcome Of Patients With Sclerosing Cholangitis In Critically Ill Patients (Sc-Cip): High Mortality Without Liver Transplantation

Harald Hofer, Gernot Zollner, Peter Fickert, Ivo Graziadei, Michael Trauner

307: Successful Immunotherapy of Autoimmune Cholangitis by Adoptive Transfer of Foxp3+ Regulatory T Cells

Hajime Tanaka, Weici Zhang, Guo-Xiang Yang, Koichi Tsuneyama, Patrick S. Leung, Ross L. Coppel, Aftab A. Ansari, Zhe-Xiong Lian, William M. Ridgway, M. Eric Gershwin

308: Protein Profiles of Apoptotic Bodies from Biliary Epithelial Cells

Ana Lleo, Weici Zhang, W. Hayes McDonald, Patrick S. Leung, Ross L. Coppel, Aftab A. Ansari, David H. Adams, Simon C. Afford, Pietro Invernizzi, M. Eric Gershwin

309: Efficacy of Obeticholic Acid In Primary Biliary Cirrhosis as Assessed by Response Criteria Associated With Clinical Outcome: A Poise Analysis

Velimir A. Luketic, Pietro Invernizzi, Michael Trauner, Jaroslaw Regula, Giuseppe Mazzella, Simone I. Strasser, Annarosa Floreani, Simon Hohenester, Karel J. van Erpecum, Paul J. Pockros, Bettina E. Hansen, Henk R. van Buuren, Frederik Nevens, Richard Pencek, Roya Hooshmand-Rad, David Shapiro

Laura Griffiths, David Jones, Jessica K. Dyson, George F. Mells, Richard N. Sandford Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


297: Applicability and Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis

302: Ongoing Activation of Autoantigen-Specific B cells in Primary Biliary Cirrhosis



HEPATOLOGY, October, 2014

Poster Sessions 310: FXR Agonist Obeticholic Acid: Pruritus, A Common Side Effect Ameliorated by Dose Titration

Ulrich Beuers, David E. Jones, Marlyn J. Mayo, Pietro Andreone, Giuseppe Mazzella, Simon Hohenester, Annarosa Floreani, Simone I. Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost Drenth, Paul J. Pockros, Jaroslaw Regula, Velimir A. Luketic, Karel J. van Erpecum, Victor Vargas, Catherine Vincent, Roya HooshmandRad, Shawn Sheeron, David Shapiro

311: Incidence of and Risk Factors for Primary Biliary Cirrhosis-associated Hepatocellular Carcinoma: LargeScale Data from China Xue-Xiu Zhang, Li-Feng Wang, Zheng Zhang, Fu-Sheng Wang

312: Possible impairment of mucosal-associated invariant T cells in the liver of patients with primary biliary cirrhosis

Toru Setsu, Satoshi Yamagiwa, Kentaro Tominaga, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Masaaki Takamura, Minoru Nomoto

313: Circulating bile acids and sterol levels in patients with cholestatic pruritus. Effects of albumin dialysis using MARS

Albert Pares, Miriam Perez-Cormenzana, Alvaro Diaz-Gonzalez, Rebeca Mayo, Azucena Castro, Antoni Mas

314: The neogenesis of high endothelial venules and the formation of tertiary lymphoid organs in primary biliary cirrhosis


Hayato Baba, Koichi Tsuneyama

315: Geoepidemiology of primary biliary cirrhosis in Central Greece

Nikolaos Gatselis, Kalliopi Zachou, Asterios I. Saitis, Elias Spyrou, George K. Koukoulis, George N. Dalekos

316: Hepatic sarcoidosis: To treat or not to treat?

Nicole M. Welch, Andrew Aronsohn, K. Gautham Reddy, Nancy Reau, Donald M. Jensen, Helen S. Te

317: Age at Presentation and Gender are Predictors of Increased Mortality Over Long-Term Follow-Up in Primary Biliary Cirrhosis (PBC)

Jessica K. Dyson, Laura Griffiths, Samantha J. Ducker, David E. Jones

318: The FXR Agonist Obeticholic Acid (OCA) Improves Liver Biochemistry Parameters Correlated With Clinical Benefit Across a Range of Patient Characteristics

Pietro Andreone, Giuseppe Mazzella, Simone I. Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost Drenth, Paul J. Pockros, Jaroslaw Regula, Michael Trauner, Annarosa Floreani, Simon Hohenester, Velimir A. Luketic, Mitchell L. Shiffman, Karel J. van Erpecum, Victor Vargas, Catherine Vincent, Bettina E. Hansen, Frederik Nevens, Richard Pencek, Roya Hooshmand-Rad, Shawn Sheeron, David Shapiro

Denotes AASLD Presidential Poster of Distinction

319: FXR Agonist Obeticholic Acid: Sustained Improvement in Markers of Cholestasis and Long-Term Safety in Patients with Primary Biliary Cirrhosis through 4 Years

Kris V. Kowdley, Richard Pencek, Tonya Marmon, David Shapiro, Roya Hooshmand-Rad

320: Secondary Sclerosing Cholangitis Following Major Burn Injury

Ella Veitsman, Yael Haviv-Yadid, Oranit Cohen-Ezra, Orit Pappo, Yael Inbar, Josef Haik, Galia Rahav, Ziv Ben Ari

321: Discrepant Expression of miR-139-5p Between Serum and Liver in Patients with Primary Biliary Cirrhosis, and its Possible Cellular Origin

Tomohiro Katsumi, Masashi Ninomiya, Kyoko Tomita, Chikako Sato, Kazuo Okumoto, Yuko Nishise, Hisayoshi Watanabe, Takafumi Saito, Yoshiyuki Ueno

322: Patient Experience and Characteristics of Cholestatic Pruritus in the UK-PBC Research Cohort

Vinod S. Hegade, George F. Mells, Ulrich Beuers, Andreas E. Kremer, Pietro Invernizzi, Tom H. Karlsen, Gideon Hirschfield, Richard N. Sandford, Stuart Kendrick, David E. Jones

323: HLA-DR3 transgenic NOD mice, a novel model for autoantigen induced autoimmune hepatitis

Yipeng Wang, Muhammed Yuksel, Junhua Guo, Ningwen Tai, Xiaoyan Xiao, Pascal Lapierre, David Chella, Huiping Yan, Isabelle Colle, Giorgina Mieli Vergani, Diego Vergani, Yun Ma, Li Wen

324: Long term follow-up and 10-year outcomes of second-line therapy in Autoimmune Hepatitis

Daniel Klintman, Naina Shah, Javier Bustamante, Michael A. Heneghan

325: Circulating macrophage activation markers, CD163 and CD206, are associated with disease severity and treatment response in patients with autoimmune hepatitis

Henning Gronbaek, Martin Kreutzfeldt, Niels Jessen, Sidsel Rødgaard-Hansen, Konstantin Kazankov, Thomas D. Sandahl, Hendrik V. Vilstrup, Holger J. Møller

326: Can a dietary supplement induce autoimmune hepatitis?

Marina Roytman, Peter Poerzgen, Christine L. Lee, Leslie Huddleston, Peter K. Bryant-Greenwood, Timothy Kuo, Linda L. Wong, Naoky Tsai

327: Analysis of Liver Stiffness Measured by Transient Elastography in Autoimmune Hepatitis Ja Kyung Kim, Hae Won Kim, Jung Il Lee, Kwan Sik Lee

328: The IL-7/CD127 axis negatively modulates the function of regulatory T-cells in autoimmune hepatitis

Rodrigo Liberal, Charlotte R. Grant, Yun Ma, Michael A. Heneghan, Giorgina Mieli-Vergani, Diego Vergani, Maria Serena Longhi




Poster Sessions 329: Down-regulation of hepcidin production in patients with autoimmune liver diseases

Nikolaos Gatselis, Aggeliki Lyberopoulou, Kalliopi Zachou, Georgia Chachami, Petros Eliades, Stella Gabeta, Efrosyni Paraskeva, Avgi Mamalaki, George K. Koukoulis, George Simos, George N. Dalekos

330: Prevalence, Natural History And Outcome Of Overlap Syndrome Versus Autoimmune Hepatitis In The Indian Continent

Lovkesh Anand, Cyriac A. Philips, Varsha Bhat, Chhagan Bihari, Ajeet S. Bhadoria, Shiv K. Sarin

331: Prednisolone Changes mRNA and lincRNA Expression Profiles to Suppress Autoimmunity in CD4+ T Cells of Autoimmune Hepatitis Type 1

Ryo Nakagawa, Ryosuke Muroyama, Sayaka Ito, Keiko Takano, Wenwen Li, Kaku Goto, Masanori Nakano, Chisato Saeki, Yasuo Matsubara, Naoya Kato, Mikio Zeniya

332: Fast corticosteroid tapering and early fibrosis stages: important risk factors for type 1 autoimmune hepatitis relapse in Japan

Atsushi Takahashi, Kazumichi Abe, Hiromasa Ohira, Yasuhiro Miyake, Masanori Abe, Kazuhide Yamamoto, Yoshiyuki Suzuki, Morikazu Onji, Hirohito Tsubouchi

333: Serum sterol levels indicate distorted cholesterol homeostasis in cirrhotic patients with primary biliary cirrhosis

Marcin Krawczyk, Ewa Wunsch, Dieter Luetjohann, Frank Lammert, Piotr Milkiewicz

Nora Cazzagon, Laura Costa, Irene Franceschet, Alessandra Buja, Liliana Chemello, Luisa Cavalletto, Francesco P. Russo, Annarosa Floreani

335: Fibrates improve liver tests in primary sclerosing cholangitis with incomplete biochemical response to ursodeoxycholic acid: update of a pilote study

Sara Lemoinne, Christophe Corpechot, Astrid Donald D. Kemgang Fankem, Farid Gaouar, Raoul Poupon, Olivier Chazouillères

336: Related Factors for Treatment-Dependent Autoimmune Hepatitis

Berna Gürsel, Fulya Gunsar, Funda Yilmaz, Zeki Karasu, Galip ERsoz, Ulus S. Akarca

Donor Factors and Allocation 337: Successful ex-vivo normothermic oxygenated machine perfusion of human donor livers

Kilian Friedrich, Christian Rupp, Andreas Wannhoff, Wolfgang Stremmel, Daniel Gotthardt

339: The impact of Model for End Stage Liver Disease Sodium (MELD-Na) prioritization for liver transplantation on wait list and post-transplant survival Sheeva Johnson, Barry Schlansky, Willscott E. Naugler

340: Impact of Donation after cardiac death (DCD) allografts on incidence and severity of recurrent hepatitis C (HCV) and graft survival post liver transplantation (LT) for HCV Shiva Kumar, Rachel Pedersen

341: Improving the Quality of MELD Upgrade Petitions for Hepatocellular Carcinoma Beyond the Milan Criteria in UNOS Region 8

Joel P. Wedd, Jane Gralla, Betsy Gans, Sue Dunn, Harvey Solomon, Michael D. Voigt, Scott W. Biggins

342: Utilization of Simultaneous Liver-Kidney Transplants Continues to Vary Dramatically by UNOS Region

Paul J. Gaglio, Wendy Rabbenou, Sander S. Florman, Tomoaki Kato, Milan Kinkhabwala, Glyn Morgan, Mark S. Orloff, Lewis Teperman, Samantha DeLair

343: Palliative Care Utilization in ESLD Patients Denied Transplant Candidacy Sean G. Kelly, Parul D. Agarwal

344: Waiting for liver transplant (LT): Outcomes for LT candidates listed with low MELD without exception points

Allison J. Kwong, Jennifer C. Lai, Jennifer L. Dodge, John P. Roberts

345: Predicting Recurrent Hepatocellular Carcinoma and Survival after Liver Transplantation: The importance of time to transplant

Marypat Pauly, Bradley Winston, Jean-Luc Szpakowski, Lisa M. Nyberg, David H. Smith, Jin Sun, Alice Ducey, Celia D. Clarke, Barbara Piasecki, Ruth Brentari

346: Value Of Preoperative Evaluation Of Cadavaric Liver Donors With Transient Elastography In Marginal Liver Donors

Remy Schwarzer, Simona Bota, Rafael Paternostro, Jagdeep Singh, Tamara Braunschmid, Ferdinand Mühlbacher, Clemens Kietaibl, Thomas Reiberger, Mattias Mandorfer, Michael Trauner, Markus Peck-Radosavljevic, Gabriela Berlakovich, Arnulf Ferlitsch

347: Significance of Initial Poor Function after Liver Transplantation

Janske Reiling, David S. Lockwood, Andrew H. Simpson, Catherine M. Campbell, Kim Bridle, Nishreen Santrampurwala, Laurence J. Britton, Darrell H. Crawford, Cornelis H. Dejong, Jonathan Fawcett

Gilles Uijtterhaegen, Thamara Perera, Jan R. Colpaert, Hans Van Vlierberghe, Roberto Troisi, Xavier Rogiers, Darius Mirza

Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM



334: Metabolic syndrome induces a more rapid progression of fibrosis evaluated with transient elastography in early primary biliary cirrhosis

338: Serum zinc levels are associated with decompensated liver function and reduced survival in patients awaiting liver transplantation



HEPATOLOGY, October, 2014

Poster Sessions 349: Clinician Assessments of Health Status Predict Need for Liver Transplant (LT) Independent of MELD, Especially in Women

Jennifer C. Lai, Kenneth E. Covinsky, Hilary Hayssen, Blanca C. Lizaola, John P. Roberts, Norah Terrault, Sandy Feng

350: Transplant-needed alcoholic cirrhosis: which patients can reach the transplant waiting list? A preliminary case-control study

Benjamin Rolland, Anne Clerget, Alexandre Louvet, Sébastien Dharancy, Philippe Mathurin, Olivier COTTENCIN

351: The Impact of an Institutional Change in Prothrombin Time Methodology on INR and MELD Scores in Liver Transplant Evaluations

Dennis Kumral, Nicolas M. Intagliata, Neeral L. Shah, Stephen H. Caldwell, Patrick G. Northup, Curtis K. Argo

Encephalopathy and Other Complications 352: iPod Video Games Training Improves Overall Cognitive Performance in Patients with Covert Hepatic Encephalopathy


Jasmohan S. Bajaj, Leroy Thacker, Douglas M. Heuman, James Hovermale, Edith A. Gavis, HoChong Gilles, Melanie White, James Wade

353: The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study

Jiannis Vlachogiannakos, Panayota Vasianopoulou, Nikos Viazis, Matilda Chroni, Theodoros Voulgaris, Spiros D. Ladas, Dimitrios G. Karamanolis

354: Differential expression of neurodegeneration related genes in a new model of episodic hepatic encephalopathy

Teresa García-Lezana, Jordi Romero-Giménez, Laia Chavarria, Marc Oria, Joan Genescà, Juan Cordoba

355: Ammonia acts as a damage associated molecular pattern (DAMP) producing multi organ injury and inflammation through a Toll-Like-Receptor-4 (TLR4) dependent pathway

Yalda Sharifi, Gavin Wright, Francesco De Chiara, Nathan Davies, Laia Chavarria, Marc Oria, Francesco Scaravilli, Rajiv Jalan

356: Portal hypertension due to outflow block in noncirrhotic patients with nonalcoholic fatty liver disease

Yohei Koizumi, Masashi Hirooka, Hironori Ochi, Fujimasa Tada, Teruki Miyake, Yoshio Tokumoto, Atsushi Hiraoka, Masanori Abe, Bunzo Matsuura, Yoichi Hiasa

357: Adrenal insufficiency is associated with the clinical outcome in patients with decompensated cirrhosis

Evangelos Cholongitas, Ioannis Goulis, George Kokkonis, Parthenis Chalevas, Spyros Gerou, Evangelos Akriviadis

Denotes AASLD Presidential Poster of Distinction

358: Hepatic and Renal expression of the ammonia transporter Rhesus protein (Rhcg) plays a critical role in modulating hyperammonemia and hepatic encephalopathy in liver failure

Yalda Sharifi, Gavin Wright, Nathan Davies, Abeba Habtesion, Fausto Andreola, Rajiv Jalan

359: Pentoxifylline therapy for hepatopulmonary syndrome: Longer duration is superior to combination with rifaximin, a RCT

Naveen Kumar, Chandan K. Kedarisetty, Sachin Kumar, Ankur Jindal, Ajeet S. Bhadoria, Shiv K. Sarin

360: Prevalence of Bone Disease in Cirrhosis

Mohamed A. Chinnaratha, Rosemary J. McCormick, Rachel Wundke, Richard J. Woodman, Alan J. Wigg

361: Branched-chain amino acids improve intestinal malabsorption of dietary long-chain fatty acids and preserve intestinal fatty acid transporters in liver cirrhosis

Yasunori Yamamoto, Hiroki Utsunomiya, Teruki Miyake, Keitaro Kawasaki, Hiroaki Nunoi, Kenichirou Mori, Yoshio Ikeda, Yoichi Hiasa

362: Association between Malnutrition in Patients with Liver Cirrhosis and the Presence of Hepatic Encephalopathy

Astrid Ruiz-Margáin, Ricardo Macías-Rodríguez, Andres DuarteRojo, Angeles Espinosa-Cuevas, Aldo Torre

363: Bumetanide normalizes brain edema in rats with bile duct ligation: evidence for increased BBB permeability via NKCC1

Jimmy Huynh, Cristina R. Bosoi, Christian Parent-Robitaille, Mélanie Tremblay, Christopher F. Rose

364: Incidence and outcome of newly diagnosed portal vein thrombosis in patients with cirrhosis awaiting liver transplantation

Cindy S. Law, Manjil Chatterji, Kristina Chacko, Thomas D. Schiano, Charissa Y. Chang

365: The determination of prognosis and disease progression in patients with established cirrhosis

Zita Galvin, Audrey Dillon, Jennifer Russell, Damien Lowry, Stephen Stewart

366: Effect of lactulose administration on gut microbiota in patients with liver cirrhosis

Rakesh Aggarwal, Amit Goel, Aditya N. Sarangi, Ankur Singh, S. Avani

367: Relation of CT determined Sarcopenia to Anthropometry, Dietary Calorific and Protein Intake and Survival in Patients with Chronic Liver Disease

Sarah E. Brown, Ziva Mrevlje, Frances Dorman, Natasha Vidas, Pauline A. Kane, Michael A. Heneghan, Julia Wendon, William Bernal




Poster Sessions 368: Comparison of Psychometric Hepatic Encephalopathy Score (PHES) and Inhibitory Control Test (ICT) in diagnosis of minimal hepatic encephalopathy

Jerzy Jaroszewicz, Justyna Zbrzezniak, Natalia Kilisinska, Agnieszka Stawicka, Aleksandra Swiderska, Mateusz Panasiuk, Tadeusz W. Lapinski, Robert Flisiak

369: Comorbid Conditions and Demographic Factors Associated With Poor Outcome in Cirrhotic Patients Undergoing Orthopedic Surgery in a Large Health Maintenance Organization

Eric M. Nyberg, Michael Batech, T Craig Cheetham, Anshuman Singh

370: The Challenging Diagnosis of Minimal Hepatic Encephalopathy: Does Critical Flicker Frequency Correlate to the Psychometric Hepatic Encephalopathy Score? Audrey Dillon, Zita Galvin, Stephen Stewart

371: Sarcopenia and Myosteatosis Increase the Risk of Hepatic Encephalopathy in Cirrhotic Patients Aldo J. Montano-Loza, Andres Duarte-Rojo, Christopher F. Rose

372: Bacterial antigen translocation in patients with cirrhosis and minimal hepatic encephalopathy is associated with increased serum ammonia and nitric oxide levels

Pablo Bellot, Rocío Gallego-Durán, Alba Moratalla, Javier Ampuero, Pedro Zapater, Manuela Roger, Blanca Figueruela, Belén Martínez, José M. González-Navajas, Jose Such, Manuel Romero-Gómez, Ruben Frances

Manuel Mendizabal, David S. Goldberg, Federico Piñero, Diego T. Arufe, Pablo A. Testa, Juan M. Coronel, Maria Pia Raffa, Sergio Baratta, Luis G. Podesta, Michael B. Fallon, Marcelo O. Silva

378: Disturbed sleep is highly prevalent in patients with cirrhosis and is independently associated with poor quality of life

Mollie Jackson, Raghavender Gotur, Edra Nordstrom, Eric S. Orman, Raj Vuppalanchi, Naga P. Chalasani, Marwan Ghabril

379: Apraxia in Patients with Liver Cirrhosis. Influence of Hepatic Encephalopathy

Montserrat O. Flavia, Victor Vargas, Carlos Jacas, M. Ventura, Irene Conejo, Rafael Esteban, Joan Cordoba

380: Trends of Serial MELD Scores has an Incremental Prognostic Value in Predicting In-Hospital Mortality of ICU Cirrhotic Patients

Thoetchai Peeraphatdit, Charat Thongprayoon, Niyada Naksuk, Roongruedee Chaiteerakij, Lewis R. Roberts

381: Metformin reduces hyperammonemia in portacaval shunted rats inhibiting intestinal glutaminase activity

Antonio Gil-Gómez, Isidora Ranchal, Ana Isabel Gomez-Sotelo, Marta García-Valdecasas, Angela Rojas, Jose A. Del Campo, Manuel Romero-Gómez

382: Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy Duygu Bozkaya, Andrew C. Barrett, Kristen Migliaccio-Walle

383: Fragmented QRS is an independent predictor of mortality in patients with decompensated cirrhosis

Peter Jepsen, Hendrik V. Vilstrup, Hugh R. Watson

Mehmet Demir

374: The combination of MELD-Score and Critical Flicker Frequency could filter patients needing no further testing for covert hepatic encephalopathy

384: Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion

Robin A. Greinert, Cristina Ripoll, Marcus Hollenbach, Alexander Zipprich

Taira Kuroda, Masashi Hirooka, Mitsuhito Koizumi, Hironori Ochi, Yoshiko Hisano, Kenji Bando, Bunzo Matsuura, Teru Kumagi, Yoichi Hiasa

375: High Prevalence of Nodular Regenerative Hyperplasia in Patients with End-Stage Heart Failure and Outcomes after Cardiac Transplantation

385: Correlations of portal hypertensive gastropathy with clinical/hemodynamic complications and survival in patients with liver cirrhosis

Ken D. Nguyen, Aung Kaung, Anish V. Patel, Michelle Kittleson, Marc L. Friedman, Maha Guindi, Vinay Sundaram, Tram T. Tran

Hyo Sun Kim, Ki Tae Suk, Eun Jin Kim, Sang Hyun Park, Chang Seok Bang, Dong Joon Kim

376: Algorithm for Correcting Vitamin D Deficiency in Patients Awaiting or Being Evaluated for Liver Transplantation

386: Portal vein thrombosis is not associated with increased mortality in cirrhotic patients

Shai Posner, Emily Schonfeld, Alexis Pappas, Dana R. Berg, Kian Bichoupan, Thomas D. Schiano, Andrea D. Branch, Jonathan Barsa

Kristin Berry, Justin Taylor, Iris W. Liou, George N. Ioannou

387: Pre-Transplant Hepatic Encephalopathy is Associated with Significantly Lower Survival Following Liver Transplantation

Robert J. Wong, Robert G. Gish, Ramsey Cheung, Aijaz Ahmed

Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


373: Diabetes causes hepatic encephalopathy through bacterial translocation—analysis of data from three randomized controlled trials

377: Hepatopulmonary syndrome screening in a large transplant center: Prevalence and impact on survival



HEPATOLOGY, October, 2014

Poster Sessions 388: Increased risk of Portal Vein Thrombosis in NonAlcoholic Steatohepatitis (NASH) and Cryptogenic Cirrhosis: Evidence for a Thrombophilic State

Jonathan G. Stine, Neeral L. Shah, Curtis K. Argo, Shawn Pelletier, Stephen H. Caldwell, Patrick G. Northup

389: Hypercalcemia: A complication and predictor of mortality among patients with severe liver dysfunction

Suman Nayak, Rajendra P. Mathur, Sivaramakrishnan Ramanarayanan, Gyan Prakash, Shiv K. Sarin, Manoj Kumar, Chitranshu Vashishtha, Rakhi Maiwall, Ajeet S. Bhadoria

390: Platelet-derived microparticles in decompensated cirrhosis: relation to blood platelet level and indices of coagulation

Nicolas M. Intagliata, Stephen H. Caldwell, Christine K. Rudy, Tae Hee Lee, Patrick G. Northup, Patcharin Pramoonjago, Josephine Lannigan, Uta Erdbrugger

391: Splenomegaly : splenic volume measurement by ultrasound, validity and reliability, clinical implications in liver cirrhosis

Sang Gyune Kim, Young Seok Kim, Hee Jae Jung, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon, Hong Soo Kim, Boo Sung Kim

392: Hepatic encephalopathy may be associated with enzymatic impairment of ammonia metabolism: Is there a case for studying urea cycle function in cirrhosis?


Raghavender Gotur, Bryan E. Hainline, Qin Sun, Eric S. Orman, Naga P. Chalasani, Marwan Ghabril

393: Nutritional assessment in cirrhotic outpatients and its impact on quality of life

Claudia I. Blanco, Ma Guadalupe Martinez Galindo, Alejandro Ramon R. Angeles Labra, Jose Armando Carmona Castañeda, Griselda Martínez Ramírez, Adriana López Luría, María D. Avila Langarica, María A. Barragán Valarezo, Elizabeth Perez Cruz, Dolores Enciso González, Felipe Zamarripa Dorsey

394: Splenic artery embolization is associated with increased morbidity and mortality in patients with cirrhosis or liver transplantation

Indira Donepudi, Narayan Dharel, Angelo H. Paredes, Richard K. Sterling, R. Todd Stravitz, Brian J. Strife, Mohammad S. Siddiqui, Scott Matherly, Puneet Puri, Velimir A. Luketic, Carolyn Driscoll, Arun J. Sanyal

395: Clinical significance of minimal hepatic encephalopathy

Zita Galvin, Audrey Dillon, Damien Lowry, Jennifer Russell, Stephen Stewart

Denotes AASLD Presidential Poster of Distinction

396: Hyperammonemia (HA) as a Predictor of Episodic Neurocognitive Dysfunction: Lessons From Clinical Studies of Patients with Urea Cycle Disorders (UCDs) and Hepatic Encephalopathy (HE)

Bruce F. Scharschmidt, Richard Rowell, Marzena Jurek, Dion F. Coakley, Masoud Mokhtarani, Uta Lichter-Konecki, Susan A. Berry, George Diaz, Brendan Lee, William Rhead, Don C. Rockey, Marwan Ghabril, Parvez S. Mantry, Robert S. Brown, John M. Vierling

397: Hepatic Encephalopathy, A Preventable Readmission: Implementation of Quality Indicators at a Tertiary Care Center Abdul Haseeb, Juan F. Gallegos-Orozco

398: Sarcopenia in patients with liver cirrhosis – a gender specific complication?

Thomas Zimmerer, Thomas Hoertig, Christoph Antoni, Matthias Ebert, Johanna C. Nissen

399: VIATORR endoprosthesis do not self-expand to their nominal diameters in cirrhotic livers: new evidence toward the risk reduction of post-TIPS hepatic encephalopathy

Filippo Schepis, Francesco Vizzutti, Guido Marzocchi, Pietro Quaretti, Antonio G. Rampoldi, Roberto Agazzi, Rita Golfieri, Angelo Luca, Fabrizio Fanelli, Cristian Caporali, Stefano Colopi, Luigi Rega, Umberto Arena, Ilaria Fiorina, Lorenzo Moramarco, Aldo Airoldi, Roberto Nani, Matteo Renzulli, Cristina Mosconi, Raffaele Bruno, Stefano Fagiuoli, Alessandro Cannavale, Tommaso Di Maira, Stefano Gitto, Erica Villa

400: Portal vein thrombosis significantly increases mortality in advanced cirrhosis with improved prognosis being associated with portal vein recanalization

Carlos Noronha Ferreira, Teresa Rodrigues, Patrícia Sousa, Fernando Ramalho, Paula Alexandrino, José F. Velosa

401: The Performance of Objective Nutrition Assessment Tools and the Evaluation of Nutritional Intake in the PreLiver Transplant Populatio

Kaleb J. Marr, Abdel Aziz M. Shaheen, Louisa Lam, Lauren Schock, Melanie Stapleton, Kelly W. Burak, Maitreyi Raman

402: A multicenter survey of the efficacy and safety of danaparoid sodium treatment for portal vein thrombosis

Takaaki Ohtake, Kunihiko Tsuji, Teruaki Kawanishi, Takuro Machida, Hideyasu Takagi, Shinichi Mezawa, Yasuyuki Yazaki, Yasuhisa Shinomura, Yutaka Kohgo

403: Change in epidemiology of chronic liver disease, 2004-2013

Sumeet K. Asrani, Maria A. Kouznetsova, Andrew Masica, Brett Stauffer, Michael Hagan, Patrick Kamath, James F. Trotter, Fasiha Kanwal




Poster Sessions 404: Blood Group Non-O is a Risk Factor for Portal Vein Thrombosis

Elisabeth P. Plompen, Sarwa Darwish Murad, Massimo Primignani, Elwyn Elias, Jonel Trebicka, Luc Lasser, Bettina E. Hansen, Juan Carlos Garcia-Pagan, Dominique Valla, Frank W. Leebeek, Harry L. Janssen

Experimental Cholestasis 405: Role of the microRNA-FoxA2 axis in biliarycommitted progenitor cells during cholestatic liver injury

Kelly McDaniel, Fanyin Meng, Heather L. Francis, Yuyan Han, Julie Venter, Nan Wu, Morgan Quezada, Ying Wan, Shannon S. Glaser, Gianfranco Alpini

406: Modulation of β-catenin in experimental cholestasis: A therapeutic opportunity

413: Inhibition of mast cell histamine secretion by cromolyn sodium treatment decreases BDL-induced liver inflammation and fibrosis

Laura Hargrove, Fanyin Meng, Lindsey Kennedy, Allyson B. Graf, Quy P. Nguyen, Yuyan Han, Victoria Huynh, Heather L. Francis

414: Disruption of the normal circadian cycle by prolonged exposure to darkness attenuates biliary hyperplasia and liver fibrosis in MDR2 KO mice by modulation of core clock gene expression

Allyson Martinez, Debolina Ray, Yuyan Han, Fanyin Meng, Julie Venter, Heather L. Francis, Sharon DeMorrow, Shanika Avila, Micheleine Guerrier, Kelly McDaniel, Lindsey Kennedy, Haibo Bai, Holly A. Standeford, Gianfranco Alpini, Shannon S. Glaser

415: Absence of BSEP/ABCB11 protects from cholestatic liver injury in mice

Kari Nejak-Bowen, Satdarshan (Paul) S. Monga

Claudia D. Fuchs, Gustav Paumgartner, Annika Wahlström, Peter Chiba, Tatjana Stojakovic, Thierry Claudel, Hanns-Ulrich Marschall, Michael Trauner

407: Post-translational regulation of Polycystin 2 (PC2) protein expression by ubiquitination and autophagy as a novel mechanism of cholangiocyte repair and reaction to biliary damage

416: Endoplasmic reticulum stress suppresses hepatic Abcb11 expression but does not induce overt cholestasis in mice

Carlo Spirli, Carola M. Morell, Ambra Villani, Luca Fabris, Romina Fiorotto, Mario Strazzabosco

408: ENDTP1/CD39 deficiency aggravates liver injury and fibrosis in sclerosing cholangitis model in Mdr2-/mice

Zhen-Wei Peng, Naoki Ikenaga, Susan B. Liu, Simon C. Robson, Yury Popov Ruth Bolier, Dagmar Tolenaars, Andreas E. Kremer, Joanne Verheij, Ulrich Beuers, Piter J. Bosma, Ronald Oude Elferink

410: Knockdown of the melatonin receptor, MT2, enhances biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated (BDL) mice: novel evidence for a hepatoprotective role of MT2

Nan Wu, Yuyan Han, Debolina Ray, Julie Venter, Kelly McDaniel, Allyson Martinez, Shanika Avila, Eugenio Gaudio, Paolo Onori, Antonio Franchitto, Fanyin Meng, Micheleine Guerrier, Holly A. Standeford, Gianfranco Alpini, Shannon S. Glaser

411: Attenuated liver fibrosis modulated by miR-141 in secretin knockout mice during cholestatic liver injury induced by bile duct ligation (BDL)

Yuyan Han, Allyson Martinez, Ying Wan, Kelly McDaniel, Julie Venter, Heather L. Francis, Holly A. Standeford, Shanika Avila, Debolina Ray, Haibo Bai, Nan Wu, Yoshiyuki Ueno, Shannon S. Glaser, Gianfranco Alpini, Fanyin Meng

412: Activation of Sirtuin1 pathway reverses liver injury in a cholic acid fed mouse model of cholestasis Supriya Kulkarni, Carol J. Soroka, James L. Boyer

Poster Viewing: 2:00 – 7:30 PM

417: Central expression of the hypothalamic neuropeptide galanin is upregulated in rodent models of primary sclerosing cholangitis

Matthew McMillin, Gabriel A. Frampton, Cheryl Galindo, Heather L. Francis, Sharon DeMorrow

418: Ezetimibe prevents diosgenin-induced cholestatic liver injury in mice Yuji Tanaka, Toshinori Kamisako

419: Necroptosis in human primary biliary cirrhosis and in murine models of bile acid toxicity

Marta B. Afonso, Marta Caridade, Pedro M. Rodrigues, Helena Cortez-Pinto, Rui E. Castro, Cecília M. Rodrigues

Fibrosis: Clinical and Translational 420: Paracrine Signaling From Transplanted Hepatocytes But not From Liver Sinusoidal Endothelial Cells (LSEC) Rescues Mice From Acetaminophen (APAP)Induced Acute Liver Failure (ALF)

Preeti Viswanathan, Yogeshwar Sharma, Sriram Bandi, Sanjeev Gupta

421: Pleiotrophin Regulates the Ductular Reaction by Controlling the Migration of Cells in Liver Progenitor Niches

Gregory A. Michelotti, Anikia Tucker, Mariana V. Machado, Marzena Swiderska-Syn, Steve S. Choi, Leandi Kruger, Katherine S. Garman, Cynthia A. Moylan, Cynthia D. Guy, Heather Himburg, John P. Chute, Anna Mae Diehl

Presenters in Attendance 5:30 – 7:00 PM


409: High Systemic Autotaxin Induces Itch in Mice

Anne S. Henkel, Brian E. LeCuyer, Shantel Olivares, Richard Green



HEPATOLOGY, October, 2014

Poster Sessions 422: Vivo Morpholino local inhibition of hepatic gonadotropin-releasing hormone (GnRH) expression reduces liver fibrosis in cholestatic rats through increased miR-125a expression

Debolina Ray, Yuyan Han, Fanyin Meng, Julie Venter, Heather L. Francis, Sharon DeMorrow, Yoshiyuki Ueno, Matthew McMillin, Paolo Onori, Haibo Bai, Allyson Martinez, Eugenio Gaudio, Shannon S. Glaser, Gianfranco Alpini

423: Alternatively activated M2 macrophages promotes hepatocyte differentiation in hepatic progenitor cell mediated liver regeneration in acute on chronic liver failure patients

Dhananjay Kumar, Sheetalnath Rooge, Smriti Shubham, Adil Bhat, Charvi Syal, Archana Rastogi, Chhagan Bihari, Viniyendra Pamecha, Anupam Kumar, Shiv K. Sarin

424: The pro-inflammatory and pro-fibrogenic actions of the HIV-envelope protein gp120 are mediated by inflammasome activation and miR-29b

Andrea Cappon, Raffaele Bruno, Sandra Gessani, Andrea Masotti, Fabio Marra

425: Activation of Toll-Like-Receptors (TLR) on isolated Kupffer cells (KC) and sinusoidal endothelial cells (SEC) of the liver: Opposing effects on the production of the vasoconstrictor Thromboxane B2


Julia Schewe, Lisa Selzner, Ingrid Liss, Burkhard Göke, Alexander L. Gerbes, Christian J. Steib

426: Cannabinoid Receptor 1 is Involved in Hepatic Inflammation and Fibrosis in Mice by Regulating Bone Marrow-Derived Monocyte/Macrophage

Ping Mai, Le Yang, Lin Wang, Lei Tian, Shuangshuang Jia, Yuanyuan Zhang, Xin Liu, Lin Yang, Liying Li

427: Hepatic progenitor cells contribute to the progression of liver fibrosis induced by 2-AAF/CCl4 in rats through the non-canonical wnt pathway Jiamei Chen, Yongping Mu, Yuyou Duan, Ping Liu

428: Downregulation of pro-fibrotic and proinflammatory genes in liver sinusoidal endothelial cells following activation of the bile acid receptors FXR and TGR5

Rachel McMahan, Cara Porsche, Michael Edwards, Luciano Adorini, Moshe Levi, Hugo R. Rosen

429: Repair-related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism

Brittany Bohinc, Gregory A. Michelotti, Guanhua Xie, Herbert Pang, Ayako Suzuki, Cynthia D. Guy, Dawn L. Piercy, Leandi Kruger, Marzena Swiderska-Syn, Mariana V. Machado, Thiago A. Pereira, Ann Marie Zavacki, Manal F. Abdelmalek, Anna Mae Diehl

430: MicroRNA profiling of circulating exosomes during experimental liver fibrosis Li Chen, Ruju Chen, David Brigstock

Denotes AASLD Presidential Poster of Distinction

431: Soluble CD146, a novel endothelial marker, is related to the severity of liver disease

Efrossini Nomikou, Alexandra Alexopoulou, Larisa E. Vasilieva, Danai Agiasotelli, Spyros P. Dourakis

432: Species differences in the antifibrotic effect of imatinib

Inge M. Westra, Dorenda Oosterhuis, Rick Mutsaers, Geny M. Groothuis, Peter Olinga

433: Precise liver fibrosis staging by automated morphometry of liver biopsies: E-Metavir

Paul Cales, Julien Chaigneau, Jerome Boursier, Gilles Hunault, Sophie Michalak, Frederic Oberti, Isabelle Fouchard-Hubert, Sandrine Bertrais, Marie Christine Rousselet

434: Genome Wide Association Study (GWAS) identifies a SNP near the MRC2 (mannose receptor C, type 2) gene associated with increased liver collagen content in Caucasian HBV patients Nezam H. Afdhal, Thomas J. Urban, Zachary D. Goodman, Keyur Patel, Dongliang Ge, Xin Guo, Zhaoshi Jiang, Xi Zhao, Matthew Paulson, Anuj Gaggar, Jeffrey Bornstein, Mani Subramanian, John G. McHutchison, Sarah E. Kleinstein, Nanye Long, David B. Goldstein, Rohit Loomba, Alexander J. Thompson

435: Factors influencing liver stiffness in chronic liver disease

Chikage Nakano, Hiroko Iijima, Tomoko Aoki, Kenji Hashimoto, Masahiro Yoshida, Akio Ishii, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hironori Tanaka, Hirayuki Enomoto, Masaki Saito, Seiichi Hirota, Shuhei Nishiguchi

436: Cartilage oligomeric matrix protein (COMP) serum levels: a new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis

Stella Gabeta, Kalliopi Zachou, Zakera Shums, Nikolaos Gatselis, George K. Koukoulis, Gary L. Norman, George N. Dalekos

437: New canine liver cirrhotic model to develop a less invasive regeneration therapy using cultured autologous bone marrow-derived cells

Takashi Matsuda, Taro Takami, Tsuyoshi Ishikawa, Naoki Yamamoto, Shuji Terai, Isao Sakaida

438: Spleen prevents the development of liver fibrosis by Kupffer cell deactivation through lipocalin-2 production in mice

Tomonori Aoyama, Akira Uchiyama, Kazuyoshi Kon, Hironao Okubo, Shunhei Yamashina, Kenichi Ikejima, Shigehiro Kokubu, Akihisa Miyazaki, Sumio Watanabe

439: Serum Lysyl Oxidase Like 2 (sLOXL2) Levels Correlate with Ishak Fibrosis Score and Decrease with Treatment with Tenofovir Disoproxil Fumarate (TDF) in Patients with Chronic Hepatitis B (CHB)

W. Ray Kim, Rohit Loomba, Preeti Lal, Raul E. Aguilar Schall, Ann D. Johnson, Jeffrey D. Bornstein, Mani Subramanian, John G. McHutchison, Stephen A. Harrison, Arun J. Sanyal




Poster Sessions 440: How long a prognosis by liver fibrosis tests is accurate?

Sandrine Bertrais, Jerome Boursier, Frédéric Oberti, Isabelle Fouchard-Hubert, Valerie Moal, Paul Cales

441: Exhaled Breath Analysis Reveals New Biomarkers to Diagnose Advanced Fibrosis in Patients with Chronic Liver Disease

Mohammed Eyad Yaseen Alsabbagh, Ahmad Tarek Chami, Singh Gurshawn, Mina Shaker, Ibrahim A. Hanouneh, David Grove, Rocio Lopez, Nizar N. Zein, Raed Dweik, Naim Alkhouri

442: Oral Treatment with PBI-4050 Reduces Fibrosis in Carbon Tetrachloride (CCl4)-Induced Hepatic Fibrosis

Brigitte Grouix, Kathy Hince, François Sarra-Bournet, Alexandra Felton, Mikaël Tremblay, Shaun Abbott, Jean-Simon Duceppe, Boulos Zacharie, Pierre Laurin, Lyne Gagnon

443: Wisteria floribunda agglutinin-positive Mac-2 binding protein as a predictor of liver fibrosis in patients with non-alcoholic fatty liver disease Masanori Abe, Teruki Miyake, Atsushi Kuno, Yasuharu Imai, Yoshiyuki Sawai, Keisuke Hino, Yuichi Hara, Shuhei Hige, Michiie Sakamoto, Masaaki Korenaga, Yoichi Hiasa, Masashi Mizokami, Hisashi Narimatsu

444: Less invasive liver regeneration therapy for liver cirrhosis using cultured autologous bone marrowderived mesenchymal stem cells with redox-regulatory capacity

Taro Takami, Shuji Terai, Luiz Fernando Quintanilha, Bruno D. Paredes, Koichi Fujisawa, Naoki Yamamoto, Isao Sakaida

Etsuko Iio, Makoto Ocho, Akira Togayachi, Noboru Shinkai, Masanori Nojima, Atsushi Kuno, Yuzuru Ikehara, Izumi Hasegawa, Kei Fujiwara, Shunsuke Nojiri, Takashi Joh, Masashi Mizokami, Hisashi Narimatsu, Yasuhito Tanaka

446: Cholecystectomy Is Associated with an Increased Rate of Hepatic Fibrosis Development Compared to Patients with Chronic Hepatitis C Infection who are Nonresponders to Interferon/Ribavirin Donald J. Martin, Rick A. Weideman, Terri Crook, Geri Brown

447: Pro-C3-levels in patients with HIV/HCV coinfection reflect fibrosis stage and degree of portal hypertension

Christian Jansen, Diana J. Leeming, Mattias Mandorfer, Inger Byrjalsen, Robert Schierwagen, Philipp Schwabl, Morten A. Karsdal, Evrim Anadol, Christian P. Strassburg, Jürgen K. Rockstroh, Markus Peck-Radosavljevic, Søren Møller, Flemming Bendtsen, Aleksander Krag, Thomas Reiberger, Jonel Trebicka

Eric G. Meissner, Mary McLaughlin, Lindsay A. Matthews, Bittoo Kanwar, Jeffrey D. Bornstein, Joseph A. Kovacs, Shyam Kottilil, Caryn G. Morse

449: Aspirin Use is Associated with Lower Liver Fibrosis Indices among Adults in the United States

Zhenghui G. Jiang, Linda Feldbrügge, Elliot B. Tapper, Yury Popov, Tahereh Ghaziani, Simon C. Robson, Kenneth Mukamal

450: Fibrosis regression in hepatitis C patients with cirrhosis: Ishak fibrosis score and CPA pre treatment predict regression post sustained virological response

Paolo Nieddu, Ameet Dhar, Robert D. Goldin, Nimzing Ladep, Sarosh Khan, Mark R. Thursz, Ashley S. Brown

451: Assessment of regression of fibrosis using Fibroscan® in patients with chronic hepatitis B receiving antiviral treatment beyond 5 years

Young Eun Chon, Myung Sung Min, Kyu Sik Jung, Kwang-Hyub Han, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Jun Yong Park

452: Development of Novel Lipidnanoparticle siRNA Delivery System Targeting Collagen Chaperone Protein HSP47 for Clinical Treatment of Liver Fibrosis

Wenbin Ying, Jun Zhang, Yun Liu, Li Wang, Jihua Liu, Jian Liu, Jingyuan Yu, Jean-Pierre Clamme, Jiping Yao, Lishuang Xu, Donald A. Kaiser, Yasunobu Tanaka, Miyono Miyazaki, Keiko Kajiwara, Kenjiro Minomi, Yoshiro Niitsu

453: Subclinical cirrhosis diagnosed by transient elastography demonstrates increased risk of severe clinical outcomes and HCC

Tianyan Chen, Remy E. Wong, Kathleen C. Rollet-Kurhajec, Rasha Alshaalan, Philip Wong, Marc Deschenes, Peter Ghali, Giada Sebastiani

454: Irbesartan for severe fibrosis in chronic hepatitis C: a double-blind randomized trial (ANRS HC19 Fibrosar)

Paul Cales, Yannick Bacq, Jean-Pierre Vinel, Corinne Bonny, Jean-Louis Payen, Dominique Guyader, Albert Tran, Dominique G. Larrey, Christine Silvain, Marie Christine Rousselet, Frederic Oberti, Mélanie Simony, Fabrice Carrat

455: Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks

Melanie Thompson, Will Chang, Helen Jenkins, Amy Flynt, Millie Gottwald, Eric Lefebvre

456: A 6-Gene Score Associated With Advanced Stages of Presymptomatic HBV Related Fibrosis Mingyi Xu, Ying Qu, Qingqing Zhang, Lungen Lu

Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


445: A novel glycobiomarker: Wisteria floribunda agglutinin Macrophage Colony-Stimulating Factor Receptor for predicting carcinogenesis and survival of liver cirrhosis patients

448: Longitudinal hepatic and PBMC gene expression profiling of HIV and/or HCV-infected patients with advanced liver disease treated with simtuzumab, an anti-LOXL2 antibody



HEPATOLOGY, October, 2014

Poster Sessions 457: Localizations and functional roles of MMP-1 in the early and advanced stages of human non-alcoholic steatohepatitis

Hiroaki Yokomori, Isao Okazaki, Masaya Oda, Wataru Ando, Yutaka Suzuki, Tsutsui Nobuhiro, Eigoro Yamanouchi, Hajime Kuroda, Soichi Kojima, Mitsuko Hara, Yutaka Inagaki

458: Increased autophagy is associated with ductular reaction in human cirrhotic livers Tzu-Min Hung, Po-Huang Lee

459: The hitch with non-invasive tests of liver fibrosis: evaluated by binary AUROC but used with stage classifications

Paul Cales, Jerome Boursier, Isabelle Fouchard-Hubert, Frederic Oberti, Victor de Ledinghen, Vincent Leroy

Hemochromatosis, Wilson Disease, a-1 Antitrypsin Deficiency 460: Hfe and hemojuvelin regulate hepcidin expression and iron metabolism via the same pathway: Genetic evidence from single and double knockout mice


Patricia Kent, Nicole Wilkinson, Marco Constante, Konstantinos Gkouvatsos, John Wagner, Manuela M. Santos, Kostas Pantopoulos

461: Acute Intermittent Porphyria: High incidence of Pathogenic HMB-Synthase (HMBS) Non-Synonymous SNPs (nsSNPs) in Genomic Databases Suggests Other Genetic/Environmental Factors Cause the Acute Attacks

Brenden Chen, Jörg Hakenberg, Ramakrishnan R. Srinivasan, Dana O. Doheny, Inga Peter, Constanza Solis-Villa, Rong Chen, David F. Bishop, Makiko Yasuda, Robert J. Desnick

462: Lorcaserin Improves the NASH Clinical Score in the Majority of High-Risk Patients: a Retrospective Analysis of Three Phase 3 Studies

Wajahat Z. Mehal, Randi Fain, Alan Glicklich, Yuhan Li, William Shanahan, William Soliman

463: No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson’s disease during long term follow up

Suzanne van Meer, Robert A. de Man, Aad P. van den Berg, Roderick Houwen, Francisca Linn, Peter D. Siersema, Karel J. van Erpecum

464: Patients with Wilson disease without detectable ATP7B mutations

Albert Stättermayer, Heinz M. Zoller, Karl Heinz Weiss, Ferenc Szalay, Radan Bruha, Roderick Houwen, Rudolf E. Stauber, Petra E. Steindl-Munda, Harald Hofer, Wolfgang Stremmel, Peter Ferenci

465: Sex differences in liver SAM:SAH ratios and gene transcript levels after pre-and post-natal choline supplementation and copper chelation treatment in an animal model of Wilson disease

Valentina Medici, Noreene Shibata, Kusum K. Kharbanda, Charles H. Halsted

Denotes AASLD Presidential Poster of Distinction

466: Using hIPSCs to model liver disease associated with classic mutations of alpha-1 antitrypsin Tamara Taketani, Maria P. Ordonez, Lawrence S. Goldstein

467: A propensity score-matched cohort study of the effect of vitamin E in NAFLD patients

Gi Hyun Kim, Jin Wook Kim, Jung Wha Chung, Eun Sun Jang, Sook-Hyang Jeong

468: Variability in erythrocyte and plasma porphyrin levels in erythropoietic protoporphyria and X-linked protoporphyria

Eric Gou, John D. Phillips, Manisha Balwani, Montgomery Bissell, Joseph R. Bloomer, Herbert L. Bonkovsky, Robert J. Desnick, Hetanshi Naik, Karl E. Anderson

469: Osteoporosis and bone fractures in alcoholic liver disease: A systematic review and meta-analysis

Chang Seok Bang, Hyo Sun Kim, Sang Hyun Park, Eun Jin Kim, Ki Tae Suk, Dong Joon Kim

470: Elevated alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a multi-center pooled analysis on individual patient data

Tom J. Gevers, Frederik Nevens, Vicente E. Torres, Marie C. Hogan, Joost Drenth

471: A Phase I Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson Disease

Karl Heinz Weiss, Ulrike Teufel, Jan Pfeiffenberger, Christian Rupp, Andreas Wannhoff, Wolfgang Stremmel, Daniel Gotthardt

Imaging in Cancer 472: Hemodynamic differences in the very early phase of hepatocellular carcinoma (HCC) using contrastenhanced ultrasonography (CEUS)

Akiko Saito, Satoshi Katagiri, Masakazu Yamamoto, Keiko Shiratori, Masayuki Nakano, Toshio Morizane

473: Correlation of Enhancement Pattern of CEUS with Histopathologic Feature in Small Nodular Lesions in Chronic Liver Disease

Seung Kak Shin, Yun Soo Kim, Oh Sang Kwon, Duck Joo Choi, Ju Hyun Kim

474: Preoperative predictive value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography for microvascular invasion of small hepatocellular carcinoma

Tomoki Kobayashi, Hiroshi Aikata, Hiromi Kan, Takayuki Fukuhara, Noriaki Naeshiro, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hideyuki Hyogo, Kazuaki Chayama




Poster Sessions 475: Indication of super-delayed phase image acquisition of Gd-EOB-DTPA enhanced MRI to improve poor contrast images on routine hepatobiliary phase images for detection of liver lesion

Satoshi Kobayashi, Kazuto Kozaka, Azusa Kitao, Norihide Yoneda, Hiroshi Ikeno, Osamu Matsui, Toshifumi Gabata

476: Single-center experience with stereotactic liver surgery: A review over 5 years

Vanessa M. Banz, Pascale Tinguely, Mathias Worni, Philip Mueller, Daniel Inderbitzin, Delphine Ribes, Matthias Peterhans, Stefan Weber, Daniel Candinas

477: Complications related to percutaneous biopsies of the liver, pancreas, lymph nodes and tumors in the retroperitoneal space performed under ultrasound control Stoyan S. Handzhiev

478: Increased Rate of Pre-transplant Magnetic Resonance Imaging Under-staging of Hepatocellular Carcinoma in Patients With Transjugular Intrahepatic Portosystemic Shunts

She-Yan Wong, Dina Halegoua-De Marzio, Colette Shaw, Jesse M. Civan

479: Hepatic Angiomyolipoma Mimicking Hepatocellular Carcinoma: Clinical, Magnetic Resonance Imaging and Pathological Characteristics in 9 Cases

Chunping Wang, Hongyan Li, Hong Wang, Xiaodong Guo, Changchun Liu, Xudong Gao, Jianhui Qu, Ze Liu, Xiu juan Chang, Yin Ying Lu, Zhen Zeng, Min Lou, Ke-Qin Hu, Yongping Yang

Satoru Seo, Etsuro Hatano, Yuji Nakamoto, Kenji Takemoto, Kojiro Taura, Tadahiro Uemura, Kentaro Yasuchika, Akira Mori, Toshimi Kaido, Hideaki Okajima, Shinji Uemoto

481: A safety, feasibility and accuracy study of laparoscopic computer-assisted navigated microwave ablation of liver tumors

Pascale Tinguely, Delphine Ribes, Jacob Freedman, Silja Karlgren, Fusagila Matteo, Matthias Peterhans, Stefan Weber, Daniel Candinas, Henrik Nilsson

Imaging in Fibrosis 482: Diagnostic Accuracy and Reliability of Supersonic Shear Imaging in Comparison with Transient Elastography for Assessment of Liver Fibrosis in Patients with Chronic Liver Disease

Masato Yoneda, Emmanuel Thomas, Seth N. Sclair, Eugene R. Schiff

Poster Viewing: 2:00 – 7:30 PM

Beth Thurberg, Melissa Wasserstein, Simon Jones, Thomas D. Schiano, Gerald F. Cox

484: Comparison of 2-dimensional and 3-dimensional magnetic resonance elastography (MRE) for diagnosis of advanced fibrosis in patients with biopsy-proven NAFLD: A prospective study

Rohit Loomba, Tanya Wolfson, William Haufe, Jonathan Hooker, Nikolaus M. Szeverenyi, Brandon Ang, Archana Bhatt, Cynthia A. Behling, Mark A. Valasek, Grace Y. Lin, Anthony C. Gamst, David A. Brenner, Meng Yin, Richard Ehman, Claude B. Sirlin

485: The feasability of Transient Elastography using M and XL probes for assesing liver stiffness – a practice audit of 3235 examinations on a multi-etiology cohort

Ioan Sporea, Flavia Motiu, Alina Popescu, Roxana Sirli, Ruxandra G. Mare, Oana Gradinaru Tascau, Alexandra Deleanu, Isabel Dan

486: Quantitative Assessment of Liver Fibrosis by Digital Image Analysis: Relationship to Ishak Staging and Elasticity by Shear-wave Elastography

Ender G. Yegin, Korkut Yegin, Faruk Erdem Kombak, Emrah Karatay, Davut Tüney, Cigdem Ataizi Celikel, Osman C. Ozdogan

487: Accuracy of Real-Time Shear Wave Elastography for Assessing Liver Fibrosis in Chronic Liver Disease: A Pilot Study

Oranit Cohen-Ezra, Yeroham Kleinbaum, Orit Pappo, Muriel Webb, Ella Veitsman, Tania Bradichevsky, Yael Inbar, Sima Katsherginsky, Peretz Weiss, Keren Tsaraf, Ziv Ben-Ari

488: The Usefulness of Non-invasive Liver Stiffness Measurement by Fibroscan® for Risk Management of HCC in Chronic Hepatitis C Patients Who Achieved Sustained Virological Response (SVR)

Nobuhito Taniki, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Akihiro Yamaguchi, Takeru Amiya, Yuko Wakayama, Hiroko Murata, Po-sung Chu, Shingo Usui, Hidetsugu Saito, Takanori Kanai

489: Magnetic resonance elastography is useful as noninvasive diagnostic method for predicting liver fibrosis in nonalcoholic fatty liver disease

Kento Imajo, Takaomi Kessoku, Yasushi Honda, Yuji Ogawa, Hironori Mawatari, Masato Yoneda, Satoru Saito, Atsushi Nakajima

490: Spleen stiffness correlates with spleen size but not liver fibrosis in patients with alcoholic liver disease Maja Thiele, Bjørn S. Madsen, Aleksander Krag

491: Muscle fat infiltration using total psoas density in computed tomography predicts mortality in cirrhosis

Christos K. Triantos, Andreas Karatzas, Maria Kalafateli, Paraskevi Tselekouni, Georgios Tsiaoussis, Nikolaos Koukias, Efstratios Koutroumpakis, Konstatinos Thomopoulos, Vasiliki Nikolopoulou, Christina Kalogeropoulou, Chrisoula Labropoulou-Karatza C

Presenters in Attendance 5:30 – 7:00 PM


480: Metabolic tumor volume by Fluorine-18 fluorodeoxyglucose positron emission tomography as useful predictor for early recurrence after recurrence in intrahepatic cholangiocarcinoma

483: Recombinant Human Acid Sphingomyelinase Clears Hepatic Sphingomyelin in Adults with NiemannPick Disease Type B



HEPATOLOGY, October, 2014

Poster Sessions 492: Supersonic shear imaging predicts cirrhosis and advanced fibrosis in chronic hepatitis C patients Shih-Jer Hsu, Yu L. Tan, Ding-Shinn Chen, Jia-Horng Kao

493: The usefulness of spleen stiffness evaluated by Acoustic Radiation Force Impulse (ARFI) elastography for assessing liver fibrosis

Simona Bota, Ioan Sporea, Oana Gradinaru Tascau, Alina Popescu, Roxana Sirli, Mirela Danila

494: Comparison between 2D-real time Shear Wave Elastography (2D-SWE) and simple serological scores for liver fibrosis assessment for clinical routine, considering Transient Elastography (TE) as reference method

Simona Bota, Rafael Paternostro, Alexandra Etschmaier, Remy Schwarzer, Petra Salzl, Mattias Mandorfer, Tuul Purevsambuu, Monika Ferlitsch, Christian Kienbacher, Thomas Reiberger, Michael Trauner, Markus Peck-Radosavljevic, Arnulf Ferlitsch

495: The two faces of non-invasive assessment of liver disease severity: correlation between liver stiffness and hepatic vein arrival times

Francesco Ridolfi, Teresa Abbattista, Annamaria Schimizzi, Eugenio Brunelli

496: Alkaline phosphatase, but not ongoing alcohol abuse, influence liver stiffness measurements in alcoholic liver disease


Maja Thiele, Bjørn S. Madsen, Christian Jansen, Christian P. Strassburg, Jonel Trebicka, Aleksander Krag

497: Noninvasive evaluation of portal hypertension by spleen elastography

Karel Dvorak, Vaclav Smid, Renata Sroubkova, Jaromir Petrtyl, Radan Bruha

498: Extracorporeal Shock Wave Lithotripsy for Difficult-to-Retrieve Common Bile Duct Stones: A Seven Year Single Center Experience

Syed M. Hassan, Kapeel Raja, Asad A. Khan, Nasir Hassan Luck, Munnawar Khaliq, Muhammad Manzoor, Zaigham Abbas

499: The correlation between histology and the three elastographic techniques available in our department

Ioan Sporea, Oana Gradinaru Tascau, Alina Popescu, Madalina Popescu, Roxana Sirli, Flavia Motiu

500: Usefulness of Acoustic Noninvasive Assessment of Liver Stiffness: Radiation Force Impulse (ARFI) Elastography for staging of liver fibrosis and differential diagnosis of hepatic tumor

Shunsuke Nakajima, Takaaki Ohtake, Takumu Hasebe, Koji Sawada, Masami Abe, Yasuaki Suzuki, Mikihiro Fujiya, Yutaka Kohgo

501: Assessment of hepatic fibrosis with Superb Microvascular Imaging: a preliminary report

Nobuko Koyama, Jiro Hata, Takeshi Sato, Noriaki Manabe, Hiroshi Imamura, Ken Haruma, Keisuke Hino

Denotes AASLD Presidential Poster of Distinction

502: Shear Wave Elastography and Hepatorenal Index for the Assessment of Liver Fibrosis and Steatosis: a Novel technique and its Predictive Accuracy and Optimal Measurement Location

George Therapondos, Michael T. Perry, Neal Savjani, Adriana Dornelles, Edward I. Bluth

503: Liver stiffness measurement in psoriatic patients: metabolic factor, disease factor or methotrexate play important role?

Jamrus Pongpit, Saneerat Porntharukchareon, Wasana Stitchantrakul, Ammarin Thakkinstian, Piyaporn Kaewdoung, Kwannapa Promson, Supanna Petraksa, Natta Rajatanavin, Chomsri Kositchaiwat, Abhasnee Sobhonslidsuk

Immunosuppression 504: Short Waiting Time Predicts Early Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Study Supporting the “Ablate and Wait” Principle

Neil Mehta, Julie Heimbach, Denise M. Harnois, Jennifer L. Dodge, Justin M. Burns, David Lee, William Sanchez, John P. Roberts, Francis Y. Yao

505: Biomarkers significantly improve the performance of the Milan criteria in predicting Hepatocellular carcinoma (HCC) recurrence post liver transplantation (LT)

Roongruedee Chaiteerakij, Xiaodan Zhang, Benyam D. Addissie, Essa A. Mohamed, William S. Harmsen, J Paul Theobald, Brian E. Peters, Joseph Balsanek, Melissa M. Ward, Nasra H. Giama, Catherine D. Moser, Abdul M. Oseini, Naoki Umeda, Denise M. Harnois, Michael Charlton, Hiroyuki Yamada, Shinji Satomura, Alicia Algeciras-Schimnich, Melissa R. Snyder, Terry M. Therneau, Lewis R. Roberts

506: Injury of Peribiliary Glands of Donor Liver Bile Ducts Plays a Pivotal Role in the Development of Nonanastomotic Biliary Strictures after Liver Transplantation

Negin Karimian, Sanna op den Dries, Pepijn D. Weeder, Andrie Westerkamp, Fernanda Bomfati, Janneke Wiersema-Buist, Bote G. Bruinsma, Annette S. Gouw, James F. Markmann, Ton Lisman, Heidi Yeh, Korkut Uygun, Paulo N. Martins, Robert J. Porte

507: Early Post-Operative Neutrophil Gelatinase Associated Lipocalin (NGAL)-Associated Acute Kidney Injury Predicts the Development of Chronic Kidney Disease and Mortality Following Liver Transplantation

Elizabeth C. Verna, Giuseppe Cullaro, Joseph F. Pisa, Robert S. Brown, Gebhard Wagener

508: The Impact of Deconditioning In Advanced Cirrhosis

Michael A. Dunn, Deborah A. Josbeno, Mark Sturdevant, Amy R. Schmotzer, Elizabeth A. Kallenborn, Jaideep Behari, Doug Landsittel, Andrea DiMartini, Anthony Delitto




Poster Sessions 509: Narcotics Increase Rate of Rejection and Mortality After Liver Transplantation Regardless of Underlying Disease Etiology

Mina Pirzadeh, Amir Prushani, Syed-Mohammed R. Jafri, Maria C. Segovia

510: Positive impact of everolimus on regulatory T cells after liver transplantation

Clement Barjon, Kaldoun Ghazal, Geraldine Dahlqvist, Faouzi Saliba, Francois Durand, Christophe Duvoux, Lynda Aoudjehane, Yvon Calmus, Filomena Conti

511: Predictors of excessive alcohol use following liver transplantation for alcoholic liver disease: A nationwide competing risks analysis of psychiatric comorbidity and occupational status (1990-2013)

Gro Askgaard, Janne S. Tolstrup, Thomas A. Gerds, Ole Hamberg, Mette Kjær

512: Prevalence and prediction of major adverse cardiovascular events after liver transplantation using a novel database

Lisa B. VanWagner, Marina Serper, Raymond Kang, Anton I. Skaro, Josh Levitsky, Samuel Hohmann, Donald M. Lloyd-Jones

513: Calcineurin inhibitor withdrawal following by mycophenolate mofetil monotherapy using therapeutic drug monitoring in maintenance liver transplant recipients

514: Alpha-fetoprotein Slope >7.5 ng/mL/month Predicts Post-transplant Tumor Recurrence and Microvascular Invasion for Hepatocellular Carcinoma within Milan Criteria

Jeanne-Marie Giard, Neil Mehta, Jennifer L. Dodge, John P. Roberts, Francis Y. Yao

515: WITHDRAWN 516: Treatment of acute cellular rejection episodes does not influence fibrosis progression rate in patients with recurrence HCV after liver transplantation

Pinelopi Manousou, Emmanuel Tsochatzis, Ioanna Parisi, Francesca Saffioti, Alexandra Mansell, Silvia Aspite, David W. Patch, James O’Beirne, Douglas Thorburn, Tu Vinh Luong, Amar P. Dhillon, Massimo Pinzani, Andrew K. Burroughs

517: Pre-transplant Type 2 Hepatorenal Syndrome is Associated with Persistently Impaired Renal Function after Liver Transplantation

Hiang K. Tan, Max Marquez, Florence Wong, Eberhard L. Renner

Carlos G. Fasola, Parvez S. Mantry, Bahar Madani, Jeffrey S. Weinstein, Abdullah Mubarak, Hector Nazario, Adil Habib, Maisha N. Barnes, Alejandro Mejia, Richard Dickerman, Edward A. Dominguez, Stephen Cheng

519: HMGB1 and nucleosomes as biomarkers of clinical outcome in human liver transplantation

Antônio Márcio F. Andrade, Marcus V. Andrade, Agnaldo S. Lima, Luciana C. Faria

520: Improved but persistent poor functional performance at 1 year after liver transplantation: Predictors of performance and opportunities for intervention

Sarah Uttal, Lisa B. VanWagner, Brittany Lapin, Amanda Jichlinkski, Joshua Lee, Madeleine Heldman, Brian Poole, Tanvi Subramanian, Eduardo A. Bustamante, Suvai Gunasekaran, Christopher S. Tapia, Annapoorani Veerappan, She-Yan Wong, Josh Levitsky

521: Younger Hepatitis C Virus (HCV) Liver Transplant (LT) Recipients have Significantly Reduced Graft Survival

Varun Saxena, Jennifer L. Dodge, John P. Roberts, Norah Terrault

522: Impact of portal vein thrombosis prior to liver transplantation: a multi-center retrospective cohort study

Constantine J. Karvellas, Filipe S. Cardoso, Malcolm M. Wells, Fayaz A. Handoo, Lukasz Kwapisz, Mansour G. Alghanem, Norman Kneteman, Paul Marotta, Bandar Al-Judaibi

523: Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity

Kaldoun Ghazal, Fabien Stenard, Clement Barjon, Lynda Aoudjehane, Fabiano Perdigao, Olivier Scatton, Yvon Calmus, Filomena Conti

524: Cardiovascular Risk in Liver Transplant Patients

Tommaso Di Maira, Lorena Puchades, Angel Rubin, Carmen Vinaixa, María García Eliz, Fernando San Juan, Rafael López Andujar, Erica Villa, Martin Prieto, Marina Berenguer

525: Long-Term Transplant Outcomes: The Role of PreTransplant Depression

Shari S. Rogal, Gautam Mankaney, Viyan Udawatta, Christopher B. Hughes, Amit D. Tevar, Mark Sturdevant, Abhinav Humar, Andrea DiMartini

526: C4d is Present in Portal Venules in Plasma Cell Hepatitis and May Also be Used as a Predictor for its Development

Anshu Trivedi, Thomas D. Schiano, Stephen C. Ward, Swan N. Thung, M. Isabel Fiel, Josh Levitsky Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


Guillaume Lassailly, Franck Saint-Marcoux, Juliette Boulanger, Valerie Canva, Philippe Mathurin, Alexandre Louvet, Odile Goria, Stephanie Truant, Gilles Lebuffe, Emmanuel Boleslawski, François René Pruvot, Sebastien Dharancy

518: A Single-Center Experience with Preoperative Selective Internal Radiation Therapy (SIRT) with Y-90 with or without Transarterial Chemoembolization (TACE), as a Bridging Procedure, in Liver Transplant Recipients (OLT) with Unresectable Hepatocellular Carcinoma (uHCC): Efficacy of Combination Therapy (Rx)



HEPATOLOGY, October, 2014

Poster Sessions 527: Probiotic decreases post-liver transplant infection: A meta analysis

Tarek Sawas, Shadi Al Halabi, Mubarak W. Sayyar, Won Kyoo Cho

528: Should Patients Check (WWW.SRTR.ORG) Before They Get a Liver Transplant? Bashar M. Attar, David Van Thiel

529: Liver allograft provides immunoprotection for the cardiac allograft in combined heart-liver transplantation

Tina W. Wong, John M. Stulak, Mark D. Stegall, Julie Heimbach, Timucin Taner

530: Everolimus with early withdrawal or reduced dose Calcineurin-Inhibitors (CNI) improves renal function in Liver Transplant (LT) Recipients: A Meta analysis Frahad Sahebjam, Sahil Mittal, Gagan K. Sood

531: Portal vein thrombosis is a risk factor for early mortality and graft loss post liver transplantation: Analysis of the UNOS database.

Marwan Ghabril, Saurabh Agrawal, Marco A. Lacerda, Eric S. Orman, Raj Vuppalanchi, Craig Lammert, Howard C. Masuoka, Samer Gawrieh, Suthat Liangpunsakul, Naga P. Chalasani, A. Joseph Tector, Paul Y. Kwo

532: The association between early anemia and the development of renal insuffiency after liver transplantation


Dilip Moonka, Wadih Chacra, Mohammad Elbatta, Aishwarya Kuchipudi, Alexander Weick, Charlotte Burmeister, George Divine

533: Impact of mTOR inhibition on expression of immune regulatory molecules by circulating dendritic cells and regulatory T cells in stable liver transplant patients

Antonino Castellaneta, Antonio Massaro, Maria Rendina, Francesca D’Errico, Sonia Carparelli, Angus W. Thomson, Alfredo Di Leo

534: Abusive drinking after liver transplantation for pure alcoholic cirrhosis is associated with significant allograft fibrosis

Marika Rudler, Géraldine Rousseau, Pascal Lebray, Corinne Vezinet, Daniel Eyraud, Jean-Christophe Vaillant, Thierry Poynard, Dominique Thabut

535: Early evaluation of regulatory T cells to predict severity of HCV recurrence after liver transplantation

Kaldoun Ghazal, Morales Olivier, Clement Barjon, Geraldine Dahlqvist, Lynda Aoudjehane, Laurissa Ouaguia, Yvon Calmus, Delhem Nadira, Filomena Conti

536: Predictors of Delirium after Liver Transplantation and its Relationship to Outcomes

Koki Yamada, Max Marquez, Khalid Mumtaz, Eberhard L. Renner

537: Bacterial antigen translocation persists after liver transplantation in peripheral blood of patients with decompensated cirrhosis

Gonzalo Rodriguez-Laiz, Pedro Zapater, Paola Melgar, Mariano Franco, Cándido Alcázar, Sonia Pascual, Pablo Bellot, Jose María Palazón, Jose Such, Félix Lluis, Ruben Frances

538: Early Liver Transplantation in Severe Alcoholic Hepatitis: the U.S. Experience

Brian P. Lee, David W. Victor, R. Mark Ghobrial, Mary E. Rinella, Zhiping Li

539: Deleterious Effect of Body Mass Index and Prior Abdominal Surgery on Liver Transplant Complications

Angel Alsina, Jian Zheng, Alexia M. Makris, Jason Shim, Edson S. Franco, Chris Albers, Nyingi M. Kemmer

540: Primary Non Function after liver transplant in children in the PELD era: Analysis of UNOS database

Jaime Chu, Rachel A. Annunziato, Christie DiPietrantonio, Ailie M. Posillico, Ronen Arnon

541: Pro-Atherogenic Lipoproteins And Metabolic Biomakers Drive Serum Cardiovascular Risk In Liver Transplant Recipients

Ravi Chhatrala, Mohammad B. Siddiqui, R. Todd Stravitz, Carolyn Driscoll, Arun J. Sanyal, Robert A. Fisher, Carol Sargeant, Fareed R. Riyaz, Velimir A. Luketic, Scott Matherly, Richard K. Sterling, Puneet Puri, Mohammad S. Siddiqui

542: Coronary artery calcium score in evaluating cardiovascular risk 1 and 4 years after liver transplant

Livia M. Linhares, Mario R. Alvares-da-Silva, Claudia P. Oliveira, José Tadeu Stefano, Eloisa M. Gebrim, Flair J. Carrilho, Luiz C. D`Albuquerque

543: Control of Diabetes Mellitus in Liver Transplant Recipients:a multicentric spanish study

Beatriz Rodríguez-Medina, Diego Alvarez de Sotomayor, Carla Satorres, Jose Ignacio Herrero, Trinidad Serrano, Manuel De la Mata, Carmen Vinaixa, Victoria Aguilera, Angel Rubin, Martin Prieto, Marina Berenguer

544: Non-coronary causes account for the majority of early major adverse cardiac events after liver transplantation

Lisa B. VanWagner, Bing Bing Weitner, Tanvi Subramanian, Sarah Uttal, Alfred W. Rademaker, Josh Levitsky, Donald M. LloydJones, Anton I. Skaro

545: Sphincter of Oddi Dysfunction after Liver Transplantation: Experience in a High Volume Transplant Center

Alejandro Fernandez Simon, Diego S. Royg, Oriol Sendino, Claudio Zulli, Cristina Rodriguez de Miguel, Domingo Balderramo, Gonzalo Crespo, Jordi Colmenero, Josep Llach, Miquel Navasa, Andres Cardenas

546: Hyperhomocysteinemia is Associated with Reduced Survival after Liver Transplantation

Rahima A. Bhanji, Mang M. Ma, Aldo J. Montano-Loza

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 547: Use of mTOR inhibitor is associated with increased frequency of late anastomotic biliary strictures and need for repeat ERCP in Orthotopic liver transplant recipients.

558: Evolving renal function in the post-operative period correlates with over all graft survival following liver transplantation

548: Sexual Functioning in Patients With End-Stage Liver Disease Before and After Liver Transplantation (LT)

559: Listing practices for Morbidly Obese Patients at Liver Transplant Centers in the United States

Cheri Ogwo, Satheesh Nair, Jason M. Vanatta, James Eason, Sanjaya K. Satapathy

Beatriz Rodríguez-Medina, Diego Alvarez de Sotomayor, Carla Satorres, Agustin Ramos-Prol, Carmen Vinaixa, Angel Rubin, María García Eliz, Victoria Aguilera, Martin Prieto, Marina Berenguer

549: Adherence to Immunosuppressive therapy in Adult and Adolescent Liver Transplant Recipients in a MultiEthnic Asian Centre: A Questionnaire Survey

Kieron B. Lim, Juanda Leo Hartono, Yock Young Dan, Maung Aye Thwin, Poh Seng Tan, Charlene Soon, Alfred W. Kow, Krishnakumar Madhavan, Seng Gee Lim

550: Orthotopic liver transplantation for hepatocellular carcinoma after successful downstaging: results from the Belgian multicentre cohort

Jonas Schreiber, Jan P. Lerut, Chris Verslype, Hans Van Vlierberghe, Valerio Lucidi, Olivier Detry, Luisa Vonghia, Francesco Puleo, Eric Trépo, Milton E. Inostroza, Hélène Poels, Roberto Troisi, Jean Delwaide, Sven M. Francque, Vincent Donckier, Christophe Moreno

551: Outcomes for Patients with Decompensated Cirrhosis Transferred from Outlying Hospitals to a Tertiary Care Liver Transplant Center

552: MELD score does not impact the outcomes of simultaneous liver and kidney transplantation

Mohsen Hasanin, Siddharth Bansal, Yong-Fang Kuo, Ashwani K. Singal, Russell H. Wiesner

553: WITHDRAWN 554: Diabetes Mellitus is associated with Lower Survival following Simultaneous Liver Kidney Transplantation

Ryan B. Perumpail, Robert Wong, Andrew M. Su, Jane Tan, John Scandling, Aijaz Ahmed

555: Histological correlates of ERCP confirmed biliary anastomotic strictures

Fazal Yahya, Pamela B. Sylvestre, Saradasri Karri, Satheesh Nair, Jason Vanatta, James Eason, Sanjaya K. Satapathy

556: Pre-operative renal failure predicts reduced survival following liver transplantation but not liver specific graft failure or death

Francis P. Robertson, Pulathis Siriwardana, Paul R. Bessell, Rafael Diaz-Nieto, Nancy Rolando, Brian R. Davidson

557: Long term outcomes of patients with new portal vein thrombosis occurring after liver transplantation

Dina Halegoua-De Marzio, She-Yan Wong, Jonathan M. Fenkel, Cataldo Doria, David A. Sass

560: Racial/Ethnic Disparities in Simultaneous Liver Kidney Transplantation: An Analysis from the UNOS Database

Ryan B. Perumpail, Robert Wong, Andrew M. Su, Robert Isom, John Scandling, Aijaz Ahmed

561: The mTOR inhibitor everolimus is safe within the first month after liver transplantation

Indhira Perez Medrano, Manuel Rodríguez-Perálvarez, Marta Guerrero Misas, Mercedes Muñoz Nuñez, Víctor M. González Cosano, María Muñoz Garcia-Borruel, Antonio Poyato, Pilar Barrera Baena, Enrique Fraga Rivas, Gustavo Ferrín, Guadalupe Costan Rodero, Juan Carlos Pozo Laderas, Marina Sánchez Frías, Ruben Ciria, Javier Briceño, Jose Luis Montero, Manuel De la Mata

562: Magnetic Resonance Cholangiopancreatography is Significantly Superior to Ultrasound in the Diagnosis of Biliary Anastomotic Strictures After Liver Transplantation Anoop Prabhu, James Park, Jawad Ahmad

563: Primary Sclerosing Cholangitis is a Risk Factor for Developing Intra-abdominal Thrombosis Following Liver Transplantation

Paul Reynolds, Elnaz Jafarimehr, Xiao Jing Wang, Ram M. Subramanian

564: Prevalence and risk factors of metabolic syndrome after liver transplantation: a single centre experience

Veronica Pepe, Giacomo Germani, Alberto Ferrarese, Alberto Zanetto, Ilaria Bortoluzzi, Elena Nadal, Francesco P. Russo, Marco Senzolo, Enrico Gringeri, Umberto Cillo, Patrizia Burra

565: 20 year followup of liver transplantation for HCV+ patients. Rustgi V, Landsittel D, Humar A, Hughes C, Malik S, Behari J, Jazwinski A, Chopra K. The Thomas Starzl Transplant Institute, Univ of Pittsburgh

Vinod K. Rustgi, Doug Landsittel, Abhinav Humar, Christopher B. Hughes, Shahid M. Malik, Jaideep Behari, Alison Jazwinski, Kapil B. Chopra

566: Serum aspartate transaminase levels on the third post-operative day correlate with overall survival and liver specific survival at 10 years following liver transplantation

Francis P. Robertson, Paul R. Bessell, Rafael Diaz-Nieto, Nancy Rolando, Brian R. Davidson

Scott Duncan, Laxmi B. Parsa, Nader Dbouk

Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


Chad Cornish, Michael Winter, Thomas D. Rodgers, Gopal A. Ramaraju, Benedict Maliakkal, Jonathan Huang

Francis P. Robertson, Pulathis Siriwardana, Paul R. Bessell, Rafael Diaz-Nieto, Nancy Rolando, Brian R. Davidson



HEPATOLOGY, October, 2014

Poster Sessions 567: Clinical impact of cholestasis after liver transplantation: a retrospective cohort study

Constantine J. Karvellas, Filipe S. Cardoso, Andrew Mason, Norman M. Kneteman, Glenda Meeberg, Aldo J. Montano-Loza

568: Analytic Morphomics Identifies Predictors of NewOnset Diabetes After Transplantation

Valerie Vaughn-Sandler, David C. Cron, Michael Terjimanian, Zachary Gala, Stewart C. Wang, Grace L. Su, Michael Volk

569: Everolimus treatment start POD 1 in combination with low dose CNI is safe and effective post liver transplantation

Martina Sterneck, Antonio Galante, Gesa Pamperin, Martina Koch, Jun Li, Lutz Fischer, Bjoern Nashan

570: Non-adherence related mortality in adolescents and young people after Liver transplantation

Marianne Samyn, Nigel Heaton, Michael A. Heneghan, Anil Dhawan

571: Model to Predict Long-term Survival after Liver Transplantation

Giuliano Testa, Giovanna Saracino, James F. Trotter, Greg J. McKenna, Richard Ruiz, Nicholas Onaca, Tiffany Anthony, Peter T. Kim, Marlon F. Levy, Robert M. Goldstein, Goran Klintmalm


572: Combined Heart and Liver Transplantation: Analysis of a Single-Center Experience

Abimbola Aderinto, Maha R. Boktour, Mina Elnemr, Andrea M. Cordero-Reyes, Jerry Estep, Sherilyn Gordon Burroughs, Ashish Saharia, Barry Trachtenberg, Arvind Bhimaraj, Rafik M. Ghobrial, Howard P. Monsour

Infections and Acute on Chronic Liver Failure 573: Clinical and prognostic relevance of albumin dimers in patients with cirrhosis: a novel identified structural alteration of the molecule

Maurizio Baldassarre, Marco Domenicali, Ferdinando A. Giannone, Marina Naldi, Maristella Laggetta, Daniela Patrono, Carlo Bertucci, Mauro Bernardi, Paolo Caraceni

574: The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis: results of a randomized controlled clinical trial

Salvatore Piano, Freddy Salinas, Filippo Morando, Marta Cavallin, Antonietta Romano, Silvia Rosi, Marialuisa Stanco, Silvano Fasolato, Antonietta Sticca, Marco Senzolo, Patrizia Burra, Enrico Gringeri, Umberto Cillo, Angelo Gatta, Paolo Angeli

575: Determinants and prognostic significance of bacterial infections occurring in patients with HBV- or HCV-related compensated cirrhosis. A multicenter prospective cohort study in 1672 patients (ANRS CO12 CirVir)

Pierre Nahon, Valérie Bourcier, Richard Layese, Nabila Talmat, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique G. Larrey, Victor de Ledinghen, Denis Ouzan, Fabien Zoulim, Jean Claude Trinchet, Françoise Roudot-Thoraval

576: The detection of bacterial DNA by in situ hybridization method may prove the evidence of bacterial translocation in patients with decompensated liver cirrhosis

Shingo Usui, Hirotoshi Ebinuma, Po-sung Chu, Nobuhito Taniki, Yuko Wakayama, Nobuhiro Nakamoto, Yoshiyuki Yamagishi, Kazuo Sugiyama, Hidetsugu Saito, Takanori Kanai

577: ‘Eastern type’ of Acute-on-chronic Liver Failure (ACLF) is similar in pathophysiologic, diagnostic and prognostic criteria to the ‘Western type’: A comparison of Chinese hospitalized patients with Hepatitis B with CANONIC data

Hai Li, Marco Pavesi, Bo Zeng, Liu-Ying Chen, Shu-Ting Li, De-Kai Qiu, Richard Moreau, Pere Gines, Vicente Arroyo, Rajiv Jalan

578: Utility Of A Modified PIRO (Predisposition, Injury, Response, Organ Failure) Model For Predicting Kidney Failure In Patients With ACLF- A Multinational Cohort Study

Rakhi Maiwall, Shiv K. Sarin, Chandan K. Kedarisetty, Richard Moreau, Suman Kumar, Zaigham Abbas, Deepak N. Amarapurkar, Ankit Bhardwaj, Ajeet S. Bhadoria, Chhagan Bihari, Amna S. Butt, Chan Albert, Yogesh K. Chawla, Abdulkadir Dokmeci, Hasmik Ghazinyan, Saeed S. Hamid, Cho Mong, George K. Lau, Guan Huei Lee, Laurentius A. Lesmana, Mamun A. Mahtab, Qin Ning, Viniyendra Pamecha, Diana A. Payawal, Archana Rastogi, Salimur Rahman, Mohamed Rela, Amrish Sahney, Vivek A. Saraswat, Samir R. Shah, Gamal Shiha, Barjesh C. Sharma, Manoj Kumar, Soek Siam Tan, Chitranshu Vashishtha, Ashok Choudhary, Man Fung Yuen, Osamu Yokosuka

579: Gene-specific control of inflammation during lipopolysaccharide tolerance is altered in immune cells from patients with advanced cirrhosis

Mikhael Giabicani, Emmanuel Weiss, Pierre-Emmanuel Rautou, Magali Fasseu, Catherine Paugam-Burtz, Dominique Valla, Francois Durand, Sophie Lotersztajn, Richard Moreau

580: Systemic Inflammatory Response Syndrome (SIRS) - a potential clinical marker for early sepsis and survival in Acute on chronic liver failure (ACLF)

Ashok K. Choudhury, Chitranshu Vashishtha, Chandan K. Kedarisetty, Shiv K. Sarin

581: Genetic polymorphism of mannose binding lectin 2: a potential new risk factor for spontaneous bacterial peritonitis in cirrhotic patients

Cornelius Engelmann, Janett Fischer, Sandra Krohn, Adam Herber, Albrecht Boehlig, Danilo Deichsel, Stephan Boehm, Thomas Berg

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 582: Overexpression Of The Genetic Effector Pathway Of Inflammasome In Peripheral Blood Mononucleated Cells (Pbmc) Of Patients With Acute On Chronic Liver Failure

Elisabetta Gola, Alessandra Brocca, Salvatore Piano, Antonietta Sticca, Filippo Morando, Silvia Rosi, Marta Cavallin, Marialuisa Stanco, Antonietta Romano, Silvano Fasolato, Angelo Gatta, Paolo Angeli

583: CD64 Expression may be a Promising Marker for Early Diagnosis of Sepsis in Hospitalized Patients with Cirrhosis

Sakkarin Chirapongsathorn, Jody C. Olson, Stacy C. League, Siddharth Singh, Sarah Jenkins, Roshini Abraham, Patrick Kamath

584: Improving survival for patients with cirrhosis admitted to United Kingdom critical care units

Mark J. McPhail, Francesca Parrott, Julia Wendon, David A. Harrison, Kathy M. Rowan, William Bernal

585: The Economic Burden and Mortality of Patients with Acute on Chronic Liver Failure (ACLF) in the United States

Alina M. Allen, W. Ray Kim, James P. Moriarty, Nilay Shah, Patrick S. Kamath

586: Mortality risk associated with Acute on Chronic Liver Failure varies dependent on inciting event: a NACSELD study

587: The impact of nutritional status on infections in liver cirrhosis

Aung Kaung, Ken D. Nguyen, Amit Rajaram, Phillip Zakowski, Tram T. Tran, Vinay Sundaram

588: Delay in appropriate antimicrobial therapy increases mortality in cirrhotics with spontaneous bacterial peritonitis and septic shock

Constantine J. Karvellas, Juan G. Abraldes, Yaseen Arabi, Anand Kumar

589: Prognostic Value of Procalcitonin in patients with Spontaneous Bacterial Peritonitis: Preliminary Results from a Multicenter Study in Argentina

Sebastian Marciano, Natalia Sobenko, Alfredo Martinez, Manuel Mendizabal, Luis A. Gaite, Federico Piñero, Leila Haddad, Marcelo O. Silva, Ezequiel Ridruejo, Oscar G. Mandó, Diego H. Giunta, Adrian Gadano

590: CLIF-SOFA score and serum sodium are independent predictors of short term survival in decompensated cirrhosis. A prospective study

Vikram Sharma, Junpei Soeda, Jane MacNaughtan, Abeba Habtesion, Pamela Leckie, Nathan Davies, Rajiv Jalan, Rajeshwar Mookerjee

592: Pathophysiological basis of Hepatic Encephalopathy (HE) in patients with Acute-on-chronic liver failure (ACLF): A prospective, longitudinal study determining the role of ammonia, inflammation and cerebral oxygenation

Rohit Sawhney, Peter Holland-Fischer, Rajeshwar Mookerjee, Matteo Rosselli, Banwari Agarwal, Rajiv Jalan

593: Inhibition of MER receptor tyrosine kinase in patients with acute on chronic liver failure: a potential target for immunotherapy?

Christine Bernsmeier, Oltin T. Pop, Evangelos Triantafyllou, Chris J. Weston, Stuart M. Curbishley, Vishal C. Patel, Arjuna Singanayagam, Wafa Khamri, Christopher Willars, William Bernal, Georg Auzinger, Michael A. Heneghan, Yun Ma, Wayel Jassem, Nigel Heaton, David H. Adams, Mark R. Thursz, Alberto Quaglia, Julia Wendon, Charalambos G. Antoniades

594: Acquired Hemophagocytic Lymphohistiocytosis (HLH) mimicking acute hepatic insult presenting as Acute on chronic liver failure (ACLF) is associated with high mortality Ankur Jindal, Ashok Choudhary, Shiv K. Sarin

595: Prognosis of cirrhotic patients admitted in Intensive care Unit: A Meta-analysis

Delphine Weil, Heng-Chih Pan, Eric Levesque, Bertrand Sauneuf, Eleni Theocharidou, Evangelos Cholongitas, Constantine J. Karvellas, René Robert, Arnaud Galbois, Jérôme Fichet, Rodrigo Cavallazzi, Jean Paul Cervoni, Gaël Piton, Thierry Thevenot, Gilles Capellier, Vincent Di Martino

596: Chronic Liver Failure Sequential Organ Failure Assessment (CLIF-SOFA) is better than the Asia-Pacific Association for the Study of Liver (APASL) criteria for defining Acute-on-Chronic Liver Failure (ACLF) and Predicting Outcome

Radha K. Dhiman, Tarana Gupta, Swastik Agrawal, Ajay K. Duseja, Yogesh K. Chawla

597: Copeptin: a marker of circulatory derangement, is independently associated with outcome in patients admitted for acute decompensation of cirrhosis

Hein W. Verspaget, Amorós Àlex, Rajiv Jalan, Daniel Benten, Francois Durand, Johan van der Reijden, Bart Van Hoek, Minneke Coenraad

Gustavo Pereira, Flavia F. Fernandes, Vanessa L. Zenatti, Camila M. Alcântara, Tatiana Valdeolivas, Zulane D. Veiga, Daniela M. Mariz, João Luiz Pereira

Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


Patrick S. Kamath, Jacqueline G. O’Leary, K. Rajender Reddy, Florence Wong, Siddharth Singh, Michael B. Fallon, Guadalupe Garcia-Tsao, Scott W. Biggins, Benedict Maliakkal, Ram M. Subramanian, Heather M. Patton, Leroy Thacker, Jasmohan S. Bajaj

591: Alpha 2a adrenergic receptor antagonism abrogates innate immune dysfunction and hepatic inflammatory cytokine generation in a rodent model of Acute-on-Chronic Liver Failure (AoCLF): Proof of concept for a new target for therapy



HEPATOLOGY, October, 2014

Poster Sessions 598: High enrichment of circulating mononuclear cells with transcripts encoding CXCL neutrophil-attracting chemokines is a predictor of death in patients with decompensated cirrhosis

Emmanuel Weiss, Rakhi Maiwall, Pierre-Emmanuel Rautou, Magali Fasseu, Mikhael Giabicani, Francois Durand, Dominique Valla, Didier Lebrec, Sophie Lotersztajn, Richard Moreau

599: Percutaneous Cholecystostomy (PC) for Acute Cholecystitis (AC) in Advanced Cirrhosis is Associated with High Morbidity and Poor Survival

Caitlin Sullivan, Charles Gabbert, Melissa Saul, Kapil B. Chopra, Adam Slivka, Dhiraj Yadav

600: Epidemiologic trends in mortality of cirrhosis in the intensive care unit: a large, Australasian, multi-centre cohort

Avik Majumdar, Michael J. Bailey, William W. Kemp, Stuart K. Roberts, David Pilcher

601: Bacterial translocation in liver failure: a possible mechanism of impaired innate immune responses and immuneparesis?


Vishal C. Patel, Susanne Knapp, Glory Y. Lai, Christine Bernsmeier, Arjuna Singanayagam, Mark J. McPhail, Christopher Willars, William Bernal, Georg Auzinger, Michael A. Heneghan, Krishna Menon, Wayel Jassem, Parthi Srinivasan, Andreas Prachalias, Hector Vilca-Melendez, Nigel Heaton, Mark R. Thursz, Julia Wendon, Charalambos G. Antoniades

602: Number Needed to reTap: Assessing the Utility of Repeat Diagnostic Paracentesis in Spontaneous Bacterial Peritonitis

Aparna Goel, Mollie A. Biewald, Gopi Patel, Shirish Huprikar, Thomas D. Schiano, Gene Y. Im

603: Prognostic significance of Insulin-like growth factor-1 (IGF-1) serum levels in patients admitted for acute decompensation of cirrhosis

Bruno S. Colombo, Marcelo F. Ronsoni, Pedro E. Soares e Silva, Leonardo Fayad, Letícia M. Wildner, Maria Luiza Bazzo, Esther B. Dantas-Correa, Janaína L. Narciso-Schiavon, Leonardo L. Schiavon

604: Prognostic value of C-reactive protein in patients with cirrhosis: external validation from the CANONIC cohort

Jean Paul Cervoni, Amorós Àlex, Richard Moreau, Vicente Arroyo, Rajiv Jalan, Faouzi Saliba, Francois Durand, Julia Wendon, Thierry Gustot, Paolo Angeli, Pere Gines, Thierry Thevenot, Vincent Di Martino

605: Factors associated with low cardiac T2* MRI in liver transplant (LT) candidates at risk for iron overload

Moises Nevah Rubin, Monika Sarkar, Karen Ordovas, Oren K. Fix, Neil Mehta

Inflammation and Immunobiology: Animal Models 606: Involvement of the TNF and FasL produced by CD11b Kupffer cells/macrophages in CCl4-induced acute hepatic injury

Hiroyuki Nakashima, Atsushi Sato, Masahiro Nakashima, Masami Ikarashi, Kiyoshi Nishiyama, Manabu Kinoshita, Shuhji Seki

607: Acid sphingomyelinase inhibits growth of metastatic liver tumor Yosuke Osawa, Jun Imamura, Kiminori Kimura

608: Dose-limiting toxicity of in vivo TLR7 ligation differs according to the kinetics of systemic and hepatic inflammation after LCMV infection

Thomas Vanwolleghem, Dowty Movita, Martijn D. van de Garde, Florence Herschke, Gregory C. Fanning, Harry L. Janssen, Andre Boonstra

609: Cytotoxic CD4+ Cells Play a Pivotal Role in Cyclophosphamide-Mediated Cytotoxicity against Hepatoma without Antigen Priming

Tatsushi Naito, Tomohisa Baba, Naofumi Mukaida, Yasunari Nakamoto

610: Activation of cellular innate immunity during primary Hepacivirus infection Cordelia Manickam, R. Keith Reeves

611: DSS-induced colitis and simultaneous hepatic inflammation lead to immunological tolerance in the murine liver

Nobuhito Taniki, Nobuhiro Nakamoto, Hirotoshi Ebinuma, Hiroko Murata, Yuko Wakayama, Po-sung Chu, Shingo Usui, Akihiro Yamaguchi, Takeru Amiya, Hidetsugu Saito, Takanori Kanai

612: A novel mouse model of hepatocyte apoptosisinduced sterile liver inflammation and wound healing response

Heng-Fu Bu, Fangyi Liu, Xiao Wang, Pauline M. Chou, Catherine Marek, Ke Tian, Peng Wang, Hua Geng, M. S. Rao, Suhail Akhtar, Monique E. De Paepe, Xiao-Di Tan

613: Administration of antisense oligodeoxynucleotides to nerve growth factor attenuates inflammation and liver damage in acute liver damage models Rafael Bruck, Einav Hubel, Isabel Zvibel

614: High fat diet impairs hepatic microRNAs related to inflammation and macrophage infiltration contributing to nonalcoholic steatohepatitis in a mouse model with metabolic syndrome

Priya Handa, Vicki Morgan-Stevenson, Bryan D. Maliken, Yu Li, James E. Nelson, Matthew M. Yeh, Kris V. Kowdley

615: Murine natural killer cells transiting through the liver demonstrate hyporesponsiveness to activation receptor mediated stimulation Claire Meyer, Sandeep K. Tripathy

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 616: Characterization of the liver:lung axis in alcoholinduced lung damage

Veronica L. Massey, Lauren G. Poole, Edilson Torres-Gonzalez, Robin H. Schmidt, Michael L. Merchant, Keith C. Falkner, Jeffrey D. Ritzenthaler, Jesse Roman, Gavin E. Arteel

617: DSS-induced Chronic Colitis Aggravates Inflammation and Fibrogenesis in Mice with CCl4induced Hepatic Fibrosis Xiaolan Zhang, Yufeng Liu, Guochao Niu, Libo Zheng

Innate Immunity and Adaptive 618: Beta-hydroxybutyrate and niacin protect the murine liver from acute inflammatory injury via activation of the Gpr109 receptor

626: Neutrophil toll-like receptor 9 expression and plasma lactoferrin in acute alcoholic hepatitis and the susceptibility to fungal infection

Jennifer M. Ryan, Godhev K. Manakkat Vijay, (Robin) Daniel Abeles, Thomas Tranah, Laura J. Blackmore, Victoria T. Kronsten, Lee J. Markwick, Antonio Riva, Nikhil Vergis, Nicholas J. Taylor, Shilpa Chokshi, Yun Ma, John G. O’Grady, Debbie Shawcross

627: TLR3/4 Signaling is Mediated via the MyD88-NFκB-CXCR4/7 Pathway in Human Alcoholic Hepatitis and Non Alcoholic Steatohepatitis, Where Mallory-Denk Bodies Form

Samuel W. French, Hui Liu, Barbara A. French, Brittany C. Tillman, Jun Li

Rafaz Hoque, Ahmad Farooq, Fred Gorelick, Wajahat Z. Mehal

628: Liver Injury and Inflammation Leads to Profound Hepatic Natural Killer Cell Dysfunction and Predisposes the Liver to Metastatic Disease

619: Type III interferons, including IFNL4, drive interferon-stimulated gene (ISG) pre-activation and the interferon-refractory state

629: Role of interactions of circulating monocytes in vascular sprouting during liver regeneration in mice

Justin B. Mendel, Aryn Price, Arash Grakoui

Jordan J. Feld, Vera A. Cherepanov, Nicholas Anand, Sonya A. MacParland, Tawnya Hansen, Harry L. Janssen, Matthew Kowgier, Ian McGilvray

Pedro Melgar-Lesmes, Elazer R. Edelman

620: Iron decreases IL-4- mediated STAT6 phosphorylation, Arginase-1 production and M2 activation, while increasing NF-KB phosphorylation, INOS protein levels and M1 activation in primary murine macrophages

Kentaro Tominaga, Toru Setsu, Satoshi Yamagiwa, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Masaaki Takamura, Minoru Nomoto

621: Role of NADPH oxidase 4 in hepatic inflammation and TGFβ response mediated by Toll-like receptor 4

Svenja Hardtke, Julia Hengst, Katja Deterding, Michael P. Manns, Falk S. Christine, Markus Cornberg, Heiner Wedemeyer, Verena Schlaphoff

Priya Handa, Vicki Morgan-Stevenson, Kris V. Kowdley

622: MicroRNA-155 deficiency attenuates chronic alcohol induced hepatic and intestinal inflammation in mice

Shashi Bala, Dora Lippai, Timea Csak, James V. Zatsiorsky, Donna Catalano, Karen Kodys, Gyongyi Szabo

623: Human Mucosal Associated Invariant T cells express high levels of MDR-1 and maintain innate effector function following exposure to immunosuppressive MDR-1 substrates Joannah R. Fergusson, Lucy J. Walker, Paul Klenerman

624: Circulating monocytes from chronic HCV-infected patients display a pro-fibrotic phenotype mediated by IL-1β and correlates with liver fibrosis Banishree Saha, Karen Kodys, Gyongyi Szabo

625: Glycine minimizes hepatic innate immune responses and autoimmunity caused by doublestranded RNA

Akira Uchiyama, Kenichi Ikejima, Kumiko Arai, Kazuyoshi Kon, Kyoko Fukuhara, Tomonori Aoyama, Shunhei Yamashina, Sumio Watanabe Poster Viewing: 2:00 – 7:30 PM

631: Large scale biomarker profiling reveals distinct cytokine and chemokine signatures distinguishing different acute and chronic hepatitis virus infections

632: Functional features of antigen-specific T-cell receptors reflected clinical responses of α-fetoproteinderived peptides vaccine treatment for advanced hepatocellular carcinoma

Hidetoshi Nakagawa, Eishiro Mizukoshi, Eiji Kobayashi, Takeshi Terashima, Masaaki Kitahara, Noriho Iida, Hiroyuki Kishi, Atsushi Muraguchi, Shuichi Kaneko

633: Immunomodulatory Effects of OK432-Stimulated Monocyte-Derived Dendritic Cell Injection into Hepatocellular Carcinoma after Radiofrequency Ablation

Masaaki Kitahara, Eishiro Mizukoshi, Hidetoshi Nakagawa, Noriho Iida, Hajime Sunagozaka, Kuniaki Arai, Tatsuya Yamashita, Shuichi Kaneko

634: Identification of a Novel HLA-A2 Restricted Immunotherapeutic Target Derived from an EGFR Mutated Antigen for the Treatment of Metastatic Liver Tumors

Kazuya Ofuji, Toshiaki Yoshikawa, Yoshitaka Tada, Manami Shimomura, Yasunari Nakamoto, Tetsuya Nakatsura

Presenters in Attendance 5:30 – 7:00 PM


Bhargav Koduru, Rui-Ming Liu, Nicole L. Corder, Katrin Schroder, Ralf P. Brandes, Jinah Choi

630: Distinctive phenotypic features of human mucosalassociated invariant T cells in the liver



HEPATOLOGY, October, 2014

Poster Sessions 635: The dynamic changes of Th1/Th2/Th17 cytokines in serum of patients with acute-on-chronic liver failure

645: Impact of Donor Minimal Histological Changes on the Outcome of Living Donor Liver Transplantation

636: Regulation of hepatic inflammation by the macrophage-expressed, sulfated steroid transporter, Slc10a6

646: Surgical and Percutaneous Ablation are Both Safe and Effective in Patients with Small Hepatocellular Carcinoma

Li Jin, Yingli He, Dan Du, Yuanyuan Li, Ruitian Yi, Jing Wang, Tianyan Chen, Yingren Zhao

Astrid Kosters, Demesew Abebe, Julio Felix, Saul J. Karpen

Living Donors and Split Transplant 637: Living donor liver transplantation in high model for end-stage liver disease score

Murat Dayangac, Murat Akyildiz, Yalcin Erdogan, Gokhan Gungor, Yaman Tokat

638: Priming hepatocytes to G2 enhances liver regeneration in elderly mice

Fatima K. Rehman, Toshiyuki Hata, Zhaoyu Li, Guojun Bu, Justin H. Nguyen

639: Cadaveric versus Living donor Liver Transplant Survival in Relation to MELD Score

Mohammed Al Sebayel, Almoutaz Hahim, Faisal A. Abaalkhail, Hussien Elsiesy, Hamad M. Al-bahili, Saleh Alabbad, Mohamed Shoukri, Markus U. Boehnert, Dieter C. Broering


640: Hepatocellular Carcinoma is associated with Lower Survival following Living Donor Liver Transplantation in the U.S

Ryan B. Perumpail, Robert Wong, Andrew M. Su, Clark A. Bonham, Carlos O. Esquivel, Aijaz Ahmed

641: Effect of Fully Laparoscopic Left Hepatectomy on Donor Interest in Living Donor Liver Transplantation (LDLT)

Anna Yegiants, Darby Santamour, Tarek Mansour, Joseph F. Pisa, Jean C. Emond, Benjamin Samstein

642: “Patient positioning” in living liver donors – reinventing the wheel each time

Daniela Ladner, Robert A. Fisher, James V. Guarrera, Elizabeth A. Pomfret, Mary Ann Simpson, Donna Woods

643: Liver regeneration after right lobe donor hepatectomy: serial changes of HGF, TNF α, IL6, Interferon α, Interferon γ, TGF β1 and Thrombopoietine

Shridhar Sasturkar, Shreya Sharma, Paul David, Shiv K. Sarin, Nirupma Trehanpati, Viniyendra Pamecha

644: Donor Safety in Live Left-Lobe Liver Donation

Roger Patron-Lozano, Manuel Rodriguez Davalos, James E. Tooley, Armando Salim Munoz-Abraham, Peter S. Yoo, Brett E. Fortune, Stephen M. Luczycki, Michael L. Schilsky, David C. Mulligan, Sukru Emre

Denotes AASLD Presidential Poster of Distinction

Naglaa A. Allam, Wael Abdel-Razek, Nermine Ehsan, Asmaa Gomaa, Deena El-Azab, Imam Waked

Jonathan M. Schwartz, Corbett Shelton, Aws Aljanabi, Mustafa A. Alani, Dina Ginzberg, Akiva J. Marcus, Javier ChapochnickFriedmann, Sarah Bellemare, Yosef Golowa, Jacob Cynamon, Andreas Kaubisch, Nitin Ohri, Milan Kinkhabwala

647: Role of Portocaval Shunt for Patients with Glycogen Storage Disease Type I in the Era of Liver Transplantation : Reappraisal of Portocaval Shunt for Growth

YoungRok Choi, Nam-Joon Yi, Suk-won Suh, Jeong-moo Lee, Hyeyoung Kim, Hae Won Lee, Kwang-Woong Lee, Kyung-Suk Suh

648: Success of meso-Rex bypass in the management of extrahepatic portal vein obstruction in children

Andrew Wehrman, Nadia Ovchinsky, Adam Griesemer, Steven J. Lobritto, Mercedes Martinez, Tomoaki Kato, Jean C. Emond

649: PET/CT Positivity Has Lower Survival in Adult Living Donor Liver Transplantation for Hepatocellular Carcinoma

Murat Akyildiz, Arzu Oezcelik, Gokhan Gungor, Nergis Ekmen, Necdet Guler, Onur Yaprak, Yalcin Erdogan, Gulen B. Dogusoy, Murat Dayangac, Yildiray Yuzer, Yaman Tokat

650: Adult Living Donor Liver Transplantation From Donors with Gilbert’s Syndrome: is it Safe?

Murat Akyildiz, Gokhan Gungor, Necdet Guler, Arzu Oezcelik, Tonguc Utku Yilmaz, Onur Yaprak, Yalcin Erdogan, Murat Dayangac, Yildiray Yuzer, Yaman Tokat

651: Laparoscopic Liver Resection in the Pediatric Population: A Single Center Case Series

Ashley Walther, Shrawan Gaitonde, Greg Tiao, Maria H. Alonso, Jaimie D. Nathan

652: Novel colonoscopy preparation of organic coconut water with Miralax and Dulcolax in split doses for decompensated cirrhotics. A randomized double blinded open labelled clinical pilot single centered observational study. COSMIC Study

Patrick Basu, Niraj J. Shah, David Lee, M. Aloysius, Frank G. Gress

653: The technical success rate and clinical efficacy of Hepatic Vein Stenting of Hepatic Vein Outflow Stenosis complicating Orthotropic Liver Transplant

Faiz Francis, Thomas Lowe, Matthew Johnson, David Agarwal, Daniel E. Wertman, Sabah Butty, Thomas Casciani




Poster Sessions Mechanisms of Injury 654: Elevated plasma DNA in patients with NASH and reduced liver injury in mice with absence of TLR9 on Kupffer cells

Irma Garcia-Martinez, Xinshou Ouyang, Nicola Santoro, Mark J. Shlomchik, Wajahat Z. Mehal

655: Thalidomide Pretreatment Improves Cell Engraftment and Liver Repopulation Independently of Chemokines/Cytokines/Receptors Expressed after Neutrophil or Kupffer cell Activation

Preeti Viswanathan, Sorabh Kapoor, Brigid Joseph, Ekaterine Berishvili, Sanjeev Gupta

656: Low dose digoxin protects from NASH and alcoholic hepatitis in mice by inhibiting a ROS-HIF-1αinflammasome pathway

Xinshou Ouyang, Ji-Yuan Zhang, Dechun Feng, Shi-Ying Cai, Irma Garcia-Martinez, Fu-Sheng Wang, Bin Gao, Wajahat Z. Mehal

657: A distinct role for the TLR9 pathway in immune activation and tolerance during acute liver injury in mice

Nobuhiro Nakamoto, Hirotoshi Ebinuma, Nobuhito Taniki, Yuko Wakayama, Po-sung Chu, Akihiro Yamaguchi, Takeru Amiya, Hidetsugu Saito, Takanori Kanai

658: Sonic hedgehog in microparticles from apoptotic T cells modulate vascular endothelial function via a rhokinase pathway

Samantha A. Canipe, Nicole Feilen, Didier Dréau, Mark G. Clemens

Priya Handa, Vicki Morgan-Stevenson, Bryan D. Maliken, James E. Nelson, Matthew M. Yeh, Kris V. Kowdley

660: NLRP3 inflammasome driven liver injury and fibrosis: roles of IL- 17 and TNF-alpha

Alexander Wree, Matthew D. McGeough, Maria E. Inzaugarat, Carla A. Pena, Alejandra Cherñavsky, Hal M. Hoffman, Ariel E. Feldstein

661: PAD4-mediated neutrophil extracellular trap formation increases liver ischemia/reperfusion injury in mice Samer Tohme, Hai Huang, Allan Tsung

662: Visceral Adipose Levels of mRNA Encoding GATA3 and FOXP3 Transcription Factors and CSF1 Marker of Macrophage Infiltration Negatively Correlate with Histologically Assessed Inflammatory Scores in Liver Biopsies

Yoseph Shaaltiel, Yehudit Shabat, Ami Ben Ya’acov, Sveta GingisVelitski, Einat Almon, David Aviezer, Yaron Ilan

664: Liver lymphocytes from NLG4-/- (KO) mice showed chronic oxidative stress with reduced respiratory burst response

Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi

665: Warm ischemia and reperfusion causes liver microcirculatory injury and acute endothelial dysfunction. Simvastatin prevents these deleterious events

Diana Hide, Marti Ortega-Ribera, Sergi Vila, Carmen Peralta, Juan Carlos Garcia-Pagan, Jaime Bosch, Jordi Gracia-Sancho

Metabolic and Genetic Diseases 666: Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis: a retrospective, multi-institutional study

Kasper S. Wang, Benjamin L. Shneider, Colleen G. Azen, Ronen Arnon, Lee M. Bass, Molly A. Bozic, Mary L. Brandt, Matthew S. Clifton, Patrick A. Dillon, Annie Fecteau, Paula M. Hertel, Shinjiro Hirose, Kishore Iyer, Binita M. Kamath, Saul J. Karpen, Frederick M. Karrer, Nanda Kerkar, Kathleen M. Loomes, Cara Mack, Peter Mattei, Alexander G. Miethke, Douglas Mogul, Philip Rosenthal, Kyle A. Soltys, Riccardo Superina, Dylan Stewart, Greg Tiao, Yumirle P. Turmelle, Karen West

667: Oxidative Stress Caused by Nocturnal Hypoxia is Related to the Severity of Pediatric Non-Alcoholic Fatty Liver Disease

Shikha Sundaram, Ann C. Halbower, Zhaoxing Pan, Kristen N. Robbins, Kelley E. Capocelli, Jelena Klawitter, Ronald J. Sokol

668: Monitoring of bile acid urine profile with Liquid Chromatography-Tandem Mass Spectrography (LC-MS/ MS) allows achievement and maintenance of metabolic control with minimal doses of chenodeoxycholic acid in patients affected by 3β-hydroxy-Δ5-C27-steroid dehydrogenase/isomerase deficiency

Giorgia Curia, Paola Gaio, Francesca Parata, Giuseppe Giordano, Graziella Guariso, Mara Cananzi

669: Predictive factors of response to non-transplant treatment strategies in progressive familial intrahepatic cholestasis type II

Sharat Varma, Xavier Stephenne, Nicole Revencu, Isabelle Scheers, Raymond Reding, Françoise Smets, Etienne M. Sokal

Maria Keaton, Katherine Doyle, Lei Wang, Zahra Younoszai, Rohini Mehta, Zachary D. Goodman, Aybike Birerdinc, Ancha Baranova, Zobair Younossi

Poster Viewing: 2:00 – 7:30 PM

Presenters in Attendance 5:30 – 7:00 PM


659: Chronic dietary iron overload in genetically obese mice causes nonalcoholic steatosis, whereas acute iron excess leads to increased inflammation and reduced steatosis

663: A novel method for anti-TNF based-oral immunotherapy: Oral administration of a plant cellexpressed recombinant anti-TNF fusion protein for treating of fatty liver disease



HEPATOLOGY, October, 2014

Poster Sessions 670: Phase I/II clinical trial of Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC, hepastem) in urea cycle disorders (UCD) and Crigler-Najjar syndrome (CN): six months follow-up results

Etienne M. Sokal, Patrick J. McKiernan, Emmanuel Jacquemin, Giuliano Torre, Pierre Broue, Francois Eyskens, Dries Dobbelaere, Carlo Dionisi-vici, Paul Gissen, Philippe Clapuyt, Daniele Pariente, Marc Yudkoff, Doreen Dekker, Joelle J. Thonnard, Beatrice A. De Vos, Françoise Smets

671: Post-Developmental Genetic Screening for Zebrafish Models of Inherited Liver Diseases Seok-Hyung Kim, Simon Wu, Josh Gamse, Kevin Ess

672: Genetic, clinical, and histopathologic features of intermediate tight junction protein 2 deficiency Melissa Sambrotta, A. S. Knisely, Richard J. Thompson

673: The Burden of Pruritus on Patients with Alagille Syndrome: Results from a Qualitative Study with Pediatric Patients and their Caregivers

Linda Abetz-Webb, Ciara Kennedy, Bonnie Hepburn, Martha Gauthier, Nathan Johnson, Sharon Medendorp, Alejandro Dorenbaum, Benjamin L. Shneider, Binita M. Kamath

674: A Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients


Nirav K. Desai, Sarah Harney, Roshan Raza, Paul D. Mitchell, Maureen M. Jonas

675: Hepatic mast cell infiltration is associated with progression of congenital hepatic fibrosis in the PCK rat

Pingping Fang, James Weemhoff, Seth Septer, Briana Holt, Udayan Apte, Michele Pritchard

676: Silent progression of liver disease and development of cirrhosis in children several years after cranial tumor resection

Anita K. Pai, Shengmei Zhou, Mark Krieger, Sophoclis Alexopoulos, Yuri Genyk, Nanda Kerkar

677: Serial Enhanced Liver Fibrosis Test (ELF) to monitor disease progression in Pediatric Non-Alcoholic Fatty Liver Disease Jeremy K. Rajanayagam, Andrew W. Lee, Patrick J. McKiernan

Viral and Autoimmune Hepatitis 678: Predicting future outcome in infancy-acquired chronic hepatitis B – importance of quantitative HBeAg and HBsAg plasma levels, HBV DNA viral load and IP10 plasma levels

Mary Horner, Matthew J. Bruce, Sanjay Bansal, Sarah Tizzard, Diego Vergani, Phillip M. Harrison, Kosh Agarwal, Giorgina MieliVergani, Ivana Carey

Denotes AASLD Presidential Poster of Distinction

679: Association Between Hepatitis C Virus Infection with Insulin Resistance and Total Cholesterol Levels in Children and Youth

Aymin Delgado-Borrego, Roshan Raza, Michelle Godbee, Andrea Barreto, Elsa Yumar, Betania Negre, David A. Ludwig, Maureen M. Jonas, Raymond Chung

680: Differences in clinical characteristics of children with chronic hepatitis B (CHB) by adoption status: findings from the Hepatitis B Research Network (HBRN)

Simon C. Ling, Yona K. Cloonan, Philip Rosenthal, G. Johnson, Karen F. Murray, Sarah J. Schwarzenberg, Norberto RodriguezBaez, Jeffrey Teckman, Kathleen B. Schwarz

681: APRI, FIB-4 and Fibroscan in Prediction of Significant Fibrosis in Adolescent Cancer Survivors in a Resource Limited Country

Manal H. El-Sayed, Dalia N. Toaima, Fatma A. Marzouk, Amira Mohsen, Aisha Elsharkawy, Gamal E. Esmat, Alaa El-Haddad

682: Pegylated Interferon Therapy in Chronic Hepatitis B Infection- Is it the best option available in Children?

Vikrant Sood, Sanjeev K. Verma, Seema Alam, Rajeev Khanna, Dinesh Rawat

683: Can expression of interferon-stimulated genes in pre-treatment liver biopsy of chronic hepatitis B patients predict therapy response and long-term HBV infection outcome?

Ivana Carey, Kate Childs, Sanjay Bansal, Sarah Tizzard, Matthew J. Bruce, Mary Horner, Diego Vergani, Kosh Agarwal, Giorgina Mieli-Vergani

Viral Hepatitis and Liver Transplant 684: Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study

Jessica L. Mueller, Lindsay Y. King, Kara B. Johnson, Tian Gao, Lauren D. Nephew, Darshan Kothari, Mary Ann Simpson, Lan Wei, Kathleen E. Corey, Joseph Misdraji, Joon Hyoek Lee, Bryan C. Fuchs, Kenneth K. Tanabe, Frederic D. Gordon, Michael P. Curry, Raymond T. Chung

685: Genetic polymorphisms of toll–like receptors 1 and 9 are associated with increased risk of severe hepatitis C virus recurrence after liver transplantation

Ana Maria Duca, María J. Cítores, Sara de la Fuente, Isolina Baños, Ana B. Cuenca, Valentin Cuervas-Mons

686: The influence of mTor-Inhibitors on HCV replication after liver transplantation

Eva-Maria Ecker, Alexandra Frey, Katja Piras-Straub, Andreas Walker, Guido Gerken, Kerstin Herzer




Poster Sessions 687: Hepatitis C Treatment Does Not Affect Waiting Time for Liver Transplantation in Hepatitis C Positive Patients

Mohannad Dugum, Nizar N. Zein, Naim Alkhouri, Rocio Lopez, Brigette Bevly, Charles M. Miller, Teresa Diago, Ibrahim A. Hanouneh

688: Sofosbuvir and ribavirinin in hcv-infected patients listed for liver transplantation: a cost-effectiveness analysis

Paolo A. Cortesi, Lorenzo G. Mantovani, Antonio Ciaccio, Matteo Rota, Giancarlo Cesana, Mario Strazzabosco, Luca S Belli

689: Hepatitis E Virus (HEV) Infection is Rare Cause of Hepatitis Among US Liver Transplant Recipients

Norah Terrault, Ronald E. Engle, Jennifer L. Dodge, Chris Freise, Averell H. Sherker, Patrizia Farci, Robert H. Purcell

690: Characteristics of Post Transplantation Hepatitis E Virus Infection Among Solid Organ Transplant Recipients at a North American Transplant Center

Paul K. Sue, Nora Pisanic, Christopher D. Heaney, Kenrad Nelson, Kathleen B. Schwarz, Alexandra Valsamakis, Michael Forman, Annette M. Jackson, John R. Ticehurst, Robert A. Montgomery, Wikrom Karnsakul

691: Validation of The Hepatitis Aggressiveness Score in a Liver Transplant Population with Recurrent Hepatitis C

Alberto Unzueta, Roger K. Moreira, Giovanni DePetris, Maxwell L. Smith, Yu-Hui H. Chang, Meng-Ru Cheng, Angela Eyshou, Juan F. Gallegos-Orozco, Bashar Aqel, Hugo E. Vargas

696: Long-Term Results of Prophylaxis of De Novo Hepatitis B Virus (HBV) Infection With Lamivudine in HBsAg-negative Naive Recipients of anti-HBc-positive Liver Grafts: A 13-year Single-center Experience

Martin Prieto, María García Eliz, Ana M. Braithwaite, Angel Rubin, Victoria Aguilera, Salvador Benlloch, Marina Berenguer, Carmen Vinaixa

697: Reinfection prophylaxis with entecavir monotherapy is successful and safe in patients with hepatitis B virus infection after liver transplantation

Kerstin Herzer, Ingmar Mederacke, Guido Gerken, Frank Lehner, Juergen Klempnauer, Michael P. Manns, Karsten Wursthorn

698: Accessibility to Liver Transplantation for HIVHCV Coinfected Patients with End Stage Liver Disease: the French Prospective Multicenter ANRS HC EP 25 PRETHEVIC COHORT

Maria Ostos, Moana Gelu-Simeon, Laetitia A. Johnson, Elina Teicher, Hélène Fontaine, Pierre Tattevin, Isabelle Poizot-Martin, Stephanie Dominguez, David Zucman, Julie Chas, Pascal P. Crenn, Anne Gervais, Karine Lacombe, Philippe Morlat, Rodolphe Anty, Faroudy Boufassa, Inga Bertucci, Georges-Philippe Pageaux, Laurence Meyer, Jean-Charles Duclos-Vallée

699: Hepatitis C Virus Infection is an Independent Predictor of Post-Liver Transplant Diabetes: Data from the U.S. Scientific Registry of Transplant Recipients

Zobair Younossi, Maria Stepanova, Sammy Saab, Gregory Trimble, Alita Mishra, Shirley K. Kalwaney, Zahra Younoszai, Fatema Nader, Linda Henry

693: Performance Characteristics of the Procleix HEV Assay on the Fully Automated Procleix Panther System

701: Early Safety and Efficacy Profiles of Renal Transplant Recipients with Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin

Tomohiro Tanaka, Nobuhisa Akamatsu, Yasuhiko Sugawara, Junichi Kaneko, Sumihito Tamura, Taku Aoki, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo

Marshall E. McCabe, Saurabh Agrawal, Marco A. Lacerda, A. Joseph Tector, Paul Y. Kwo, Marwan Ghabril

Edgar Ong, Alanna Janssen, Robin Cory, Maria Babizki, Tim Shin, Andre Lindquist, Ngoc-Anh Hoang, Lee P. Vang, Lisa Danzig, Jeffrey M. Linnen

Genevieve Huard, Brian Kim, Anna Patel, Badr Aljarallah, Ponni Perumalswami, Joseph A. Odin, Sara Geatrakas, Jawad Ahmad, Douglas Dieterich, Vinay Nair, Thomas D. Schiano, Gene Y. Im

694: Sofosbuvir as the backbone of treatment for HCV after liver transplantation: a real-life multicenter experience

702: T Regulatory Cells in De Novo Hepatitis B Virus Infection after Liver Transplantation

Rohit Satoskar, Joseph Ahn, Helen S. Te, Adam Deising, Andrew Aronsohn, Suzanne Robertazzi, Thomas D. Schiano

695: The Impact of Pre-Transplant Obesity and Diabetes on Survival Following Liver Transplantation among Hepatitis C Virus Patients With and Without Hepatocellular Carcinoma

Robert J. Wong, Ramsey Cheung, Edward W. Holt, Aijaz Ahmed

Poster Viewing: 2:00 – 7:30 PM

Yinjie Gao, Min Zhang, Jingmin Zhao, Hanwei Li

703: The long-term efficacy of combination of nucleos(t) ide analogue treatment and low dose hepatitis b immunoglobulin on posttransplant HBV recurrence

Ramazan Idilman, Murat Akyildiz, Onur Keskin, Ali Tuzun, Tonguc U. Yilmaz, Necdet Guler, Onur Yaprak, Gokhan Gungor, Yalcin Erdogan, Murat Dayangac, Deniz Balci, Kubilay Cinar, Acar Tuzuner, Selcuk Hazinedaroglu, Yaman Tokat, Sadik Ersoz, Abdulkadir Dokmeci

Presenters in Attendance 5:30 – 7:00 PM


692: Living donor liver transplantation for hepatitis C virus-positive recipients in Japan: a nationwide survey

700: Sustained Virologic Responses with Nitazoxanide Therapy in Recurrent Hepatitis C (genotype 1) Infection Post Liver Transplantation



HEPATOLOGY, October, 2014

Poster Sessions 704: Efficacy of protease inhibitor in combination with pegylated interferon and ribavirin to treat hepatitis C after living donor liver transplantation

Satoshi Miuma, Tatsuki Ichikawa, Hisamitsu Miyaaki, Naota Taura, Kazuhiko Nakao

705: Post-transplant Treatment of Severe Recurrent Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus or Minus Ribavirin

Natalie H. Bzowej, Shobha Joshi, George Therapondos, Nigel Girgrah, Gia Tyson, Inna Goldvarg-Abud, Jennifer B. Scheuermann, Humberto E. Bohorquez, Ari J. Cohen, Ian C. Carmody, Trevor W. Reichman, David S. Bruce, George E. Loss

706: Sofosbuvir + Simeprevir is Safe in Liver Transplant Recipients

Fredric D. Gordon, Andreana L. Kosinski, Sheila J. Coombs, Pauline Goucher, Emad S. Aljahdli, Elizabeth A. Pomfret

707: Telbivudine is associated with improvement of renal function in patients after liver transplantation


Evangelos Cholongitas, Themistoklis Vasiliadis, Ioannis Goulis, Ioannis Fouzas, Vasileios Papanikolaou, Evangelos A. Akriviadis

Denotes AASLD Presidential Poster of Distinction

708: Survey on Pre- and Post-Transplant Management of Hepatitis C: Response from Medical Directors of US Transplant Programs Paul J. Gaglio, Carly E. Glick, John F. Reinus

709: Liver transplantation for patients with HCV-related end-stage liver disease and undetectable HCV-RNA: the Turin Centre experience

Alessandro Risso, Francesco Tandoi, Silvia Martini, Renato Romagnoli, Mauro Salizzoni

710: Safety and Efficacy of Hepatitis C Therapy with Sofosbuvir and Simeprevir after Liver Transplantation

Julio A. Gutierrez, Alla Grigorian, Andres F. Carrion, Michael D. Schweitzer, Danny J. Avalos, Kalyan R. Bhamidimarri, Adam Peyton

711: The Combination of Simeprevir and Sofosbuvir for the Treatment of HCV Infection in Patients Post Liver Transplant With Significant Fibrosis

Idrees Suliman, Renee Pozza, Yaseen Kady, Catherine Hill, Thomas A. Couturier, Preeti Reshamwala, Tarek Hassanein    




Poster Sessions Poster Session 2 Sunday, November 9 POSTER VIEWING: 8:00 AM - 5:30 PM Hall C Presenters in attendance: 12:30 - 2:00 PM Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Acute Liver Failure 712: The Mortality of Acute-on-Chronic Liver Failure by APASL vs. EASL-CLIF definition: A Multicenter, Retrospective Cohort Study in Korea (KACLiF Study)

Tae Yeob Kim, Dong Joon Kim, Do Seon Song, Dong Hyun Sinn, Eileen L Yoon, Joo Hyun Sohn, Chang wook Kim, Young Kul Jung, Ki Tae Suk, Jin Mo Yang, Heon Ju Lee

713: Predicting Progression from Acute Liver Injury to Acute Liver Failure Using a Machine Learning Algorithm Jaime L. Speiser, David G. Koch, William M. Lee

714: Development and Validation of the CLIF-C AD score for the prognosis of patients with acute decompensation (AD) of cirrhosis not fulfilling diagnostic criteria for acute-on-chronic liver failure (ACLF)

Rajiv Jalan, Marco Pavesi, Faouzi Saliba, Alex Amorós, Javier Fernandez, Peter Holland-Fischer, Rohit Sawhney, Rajeshwar Mookerjee, Paolo Caraceni, Tania M. Welzel, Richard Moreau, Pere Gines, Francois Durand, Paolo Angeli, Carlo Alessandria, Wim Laleman, Jonel Trebicka, Didier Samuel, Stefan Zeuzem, Thierry Gustot, Alexander L. Gerbes, Julia Wendon, Mauro Bernardi, Vicente Arroyo

Anne M. Witt, Fin Stolze Larsen, Peter N. Bjerring

716: Alginate biocompatibility for use in tissue engineering and cell therapy applications: biological responses to hydrogel-encapsulated HepG2 cells in vitro - leukocyte cytokine release and peripheral blood mononuclear cell proliferation

Jordi G. Molina, Graham Wright, Sam Coward, Hardeep Kalsi, Eloy Erro, Barry Fuller, Clare Selden

717: Implanted human bone mesenchymal stem cells rescue fulminant hepatic failure within one week through paracrine and transdifferentiation in pigs

Jun Li, Dongyan Shi, Jianing Zhang, Ding Wenchao, Jiaojiao Xin, Qian Zhou, Hongcui Cao, Xin Chen, Lanjuan Li

Poster Viewing: 8:00 AM – 5:30 PM

Thibault Degand, Elisabeth Monnet, Francois Durand, Emilie Grandclement, Philippe Ichai, Franck Schillo, Arnaud Agin, Alexandre Louvet, Jérôme Dumortier, Gilles Dumoulin, Vincent Di Martino, Thierry Thevenot

719: Characterization of Acute-on-Chronic Liver Failure And Prediction of Mortality in Patients with Alcoholic Hepatitis

Hwi Young Kim, Yong Jin Jung, Byeong Gwan Kim, Kook Lae Lee, Won Kim

720: Acute Liver Decompensation Following Radioembolization For Liver Cancer: A Retrospective Study

Michael Min, Totianna Prudhomme, Eduardo Ehrenwald, Jill May, Kai Hanson, Andrew J. Henn, Joseph Leach, Coleman Smith

721: Improved survival of hepatocytes in co-culture with mesenchymal stromal cells following exposure to acute liver failure serum: the role of paracrine factors

Emer Fitzpatrick, Sunitha Vimalesvaran, Celine Filippi, Ragai R. Mitry, Tracey Dew, Charalambos G. Antoniades, Anil Dhawan

722: Alpha fetoprotein: A biomarker for the recruitment of progenitor cells in the liver of the patients with acute liver injury/acute liver failure

Keisuke Kakisaka, Kojiro Kataoka, Yuji Suzuki, Yasuhiro Miyamoto, Yasuhiro Takikawa

723: The Safety of Therapeutic Plasma Exchange in Pediatric End Stage Liver Disease

Amy S. Arrington, Moreshwar S. Desai, Ayse Akcan Arikan, Jun Teruya, Poyyapakkam R. Srivaths

724: Acetaminophen (APAP)-induced Acute Liver Failure (ALF) Leads to Activation Of Endogenous Hepatic Stem/ Progenitor Cells with Inability to Complete Hepatic Regeneration

Nicole Pattamanuch, Preeti Viswanathan, Sriram Bandi, Leslie E. Rogler, Charles E. Rogler, Sanjeev Gupta

725: TNF-α Induces Receptor Interacting Protein-3 Kinase to Mediate Necrotic Cell Death in Acute-onChronic Liver Failure

Arshi Khanam, Nirupma Trehan Pati, Archana Rastogi, Shiv K. Sarin

726: The Usefulness of Prognostic Factors of Acute-onChronic Liver Failure in Patients with Liver Cirrhosis: A Multicenter, Retrospective Cohort Study in Korea (KACLiF Study)

Do Seon Song, Dong Joon Kim, Tae Yeob Kim, Dong Hyun Sinn, Eileen L Yoon, Joo Hyun Sohn, Chang wook Kim, Young Kul Jung, Ki Tae Suk, Jin Mo Yang, Heon Ju Lee

Presenters in Attendance 12:30 – 2:00 PM


715: Hyperammonaemia and systemic inflammation is associated with intracellular lactate accumulation

718: Assessment of adrenal function in patients with severe acute hepatitis: a growing interest of serum free cortisol and salivary cortisol. A prospective observational multicenter study



HEPATOLOGY, October, 2014

Poster Sessions 727: Acute Liver Failure related to Drug reaction with eosinophilia and systemic symptoms (DRESS): Outcome and Predictive Factors for improvement

Philippe Ichai, Camille Besch, Catherine Guettier, Claire Francoz, Laurence Valeyrie-Allanore, Sylvie Roussin-Bretagne, Olivier Roux, Alexia Letierce, Faouzi Saliba, Florent Artru, Marc Boudon, Teresa Maria Antonini, Francois Durand, Didier Samuel

728: A non-invasive method for enumerating cell number in three dimensional cell cultures; the integrated variable cell count, a tool for regenerative medicine, enabling quality assurance of cell therapy applications

Eloy Erro, Hyun Woo Yu, Dominic Davis, James T. Bundy, Aurelie Le lay, Humphrey Hodgson, Barry Fuller, Clare Selden

729: Arterial ammonia concentration determined by point of care testing in acute liver failure; clinical associations and utility in prediction of complications and outcome

Vishal C. Patel, Beatriz Mateos Muñoz, Elizabeth Sizer, Charalambos G. Antoniades, Christopher Willars, Georg Auzinger, Julia Wendon, William Bernal

730: Impaired Neutrophil Function Aggravates Liver Injury and Correlates with Clinical Severity Indices in Acute-on-Chronic Liver Failure

Arshi Khanam, Nirupma Trehan Pati, Peggy Riese, Archana Rastogi, Carlos A. Guzman, Shiv K. Sarin

731: Genome editing with Cas9 in adult mice corrects a liver disease mutation and phenotype Hao Yin

732: LDH in the determination of cause in acute liver failure, revisited


Michelle Gottfried, Kurt Kleinschmidt, William M. Lee

733: Liver failure determines the extra-hepatic organ failure and outcome in patients with acute-on-chronic liver failure: Analysis of 1363 patients of AARC Data Base

Chandan K. Kedarisetty, Shiv K. Sarin, Lovkesh Anand, Zaigham Abbas, Deepak N. Amarapurkar, Ankit Bhardwaj, Ajeet S. Bhadoria, Chhagan Bihari, Amna S. Butt, Ashok Choudhary, Chan Albert, Yogesh K. Chawla, Abdulkadir Dokmeci, Hitendra K. Garg, Hasmik Ghazinyan, Saeed S. Hamid, Ankur Jindal, Naveen Kumar, Avinash Kumar, Guan Huei Lee, Laurentius A. Lesmana, Mamun A. Mahtab, Rakhi Maiwall, Qin Ning, Devraj Rangegowda, Archana Rastogi, Amrish Sahney, Samir R. Shah, Gamal Shiha, Barjesh C. Sharma, Manoj Kumar, Saggere M. Shasthry, Soek Siam Tan, Chitranshu Vashishtha, Man-Fung Yuen, Osamu Yokosuka

734: Higher thyroid-stimulating hormone, triiodothyronine and thyroxine values are associated with better outcome in acute liver failure

Olympia Anastasiou, Jan-Peter Sowa, Paul P. Manka, Christian D. Fingas, Wing-Kin Syn, Antonios Katsounas, Dagmar Führer, Robert K. Gieseler, Lars Bechmann, Guido Gerken, Lars C. Moeller, Ali Canbay

Denotes AASLD Presidential Poster of Distinction

735: Ambient temperature short-term preservation of liver cells for bioengineering applications using perfluorodecalin as an oxygen source

Darren L. Scroggie, Eloy Erro, James T. Bundy, Aurelie Le lay, Dominic Davis, Sunil R. Modi, Barry Fuller, Clare Selden

736: Hepatocyte Krüppel-Like-Factor 6 expression is upregulated in acute liver injury and represses hepatocyte proliferation

Svenja Sydor, Jan Best, Paul P. Manka, Martin Schlattjan, Thomas Schreiter, Diana Vetter, Andreas Paul, Scott L. Friedman, Guido Gerken, Ali Canbay, Lars Bechmann

737: Impaired monocyte and macrophage function in Hepatitis E Virus (HEV) infected pregnant women with Acute Liver Failure

Rashi Sehgal, Paul David, Ashish Vyas, Arshi Khanam, Ankit Bhardwaj, Preety Rawal, Syed Hissar, Sharda Patra, Shubha S. Trivedi, Shyam Kottilil, Shiv K. Sarin, Nirupma Trehanpati

738: Increased neutrophil actin production and translocation of myeloperoxidase in patients with acetaminophen-induced acute liver failure may contribute to multiorgan failure

Godhev K. Manakkat Vijay, Gema Vizcay-Barrena, Thomas Tranah, Leanne Glover, Vishal C. Patel, Christine Bernsmeier, Jennifer M. Ryan, Laura J. Blackmore, Xiaohong Huang, Victoria T. Kronsten, Nicholas J. Taylor, William Bernal, Georg Auzinger, Christopher Willars, Julia Wendon, Yun Ma, Barbara Bain, Alice Warley, Debbie Shawcross

739: Granulocyte-colony stimulating factor for acuteon-chronic liver failure: systematic review and metaanalysis of randomized control trials

Victoria J. Ornelas-Arroyo, Desiree Vidaña-Pérez, Guadalupe Delgado-Sánchez, Indira R. Mendiola Pastrana, Camilo NoreñaHerrera, Tonatiuh Barrientos-Gutierrez, Eva Juárez Hernández, Nahum Méndez-Sanchéz, Misael N. Uribe-Esquivel, Norberto C. Chavez-Tapia

740: Etiology, Clinical Features and Outcome of Acute Liver Failure in Japan Nobuaki Nakayama, Hirohito Tsubouchi, Satoshi Mochida

741: Secretory Leukocyte Protease Inhibitor (SLPI) promotes hepatic resolution responses in acute liver failure (ALF)

Evangelos Triantafyllou, Oltin T. Pop, Evaggelia Liaskou, Christine Bernsmeier, Wafa Khamri, Zania Stamataki, Yun Ma, Mark R. Thursz, Julia Wendon, Alberto Quaglia, Chris J. Weston, Stuart M. Curbishley, David H. Adams, Charalambos G. Antoniades

742: Characterization of disease-specific biomarkers in hepatitis B virus-related acute-on-chronic liver failure and their predictive value for mortality

Jun Li, Jiaojiao Xin, Ding Wenchao, Qian Zhou, Longyan Jiang, Dongyan Shi, Lanjuan Li




Poster Sessions 743: Traditional prognostic factors do not differentiate between survivors and non-survivors in pediatric liver failure patients on renal support

Ayse Akcan Arikan, Keila L. de la Garza, Poyyapakkam R. Srivaths, Alyssa Riley, Kathleen Thompson, Ryan Himes, Moreshwar S. Desai

Basic Fibrosis 752: Raf kinase inhibitor 1 (Rkip1): a potential modifier of fibrogenesis in liver and heart

Rabea A. Hall, Andrey Kazakov, Ulrich Laufs, Michael Boehm, Frank Lammert

744: Inclusion of Admission Red Cell Distribution Width (RDW) and Mean Corpuscular Volume (MCV) improves predictive accuracy of prognostic models of Acute Liver Failure (ALF)

753: The Role of Toll Like Receptor 4 signaling by Hepatic Stellate Cells in Hepatocarcinogenesis

Kimberly A. Forde, Thure Caire, Craig Newcomb, R. Todd Stravitz

Jinsheng Guo, Yangyang Ouyang, Chengzhao Lin, Yujing Wu, Yuanqing Zhang, Yirong Cao, Shiyao Chen, Jiyao Wang, Scott L. Friedman

745: Pre-existing liver diseases lead acute HEV infection to progressive liver failure

754: Highly Efficient Gene Targeting of a LncRNA in Human LX-2 Hepatic Stellate Cells using TALENs

Jong-Hon Kang, Takeshi Matsui, Kazumasa Nagai, Akiko Tomonari, Kazunari Tanaka, Kunihiko Tsuji, HIroyuki Maguchi, Yoshiyasu Karino, Itaru Ozeki, Shuhei Hige, Tomoaki Nakajima, Takumi Ohmura, Kazuaki Takahashi, Masahiro Arai, Shunji Mishiro

746: A pilot study to determine the efficacy and safety of ribavirin in patients of acute severe hepatitis E Rahul Gupta, Sandeep S. Sidhu, Varun Mehta, Ajit Sood

747: Granulocyte colony stimulating factor (G-CSF) to treat acute (on chronic) liver failure: effect on immune and stem cell mobilisation

Cornelius Engelmann, Katrin Splith, Thomas Berg, Moritz Schmelzle

748: C/EBP homologous protein (CHOP) promotes hepatocyte death by ERO1α signaling during acute liver failure Ling Lu, Jianhua Rao, Haoming Zhou, Xuehao Wang

749: The clinical and immunological chracteristics of acute liver failure with autoimmune features – for early diagnosis and proper treatment–

750: Increased CD11b+CD163+ macrophages caused liver injury in acute liver Failure (ALF) non-survivors

Rashi Sehgal, Arshi Khanam, Ashish Vyas, Shiv K. Sarin, Nirupma Trehanpati

751: Micro RNAs miR-106a, miR-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathy

Lukas Weseslindtner, Iris F. Macheleidt, Hannah Eischeid, Robert Paul Strassl, Theresia Popow-Kraupp, Harald Hofer, Margarete Odenthal, Heidemarie Holzmann

755: The role of Fyn in hepatic stellate cells activation and liver fibrosis

Yin Ying Lu, Guanghua Rong, Dechun Feng, Chunping Wang, Xiujuan Chang, Xudong Gao, Yan Chen, Jianhui Qu, Zhen Zeng, Hong Wang, Bin Gao, Yongping Yang

756: A Hepatic Stellate Cell Expression Signature Identifies Novel Cell Markers and Predicts Outcomes in Chronic Liver Disease David Zhang, Hsin I Chou, Yujin Hoshida, Scott L. Friedman

757: Grb2-associated binder 1 protects against liver fibrosis via suppression of CCL5 production from hepatocytes

Yuichi Yoshida, Takashi Kizu, Kunimaro Furuta, Satoshi Ogura, Mayumi Egawa, Norihiro Chatani, Yoshihiro Kamada, Shinichi Kiso, Tetsuo Takehara

758: The peripherally-restricted CB1 antagonist AM6545 reduces liver fibrogenesis via growth inhibitory effects for hepatic myofibroblasts and antiinflammatory properties

Jinghong Wan, Aida Habib, Jasper Lodder, Arthur Brouillet, Fouad Lafdil, Adrien Guillot, Catherine Pavoine, Richard Moreau, Ariane Mallat, Sophie Lotersztajn

759: MicroRNA-155 (miR-155) deficiency attenuates liver fibrosis and not liver injury or inflammation in an animal model of steatohepatitis

Timea Csak, Shashi Bala, Dora Lippai, Karen Kodys, Donna Catalano, Gyongyi Szabo

760: The adiponectin peptide agonist ADP355 attenuates CCl4-mediated liver fibrosis: therapeutic implications by multiple molecular mechanisms in vivo and in vitro

Pradeep Kumar, Tekla Smith, Khalidur Rahman, Natalie Thorn, Frank A. Anania

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Hirotoshi Ebinuma, Hidetsugu Saito, Yoshiyuki Yamagishi, Nobuhiro Nakamoto, Po-sung Chu, Yuko Wakayama, Nobuhito Taniki, Akihiro Yamaguchi, Shunsuke Shiba, Shingo Usui, Kazuo Sugiyama, Takanori Kanai

Daniel L. Motola, Kaveh Daneshvar, Samuel R. York, Alan Mullen, Raymond T. Chung



HEPATOLOGY, October, 2014

Poster Sessions 761: The interaction of beta-Arrestin-2 with AT1receptor signalling in liver fibrosis

Robert Schierwagen, Judith Heinzen, Sabine Klein, Frank E. Uschner, Kanishka Hiththetiya, Christian P. Strassburg, Tilman Sauerbruch, Jonel Trebicka

Andrea Schmetz, Frank Lammert, Susanne N. Weber

762: Identification of long noncoding RNAs induced in hepatic stellate cell myofibroblasts

772: Signaling via the osteopontin and high-mobility group box-1 axis drives the fibrogenic response to liver injury

Samuel R. York, Chan Zhou, Jennifer Y. Chen, Kaveh Daneshvar, Alan Mullen

Elena Arriazu, Xiaodong Ge, Tung Ming Leung, Aritz Lopategi, Yongke Lu, Raquel Urtasun, Neil D. Theise, Natalia Nieto

763: Genetic or pharmacologic inhibition of microRNA-21 does not prevent liver fibrosis or hepatocellular carcinoma in mice

773: Sortilin deficiency affects fibrosis differently in hepatocellular versus cholangiocyte models of liver injury

J Matias Caviglia, Myoung Kuk Jang, Geum-Youn Gwak, Ingmar Mederacke, Xueru Mu, Dianne H. Dapito, Robert F. Schwabe

764: Pharmacological inhibition of apoptosis signalregulating kinase 1 (ASK1) in a murine model of NASH with pre-existing disease blocks fibrosis, steatosis, and insulin resistance

Satyajit Karnik, Michael Charlton, Yury Popov, Zachary D. Goodman, Michelle Nash, Maisoun Sulfab, Vivian Barry, Erik G. Huntzicker, Dorothy French, Kelvin Li, Martin Decaris, Claire Emson, Scott M. Turner, David Breckenridge, Daniel Tumas

765: Inhibition of MAP3K5, Apoptosis signalregulating kinase 1, with an oral small molecule inhibitor blocks hepatic fibrosis and steatosis in murine models of NASH and PSC

Satyajit Karnik, Michael Charlton, Michelle Nash, Maisoun Sulfab, Vivian Barry, Erik G. Huntzicker, Dorothy French, David Breckenridge, Britton Corkey, Gregory Notte, James E. Nelson, Kris V. Kowdley, Daniel Tumas

766: Differential roles of C5a receptors C5aR and C5L2 in liver and kidney fibrosis

Ina V. Martin, Tammo Ostendorf, Jürgen Floege, Frank Lammert, Susanne N. Weber


771: ‘Lucky grandchildren’: Inbred mice whose grandparents developed liver fibrosis appear to be protected against the same disease

767: Coniferyl Ferulate Attenuated Liver Fibrosis Through Inhibition Of Transforming Growth Factor-Β Receptor Ya N. Zhou, Wen W. Fu, Ping Liu

768: Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits hepatic fibrosis reversal in mice

Susan B. Liu, Naoki Ikenaga, Deanna Sverdlov, Zhen-Wei Peng, Detlef Schuppan, Yury Popov

769: Deficiency of stress induced heat shock transcription factor 1 (HSF1) Exacerbates Liver Fibrosis: Regulation of Inflammatory Cytokines and Fibrogenesis Pranoti Mandrekar, Arlene Lim

770: Cthrc1 alleviates cholestatic liver fibrosis through a negative feedback loop with p-smad3 in mice Zhaolian Bian, Qi Miao, Wei Zhong, Xiong Ma

Denotes AASLD Presidential Poster of Distinction

Rafael Bruck, Einav Hubel, Tamar Thurm, Isabel Zvibel

774: Linagliptin mediated DPP-4 inhibition ameliorates inflammation and fibrosis in models of NASH and biliary fibrosis

Xiao-Yu Wang, Shih-Yen Weng, Yong Ook Kim, Thomas Klein, Detlef Schuppan

775: The Hippo pathway effector YAP is an early regulator of hepatic stellate cell activation

Inge Mannaerts, Sofia B. Leite, Stefaan Verhulst, Lien F. Thoen, Sofie Claerhout, Georg Halder, Leo A. van Grunsven

776: Toll-like Receptor 3 Accelerates Liver Fibrosis by Enhancing IL-17 Production in Mice

Wonhyo Seo, Hyuk-Soo Eun, Young-Sun Lee, Hyon-Seung Yi, JongMin Jeong, So Yeon Kim, Yoo Kyung Kang, Jin Yong Kim, Byung Jun Choi, Won-Il Jeong

777: Deletion of the cytoplasmic domain of Tissue Factor ameliorates liver fibrosis and decreases TGFβ expression in a murine model of cirrhosis

Virginia Knight, Jorge Tchongue, Dinushka Lourensz, Alison X. Liu, Peter Tipping, William Sievert

778: Platelets as a novel target in liver fibrosis: extrahepatic supply of PDGF-B by platelets drives hepatic stellate cell activation and biliary liver fibrosis progression

Shuhei Yoshida, Naoki Ikenaga, Susan B. Liu, Deanna Sverdlov, Masahiko Shimada, Maki Tobari, Tetsuya Hamano, Takayoshi Nishino, Atsushi Mitsunaga, Detlef Schuppan, Yury Popov

779: Anti-fibrotic and anti-inflammatory activity of the adenosine receptor 2b antagonist, GS-6201, in a murine model of PSC

Satyajit Karnik, Yong Ook Kim, Michelle Nash, Maisoun Sulfab, Dewan Zeng, Hongyan Zhong, Simon C. Robson, Detlef Schuppan, Daniel Tumas

780: Role of LARP6 and nonmuscle myosin in partitioning of collagen mRNAs to the ER membrane Hao Wang, Yujie Zhang, Lela Stefanovic, Branko Stefanovic




Poster Sessions 781: Differential roles of non-receptor tyrosine kinase Fak family members in TGF-β-mediated fibrogenic signaling in hepatic stellate cells

791: Pharmacological modulation of IL-4Ralpha regulates liver fibrosis progression and regression by tuning M2 macrophage polarization

782: Liver injury and pro-fibrotic markers, but not frank fibrosis, are enhanced in Has3-/- mice after carbon tetrachloride exposure: potential role for enhanced matrix metabolism

792: Development of Sonic hedgehog transgenic mouse models using hydrodynamics-based transfection

Jonghwa Kim, SoHee Kang, Soohyun Park, Ju-Yeon Cho, Won Sohn, Geum Youn Gwak, Byung Chul Yoo, David A. Brenner, Yong-Han Paik

Jennifer M. McCracken, Krutika T. Deshpande, Michele Pritchard

783: Hepatic Stellate Cells Express the Hepatocyteenriched Transcription Factor, Hepatocyte Nuclear Factor 4α

Marzena Swiderska-Syn, Guanhua Xie, Jason D. Coombes, Gregory A. Michelotti, Anna Mae Diehl

784: Activation of JNK modulates the profibrogenic actions of myostatin in hepatic stellate cells (HSC)

Alessandra Caligiuri, Wanda Delogu, Angela Provenzano, Chiara Rosso, Elisabetta Bugianesi, Fabio Marra

785: Role of gamma-ketoaldehydes as novel mediators of experimental fibrogenesis and stellate cells activation

Lisa Longato, Dipok K. Dhar, Sean S. Davies, Jackson L. Roberts, Tu Vinh Luong, Brian Davidson, Giuseppe Fusai, Jude A. Oben, Kevin Moore, Massimo Pinzani, Krista Rombouts

786: Keratinocyte growth factor inhibits hepatic inflammation and fibrosis in murine models of hepatic injury Barbara Czech, Claus Hellerbrand

787: The Role of Receptor-Mediated Endocytosis of H-ferritin in Induction of NFkappaB-dependent Proinflammatory Signalling in Hepatic Stellate Cells

Manuel A. Fernandez-Rojo, Anita Burgess, Amber Glanfield, Diem Hoang-Le, Grant A. Ramm

Shih-Yen Weng, Santosh Vijayan, Xiao-Yu Wang, Kornelius Padberg, Yong Ook Kim, Brombacher Frank, Detlef Schuppan

789: Hepatic stellate cell activation is regulated by neuropilin-synectin mediated autophagic degradation of PDGFR-α

Mary Drinane, Usman Yaqoob, Debabrata Mukhopadhyay, Shengbing Huang, Frank A. Sinicrope, Sheng Cao, Vijay Shah

790: microRNA-194 regulates the expression of TNF-α, IL-1α and IL-6 via modulating akt/NF-κB pathway in hepatic stellate cells

Sook In Chung, Hye Lim Ju, Kwang-Hyub Han, Weonsang S. Ro

793: Human neutrophil peptide-1 exacerbates hepatic fibrosis associated with Kuppfer cell activation and hepatocyte apoptosis in a murine model of alcoholic liver disease

Rie Ibusuki, Hirofumi Uto, Kozono Masaya, Kohei Oda, Akihiko Oshige, Kotaro Kumagai, Seiichi Mawatari, Tsutomu Tamai, Akihiro Moriuchi, Hirohito Tsubouchi, Akio Ido

794: Epigallocatechin gallate treatment decreases osteopontin expression and attenuates N-Nitrosodimethylamine induced hepatic fibrosis in rats Joseph George, Mikihiro Tsutsumi

795: Iron excess exacerbates proinflammatory and fibrogenic gene expression in genetically obese mice and in primary human hepatic stellate cells in response to TNF- α or TGF-β

Priya Handa, Vicki Morgan-Stevenson, Bryan D. Maliken, James E. Nelson, Matthew M. Yeh, Kris V. Kowdley

796: Modulating Tumor-Stromal Interactions by Targeting Adenosine Monophosphate-Activated Kinase (AMPK) in Human Hepatic Stellate Cells and Hepatocellular Carcinoma

Katrin Schölzel, Lisa Longato, Tu Vinh Luong, Brian Davidson, Giuseppe Fusai, Massimo Pinzani, Krista Rombouts

797: A new communication system regulating extracellular matrix in liver fibrosis: RANK/RANKL/ OPG

Leonie Beljaars, Carian E. Boorsma, Burak Guney, Klaas Poelstra, Barbro N. Melgert

798: Markers of extracellular matrix remodeling can elucidate the matrix turnover profile of the fibrotic liver

Niels Ulrik B. Hansen, Federica Genovese, Diana J. Leeming, Morten A. Karsdal

Clinical Steatohepatitis 799: Role of Genetic Polymorphisms in the Development of Nonalcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH)

Pushpendra K. Sahu, Satendra Kumar, Parul Gupta, Senthil K. Venugopal

Fernando Bril, Marina Kawaguchi-Suzuki, Reginald Frye, Paola Portillo Sanchez, Maryann Maximos, Song Lai, Jean Hardies, Fermin Tio, Kenneth Cusi

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


788: Alternative regulation of macrophages activation by IL-4 receptor alpha in fibrosis progression and reversal

Shih-Yen Weng, Xiao-Yu Wang, Santosh Vijayan, Kornelius Padberg, Yong Ook Kim, Jeff R. Crosby, Michael L. McCaleb, Detlef Schuppan



HEPATOLOGY, October, 2014

Poster Sessions 800: Low serum vitamin D concentration in patients with nonalcoholic fatty liver disease is not associated with increased mortality: Results from the National Health and Nutrition Examination Survey 18-year mortality follow-up data

Ivo C. Ditah, Albert Ndzengue, Zeenat Y. Bhat, Chijioke Enweluzo, Chobufo M. Ditah, Callistus Ditah, Michael Charlton, Patrick S. Kamath

801: Prevalence of nonalcoholic fatty liver disease and its association with aging

Ainara Cano, Cristina Alonso, Itziar Mincholé, David Balgoma, Pablo Ortiz, Maria L. Martinez-Chantar, Shelly C. Lu, Jose M. Mato

802: Hepatic Steatosis as a Component of Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy’s Disease)

Hawwa Alao, Derrick Fox, Angela Kokkinis, Colleen Hadigan, Christopher Grunseich, Kenneth Fischbeck, Yaron Rotman

803: Protease-Activated Receptor-2 (PAR2)–A Novel Therapeutic Target in Nonalcoholic Steatohepatitis (NASH)

Andrew M. Shearer, Karyn Austin, Srijoy Guha, Nga Nguyen, Richard Looby, Allyson Clappin, James Baleja, Lidija Covic, Athan Kuliopulos

804: Cardiovascular Death in Recipients of Liver Transplants with Nonalcoholic Steatohepatitis: An Analysis of the UNOS Database

Emily H. Wong, Jason Vanatta, Donna Hathaway, Elizabeth A. Tolley, Satheesh Nair, James Eason, Sanjaya K. Satapathy

805: Progression to hepatic steatosis and fibrosis by serum biomarkers is frequent in HIV mono-infection and is associated with black ethnicity, poor HIV control and hyperglycemia: a 7-year study of 1,291 cases


Giada Sebastiani, Kathleen C. Rollet-Kurhajec, Norbert Gilmore, Costas Pexos, Richard Lalonde, Marina B. Klein

806: Histological Severity And Glycemic Stage Drive The Evolution Of Atherogenic Risk Profile In Nonalcoholic Fatty Liver Disease

Mohammad S. Siddiqui, Kavish Patidar, Ankit V. Patel, Velimir A. Luketic, Sherry L. Boyett, Michael O. Idowu, R. Todd Stravitz, Scott Matherly, Puneet Puri, Richard K. Sterling, Arun J. Sanyal

807: Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease

Chiara Rosso, Ester Vanni, Lavinia Mezzabotta, Roberto Gambino, Francesca Saba, Federico Salomone, Ramy Ibrahim Kamal Jouness, Melania Gaggini, Emma Buzzigoli, Chiara Saponaro, Fabrizia Carli, Gian Paolo Caviglia, Maria Lorena Abate, Antonina Smedile, Mario Rizzetto, Maurizio Cassader, Amalia Gastaldelli, Elisabetta Bugianesi

808: Progression of early atherosclerotic vascular damage in patients with NAFLD and in controls of general population during 10 years of follow up

Anna Ludovica Fracanzani, Giuseppina Pisano, Silvia Tiraboschi, Marianna Porzio, Rosa Lombardi, Cristina Bertelli, Luca Valenti, Andrea Baragetti, Liliana Grigore, Alberico Catapano, Silvia Fargion

809: 5-aminolevulinic acid combined with ferrous iron protects from ischemia-reperfusion injury in mouse steatotic liver model by inducing carbon monoxide generation

Shao-Wei Li, Terumi Takahara, Toshiro Sugiyama, Kazuhiro Tsukada, Tohru Tanaka, Xiao-Kang Li

810: Oral glucose tolerance test predicts hepatic fibrosis in nonalcoholic fatty liver disease patients without overt diabetes mellitus

Sohji Nishina, Hideyuki Hyogo, Miwa Kawanaka, Teruki Miyake, Masanori Abe, Satoyoshi Yamashita, Hiroshi Tobita, Shuichi Sato, Yoichi Hiasa, Kazuaki Chayama, Keisuke Hino

811: Natural history of NAFLD: A study of 108 patients with paired liver biopsies

Stuart McPherson, Elsbeth Henderson, Timothy Hardy, Alastair D. Burt, Chris Day, Quentin M. Anstee

812: Role of Genetic Polymorphisms on the Improvement of Liver Histology after Pioglitazone Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)

Marina Kawaguchi-Suzuki, Fernando Bril, Kenneth Cusi, Taimour Langaee, Yan Gong, Reginald Frye

813: The Protease Fibroblast Activation Protein (FAP) in Liver Disease

Mark D. Gorrell, Kathryn H. Williams, Ana Julia Vieira de Ribeiro, Sumaiya Chowdhury, Elizabeth J. Hamson, Oliver Schilling, Emilia Prakoso, Nicholas A. Shackel, Susan V. McLennan, William W. Bachovchin, Fiona M. Keane, Geoffrey W. McCaughan, Amany Zekry, Stephen Twigg

814: Association of Hepatic Nuclear Hormone Receptor Expression Profiles with Features of Hepatic Histology in Children with Nonalcoholic Fatty Liver Disease

Joel E. Lavine, Michael Downes, Kevin P. May, Ruth Yu, Jeffrey B. Schwimmer, Cynthia A. Behling, Elizabeth M. Brunt, Mark L. van Natta, James Tonascia, Ronald M. Evans

815: There is substantial phenotypic variability in lean versus obese subjects with NAFLD across the world: The Global NASH Study

Angelo H. Paredes, Lawrence Serfaty, Claudia P. Oliveira, Abhijit Chowdhury, Sherry L. Boyett, Mohammad S. Siddiqui, Arun J. Sanyal

816: Prevalence and Risk Factors for Advanced Liver Fibrosis in Adults Undergoing Intestinal Transplantation

Genevieve Huard, M. Isabel Fiel, Jang Moon, Lauren Schwartz, Kishore Iyer, Thomas D. Schiano

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 817: Racial disparities in nonalcoholic fatty liver disease related mortality among US Adults: Results of the National Health and Nutrition Examination Survey 18-year mortality follow-up data

Ivo C. Ditah, Taiwo N. Ngwa, Albert Ndzengue, Zeenat Y. Bhat, Chijioke Enweluzo, Callistus Ditah, Michael Charlton, Patrick S. Kamath

818: Steatosis Assessment By Cap™ Using Xl Probe

Victor de Ledinghen, Christophe Corpechot, Julien Vergniol, Pierre Bedossa, Andrew R. Hall, Olivier Chazouillères, Yves Menu, Amar P. Dhillon, Valerie Paradis

819: Distinction between non-alcoholic steatohepatitis and simple steatosis according to the controlled attenuation parameter and liver stiffness value using transient elastography in patients with non-alcoholic fatty liver disease: a Korean multicenter study

Young Eun Chon, Soo Young Park, Hana Park, Ja Kyung Kim, Jae Young Jang, Chun Kyon Lee, Kwang-Hyub Han, Seung Up Kim

820: Non- Viral Liver Disease Burden In HIV Positive Individuals: An Observational Retrospective Cohort Study Natalie Shur, Martin Fisher, Yvonne Gilleece, Sumita Verma

821: Patients with Non-Alcoholic Steatohepatitis are at High Risk of Developing Post-Transplant Diabetes

Zobair Younossi, Maria Stepanova, Sammy Saab, Kelly E. Hoyle, Rebecca Cable, Alita Mishra, Stephen C. Clement, Sharon L. Hunt

822: Population incidence of nonalcoholic fatty liver disease: A prospective study using serial protonmagnetic resonance spectroscopy and transient elastography

Vincent W. Wong, Grace LH Wong, David K. Yeung, Winnie C. Chu, Henry Lik-Yuen Chan

Giada Sebastiani, Marc Deschenes, Rasha Alshaalan, Maria Rubino, Philip Wong, Peter Metrakos, Maged Peter Ghali

824: Liver Fat and Insulin Resistance as Major Determinants of Plasma Alanine Aminotransferase Levels in Nonalcoholic Fatty Liver Disease

Maryann Maximos, Fernando Bril, Paola Portillo Sanchez, Romina Lomonaco, Diane Biernacki, Amitabh Suman, Michelle Weber, Beverly Orsak, Kenneth Cusi

825: Plasma cytokeratin-18 in a healthy population: how does it correlate with metabolic risk factors, alcohol consumption, steatosis and elastography

Vikrant Rachakonda, Valerie L. Reeves, Jules Aljammal, James P. DeLany, Petra Kienesberger, Erin E. Kershaw

827: Circulating Cholesteryl Ester Transfer Protein is Associated with Percentage of Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease

Elzafir Elsheikh, Zahra Younoszai, Munkhzul Otgonsuren, Fanny Monge, Lakshmi Alaparthi, Brian P. Lam, Sharon L. Hunt, Zachary D. Goodman, Zobair Younossi

828: Body Fat Distribution and the Risk of Incident and Remittent Nonalcoholic Fatty Liver Disease: Prospective Cohort Study

Donghee Kim, Goh Eun Chung, Min-Sun Kwak, Won Kim, Yoon Jun Kim, Jung-Hwan Yoon

829: Dynamicity of Adiposity determine evolution of non-alcoholic fatty liver even in lean subjects: a prospective cohort study

Pankaj Singh, Kausik Das, Debashis Misra, Gautam Ray, Amal Santra, Abhijit Chowdhury

830: Lesser risk of advanced liver fibrosis in morbidly obese patients

Fabio Nascimbeni, Judith Aron-Wisnewsky, Pierre Bedossa, Joan Tordjman, Raluca Pais, Thierry Poynard, Karine Clément, Vlad Ratziu

831: Altered Fasting and Postprandial Serum Bile Acids in Patients with Non-Alcoholic Steatohepatitis (NASH)

Brian C. Ferslew, Curtis K. Johnston, Eleftheria Tsakalozou, Mingming Su, Guoxiang Xie, Wei Jia, Kim L. Brouwer, Alfred S. Barritt

832: HLA Class II Alleles Are Strongly Associated with Non-alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Azza Karrar, Zheng Li, Ali M. Moosvi, Siddharth Hariharan, Yun Fang, Maria Stepanova, Zachary D. Goodman, Zobair Younossi

833: Serum soluble CD163 is associated with steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease

Eoin R. Feeney, Jessica L. Mueller, Kyle Malecki, Lindsay Y. King, Joseph Misdraji, Kathleen E. Corey, Raymond T. Chung

834: Serum levels of apoptosis inhibitor of macrophage (AIM) are associated with hepatic fibrosis and insulin resistance in patients with nonalcoholic fatty liver disease

Sofia Carvalhana, Jorge Leitão, Ana C. Alves, Mafalda Bourbon, Helena Cortez-Pinto

Kohei Oda, Hirofumi Uto, Yoshio Sumida, Takeshi Okanoue, Seiichi Mawatari, Rie Ibusuki, Hiroka Onishi, Haruka Sakae, Kaori Ono, Eriko Toyokura, Akihiko Oshige, Dai Imanaka, Tsutomu Tamai, Akihiro Moriuchi, Hirohito Tsubouchi, Akio Ido

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


823: Prediction of 10-year clinical outcomes in NASH by non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and liver histology

826: Serum autotaxin levels are independently associated with hepatic steatosis in morbidly obese women



HEPATOLOGY, October, 2014

Poster Sessions 835: Moderate-Vigorous Physical Activity (MVPA) Volume is an Important Factor for Management of NonAlcoholic Fatty Liver Disease: A Retrospective Study

Sechang Oh, Takashi Shida, Rina So, Takehiko Tsujimoto, Kiyoji Tanaka, Junichi Shoda

836: Performance of FibroMax (SteatoTest, ActiTest, FibroTest) in patients with NAFLD for predicting liver lesions (Steatosis, Activity and Fibrosis) assessed by SAF scoring system and FLIP algorithm

Yoshihiro Kamada, Motoya Sato, Yuri Takeda, Sachiho KIda, Yuka Ohara, Hironobu Fujii, Maaya Akita, Kayo Mizutani, Yuichi Yoshida, Makoto Yamada, Hidetaka Hougaku, Tetsuo Takehara, Eiji Miyoshi

845: Clinical validation of the FLIP algorithm and the SAF score in Non-Alcoholic Fatty Liver Disease

Mona Munteanu, Fabio Nascimbeni, Pierre Bedossa, Marion Houot, Frederic Charlotte, Yen Ngo, Raluca Pais, Olivier Deckmyn, Vlad Ratziu, Thierry Poynard

Fabio Nascimbeni, Pierre Bedossa, Larysa Fedchuk, Raluca Pais, Sven M. Francque, Dominique G. Larrey, Guruprasad P. Aithal, Lawrence Serfaty, Mihai Voiculescu, Pascal Lebray, Thierry Poynard, Klaudia M. Traudtner, Vlad Ratziu

837: Adverse outcomes of pregnancy in mothers with NAFLD and their offspring

846: Serum Vitamin D Deficiency is Associated with Nonalcoholic Steatohepatitis in Adults

838: Survey of Diagnostic and Treatment Patterns of NAFLD and NASH in the United States: Real Life Practices Differ From Published Guidelines

847: Hepatic copper and PNPLA3 in patients with nonalcoholic fatty liver disease

Hannes Hagström, Jonas F. Ludvigsson, Anders Ekbom, Rolf W. Hultcrantz, Olof Stephansson, Knut Stokkeland

Zurabi Lominadze, Stephen A. Harrison, Michael Charlton, Rohit Loomba, Brent A. Neuschwander-Tetri, Stephen H. Caldwell, Kris V. Kowdley, Mary E. Rinella

839: The features and differences of GLP-1 analogues and DPP-4 inhibitors as treatments for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus Takamasa Ohki, Isogawa Akihiro, Koki Sato, Nobuo Toda

840: Metabolic Stressors Associated with Progressive Nonalcoholic Fatty liver Disease and Liver Transcriptional Activity of Alanine and Aspartate Aminotransferases

Silvia Sookoian, Gustavo O. Castaño, Tomas Fernández Gianotti, Romina Scian, Carlos J. Pirola


844: Fetuin-A negatively correlates with liver and vascular fibrosis in NAFLD subjects

841: Irisin is associated with physical activity level and hepatic steatosis grade in non-alcoholic fatty liver disease subjects

Rina So, Sechang Oh, Takashi Shida, Kiyoji Tanaka, Junichi Shoda

842: Is liver stiffness measurement (LSM) by Fibroscan better than FIB4 score for prediction of clinically significant fibrosis in patients with NAFLD?

Raj Vuppalanchi, Samer Gawrieh, Regina Weber, Naga P. Chalasani

843: Endoscopic Duodenal–Jejunal Bypass Liner (Endobarrier) Improves Hepatic Parameters of Nonalcoholic Fatty Liver Disease in Obese Uncontrolled type 2 Diabetes Mellitus Patients

Oranit Cohen-Ezra, Gabriella Segal-Lieberman, Alon Lang, Maor Lahav, Yeroham Kleinbaum, Sima Katsherginsky, Keren Tsaraf, Ziv Ben Ari

James E. Nelson, Laura Wilson, Christian Roth, Matthew M. Yeh, Kris V. Kowdley

Albert Stättermayer, Stefan Traussnigg, Elmar Aigner, Christian Kienbacher, Petra E. Steindl-Munda, Christian Datz, Fritz Wrba, Michael Trauner, Peter Ferenci

848: Impact of Liver Histology on Hepatic Elastography in Non-alcoholic Fatty Liver Disease

Ranesh Palan, William W. Kemp, Bastiaan DeBoer, Jeffrey M. Hamdorf, Michael J. House, Gerry C. MacQuillan, George Garas, Helena Ching, Ross Mac Nicholas, Stuart K. Roberts, Matthew T. Kitson, Gary P. Jeffrey, Leon Adams

849: The association of soluble lectin-like oxidized LDL receptor 1 (sLOX-1) level with histological severity in NAFLD patients

Hiroshi Ishiba, Yoshio Sumida, Saiyu Tanaka, Kazuyuki Kanemasa, Yuya Seko, Akira Okajima, Tasuku Hara, Hiroyoshi Taketani, Kanji Yamaguchi, Michihisa Moriguchi, Hironori Mitsuyoshi, Kohichiroh Yasui, Yoshito Itoh, Masahito Minami

850: Combination of Geniposide and Chlorogenic Acid May Reverse NASH Pathogenesis by Improving Gut Barrier Function

Qin Feng, Susan S. Baker, Wensheng Liu, Ricardo A. Arbizu, Ghanim Aljomah, Maan Khatib, Colleen A. Nugent, Robert D. Baker, Yiyang Hu, Lixin Zhu

851: The serum levels of SDF-1α correlated with the fibrosis and suggested the appearance of hepatic progenitor cells in the advanced stage of NASH

Wataru Ando, Hiroaki Yokomori, Yutaka Inagaki, Isao Okazaki, Yutaka Suzuki, Tsutsui Nobuhiro, Eigoro Yamanouchi, Hiroki Tanabe, Hajime Kuroda, Soichi Kojima, Mitsuko Hara, Masaya Oda, Takako Komiyama

852: Should we screen diabetic patients for fatty liver and advanced fibrosis? A prospective study with 2080 controlled attenuation parameter and liver stiffness measurements

Raymond Kwok, Grace LH Wong, Henry Lik-Yuen Chan, Juliana C. Chan, Alice P. Kong, Vincent W. Wong

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 853: Four simple risk factors predict post-transplant cardiac mortality in patients with nonalcoholic steatohepatitis

Lisa B. VanWagner, Brittany Lapin, Donald M. Lloyd-Jones, Anton I. Skaro, Mary E. Rinella

854: Patients with non-alcoholic fat liver disease (NAFLD) with lower levels of free serum copper and ceruloplasmin have different clinical and biochemical characteristics

Vinicius Nunes, Adriana R. Andrade, Ana Luiza V. Guedes, Claudia P. Oliveira, Marcio A. Diniz, Jose Estefano, Daniel F. Mazo, Eduardo Luiz R. Cancado

855: Tai chi ameliorates patient centered outcomes and markers of systemic inflammation and liver injury in subjects with nonalcoholic fatty liver disease

Angelo H. Paredes, Jo L. Robins, Jamie L. Sturgill, Mohammad S. Siddiqui, Arun J. Sanyal

856: Atherogenic Dyslipidemia in the Setting of Insulin Resistance Contributes to Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease

Fernando Bril, John Sninsky, Arthur M. Baca, Robert H. Superko, Paola Portillo Sanchez, Margaret C. Lo, Beverly Orsak, Kenneth Cusi

857: High Density Lipoprotein Dysfunction in Patients with Nonalcohol Steatohepatitis

Arthur J. McCullough, Jaividhya Dasarathy, Ling Li, Gregory Brubaker, Belinda Willard, Srinivasan Dasarathy, Jonathan D. Smith, Takhar Kasumov

858: Meta-Analysis Of Randomized Controlled Trials Comparing Current Pharmacologic Agents Vs. Placebo In Non-Alcoholic Fatty Liver Disease Ahmed Akhter, Adnan Said

859: Bile acid serum levels in adolescents with NAFLD: a biomarker for progression?

860: Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease

Lavinia Mezzabotta, Chiara Rosso, Ester Vanni, Roberto Gambino, Ramy Ibrahim Kamal Jouness, Francesca Saba, Federico Salomone, Melania Gaggini, Emma Buzzigoli, Chiara Saponaro, Fabrizia Carli, Gian Paolo Caviglia, Maria Lorena Abate, Antonina Smedile, Mario Rizzetto, Maurizio Cassader, Amalia Gastaldelli, Elisabetta Bugianesi

Edric Hee, William W. Kemp, Bastiaan de Boer, Jeffrey M. Hamdorf, Gerry C. MacQuillan, George Garas, Helena Ching, Ross Mac Nicholas, Stuart K. Roberts, Matthew T. Kitson, Gary P. Jeffrey, Leon Adams

862: Nonalcoholic Fatty Liver Disease Is Associated with Left Ventricular Diastolic Dysfunction

Jeong-Hoon Lee, Donghee Kim, Goh Eun Chung, Min-Sun Kwak, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee

863: The relationship between ALT and liver histology changes with age in NAFLD

Boon Bee George Goh, Mangesh Pagadala, Jaividhya Dasarathy, Aynur Unalp, Ruth Sargent, Carol A. Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa M. Yerian, Rish Pai, Srinivasan Dasarathy, Arthur J. McCullough

864: Non-alcoholic fatty liver disease (NAFLD) recurrence after liver transplant (OLT) for non-alcoholic steatohepatitis(NASH)

Norio Kawamura, Mustafa Nazzal, Galal El-Gazzaz, Mario Spaggiari, Masato Fujiki, Teresa Diago, Federico N. Aucejo, Koji Hashimoto, Cristiano Quintini, Charles Winans, Bijan Eghtesad, Charles M. Miller, John J. Fung, Naim Alkhouri, Dympna Kelly

865: Degree of hepatic fibrosis assessed using transient elastography is independently related with coronary artery calcification in nonalcoholic liver disease

Seng Chan You, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han

866: Associations Between Helicobacter pylori, Leptin, and Nonalcoholic Fatty Liver Disease (NAFLD) Joseph Roberts, William LeBlanc, Kiran Bambha

867: Nonalcoholic Fatty Liver Disease Is Associated With Arterial Stiffness Measured by Cardio-Ankle Vascular Index

Donghee Kim, Goh Eun Chung, Su-Yeon Choi, Min-Sun Kwak, Won Kim, Yoon Jun Kim, Jung-Hwan Yoon

868: Extremely low awareness and under-diagnosis of NAFLD in a population-based sample

Lisa B. VanWagner, Mary E. Rinella, Hongyan Ning, Donald M. Lloyd-Jones, Cora E. Lewis, Miriam B. Vos

869: Assessment of glycemic variability by continuous glucose monitoring system in patients with nonalcoholic fatty liver disease

Makiko Taniai, Etsuko Hashimoto, Kazuhisa Kodama, Tomomi Kogiso, Katsutoshi Tokushige, Keiko Shiratori

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Jörg Jahnel, Zoehrer Evelyn, Günter Fauler, Hubert Scharnagl, Tatjana Stojakovic, Valerio Nobili

861: Comparison of NAFLD Fibrosis Score (NFS) and transient elastography (Fibroscan®), alone and in combination, as non-invasive methods for the evaluation of fibrosis in non-alcoholic fatty liver disease (NAFLD)



HEPATOLOGY, October, 2014

Poster Sessions 870: Is fatty liver in diabetes a risk factor for HCC and cardiovascular disease? Prospective 10-year cohort study

879: Patients with type 2 diabetes mellitus (T2DM) and normal plasma aminotransferases are at high risk of nonalcoholic fatty liver disease (NAFLD)

871: Risk of severe fibrosis is associated with age at menopause in nonalcoholic fatty liver disease (NAFLD)

880: Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and NonAlcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study

Masataka Seike, Koichi Honda, Junya Oribe, Mizuki Endo, Mie Yoshihara, Masanori Tokoro, Masao Iwao, Hiroki Syo, Kazunari Murakami

Jagpal S. Klair, Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Katherine P. Yates, Aynur Unalp-Arida, Joel E. Lavine, Jeanne M. Clark, Anna Mae Diehl, Ayako Suzuki

872: Autoimmunity to Human Heat Shock Protein-70 is Associated with the Presence of Coronary Artery Disease in Patients with Nonalcoholic Fatty Liver Disease

Elzafir Elsheikh, Zahra Younoszai, Munkhzul Otgonsuren, Maria C. Albano, Ingrid Schneider, Hussain Allawi, Brian P. Lam, Yousef Fazel, Michael L. Campbell, Thomas Jeffers, Spencer Frost, Bryan Raybuck, Zobair Younossi

873: Performance and limitations of five steatosis biomarkers in patients with Non-alcoholic Fatty Liver Disease

Fabio Nascimbeni, Larysa Fedchuk, Raluca Pais, Frederic Charlotte, Chantal Housset, Paola Loria, Vlad Ratziu

874: A deficiency in 25-OH vitamin D is associated with increased steatohepatitis in alcoholic patients

Clémence M. Canivet, Rodolphe Anty, Stephanie Patouraux, Antonio Iannelli, Patricia Panaia-Ferrari, Imed Ben Amor, AnneSophie Schneck, Marie-Christine M. Saint-Paul, Jean Gugenheim, Philippe Gual, Albert Tran


875: Association between Type 2 Diabetes Genetic Susceptibility Loci and Hepatocellular Carcinoma in Patients with Type 2 Diabetes as Determined by Fibroscan

Masaaki Korenaga, Misuzu Ueyama, Nao Nishida, Keiko Korenaga, Takumi Kawaguchi, Hideyuki Hyogo, Hiroshi Aikata, Erina Kumagai, Yoshihiko Aoki, Masaya Sugiyama, Masatoshi Imamura, Kazumoto Murata, Tatsuya Kanto, Naohiko Masaki, Masashi Mizokami

876: NAFLD: A marker of severe Acute Pancreatitis

Sarfaraz A. Jasdanwala, Shivank Madan, Rajagopalan Sivaprasad, Capecomorin Pitchumoni

877: Berberine with Alfa Lipoic Acid (ALA) in Non Alcoholic Steato-hepatitis (NASH). A randomized double blinded placebo control trial. A Clinical pilot – The BANISH Trial Patrick Basu, Niraj J. Shah, M. Aloysius

878: Elevated biomarker-indicated liver disease and pro-inflammatory cytokines are associated with environmental PCB exposure in Anniston, Alabama

Heather B. Clair, Keith C. Falkner, Banrida Wahlang, Russell A. Prough, Matthew C. Cave

Denotes AASLD Presidential Poster of Distinction

Paola Portillo Sanchez, Fernando Bril, Maryann Maximos, Romina Lomonaco, Diane Biernacki, Beverly Orsak, Joan Hecht, Kenneth Cusi

Angelo M. Patti, Manfredi Rizzo, Rosaria V. Giglio, Dragana Nikolic, Antonino Terranova, Melchiorre Cervello, Alessandra Ferlita, Valeria A. Giannone, Giovanna Aurilio, Valentina Mistretta, Lydia Giannitrapani, Maurizio Soresi, Giuseppe Montalto

881: Oleuropein counteracts systemic inflammation and hepatic immune cells infiltration in a mouse model of NAFLD

Alessia Longo, Mario Arciello, Barbara Barbaro, Gabriele Toietta, Roberta Maggio, Carmela Viscomi, Clara Balsano

882: Serum concentration of CDCA and TCDCA are independently associated with Insulin sensitivity in a large blood donor population

Alberto Porro, Francesco Azzaroli, Simoni Patrizia, Domenico Fiorillo, Cecilia Camborata, Paolo Cecinato, Federica Buonfiglioli, Davide Festi, Silvia Spinozzi, Paolo Parini, Rosario Arena, Marco Montagnani, Rocco Maurizio Zagari, Franco Bazzoli, Aldo Roda, Giuseppe Mazzella

883: The Development of a Non-invasive Model to Predict the Presence of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease

Danny Issa, George Boon-Bee Goh, Rocio Lopez, Mangesh R. Pagadala, Jaividhya Dasarathy, Achuthan Sourianarayanane, Ruth Sargent, Carol A. Hawkins, Amer Khiyami, Lisa M. Yerian, Rish Pai, Srinivasan Dasarathy, Naim Alkhouri, Arthur J. McCullough

884: Normal ALT and advanced liver fibrosis in morbidly obese patients undergoing bariatric surgery

Fabio Nascimbeni, Judith Aron-Wisnewsky, Pierre Bedossa, Joan Tordjman, Raluca Pais, Thierry Poynard, Vlad Ratziu

885: Central obesity is associated with portal vein thrombosis

Julie Laurent, Camille Christol, Jean Bernard Ruidavets, Jean Ferrieres, Marie Angele Robic, Jean-Marie Peron, Jean-Pierre Vinel, Christophe Bureau

886: The quantitative amount of hepatic steatosis in NAFLD patients predicts the risk of developing diabetes: a prospective study with up to 25 years of follow-up

Patrik S. Nasr, Mattias Ekstedt, Ulrik L. Mathiesen, Stergios Kechagias

887: Cryptogenic cirrhosis category masks three quarters of NASH patients getting liver transplant

Angela Dolganiuc, Vikas Khullar, Virginia C. Clark, Roberto J. Firpi




Poster Sessions 888: LUM002 Positive Metabolic Profile Shown after Administration of 10mg For 28 Days in Type 2 Diabetes Mellitus Patients Leading to Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)

Renger Tiessen, Ciara Kennedy, Bradley T. Keller, Nancy Levin, Lisette Acevedo, Dee Wynne, Bronislava Gedulin, Andre A. van Vliet, Elizabeth Olek, Alejandro Dorenbaum

889: Apolipoprotein A-V Gene Expression in NonAlcoholic Steatohepatitis

Qin Feng, Susan S. Baker, Wensheng Liu, Robert D. Baker, Yiyang Hu, Lixin Zhu

890: U.S. Physician Survey of Current Practices in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis (NASH)

Stephen A. Harrison, Sheldon Y. Okada, Cathy A. Su, Matthew Paulson, Jeffrey D. Bornstein, Arun J. Sanyal

891: Wfa-M2bp Levels Are Usefull Indicators Of Progression And Inprovement For Monitoring Liver Fibrosis In Patients With Nonalcoholic Steatohepatitis

Miwa Kawanaka, Ken Nishino, Jun Nakamura, Takahito Oka, Noriyo Urata, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro Yamada

892: Vitamin D level is not associated with liver histology in non-alcoholic steatohepatitis

Matthew T. Kitson, Stephen Casey, Alan Pham, Adam Gordon, William W. Kemp, Peter Button, Stuart K. Roberts

893: Clinical and Histologic Differences Between HIVassociated NAFLD and Primary NAFLD: A Case-control Study

Irine Vodkin, Mark A. Valasek, Ricki Bettencourt, Edward R. Cachay, Rohit Loomba

Matthew T. Kitson, Alan Pham, Adam Gordon, William W. Kemp, Peter Button, Stuart K. Roberts

898: Comparison of M and XL FibroScan® probes for diagnosis of clinically significant fibrosis in patients with non-alcoholic fatty liver disease

Raj Vuppalanchi, Samer Gawrieh, Regina Weber, Naga P. Chalasani

Experimental Hepatocarcinogenesis 899: iNOS overexpression activates the Ras pathway in hepatocellular carcinoma, and targeted inhibition of iNOS suppresses Ras signaling and tumor growth Michael Li, Yujin Hoshida, Scott L. Friedman, Andrew Sikora

900: Sharpin promotes invasion of hepatocellular carcinoma through trans-activating Versican expression

Yasuo Tanaka, Keisuke Tateishi, Takuma Nakatsuka, Yotaro Kudo, Yoshinari Asaoka, Ryosuke Tateishi, Kazuhiko Koike

901: Genome-wide DNA methylation analysis in hepatocellular carcinoma: Identification and validation of STEAP4 as a novel methylated gene

Kohichiroh Yasui, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Yoshio Sumida, Hironori Mitsuyoshi, Shinji Tanaka, Shigeki Arii, Yoshito Itoh

902: Persistent Effects of Rapamycin on the Genetic Signature of Preneoplastic Foci in a Rat Model of Progenitor-Derived Hepatocellular Carcinoma (HCC)

Adeola O. Adebayo, Heather Francois-Vaughn, Kate E. Brilliant, Philip A. Gruppuso, Jennifer A. Sanders

903: Diet Associated Obesity Enhances Development of Hepatocellular Carcinoma Through Tenascin-C/Toll-like Receptor 4 Signaling

Alexander Hodge, Alexandra Mack, Caroline Tuck, Jorge Tchongue, Darcy Q. Holt, William Sievert, Gregory T. Moore

Jennifer H. Benbow, Kyle J. Thompson, Amber C. Smith, Tracy L. Walling, Catherine R. Culberson, Iain H. McKillop, Ting Li, Laura W. Schrum

895: African American Race and Hepatitis C Virus are associated with Lower Survival in Morbidly Obese Patients following Liver Transplantation: An Analysis of UNOS Data

904: Activation of the TGFβ/SMAD Pathway Underlies a Novel Tumor Promoting Role of Sulfatase1 in Hepatocellular Carcinoma

Ryan B. Perumpail, Robert Wong, Andrew M. Su, Christina Chou, Aijaz Ahmed

896: Acoustic structure quantification (ASQ): a new ultrasound-based approach for non-invasive quantification of liver fat content

Thomas Karlas, Joachim Berger, Nikita Garnov, Franziska Lindner, Harald Busse, Rima Chakaroun, Bettina Relke, Michael Tröltzsch, Volker Keim, Johannes Wiegand

Poster Viewing: 8:00 AM – 5:30 PM

Renumathy Dhanasekaran, Chunling Hu, Gang Chen, Abdul M. Oseini, Catherine D. Moser, Toin H. van Kuppevelt, Wei Zhou, Jan van Deursen, Taofic Mounajjed, Martin E. Fernandez-Zapico, Lewis R. Roberts

905: Identification of Hypermethylation and NonSynonymous Mutations in Genes Down-Regulated during the Process of Hepatocarcinogenesis in a Model of Chronic Hepatitis B

Yasunari Nakamoto, Taro Yamashita, Katsushi Hiramatsu, Tomoyuki Nemoto, Hiroyuki Suto, Shuichi Kaneko

Presenters in Attendance 12:30 – 2:00 PM


894: Non-alcoholic fatty liver disease Intermittent Fasting Time Intervention (NIFTI): Fasting without calorie restriction improves hepatic transient elastography, visceral adiposity and insulin resistance compared to standard care

897: High-dose vitamin D supplementation does not improve liver histology or metabolic profile in nonalcoholic steatohepatitis – a pilot study



HEPATOLOGY, October, 2014

Poster Sessions 906: The role of the tumor microenvironment for the CSC phenotype and progression of liver cancer: mechanistic findings and prognostic implications

Michael Fischer, Stefan Heinrich, Jesper B. Andersen, Martin F. Sprinzl, Ines Gockel, Marcus A. Woerns, Snorri S. Thorgeirsson, Peter R. Galle, Hauke Lang, Jens U. Marquardt

907: Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model

Kai Takegoshi, Masao Honda, Hikari Okada, Naoto Matsuzawa, Hisashi Takabatake, Toshinari Takamura, Takuji Tanaka, Shuichi Kaneko

908: p53 does not only suppress tumor development, but also regulates essential survival pathways in chronic liver injury

Laura E. Buitrago, Silke Marhenke, Thomas Longerich, Michelle C. Barton, Robert Geffers, Michael P. Manns, Arndt Vogel

909: Curcumin targets stem-like liver cancer cells by NF-kB mediated inhibition of histone deacetylases

Jens U. Marquardt, Luis E. Gómez-Quiroz, Lucrecia O. Arreguin Camacho, Frederico Pinna, Yun-Han Lee, Mitsuteru Kitade, Jesper B. Andersen, Kai Breuhahn, Peter R. Galle, Valentina M. Factor, Snorri S. Thorgeirsson

910: Antitumor effect of the novel sphingosine kinase-2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells

Xiwei Ding, Roongruedee Chaiteerakij, Catherine D. Moser, Albert Ndzengue, Hassan M. Shaleh, Gang Chen, Ying Li, Yanling Zhou, Shengbing Huang, Frank A. Sinicrope, Melanie B. Thomas, Charles D. Smith, Lewis R. Roberts


911: FABP4 but not FABP5 Promotes Human HCC Cell Line Proliferation In Vitro

Shayan S. Nazari, Ryan Z. Swan, Iain H. McKillop, Kyle J. Thompson

912: Preclinical Evaluation of a Selective Low-Density Lipoprotein-Docosahexaenoic Acid Nanomedicine: A Promising Alternate Treatment Strategy for Unresectable Hepatocellular Carcinoma

Ian Corbin, Xiaodong Wen, Lacy Reynolds, Rohit Mulik, Jorge A. Marrero

915: Role of Reptin in the regulation of DNA double strand breaks repair in human hepatocellular carcinoma Anne-Aurélie Raymond, Véronique Neaud, Jean Rosenbaum

916: A potential role for type XVIII collagen as a suppressor of hepatocellular carcinoma

Michael Duncan, Renumathy Dhanasekaran, Priyanka Thakur, Lewis R. Roberts

917: Two microRNA polymorphisms are associated with hepatitis B virus-related but not hepatitis C virus-related hepatocellular carcinoma in the Japanese population

Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Hiromi Abe, Tomokazu Kawaoka, Atsushi Ono, Sakura Akamatsu, Takashi Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro Uchida, Yohji Honda, Keiichi Masaki, Hiromi Kan, Masataka Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Michiaki Kubo, Kazuaki Chayama

918: The Molecular Basis of the Anti-Cyclin D1 Intrabody-Induced Inhibition of Hepatocellular Carcinoma Progression

Yan Wu, An Cui, Hanwei Li, Weiwei Tang, Ying Zhang, Ning Yang, Guannan Shen, Cynthia Ju, Guiying Li

919: Enhancing effect of retinoids on anti-cancer drugs by regulating the metabolic pathways of hepatocellular carcinoma cells Goshi Shiota, Keita Kanki

920: CXCR4 inhibition in combination with anti-PD1 immunotherapy results in an effective immune response during treatment with sorafenib in hepatocellular carcinoma

Thomas Reiberger, Rakesh R. Ramjiawan, Yunching Chen, Mei R. Ng, Tai Hato, Elizabeth C. Unan, Tejaswini P. Reddy, Yuhui Huang, Hiroki Ochiai, Peigen Huang, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda

921: Impact of connective tissue growth factor in Ras pathway-activated hepatocytes on the development of hepatocellular carcinoma

Yuki Makino, Hayato Hikita, Tsukasa Kawaguchi, Takahiro Kodama, Minoru Shigekawa, Yugo Kai, Yasutoshi Nozaki, Tasuku Nakabori, Yoshinobu Saito, Satoshi Tanaka, Ryotaro Sakamori, Takuya Miyagi, Tomohide Tatsumi, Tetsuo Takehara

913: Peretinoin, an acyclic retinoid, suppresses steatohepatitis and development of tumorigenesis by activated Atg16L1-dependent autophagy in mice fed an atherogenic high-fat diet

922: TSU-68 ameliorates the aggressiveness of hepatocellular carcinoma through inhibition of microenvironmental PDGF receptor signaling

Hikari Okada, Masao Honda, Kai Takegoshi, Naoto Matsuzawa, Taro Yamashita, Yoshio Sakai, Toshinari Takamura, Takuji Tanaka, Shuichi Kaneko

Yasumasa Hara, Taro Yamashita, Naoki Oishi, Kouki Nio, Takehiro Hayashi, Yoshimoto Nomura, Mariko Yoshida, Tomoyuki Hayashi, Tomomi Hashiba, Hikari Okada, Masao Honda, Shuichi Kaneko

914: IL-33 Facilitates Oncogene Driven Cholangiocarcinoma in Mice

923: miR-133b inhibits hepatocellular carcinoma cell growth through suppression of MET proto-oncogene

Daisaku Yamada, Sumera Rizvi, Nataliya Razumilava, Steven F. Bronk, Jun Li, Jorge A. Bezerra, Xin Chen, Gregory J. Gores

Denotes AASLD Presidential Poster of Distinction

Takayuki Kogure, Yasuteru Kondo, Jun Inoue, Yu Nakagome, Osamu Kimura, Tomoaki Iwata, Tatsuki Morosawa, Yasuyuki Fujisaka, Tooru Shimosegawa




Poster Sessions 924: Spink3 and Tff3 are overexpressed in autophagydeficient mice and may contribute to hepatocellular carcinoma development

Michael C. Wallace, Youngmin A. Lee, Luke A. Noon, Kemal M. Akat, Marie-Luise Berres, Scott L. Friedman

925: HCV NS5A blocks MG132-induced apoptosis in hepatocytes through the inhibition of NF-κB activation

Xia Jiang, Tatsuo Kanda, Shuang Wu, Yuki Haga, Reina Sasaki, Masato Nakamura, Shingo Nakamoto, Fumio Imazeki, Osamu Yokosuka

926: Liver fibrosis enhances tumorigenicity of hepatoma cells and makes them resistant to chemotherapy Benoit Lacoste, Benoît Dupont, Grégory Merlen, Marc Bilodeau

927: Polo-Like Kinase 3 is associated with improved Overall Survival in Cholangiocarcinoma

Benjamin Juntermanns, Svenja Sydor, Gernot M. Kaiser, Andreas Paul, Hideo A. Baba, Ali Canbay, Christian Dominik Fingas

928: Notch signal-activated hepatoma cells are associated with Jagged1 genomic abnormality, and Notch inhibitors efficiently suppress EpCAM+ liver cancer stem cells

Kazunori Kawaguchi, Masao Honda, Taro Yamashita, Kouki Nio, Hikari Okada, Masashi Nishikawa, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko

929: Activation of mitochondrial pathway of apoptosis in hepatocytes increases oxidative stress in hepatocytes leading to liver tumorigenesis

Hayato Hikita, Tomohide Tatsumi, Yoshinobu Saito, Satoshi Tanaka, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tetsuo Takehara

930: Difference in pattern of somatic mutations between primary sclerosing cholangitis (PSC)-related cholangiocarcinoma (CCA) and non-PSC related CCA

931: Loss of heterozygosity at 5q13.2 and 8p23.1 in dysplastic hepatocytes of cirrhotic liver are common events in hepatocellular carcinoma Zhang Zhao, Guang-Yong Chen, Jiang Long, Jian Huang

932: Sorafenib induces conversion to RAF dependence and ERK activation as a mechanism of rapidly acquired resistance in hepatocellular carcinoma

Rakesh R. Ramjiawan, Thomas Reiberger, Yunching Chen, Annique M. Duyverman, Peigen Huang, Keith Flaherty, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda

Gaia Spagnuolo, Massimiliano Cadamuro, Luisa Sambado, Stefano Indraccolo, Giorgia Nardo, Antonio Rosato, Carlo Spirli, Mario Strazzabosco, Luca Fabris

934: Galnt1 Modifies Cell Surface O-Glycosylation And Regulates Malignant Phenotypes In Hepatocellular Carcinoma Yao-Ming Wu, Miao-Juei Huang, Min-Chuan Huang

935: Role of histone demethylase Kdm3a in liver tumorigenesis

Takuma Nakatsuka, Keisuke Tateishi, Yotaro Kudo, Keisuke Yamamoto, Ryota Takahashi, Koji Miyabayashi, Yoshinari Asaoka, Yasuo Tanaka, Hideaki Ijichi, Kazuhiko Koike

936: FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis

Na Shang, Maribel Arteaga, Jimmy Stauffer, Scott Cotler, Jiwang Zhang, Wei Qiu

937: Inhibitory role of peroxisome proliferator-activated receptor-β/δ in hepatocarcinogenesis in mice and in vitro

Bo Shen, Ai min Li, Yu Qiang Nie, Yu-Jui Yvonne Wan, Yan Lei Du, Yu Yuan Li, Gui Jia Shen

938: Germline variants of highly point-mutated genes in hepatocellular carcinoma do not have strong effects on HCV-related hepatocarcinogenesis

Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Atsushi Ono, Sakura Akamatsu, Yuji Urabe, Keiichi Masaki, Hiromi Abe, Tomokazu Kawaoka, Takashi Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro Uchida, Yohji Honda, Hiromi Kan, Masataka Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Michiaki Kubo, Kazuaki Chayama

939: Statins interfere on TCTP and PI3K/AKT/ mTOR pathway and inhibit hepatocellular carcinoma progression

Marta García-Valdecasas, Antonio Gil-Gómez, Angela Rojas, Jordi Muntané, Farncisco Javier PAdillo Ruiz, Manuel RomeroGomez, Jose Antonio Del Campo

940: Role of Fatty Acid-Binding Protein 4 in liver carcinogenesis related to metabolic syndrome

Aurelie Sannier, Samira Laouirem, Mouna Mebarki, Miguel Albuquerque, Jacques Belghiti, Pierre Bedossa, Valerie Paradis

941: Hepatic steatosis and high circulating free fatty acid levels promote growth and invasiveness of hepatocellular carcinoma Andreas Koch, Claus Hellerbrand

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Roongruedee Chaiteerakij, Emily G. Barr Fritcher, Jesse Voss, Fergus J. Couch, Kevin C. Halling, Lewis R. Roberts, Benjamin R. Kipp

933: Reduction in nuclear S100A4 in Cholangiocarcinoma by low dose paclitaxel inhibits tumor invasiveness and hematogenous metastatization by interfering with Rho-A and Cdc42



HEPATOLOGY, October, 2014

Poster Sessions 942: Antioxidative selenoenzyme glutathione peroxidase 4 affects tumour vascularisation in a mice model of hepatocellular carcinoma

Nataliya Rohr-Udilova, Dagmar Stoiber, Eva Bauer, Wen Li, Martha Seif, Hubert Hayden, Gerald Timelthaler, Klaus Stolze, Regina Brigelius-Flohe, Robert Eferl, Markus Peck-Radosavljevic

943: Interplay of adenosinergic signaling and TTK mitotic kinase inhibition limits hepatocellular cancer cell growth

Ruoyu Miao, Yan Wu, Haohai Zhang, Huandi Zhou, Xiaofeng Sun, Eva Csizmadia, Lian He, Yi Zhao, Chengyu Jiang, Haitao Zhao, Simon C. Robson

944: Impaired function of CD4+ follicular helper T(Tfh) cells associated with progression of hepatocellular carcinoma Yiqiong Jia, Lifeng Wang, Zheng Zhang, Fu-Sheng Wang

945: The possibility of cancer stem cells among EpCAMpositive cells of hepatocellular carcinoma

Osamu Kimura, Yasuteru Kondo, Takayuki Kogure, Jun Inoue, Yu Nakagome, Tatsuki Morosawa, Tomoaki Iwata, Yasuyuki Fujisaka, Teruyuki Umetsu

946: Platelet-Derived Growth Factor D-Induced Secretion of Vascular Endothelial Growth Factor-C by Cancer-associated Fibroblasts stimulates lymphangiogenesis in Cholangiocarcinoma

Massimiliano Cadamuro, Marta Vismara, Simone Brivio, Mario Strazzabosco, Luca Fabris

947: Targeting the raft-associated Akt signaling in hepatocellular carcinoma


Jingmin Zhao, Yuan Liu, Jiyun Lv, Jian-Fei Shi, Jin Li, Mei Yang, Xiaodong Guo, Zhiwei Li, Hong-Bo Wang, Shaogeng Zhang, Zhenwen Liu, Jin-Biao Ding, Dong-Ping Xu

948: Hepatocyte specific Bid depletion reduces tumor development via suppression of inflammation related compensatory proliferation

Alexander Wree, Casey Johnson, Joan Font-Burgada, Michael Karin, Ariel E. Feldstein

Hepatitis C: Approved Therapeutic Agents 952: Significant Reduction of Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients with Peginterferon plus Ribavirin Therapy: A Five-year Clinical Cohort Study

Mei-Hsuan Lee, Yong Yuan, Ming-Lung Yu, Wan-Long Chuang, JiaHorng Kao, Chen-Hua Liu, Sheng-Nan Lu, I-Shyan Sheen, Gilbert J. L’Italien, Hwai-I Yang, Chien-Jen Chen

953: Early Assessment of Hepatitis C Virologic Response of US Veterans Receiving Sofosbuvir-based Therapy

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole

954: Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C infected patients in the UK Sandrine Cure, Ines Guerra, Geoffrey M. Dusheiko

955: Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin (RBV) in Patients with Genotype 1: Interim Results of a Prospective, Observational Study

Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, Jordan J. Feld, Robert S. Brown, Lynn M. Frazier, Michael W. Fried, David R. Nelson, Ira M. Jacobson

956: Safety and efficacy of Simeprevir + Sofosobuvir with or without Ribavirin in Patients with Decompensated Genotype 1 Hepatitis C induced Cirrhosis

Apurva A. Modi, Hector Nazario, Stevan A. Gonzalez, Manjushree Gautam, Jeffrey S. Weinstein, Parvez S. Mantry, Maisha Barnes, Adil Habib, Jean L. McAfee, Olga Teachenor, Lauren Tujague, James F. Trotter

957: Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II Study

Hayato Baba, Koichi Tsuneyama, Takeshi Nishida, Johji Imura

Marianne Martinello, Margaret Hellard, David Shaw, Kathy Petoumenos, Tanya L. Applegate, Jason Grebely, Barbara Y. Yeung, Laurence Maire, David M. Iser, Andrew R. Lloyd, Alexander J. Thompson, Joe Sasadeusz, Paul Haber, Gregory J. Dore, Gail Matthews

950: Hepatitis B virus X protein priors to induce expression of alpha-fetoprotein to activate PI3K/mTOR signal pathway in liver cells

958: Decrease of Cirrhosis and Hepatocellular Carcinoma (HCC) in African Americans (AA) Following Successful Treatment for Chronic Hepatitis C (CHC)

949: Insulin treatment improves disorder of glycolipid metabolism, but accelerates the progression of hepatocellular carcinoma in DIAR-nSTZ mice, which is a hepatocellular carcinoma model based on diabetes

Mingyue Zhu, Junli Guo, Hua Xia, Xieju Xie, Mengsen Li

951: Cell cycle-dependent regulation of FGFR4 in cholangiocarcinoma

Ashley M. Mohr, Mary A. Smith, Sathish Kumar Natarajan, Cody J. Wehrkamp, Carol A. Casey, Justin L. Mott

Denotes AASLD Presidential Poster of Distinction

Naveen Reddy, Paul Naylor, Zaher Hakim, Redwan Asbahi, Karthik Ravindran, Murray N. Ehrinpreis, Milton G. Mutchnick




Poster Sessions 959: Sofosbuvir plus Ribavirin in the Treatment of Egyptian Patients with Chronic Genotype 4 HCV Infection

966: Safety, Anti-Viral Efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in Patients with Severe Renal Impairment

960: Performance of Simeprevir- and Sofosbuvirbased HCV Treatment in Real World Clinical Practice

967: Plasma and Intracellular Ribavirin Pharmacokinetics and Concentration-Effect Analyses in Chronic Hepatitis C Virus Genotype 1 Patients Receiving Sofosbuvir plus Ribavirin in the NIAID SPARE Trial

Gamal E. Esmat, Gamal Shiha, Rabab F. Omar, Mohamad Hassany, Radi Hammad, Marwa Khairy, Waleed Samir, Reham Soliman, Diana M. Brainard, Deyuan Jiang, Kathryn Kersey, Steven J. Knox, Benedetta Massetto, John G. McHutchison, Wahid H. Doss

Kian Bichoupan, Rachana Yalamanchili, Keith M. Sigel, Alyson Harty, Michel Ng, Alicia Stivala, Donna Fanelli, Donald Gardenier, David B. Motamed, Badr Aljarallah, David Sachs, Michael Linderman, Viktoriya Khaitova, Meena B. Bansal, Priya Grewal, Ritu Agarwal, Charissa Y. Chang, Jennifer Leong, Gene Y. Im, Lawrence Liu, Joseph A. Odin, Nancy Bach, David C. Perlman, Jonathan Yeh, Albert Min, Henry C. Bodenheimer, Donald P. Kotler, Scott L. Friedman, Thomas D. Schiano, Ponni Perumalswami, Douglas Dieterich, Andrea D. Branch

Edward J. Gane, Richard A. Robson, Maurizio Bonacini, Benedict Maliakkal, Lin Liu, Karim Sajwani, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Catherine A. Stedman, Eric Lawitz

Joseph E. Rower, Eric G. Meissner, Leah C. Jimmerson, Anu Osinusi, Zayani Sims, Tess L. Petersen, Lane Bushman, Pamela Wolfe, John G. McHutchison, Shyam Kottilil, Jennifer J. Kiser

968: Baseline vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis

Matthew T. Kitson, Christoph Sarrazin, Pierluigi Toniutto, Guy D. Eslick, Stuart K. Roberts

961: Resistance Analysis of Treatment-Experienced HCV Genotype 1 Infected Patients Retreated with Sofosbuvir

969: Delayed early HCV RNA response during IFN-free therapy with sofosbuvir in interferon-ineligible patients with advanced cirrhosis

962: Reducing Polymorphisms Consisting of (TA)n Dinucleotide Repeat Near IL28B Gene Interact with the Deviation of IL28B SNPs and Affect the Effectiveness of PegIFN/RBV, but not PegIFN/RBV/TVR

970: Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study

Hongmei Mo, Brian Doehle, Viktoria Gontcharova, Ramakrishna K. Chodavarapu, Bittoo Kanwar, Ira M. Jacobson, Stanislas Pol, Diana M. Brainard, John G. McHutchison, Michael D. Miller

Masaaki Korenaga, Masaya Sugiyama, Yoshihiko Aoki, Keiko Korenaga, Yoko Yamagiwa, Masatoshi Imamura, Nao Nishida, Kazumoto Murata, Tatsuya Kanto, Naohiko Masaki, Masashi Mizokami

963: Efficacy and safety of sofosbuvir plus simeprevir in patients with advanced HCV cirrhosis

Laura Gragnani, Alessia Piluso, Elisa Fognani, Monica Monti, Barbara Boldrini, Teresa Urraro, Alessio Fabbrizzi, Umberto Arena, Stefania Moscarella, Jessica Ranieri, Cristina Stasi, Giacomo Laffi, Anna Linda Zignego

971: Efficacy and safety of telaprevir based triple therapy in coinfected patients with advanced fibrosis. Final results of the spanish cohort

964: Burden of Side Effects Associated with Treatment of Hepatitis C

Ami R. Buikema, Lisa C. Rosenblatt, Fang Liu, Boris Gorsh, John C. White, Bruce E. Sill

Miguel A. von Wichmann, Ana Moreno, Luis F. López Cortés, Enrique Ortega, Jose Antonio Mira, Carmen Quereda, Marisa L. Montes, Maria Tellez, Miguel García del Toro, José A. Iribarren, Angela M. Camacho, Luz Martin-Carbonero, Joseba Portu, JoséRamón Blanco, Koldo Aguirrebengoa, Juan Berenguer, Juan Gonzalez García, Manuel Márquez Solero

965: Impact of host and therapeutic factors and resistant associated variants on response to interferon based- direct acting antiviral treatment in difficult-totreat chronic hepatitis C patients

972: Safety and Effectiveness of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) or Ribavirin (RBV) for the Treatment of Hepatitis C Virus (HCV) Recurrence after Liver Transplant (LT)

Mina Nakagawa, Yasuhiro Asahina, Miki Taniguchi, Takako Watanabe, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yujiro Tanaka, Mamoru Watanabe

Glen A. Lutchman, Nghia H. Nguyen, Tiffany I. Hsiao, Vinh D. Vu, Vincent Chen, Aijaz Ahmed, Tami Daugherty, Gabriel Garcia, Radhka Kumari, W. Ray Kim, Mindie H. Nguyen

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Camelia I. Capraru, Magdalena Kuczynski, Danie La, Diana Kaznowski, Matthew Kowgier, David K. Wong, Joshua Juan, Hemant Shah, Alnoor Ramji, Harry L. Janssen, Jordan J. Feld

Katja Deterding, Christoph Hoener zu Siederdissen, Kerstin Port, Janina Kirschner, Lisa Sollik, Carola Mix, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer



HEPATOLOGY, October, 2014

Poster Sessions 973: 97% Sustained Virologic Response in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection Receiving Sofosbuvir in Combination with Ribavirin for 12 Weeks: Results from a Phase 3 Multicenter Study

Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, Hitoshi Mochizuki, Namiki Izumi, Fusao Ikeda, Hidenori Toyoda, Osamu Yokosuka, Kazushige Nirei, Takuya Genda, Takeji Umemura, Tetsuo Takehara, Naoya Sakamoto, Yoichi Nishigaki, Kunio Nakane, Nobuo Toda, Tatsuya Ide, Mikio Yanase, Keisuke Hino, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote, Diana M. Brainard, Steven J. Knox, William T. Symonds, John G. McHutchison, Hiroshi Yatsuhashi, Masashi Mizokami

974: Modeling treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago

Desarae Echevarria, Alexander Gutfraind, Basmattee Boodram, Marian E. Major, Scott Cotler, Harel Dahari

975: Efficacy of sofosbuvir and simeprevir-based regimens for 304 HCV treatment-experienced patients in a real-life setting; data from the TRIO network

Bruce R. Bacon, Douglas Dieterich, Steven L. Flamm, Kris V. Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, Naoky Tsai

976: High Response Rate and Good Tolerability of Genotype 6 Chronic Hepatitis C Patients to Pegylated Interferon alfa combining Ribavirin in China

Lai Wei, ZhiLiang Gao, Qing Mao, Dazhi Zhang, Jianning Jiang, Guozhong Gong, Zhibiao Yin, Qing Xie, Jian Sun, Huiying Rao, Bo Feng, Ruifeng Yang, Haiying Zhang


977: Poor Sustained Virologic Response (SVR) in a Multicenter Real-Life Cohort of Chronic Hepatitis C (CHC) Patients Treated with Pegylated Interferon (PEG IFN) and Ribavirin (RBV) plus Telaprevir (TVR) or Boceprevir (BOC)

Kevin P. Vo, Philip Vutien, Matthew J. Akiyama, Vinh D. Vu, Joy I. Piotrowski, Nghiem B. Ha, James M. Wantuck, Marina Roytman, Ramsey Cheung, Jiayi Li, Naoky Tsai, Mindie H. Nguyen

978: Treatment safety and efficacy of Boceprevir-based triple therapy in genotype 1 hepatitis C: the Australian multicentre Boceprevir real world experience (SABRE-C)

Anouk T. Dev, Joanne Mitchell, Kevan Polkinghorne, Richard Skoien, Katherine Stuart, Wendy Cheng, Alice Lee, Miriam T. Levy, John Lubel, Saroja Nazareth, Alan J. Wigg, Sherryne L. Warner, Stuart K. Roberts

979: DDRGK1 variants are associated with platelet decline during peginterferon and ribavirin therapy in Caucasian patients with chronic HCV infection Raoel Maan, Elisabeth P. Annemiek A. Hansen, Bart J. de Knegt

Adriaan J. van der Meer, Willem Pieter Brouwer, Plompen, Milan J. Sonneveld, Robert Roomer, van der Eijk, Zwier M. Groothuismink, Bettina E. J. Veldt, Harry L. Janssen, Andre Boonstra, Robert

980: Impact of latest direct antiviral agents (DAAs) on the cure rate and cost of hepatitis C infection treatment: a meta-analysis

Siddharth Bansal, Mohamed G. Shoreibah, Brendan M. McGuire, Ashwani K. Singal, Bhupinderjit S. Anand

981: A real life experience with COSMSOS regimen in Genotype 1 chronic hepatitis C treatment: including patients with East Asian ancestry and decompensated cirrhosis

Marina Roytman, Resham Ramkissoon, Leena K. Hong, Leslie Huddleston, Ruby Trujillo, Peter Poerzgen, Todd B. Seto, Naoky Tsai

982: Sofosbuvir plus Ribavirin for the Treatment of Russian Patients with Chronic HCV Genotype 1 or 3 Infection

Vladimir Chulanov, Konstantin Zhdanov, Kathryn Kersey, Yanni Zhu, Benedetta Massetto, Sergey Zhuravel, Svetlana Romanova, Elena Nurmukhametova, Viacheslav Morozov, Galina Kozhevnikova, Larisa Gogova, Natalia Geyvandova, Natalia Gankina, Evgenii Chesnokov, Eduard Z. Burnevich, Elena Bessonova, Djamal Abdurakhmanov, Diana M. Brainard, John G. McHutchison, Igor G. Bakulin, Vasily Isakov

983: Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of 345 HCV patients with cirrhosis; data from the TRIO network

Steven L. Flamm, Bruce R. Bacon, Douglas Dieterich, Kris V. Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi

984: Interferon based therapies (IBT) against hepatitis C (HCV) in previous kidney transplant (KT) recipients on hemodialysis (HD) do not seem to increase the risk of graft intolerance syndrome (GIS)

Javier-Enrique Hernandez Blanco, Josep M. Barrera, Sabela Lens, Zoe Mariño, Francesc Maduell, Josep-Maria Campistol, Xavier Forns, Maria-Carlota Londono

985: Telaprevir combination therapy in treatment-naïve and -experienced patients co-infected with HCV/HIV (INSIGHT STUDY): sustained virologic response at 12 weeks final analysis

Marisa L. Montes, Mark Nelson, Pierre-Marie Girard, Joe Sasadeusz, Andrzej Horban, Beatriz Grinsztejn, Natalia Zakharova, Antonio Rivero, Erkki Lathouwers, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, James Witek

986: Protease inhibitors impair renal function in HCVinfected immunocompetent patients

Carlos Fernández-Carrillo, Juan Manuel Pascasio, Martin Prieto, J. L. Montero, Javier Crespo, Inmaculada Fernández, Xavier Forns, Javier García-Samaniego, Manuel Romero-Gomez, Juan Turnes, J. Javier Moreno, Elba Llop, Cristina Serrano-Millan, Maria Buti, Jose Luis Calleja

987: MCNs, reach and treat the HCV patients other pathways can’t!

Jan Tait, Brian P. Stephens, Shirley Cleary, Paul G. McIntyre, John F. Dillon

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 988: Analysis of HCV-RNA decrease until one week after the start of the triple therapy including protease inhibitor in patients chronically infected with hepatitis C virus genotype 1

Satoru Hashimoto, Rumiko Nakao, Ayako Mine, Yuki Kugiyama, Ryu Sasaki, Shigemune Bekki, Akira Saeki, Shinya Nagaoka, Seigo Abiru, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi

989: Inosine Triphosphatase and Interleukin 28B Genetic Variants to Predict Sustained Virologic Response in Hemodialysis Patients with Hepatitis C Virus Genotype 1 or 2 Infection who Received Peginterferon alfa-2a plus Low-Dose Ribavirin: Data Analysis from HELPER-1 and HELPER-2 Trials

995: Real World Experience with Sofosbuvir and Simeprevir combination treatment in patients with HCV genotype 1

Ming V. Lin, Neliswa A. Gogela, Jessica L. Wisocky, Michael Thiim, Daniel S. Pratt, Karin L. Andersson, Nikroo Hashemi, Anna E. Rutherford, Kathleen E. Corey, Lee F. Peng, Dahlene N. Fusco, Arthur Y. Kim, Alan Mullen, Judith A. Bloom, Raymond T. Chung

996: Simeprevir plus Sofosbuvir for Patients with Recurrence of Genotype 1 Hepatitis C Infection after Liver Transplantation

Susan J. Ripper, Edward W. Holt, Stewart Cooper, Adil E. Wakil, Timothy J. Davern, Raphael Merriman, Jennifer Guy, R. Todd Frederick

Chen-Hua Liu, Chun-Jen Liu, Chung-Feng Huang, Jou-Wei Lin, Chia-Yen Dai, Cheng-Chao Liang, Jee-Fu Huang, Peir-Haur Hung, Hung-Bin Tsai, Meng-Kun Tsai, Chih-Yuan Lee, Shih-I Chen, ShengShun Yang, Tung-Hung Su, Hung-Chih Yang, Pei-Jer Chen, DingShinn Chen, Wan-Long Chuang, Ming-Lung Yu, Jia-Horng Kao

997: The impact of plasma ribavirin concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin

990: Safety and Efficacy of Simeprevir, Sofosbuvir and Riabviirn Combination Therapy in Liver Transplant Recipients with Severe Recurrent HCV

998: A real life experience with sofosbuvir-based regimens, including patients with multiple factors previously associated with inferior treatment response

Satheesh Nair, Nader Dbouk, Shilpa Lingala, Sanjaya K. Satapathy

Christina Wu, Marina Roytman, Leena K. Hong, Leslie Huddleston, Ruby Trujillo, Alvin Cheung, Peter Poerzgen, Naoky Tsai

991: Effects of Ribavirin on Red Blood Cell Concentrations of Endogenous Purines in Patients with Hepatitis C Virus Undergoing Ribavirin-Based Treatment

999: Higher sustained virologic response (SVR) in patients with early virologic response (EVR) and hepatitis C genotype 4 (HCV-4) compared to genotype 1 (HCV-1) with pegylated interferon and ribavirin (PEG IFN+RBV): a comparative analysis from a meta-analysis

Leah C. Jimmerson, James R. Burton, Fafa Baouchi, Aimee E. Truesdale, Angie Price, Michelle Ray, Lane Bushman, Kyle Hammond, Jacob Langness, Sarah Tise, Gregory T. Everson, Jennifer Kiser

992: The Effect of Rifampin on the Pharmacokinetics of Sofosbuvir in Healthy Volunteers

Kimberly L. Garrison, Yi Wang, Diana M. Brainard, Karim Sajwani, Anita Mathias

Patrick Basu, Niraj J. Shah, M. Aloysius

994: Real-World Data on HIV positive Patients with HCV Genotype 1,2 and 3 on Sofosbuvir- and Simeprevircontaining Regimens

David P. Del Bello, Kian Bichoupan, Rachana Yalamanchili, Alyson Harty, Michel Ng, Alicia Stivala, Donald Gardenier, Viktoriya Khaitova, Nadim Salomon, Donna Mildvan, David C. Perlman, Lawrence U. Liu, Joseph A. Odin, Thomas D. Schiano, Ponni Perumalswami, Daniel S. Fierer, Douglas Dieterich, Andrea D. Branch

Brittany E. Yee, Derek Lin, Nghia H. Nguyen, Bing Zhang, Philip Vutien, Carrie R. Wong, Glen A. Lutchman, Mindie H. Nguyen

1000: Renal Impairment under Triple Therapy with Boceprevir in German Real-Life: Evidence for a Pivotal Role for Peginterferon/Ribavirin Backbone, Female Gender and Age >50 Years

Peter Buggisch, Hanns F. Loehr, Gerlinde Teuber, Hermann Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer, Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl, Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher, Manfred Bilzer

1001: Relevance of early virological assessment during triple therapy combining telaprevir or boceprevir with pegylated interferon/ribavirin in chronic hepatitis C patients - The ANRS CO20 CUPIC study

François Bailly, Victor Virlogeux, Cécilie Dufour, Pierre Pradat, Christophe Hezode, Dominique G. Larrey, Laurent Alric, Didier Samuel, Marc Bourlière, Sophie Metivier, Jean-Pierre Zarski, Hélène Fontaine, Veronique Loustaud-Ratti, Lawrence Serfaty, JeanPierre Bronowicki, Ventzislava Petrov-Sanchez, Fabrice Carrat, Fabien Zoulim

1002: Successful treatment of post liver transplant patients with genotype 1 hepatitis C virus with sofosbuvir and simeprevir

Carmi S. Punzalan, Curtis Barry, Isabel Zacharias, Julie Rodrigues, Savant Mehta, Adel Bozorgzadeh, Graham Barnard Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


993: Simeprevir and Sofosbuvir with modified doses of Ribavirin (RBV) therapy on Telaprevir experienced Co infected (with HIV) cirrhotics with chronic hepatitis C (CHC) A randomized open label clinical pilot study: STOP C

Marianne Martinello, Maryam Alavi, Gregory J. Dore, Ana Schteinman, Richard O. Day, Kenneth Williams, Gail Matthews



HEPATOLOGY, October, 2014

Poster Sessions 1003: Safety and Efficacy of Simeprevir and Sofosbuvir in Patients with Decompensated Cirrhosis

Shilpa Lingala, Sanjaya K. Satapathy, Nader Dbouk, Satheesh Nair

1004: Urgent Treatment With Sofosbuvir Based Regimen For Hepatitis C Genotype 1 Patients With Severe Renal Insufficiency (GFR 90% in Patients with Early Virologic Response

Peter Buggisch, Hanns F. Loehr, Gerlinde Teuber, Hermann Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer, Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl, Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher, Manfred Bilzer

1040: Treatment of Acute Hepatitis C (HCV) Infection with Pegylated Interferon and Ribavirin (P/R) in Patients Co-infected with Human Immunodeficiency Virus (HIV): a systematic review and meta-analysis


Bing Zhang, Benjamin Yip, Nghia H. Nguyen, Brittany E. Yee, Walid S. Ayoub, Mindie H. Nguyen, Glen A. Lutchman

1041: IFNL4/IL-28B haplotype structure and predictability of their variations for spontaneous and treatment-induced clearance of HCV infection in the Japanese population

Hidenori Ochi, Daiki Miki, C. Nelson Hayes, Hiromi Abe, Michiaki Kubo, Kazuaki Chayama

1042: Estimated Glomerular Filtration Rate (eGFR) at Baseline Strongly Predicts the Frequency of Anemia in Patients Undergoing Boceprevir Triple Therapy in German Real-Life

Gerlinde Teuber, Peter Buggisch, Hanns F. Loehr, Hermann Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer, Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl, Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher, Manfred Bilzer

Denotes AASLD Presidential Poster of Distinction

1043: Interferon ineligible naive chronic hepatitis C genotype I subjects treated with Simeprevir and Sofosbuvir in special population (psychiatric). An open label prospective clinical pilot study; INSPIRE C study Patrick Basu, Niraj J. Shah, M. Aloysius, Robert S. Brown

1044: Final efficacy and safety of telaprevir, Peg-IFNalfa-2a, and ribavirin in combination with darunavir/ ritonavir-based HAART in HCV/HIV-1 co-infected patients (INSIGHT substudy)

Marisa L. Montes, Enrique Ortega, Andrzej Horban, Mark Nelson, Jacques Durant, Katrien de Backer, Katrien Janssen, Sivi Ouwerkerk-Mahadevan

Hepatotoxicity: Drug Metabolism 1045: Lysosomal Iron Mobilization in Hepatotoxicity after Acetaminophen in Vivo in Mice Jiangting Hu, Hartmut Jaeschke, John J. Lemasters

1046: A common UGT1A haplotype of genetic variants reduces the transcriptional responsiveness towards the anti-cancer drug irinotecan Sandra Kalthoff, Anja Winkler, Christian P. Strassburg

1047: ‘Dual function of Jnk1 and Jnk2 in hepatocytes is indispensable against drug-induced liver injury’

Francisco Javier Cubero, Wei Hu, Gang Zhao, Jin Peng, Yulia Nevzorova, Malika Al Masaoudi, Lars Bechmann, Mark V. Boekschoten, Michael Muller, Nikolaus Gassler, Ali Canbay, Christian Liedtke, Christian Trautwein

1048: Activation of AMPK prevents and reverses drug induced mitochondrial and hepatocellular damage in collagen sandwich culture of hepatocytes Dong Fu, Geoffrey C. Farrell, Ghada Haydar

1049: Human mercapto-albumin of chronic liver disease patients contributes to alterations in the functional properties of human serum albumin

Hiroko Setoyama, Motohiko Tanaka, Hideaki Naoe, Takehisa Watanabe, Masakuni Tateyama, Kotaro Fukubayashi, Youko Yoshimaru, Takeshi Kawasaki, Satomi Fujie, Kazuhiro Izumi, Hiroshi Watanabe, Toru Maruyama, Yutaka Sasaki

1050: Amoxicillin-clavulanate induced DILI: 113 cases from the US Drug-Induced Liver Injury Network (DILIN)

Andrew deLemos, Marwan Ghabril, Don C. Rockey, Jiezhun Gu, Huiman X. Barnhart, Mark W. Russo, Herbert L. Bonkovsky

1051: The Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz-induces an inflammatory response in hepatic cells controlled by autophagy

Ana Blas-García, Fernando Alegre, Miriam Polo, Dolores OrtizMasiá, Haryes A. Funes, Alberto Martí-Rodrigo, Nadezda Apostolova, Juan V. Esplugues




Poster Sessions 1052: The Long-Term Follow-up of 140 Patients with Drug-Induced Liver Injury (DILI): Emphasis on Phenotypes and Chronic Risk Factors

1061: Hep-114, a Novel Drug Candidate with Potent Activity against Toxic Liver Injury: Preliminary Phase 2 Results

1053: Pharmacological Inhibition of M1 Muscarinic Receptors (M1R) Reduces Oxidative Stress in AML12 Hepatocytes

Hepatotoxicity: Mechanisms

Wenjing Zhu, Xinyan Zhao, Tailing Wang, Hong Ma

Ravirajsinh Jadeja, Sandeep Khurana

1054: Risk factors for chronicity in idiosyncratic druginduced liver injury (DILI)

I. Medina-Cáliz, B. Garcia-Muñoz, Mercedes Robles Diaz, C. Stephens, Andrés González-Jiménez, Miren García-Cortés, A. Ortega, Ramón Hidalgo, Maria Carmen Fernandez, Manuel Romero-Gomez, J. M. Navarro, Hacibe Hallal, Ramon Planas, S. Avila, S. Blanco, Agustin Castiella, E. Zapata, Miguel Jimenez, J. M. Moreno-Planas, German Soriano, Carlos Guarner, E. Roman, Joaquin Primo, A. Aldea, Martin Prieto, M. I. Lucena, Raul J. Andrade

1055: Drug-induced Liver Injury (DILI) Associated with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS/TEN): Characteristics and Outcome

Harshad Devarbhavi, Sujata Raj, Keyur A. Sheth, Karnam Ravikiran, Rajvir Singh, Venu H. Aradya, T. R. Vijaykumar, Mallikarjun Patil, Adarsh Ck

1056: Characteristics of Efavirenz drug induced liver injury - a cohort analysis

Mark W. Sonderup, Helen Wainwright, Mashiko Setshedi, C. W. Spearman

1057: Endoplasmic Reticulum stress inhibitors diminish acetaminophen toxicity

Annelies Paridaens, Yves-Paul Vandewynckel, Eliene Bogaerts, Anja Van den Bussche, Hans Van Vlierberghe, Anja M. Geerts, Isabelle Colle

Tom Brundage, Herve Mommeja-Marin, Marion Morrison, Katherine J. Van Sickle

1059: Histological Changes That Reliably Differentiate Autoimmune Hepatitis from Drug-Induced Autoimmune Hepatitis: Important Role of Liver Biopsy

Sadhna Dhingra, Thomas D. Schiano, Jawad Ahmad, Joseph A. Odin, M. Isabel Fiel

1060: The effect of acetaminophen on primary hepatocytes isolated from transgenic mice with different apolipoprotein E genotypes

Vojtech Mezera, Otto Kucera, Alena Moravcova, Eva Peterova, David Rychtrmoc, Tomas Rousar, Ondrej Sobotka, Zuzana Cervinkova

Poster Viewing: 8:00 AM – 5:30 PM

1062: CD44 deficency exacerbates murine acetaminophen(APAP) hepatotoxicity in association with enhanced hepatic inflammation and impaired clearance of hyaluronan fragments Jo Suda, Luoluo Yang, Neil Kaplowitz, Zhang-Xu Liu

1063: Acetaminophen (APAP) Hepatotoxicity Leads To DNA Damage-Induced Arrest of Injured Cells In G0/ G1 Through Involvement Of Cell Cycle Regulators Preeti Viswanathan, Sriram Bandi, Sanjeev Gupta

1064: Liver fibrogenesis is controlled by innate immune activation pathways in hepatocyte apoptosis

Arvin Iracheta-Vellve, Jan Petrasek, Abhishek Satishchandran, Karen Kodys, Evelyn A. Kurt-Jones, Katherine A. Fitzgerald, Gyongyi Szabo

1065: Sumoylation regulates Cytochrome P450 2E1 (CYP2E1) expression in alcoholic liver disease Maria Lauda Tomasi, Minjung Ryoo, Diana Arsene

1066: Exposure to Vinyl Chloride Metabolites Exacerbates Liver Injury Caused by High Fat Diet in Mice

Lisanne C. Anders, Amanda N. Douglas, Adrienne M. Bushau, Keith C. Falkner, Gavin E. Arteel, Matthew C. Cave, Craig J. McClain, Juliane I. Beier

1067: Cholestatic Drug reactions are more likely to cause persistent liver injury and impaired Quality of Life during prolonged follow-up: Results from the DILIN Prospective study

Robert J. Fontana, Paul H. Hayashi, Rajender Reddy, David E. Kleiner, Thomas Phillips, Huiman X. Barnhart, Jayant A. Talwalkar, Naga P. Chalasani, William M. Lee, Andrew Stolz, Timothy J. Davern, Paul B. Watkins, Jose Serrano

1068: Microsomal prostaglandin E synthase-1 (mPGES-1) prevents Fas-induced liver injury Lu Yao, Chang Han, Tong Wu

1069: New insight into the role of liver in viral hemorrhagic fever

Gavin E. Arteel, Juliane I. Beier, Jenny Jokinen, Patrick S. Whang, Amah M. Martin, Nikole L. Warner, Igor S. Lukashevich

1070: Oxaloacetic Acid Protects the Liver Against Warm Ischemia

Grégory Merlen, Benoit Lacoste, Benoît Dupont, Valérie-Ann Raymond, Marc Bilodeau

Presenters in Attendance 12:30 – 2:00 PM


1058: Brincidofovir (CMX001) Dose and Plasma Exposure Correlates with Serum Alanine Aminotransferase Elevations

George Tets



HEPATOLOGY, October, 2014

Poster Sessions 1071: Acetaldehyde Suppresses Interferon Alpha Signaling In HCV-infected Hepatoma Cells By Impairing Protein Methylation

Murali Ganesan, Lee K. Jaramillo, Kusum K. Kharbanda, Dean J. Tuma, Natalia A. Osna

1072: A novel oral form of pentamidine (OCZ103) blocks TNF-mediated mouse liver injury from GalN/LPS

Enpeng Zhao, Ghulam Ilyas, Yu Lin, Kathryn Tanaka, Francois Ravenelle, Mark J. Czaja

C. Stephens, Antonia Moreno-Casares, MAngel López-Nevot, Miren García-Cortés, I. Medina-Cáliz, Hacibe Hallal, German Soriano, Francisco. Ruiz-Cabello, Manuel Romero-Gomez, M. I. Lucena, Raul J. Andrade

1082: Intrahepatic Neurons: Chronological Changes after Liver Transplantation, and their Associations with Liver Diseases

1073: Hepatic Stellate Cells Are Activated In A Rac1 Dependent Mechanism After Engulfment Of Isoniazid Exposed Dying Hepatocytes – Role In Drug Induced Fibrogenesis

Kei Mizuno, Keigo Murakami, Tomohiro Katsumi, Kyoko Tomita, Chikako Sato, Kazuo Okumoto, Yuko Nishise, Hisayoshi Watanabe, Takafumi Saito, Naoki Kawagishi, Yoshiyuki Ueno

1074: Moderate (2% v/v) ethanol feeding delays liver regeneration and enhances hepatic profibrotic markers after carbon tetrachloride-induced liver injury in mice

Jie Cai, Xiling Guo, Yin Chen, Yiyue Ge, Lunbiao Cui, Yali Weng

Krutika T. Deshpande, Shinlan Liu, Michele Pritchard

Imaging of Steatohepatitis

1075: Early growth response 1 attenuates ethanolaccelerated, carbon tetrachloride-induced profibrotic signatures in liver: Novel role for NAD(P)H dehydrogenase, quinone 1

1084: Diagnosis and Quantification of Fatty Liver with Quantitative Ultrasound using MRI-Derived Proton Density Fat Fraction as Reference in Patients with and without NAFLD

Suman Santra, Abhijit Chowdhury, Debasree Bishnu, Gopal K. Dhali, Amal Santra

Briana Holt, Krutika T. Deshpande, Michele Pritchard

1076: Profiles of serum microRNAs in acute druginduced liver injury and their prognostic significance

Mark W. Russo, James Norton, William Anderson, Nury Steuerwald, Huiman X. Barnhart, Naga P. Chalasani, Robert J. Fontana, Paul H. Hayashi, Jose Serrano, Herbert L. Bonkovsky

1077: Type XVIII collagen regulates hepatocyte cell survival and the anti-oxidant response during elevated oxidative stress conditions, in vitro SUNDAY NOVEMBER 9

1081: Killer Ig-like receptors (KIR) profiles and HLA class I ligands in amoxicillin-clavulanate-induced hepatotoxicity

Ravirajsinh Jadeja, Priyanka Thakur, Sandeep Khurana, Michael Duncan

1078: Severe liver and kidney injury in mouse models of acute-on-chronic alcoholic hepatitis

Shinji Furuya, Takeki Uehara, Yuki Kato, Oksana Kosyk, Gemma Odena, Hiroshi Kono, Ramon Bataller, Ivan Rusyn

1079: A New Approach To The Mechanism Of Paracetamol Hepatotoxicity: Liver 5-Ht7 Receptors

Zekai Halici, Elif Cadirci, Beyzagul Polat, Emre Karakus, Yasin Bayir, Abdulmecit Albayrak, Deniz Unal

1080: Identification of alcohol-induced tubulin acetylation sites by mass spectrometry Jennifer L. Groebner, Dean J. Tuma, Pamela L. Tuma

1083: What is the possible pathogen of the patients with fever, elevated serum enzymes and inflammatory markers, changes of WBC, PLT and Lymphocytes?

Steven C. Lin, Elhamy Heba, Tanya Wolfson, Brandon Ang, Anthony C. Gamst, Aiguo Han, John W. Erdman, William D. O’Brien, Michael P. Andre, Claude B. Sirlin, Rohit Loomba

1085: Multi-parametric MRI can diagnose steatohepatitis and cirrhosis in patients with NAFLD

Michael Pavlides, Rajarshi Banerjee, Elizabeth M. Tunnicliffe, Jane Collier, Lai Mun Wang, Fleming A. Kenneth, Stefan Neubauer, Eleanor Barnes

1086: Visceral Adiposity but not Hepatic Steatosis is Associated with Coronary Artery Calcification: a Prospective Cohort Study

Kathleen Jacobs, Sharon S. Brouha, Ricki Bettencourt, Claude B. Sirlin, Rohit Loomba

1087: T2* magnetic resonance imaging is more sensitive than histology and serum ferritin for the assessment of iron overload in patients with NAFLD

Michael Pavlides, Rajarshi Banerjee, Elizabeth M. Tunnicliffe, Lai Mun Wang, John D. Ryan, Jeremy F. Cobbold, Stefan Neubauer, Eleanor Barnes

Steatohepatitis 1088: Recipient but not Donor Adiponectin rs266729 Polymorphism is Linked to Post-Transplant Steatosis in Patients Transplanted with Chronic Hepatitis C Infection

Binu V. John, Ari Garber, Taylor Aiken, Dawn Thomas, Dongxing Chen, Venkata Rajesh Konjeti, Rocio Lopez, Stanley Mistak, Nizar N. Zein, Medhat Askar

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 1089: Notch-mediated epithelial/mesenchymal interaction influences non-alcoholic steatohepatitis (NASH) progression

Carola M. Morell, Romina Fiorotto, Marica Meroni, Aileen Raizner, Massimiliano Cadamuro, Emanuele Albano, Mario Strazzabosco

1090: Hepatic Overexpression of Thioesterase Superfamily Member 1 (Them1) Accelerates Glucose Intolerance in High Fat Fed Mice: Pathogenic Role in Non-Alcoholic Fatty Liver Disease (NAFLD) Cafer Ozdemir, David E. Cohen

1091: Palmitic acid lipotoxicity is determined by the interaction of JNK with mitochondrial Sab (SH3BP5)

Sanda Win, Tin A. Than, Carmen Garcia-Ruiz, Jose FernandezCheca, Neil Kaplowitz

1092: Distinct CD4+ T cell subset composition in peripheral blood and hepatic tissue of patients with NAFLD, NASH and healthy controls

Monika Rau, Anne-Kristin Schilling, Ilona Hering, Jan Meertens, Theodor Kudlich, Christian Jurowich, Niklas Beyersdorf, Andreas Geier

1093: Dynamics of Hepatic Lipid Composition, and Mitochondrial Function during the Evolution of Fast Food-Induced NASH – From the First Mouthful to Steatofibrosis

Anuradha Krishnan, Tasduq Abdullah, Toafic Mounajjed, Stella Hartono, Andrea L. McConico, Thomas A. White, Ian Lanza, Nathan K. LeBrasseur, k Sreekumaran Nair, Gregory J. Gores, Michael Charlton

1094: Lipotoxicity-Induced Extracellular Vesicles Activate Macrophages Through TRAIL Signaling

Petra Hirsova, Steven Bronk, Nathan W. Werneburg, Anuradha Krishnan, Gregory J. Gores

Davide Povero, Akiko Eguchi, Hongying Li, Casey Johnson, Alexander Wree, Milos Lazic, Karen Messer, Ariel E. Feldstein

1096: Hepatocyte-derived mitochondrial DNA acts as a “danger signal” to promote inflammation and fibrosis in non-alcoholic steatohepatitis

Naoki Ikenaga, Makoto Miyamoto, Susan B. Liu, Zhen-Wei Peng, Shuhei Yoshida, Konstantin Khrapko, Henry Koziel, Yury Popov

1097: Characterization Of A Diet-Induced Mouse Model Of Nonalcoholic Fatty Liver Disease With Reproducible Progression To Advanced Fibrosis And Hepatocellular Carcinoma

Amon Asgharpour, Tommy Pacana, Robert Vincent, Sophie C. Cazanave, Faridoddin Mirshahi, Mulugeta Seneshaw, Kalyani Daita, Puneet Puri, Arun J. Sanyal

Poster Viewing: 8:00 AM – 5:30 PM

Pia Svendsen, Jonas H. Graversen, Henning Gronbaek, Holger J. Møller, Hendrik V. Vilstrup, Søren K. Moestrup

1099: Regulation of the microRNA-clock gene network by melatonin during alcoholic liver injury

Ying Wan, Yuyan Han, Kelly McDaniel, Heather L. Francis, Haibo Bai, Julie Venter, Nan Wu, Morgan Quezada, Shannon S. Glaser, Gianfranco Alpini, Fanyin Meng

1100: Impaired metabolic compensation in adipose tissues and functional alignment by complemented stem cells in mice with progressive nonalcoholic fatty liver disease

Taichiro Nishikawa, Kohichiroh Yasui, Hisakazu Nakajima, Satoru Sugimoto, Ikuyo Itoh, Kazuki Koudou, Tomoki Nakajima, Kanji Yamaguchi, Michihisa Moriguchi, Yoshio Sumida, Hironori Mitsuyoshi, Masahito Minami, Yoshito Itoh

1101: TRAIL Receptor Signaling Promotes Hepatocyte Apoptosis and Liver Inflammation in a Mouse Model of Steatohepatitis

Leila Idrissova, Harmeet Malhi, Nathan W. Werneburg, Nathan K. LeBrasseur, Steven F. Bronk, Christian Dominik Fingas, Tamar Tchkonia, Tamar Pirtskhalava, Christian Liedtke, Christian Trautwein, Niklas Finnberg, Wafik S. El-Deiry, James L. Kirkland, Gregory J. Gores

1102: Liver-specific deletion of augmenter of liver regeneration (ALR) induces accelerated steatohepatitis in mice

Chandrashekhar R. Gandhi, J. Richard Chaillet, Michael A. Nalesnik, Sudhir Kumar, Anil Dangi, Robert Ferrell, Tong Wu, Senad Devanovic, Donna B. Stolz, Jiang Wang, Thomas Starzl

1103: Effects of liver-specific loss of lipin 1-mediated phosphatidate phosphohydrolase activity

Nisreen Soufi, George G. Schweitzer, Zhouji Chen, Connie Gan, Kyle McCommis, Brian Finck

1104: Free-fatty acids activate cytokine expression in cholangiocytes Mary A. Smith, Sathish Kumar Natarajan, Justin L. Mott

1105: miR-451 inhibits Palmitic acid-induced proinflammatory cytokine IL-8 expression through AMPK/AKT pathway in non-alcoholic steatohepatitis

Wonhee Hur, Jung-Hee Kim, Joon Ho Lee, Sung Woo Hong, Seung Kew Yoon

1106: HCV infection increases JNK phosphorylation and accentuates hepatocyte lipoapoptosis

Hiroko Takaki, Yuko Akazawa, Hisamitsu Miyaaki, Satoshi Miuma, Naota Taura, Hidetaka Shibata, Takuya Honda, Tsutomu Kanda, Yoko Kido, Kazuhiko Nakao

Presenters in Attendance 12:30 – 2:00 PM


1095: Circulating extracellular vesicles with a specific Proteome and liver microRNAs are novel biomarkers for liver injury in fatty liver disease

1098: Targeting of Kupffer cells with anti-CD163 antibody-dexamethasone-conjugate strongly reduces liver inflammation in rats with fructose-induced nonalcoholic steatohepatitis (NASH)



HEPATOLOGY, October, 2014

Poster Sessions 1107: eNOS dysfunction in Steatosis/Steatohepatitis

Mario Masarone, Albino Carrizzo, Alessandro Federico, Valerio Rosato, Carmine Vecchione, Marcello Persico

1108: Bcl-3 modulates hepatic glucose and lipid metabolism through insulin-signaling in a murine model of non-alcoholic fatty liver disease (NAFLD)

Nadine Gehrke, Amrit Mann, Yvonne Alt, Arno Schad, Ari Waisman, Peter R. Galle, Marcus A. Woerns, Jörn M. Schattenberg

1109: Involvement of CXCL1-S100A8 loop via CXCR2 in the development of nonalcoholic fatty liver disease

Kaori Mukai, Takuya Miyagi, Yoshinobu Yokoyama, Teppei Yoshioka, Kumiko Nishio, Akira Nishio, Yoshiki Onishi, Satoshi Aono, Yoshinobu Saito, Satoshi Tanaka, Hayato Hikita, Ryotaro Sakamori, Naoki Hiramatsu, Harumasa Yoshihara, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara

1110: Increased expression of Rubicon by high fat diet suppresses autophagic flux and induces apoptosis by increasing endoplasmic reticulum stress in mice: a possible mechanism for pathogenesis of NASH

Satoshi Tanaka, Hayato Hikita, Yasutoshi Nozaki, Yugo Kai, Tasuku Nakabori, Yoshinobu Saito, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tomohide Tatsumi, Tetsuo Takehara

1111: Treatment with the FXR-TGR5 dual agonist INT767 decreases NAFLD-NASH in mice fed a Western diet

Xiaoxin Wang, Yuhuan Luo, Cherelle Parker, Rachel McMahan, Hugo R. Rosen, David J. Orlicky, Luciano Adorini, Moshe Levi

1112: Aging Promotes Chronic Plus Binge Ethanol Feeding-Induced Liver Injury by Inhibiting Sirt1Autophagy


Teresa Ramirez, Yongmei Li, Dechun Feng, Huan Xu, Bin Gao

1113: Generation of a TALEN-mediated stem cell model to study non-alcoholic fatty liver disease associated with a PNPLA3 polymorphism Nidhi Goyal, Maria P. Ordonez, Lawrence S. Goldstein

1114: NAFLD progression to NASH is associated with cumulative danger signals, M1 macrophage phenotype and increased microRNA-155 expression that contributes to fibrosis in a high fat/cholesterol/sugar diet feeding in mice

Michal Ganz, Timea Csak, Shashi Bala, Banishree Saha, Gyongyi Szabo

1115: Thioesterase Superfamily Member 1 (Them1) Suppresses Thermogenesis and Contributes to DietInduced Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD)

Kosuke Okada, Katherine B. Leclair, Yongzhao Zhang, Susan J. Hagen, David E. Cohen

1116: Notch1 reprograms mitochondria metabolism for hepatic macrophage M1 activation in ASH through upregulation of pyruvate dehydrogenase (PDH) activity and mtDNA transcription

Jun Xu, Feng Chi, Vasu Punj, WN Paul Lee, Samuel W. French, Hidekazu Tsukamoto

1117: The association between dietary cholesterol, hepatic cholesterol crystals and experimental NASH

George N. Ioannou, Alan Chait, Savitha Subramanian, W. G. Haigh, Matthew M. Yeh, Christopher Savard

1118: Reduced Lipoapoptosis, Hedgehog Pathway Activation, and Fibrosis in Caspase-2 deficient Mice with Nonalcoholic Steatohepatitis

Mariana V. Machado, Gregory A. Michelotti, Thiago A. Pereira, Leandi Kruger, Marzena Swiderska-Syn, Gamze Karaca, Guanhua Xie, Cynthia D. Guy, Kelly Lindblom, Erika Johnson, Sally Kornbluth, Anna Mae Diehl

1119: The Pivotal Role Played by Lipocalin-2 in Experimental Alcohol-Induced Fatty Liver Injury in Mice Alvin Jogasuria, Bin Gao, Min You

1120: Whole Exome Sequencing of Extreme Phenotypes of NAFLD Identifies Potential Genetic Risk Factors for Advanced Hepatic Fibrosis

Thomas J. Urban, Cynthia A. Moylan, Matthew Rein, Manal F. Abdelmalek, David B. Goldstein, Anna Mae Diehl

1121: Fibroblast Growth Factor 21 Deficiency Exacerbates Chronic Alcohol-Induced Hepatic Steatosis and Injury in Mice

Cuiqing Zhao, Liming Liu, Fengyuan Li, Craig J. McClain, Wenke Feng

1122: Diet-induced nonalcoholic fatty liver disease is associated with sarcopenia and decreased serum insulin growth factor-1

Alex Ruiz, Daniel Cabrera, Pablo Quintero, Margarita Pizarro, Nancy Solis, Javiera Torres, Claudio Cabello-Verrugio, Enrique Brandan, Francisco Barrera, Marco Arrese

1123: The protective role of CAR and PXR in Aroclor 1260-induced Steatohepatitis

Banrida Wahlang, Keith C. Falkner, Ming Song, Heather B. Clair, Russell A. Prough, Matthew C. Cave

1124: Mechanism analysis of microRNA-27b causing the fatty liver formation and insulin resistance at the same onset

Takaomi Kessoku, Yasushi Honda, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Hironori Mawatari, Satoru Saito, Koichiro Wada, Yuichiro Eguchi, Atsushi Nakajima

1125: Sevelamer improves hepatic steatosis and modulates inflammation in a Western Diet mouse model of non-alcoholic fatty liver disease (NAFLD)

Brett McGettigan, Rachel McMahan, Cara Porsche, David J. Orlicky, Xiaoxin Wang, Yuhuan Luo, Moshe Levi, Hugo R. Rosen

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 1126: L-carnitine improves high-fat diet-induced steatohepatitis through insulin sensitization and regulation of lipid metabolism

Kazuyoshi Kon, Kenichi Ikejima, Hiromi Kusama, Maki Morinaga, Kumiko Arai, Akira Uchiyama, Tomonori Aoyama, Shunhei Yamashina, Sumio Watanabe

1127: TIGAR is a ‘Mitochondrial-Preload’ Regulator that Modulates Insulin Signaling and Fatty Acid Metabolism in the Liver

Zoltan Derdak, Asa Ohsaki, Zohra Kalani, Ragheb Harb, Jack R. Wands

1128: Human subcutaneous and visceral fat inflammatory gene signatures accurately predict histological severity of non-alcoholic fatty liver disease

Johannie du Plessis, Jos van Pelt, Hannelie Korf, Chantal Mathieu, Matthias A. Lannoo, Gary K. Fetter, Simon Nayler, Tessa van der Merwe, Luc van Gaal, Sven M. Francque, Frederik Nevens, Schalk Van Der Merwe

1129: Osteopontin mediates fibrogenic effects of leptin and enhances NASH progression

Jason D. Coombes, Steve S. Choi, Paul P. Manka, Marco A. Briones-Orta, Marzena Swiderska-Syn, Naoto Kitamura, Rasha Younis, Shanna Bitencourt, Laurent Dollé, Roger Williams, Leo A. van Grunsven, Anna Mae Diehl, Ali Canbay, Wing-Kin Syn

1130: Suppression of Liver Monoacylglycerol Acyltransferase 1 Reduces Triacylglycerol Content, but not Inflammation and Injury in Livers of Mice with Non Alcoholic Steatohepatitis

Nisreen Soufi, Angela Hall, Sara Collier, James Mathews, Elizabeth M. Brunt, Carolyn J. Albert, Mark Graham, David A. Ford, Brian Finck

1131: COX 7a2 Inhibition in Mitochondrial Complex IV Induces Hepatic Oxidative Stress and Iron Metabolic Disorder in C57BL/6N Mouse

1132: Down regulation of CD98 receptors via siRNA loaded nanoparticles attenuate NAFLD signs in mice liver

Jenniffer L. Stetler, Brandon S. Canup, Qiang Ma, Russell P. Pucket, Hamed Laroui

1133: Hepatocyte-specific deletion of UBXD8 induces periportal steatosis after high-fat diet feeding

Norihiro Imai, Michitaka Suzuki, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Masatoshi Ishigami, Toyoshi Fujimoto, Hidemi Goto

1134: Hepatic Xbp1 deficiency exacerbates high fat/ high fructose diet-induced injury in the murine liver

Yuichiro Amano, Fumi Shimizu, Ayako Harada, Masami Suzuki, Shuntarou Tsuchiya, Osamu Isono, Mari Asada, Mayumi Imai, Shigemitsu Imai, Hiroshi Nagabukuro, Ryuichi Tozawa

1136: Resveratrol improve the pathogengesis of nonalchoholic steatohepatitis with serum CD14 of high value

Takaomi Kessoku, Yasushi Honda, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Hironori Mawatari, Satoru Saito, Atsushi Nakajima

1137: Association of IL-33/sST2 Axis with Non Alcoholic Steatohepatitis (NASH) Severity

Gihan Naguib, Jason L. Eccleston, Koji Fujita, Niharika Samala, Mary Walter, Yaron Rotman

1138: Pirfenidone improves NASH features induced by high fat/carbohydrate diet in mice

Jose Macias-Barragan, Jose Vera-Cruz, Jesus Garcia-Banuelos, David A. Lopez-de la Mora, Cibeles Sanchez-Roque, Krista Rombouts, Fabio Marra, Massimo Pinzani, Juan ArmendárizBorunda

1139: Genetic characterization of variants and genes at hepatic steatosis genome wide association study associated loci Yue Chen, Andrew W. Tai, Elizabeth K. Speliotes

1140: A Diet-Induced Mouse Model With Development Of Severe Nash

Yong Ook Kim, Rambabu Surabattula, Kyoung-Sook Park, Shihyen Weng, Detlef Schuppan

1141: Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis

Margarita Pizarro, Nancy Solis, Pablo Quintero, Juan C. Roa, Rene Baudrand, Carlos B. Fardella, Arnoldo Riquelme, Marco Arrese

1142: Plasma Amino Acid Metabolome In Human Nonalcoholic Fatty Liver Disease Demonstrates Highly Enriched Lysine Degradation Pathway With High Arginine And Proline Pathway Impact

Puneet Puri, Andrew R. Joyce, Velimir A. Luketic, Mohammad S. Siddiqui, Sherry L. Boyett, Jolene Schlosser, Carol Sargeant, Kalyani Daita, Hae-Ki Min, Faridoddin Mirshahi, Arun J. Sanyal

1143: Effects of the Selective Estrogen Receptor Modulator, Raloxifene, on Nonalcoholic Steatohepatitis in Ovariectomized Mice

Fangqiong Luo, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Hidemi Goto

Xiaoying Liu, Anne S. Henkel, Brian E. LeCuyer, Richard Green

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Masaaki Korenaga, Mihoko Tsuji, Miyuki Kondo, Erina Kumagai, Misuzu Ueyama, Keiko Korenaga, Kazumoto Murata, Tatsuya Kanto, Naohiko Masaki, Masashi Mizokami

1135: Long-term histological and biochemical analyses of a mouse model of NASH using low-density lipoprotein receptor knockout mice with cholinedeficient diet



HEPATOLOGY, October, 2014

Poster Sessions 1144: Oral Administration of Tributyrin Attenuates Chronic Ethanol-Induced Hepatic Steatosis, Inflammation and Injury

Hridgandh Donde, Jingwen Zhang, Smita Ghare, Leila Gobejishvili, Swati Joshi-Barve, Vatsalya Vatsalya, Craig J. McClain, Shirish Barve

1145: Metformin decreases lipid droplets accumulation and inhibits intracellular inflammation by targeting a new EZH2-phosphoSTAT3-miRNAs pathway in an in vitro model of vescicular steatosis

Natalia Pediconi, Silvia Di Cocco, Debora Salerno, Laura Belloni, Silvia Piconese, Vincenzo Barnaba, Massimo Levrero

1146: CD36 regulates hepatic lipid metabolism and the development hepatic steatosis in mice

Camella Wilson, Jennifer L. Tran, Derek Erion, Maria Febbraio, Ethan J. Weiss

1147: Hepatic steatosis impairs acidification of autolysosomes via suppression of vacuolar ATPase subunit in lysosomes

Eisuke Nakadera, Shunhei Yamashina, Yoshihiro Inami, Kousuke Izumi, Tomonori Aoyama, Akira Uchiyama, Kazuyoshi Kon, Kenichi Ikejima, Sumio Watanabe

1148: TLR7 signaling negatively regulates the development of alcoholic steatohepatitis

Hiroshi Matsushita, Yoon Seok Roh, Bi Zhang, Shuang Liang, Ekihiro Seki

1149: High-energy diets containing starch:oleate as model carbohydrates:fats cause more hepatic steatosis and liver pathology in mice than other macronutrient combinations


Caroline C. Duwaerts, Andrew Pierce, Scott M. Turner, Carine Beysen, Mark D. Fitch, James P. Grenert, Jacquelyn J. Maher

1150: Suppressive effects of group IVA phospholipase A2-deficiency on the liver injury and hepatic fibrosis induced by oxidative stress in mice Shiho Kanai, Keiichi Ishihara, Satoshi Akiba

1151: Pathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in nonalcoholic fatty liver disease

Naoshi Nishida, Norihisa Yada, Hirokazu Chishina, Tadaaki Arizumi, Masahiro Takita, Satoshi Kitai, Tatsuo Inoue, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Toshiharu Sakurai, Masatoshi Kudo

1152: Prospective Assessment of the Abundance of Drug Metabolizing Enzymes in the P450 Pathway in Patients with Non Alcoholic Fatty Liver Disease (NAFLD)

Bashar Aqel, Paul Langlais, Hugo E. Vargas, Elizabeth J. Carey, Michael Leonard, Lawrence J. Mandarino

1153: Hedgehog pathway regulates hepatic inflammation in mice with nonalcoholic steatohepatitis Hyunjoo Kwon, Kyoungsub Song, Chang Han, Tong Wu

Denotes AASLD Presidential Poster of Distinction

1154: In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in non-alcoholic steatohepatitis

José A. Solís-Herruzo, Pablo Solís-Muñoz, Daniel FernándezMoreira, Teresa Muñoz-Yagüe, Inmaculada García-Ruiz

1155: GFT505 reverses NASH pathology, obesity and insulin resistance in the foz/foz model

Isabelle A. Leclercq, Vanessa Legry, Benoit Noel, Rémy Hanf, Dean W. Hum, Robert Walczak

1156: Oral supplementation of BCAA alleviates hepatic steatosis and liver injury associated with NASH

Takashi Honda, Masatoshi Ishigami, Fangqiong Luo, Yoji Ishizu, Teiji Kuzuya, Kazuhiko Hayashi, Yoshiharu Shimomura, Hidemi Goto

1157: L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway Hisashi Ishikawa, Akinobu Takaki, Kazuhide Yamamoto

1158: Deletion of both p62 and Nrf2 spontaneously leads to development of steatohepatitis in mice

Kentaro Akiyama, Eiji Warabi, Kosuke Okada, Miho Ikeuchi, Tetsuya Ueda, Katsumi Kose, Junichi Shoda

1159: Effect of G-CSF on non- alcoholic fatty liver disease model

Ho Hyun Nam, Dae Won Jun, Waqar K. Saeed, Sunmin Kim, Tae Yeob Kim, Joo Hyun Sohn, Min Young Kim, Eun Kyung Kim

1160: M1 Polarization bias and subsequent NASH progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1 induced oxidative stress

Ratanesh K. Seth, Suvarthi Das, Sahar Pourhoseini, Diptadip Dattaroy, Stephen Igwe, Julie Basu Ray, Gregory A. Michelotti, Anna Mae Diehl, Saurabh Chatterjee

1161: Blood ethanol levels in children and mice with NAFLD: Connection of insulin resistance and ethanol elimination

Anna Janina Engstler, Marion Duerr, Eva Weiss, Vanessa T. Rist, Ina B. Maier, Chengjun Jin, Cathrin Sellmann, Ina Bergheim

1162: Genome-wide analysis reveals predisposing nonalcoholic fatty liver disease related DNA methylation loci in peripheral white cells

Ruinan Zhang, Qin Pan, Feng Shen, Guangyu Chen, Chanyan Zhu, Jiafa Lu, Jiayu Wu, Yiming Chen, Jian-Gao Fan

1163: Expression of Cell Death-Inducing DFF45-Like Effector (CIDE) Family of Proteins in Patients with Obesity Associated Non-Alcoholic Fatty Liver Disease (NAFLD)

Rohini Mehta, Katherine Doyle, Thomas Jeffers, Drew Venuto, Aybike Birerdinc, Zobair Younossi




Poster Sessions 1164: Functional Genomic Screen Identifies Novel Mediators of Hepatocyte Lipotoxicity

1172: Hepatoprotective Effects of Farnesoid X Receptor in a Mouse Chronic Alcohol Feeding Model

1165: Hepatocyte specific keap-1 deletion selectively reduces triglyceride accumulation but not inflammation in a diet-induced model of nonalcoholic steatohepatitis

1173: Long non-coding (Lnc) RNA H19 is a critical modulator of bile acid homeostasis

Steven Bronk, Ying Peng, James A. Blau, Matthew J. Hangauer, Michael McManus, Gregory J. Gores, Yi Guo

Pierluigi Ramadori, Hannah K. Drescher, Fabienne Schumacher, Stephanie Erschfeld, Athanassios Fragoulis, Christoph Wruck, Christian Trautwein, Daniela C. Kroy, Konrad L. Streetz

1166: Establishment of repeated liver biopsy technique in experimental mice

Koichi Tsuneyama, Takahiko Nakajima, Hayato Baba, Takeshi Nishida, Shinichi Hayashi, Shigeharu Miwa, Johji Imura

1167: Does Citrulline prevent high fat high fructoseinduced non-alcoholic fatty liver disease?

Prasanthi Jegatheesan, Stéphanie Beutheu, Kim Freese, Gabrielle Ventura, Wassila Ouelaa, Perrine Marquet-de-Rougé, Jean-Pascal De Bandt

1168: Long-term plus multiple binge ethanol feeding induces steatohepatitis and fibrosis in aged mice Hua Wang, Ming-Jiang Xu, Adeline Bertola, Bin Gao

Transport, Bilirubin, Cholesterol, Lipids and Bile Salts 1169: IL-1β generated by LPS-activated CCR2positive Hepatic Macrophages regulates expression of Hepatocellular Sterol and Bile Transport Systems

Padade Vue, Karim C. El Kasmi, Aimee Anderson, Michael W. Devereaux, Natarajan Balasubramaniyan, Frederick J. Suchy, Ronald J. Sokol

Jessica M. Ferrell, Shannon M. Boehme, John Chiang

1171: Enterohepatic biomarkers of microbial pathogenesis in Clostridium difficile infection

Mary Elizabeth M. Tessier, Petri T. Urvil, Cana Ross, Toni-Ann Mistretta, Shaji K. Chacko, Michael Francis, Joseph Sorg, Alex G. Peniche, Sara M. Dann, Kevin W. Garey, Tor Savidge

Yuxia Zhang, Hiroyuki Tsuchiya, Olivier Barbier, Rana Smalling, James Cox, Don Delker, Curt H. Hagedorn, Li Wang

1174: FGF19 Exchange Across the Gut and Liver in Humans

Kiran V. Koelfat, Frank Schaap, Johanne G. Bloemen, Peter L. Jansen, Cornelis H. Dejong, Steven Olde Damink

1175: TUDC-dependent translocation of MRP2 to the plasma membrane or retrieval from the plasma membrane is determined by MKK3 status

Christopher M. Schonhoff, Se Won Park, Cynthia R. Webster, Mohammed S. Anwer

1176: Defining the Effect of a Human Gut Microbiota on Bile Acid Metabolism and FXR Signaling in Gnotobiotic Mice

Annika Wahlström, Hanns-Ulrich Marschall, Petia KovatchevaDatchary, Maria Johansson, Marcus Ståhlman, Fredrik Bäckhed

1177: Bile acids modulate pancreatic islet α cells to promote glucose homeostasis

Divya P. Kumar, Sunila Mahavadi, Faridoddin Mirshahi, John R. Grider, Karnam S. Murthy, Arun J. Sanyal

1178: Hepatic Xbp1 regulates bile acid homeostasis and bile salt injury

Xiaoying Liu, Anne S. Henkel, Brian E. LeCuyer, Eric Zhang, Richard Green

1179: 3-Dimensional Culturing of Hepatocytes Increases Fluorescent Bile Acid Accumulation and Sensitivity to Drug Induced Cell Death John W. Murray, Allan W. Wolkoff

1180: Cyclic AMP reverses taurolithocholate-induced internalization of MRP2 in part by inhibiting TLC/PKCε/ MARCKS phosphorylation pathway

Se Won Park, Christopher M. Schonhoff, Cynthia R. Webster, Mohammed S. Anwer

1181: Regulation of Multidrug and Toxin Extrusion Pump-1 (MATE-1) in Cholestasis

Priscilla C. Encarnacao, Carol J. Soroka, James L. Boyer, Meena Ananthanarayanan    

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


1170: Short-term sleep deprivation and Western diet alters the circadian rhythms of CYP7A1 and hepatic clock genes, and lipid metabolism

Bo Kong, Le Zhan, Jianliang Shen, Tanya Forostyan, Li Wang, Wen-Xing Ding, Grace L. Guo



HEPATOLOGY, October, 2014

Poster Sessions Poster Session 3 Monday, November 10 POSTER VIEWING: 8:00 AM - 5:30 PM Hall C Presenters in attendance: 12:30 - 2:00 PM Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Alcohol: Clinical and Basic Mechanisms 1182: Apolipoprotein (apo)AV deficiency exacerbates alcoholic liver injury, leading to a gradual progression from simple steatosis to steatohepatitis, and then to liver fibrosis in ethanol-fed mice

David Q. Wang, Ornella de Bari, Bin Gao, Helen H. Wang, Piero Portincasa, Linda S. Zhang, David A. Ford, Brent A. Neuschwander-Tetri, Patrick Tso

1183: Deletion of GSTA4 increases mitochondrial oxidative stress contributing to increased hepatocellular damage during chronic ethanol consumption

Colin T. Shearn, Kelly E. Mercer, Kristofer S. Fritz, James J. Galligan, Bridgette Engi, David J. Orlicky, Piotr Zimniak, Martin J. Ronis, Dennis R. Petersen

1184: Toll-Like Receptor 2 and 9 mediates alcoholic steatohepatitis via CXCL1 production and neutrophil recruitment

Yoon Seok Roh, Bi Zhang, Shuang Liang, Hiroshi Matsushita, Ekihiro Seki

1185: FOXO3-dependent macrophage apoptosis protects the liver from alcoholic injury

Zhuan Li, Jie Zhao, Sudhakiranmayi Kuravi, Josiah Cox, James Helzberg, Irina Tikhanovich, Steven A. Weinman


1186: Progression of hepatic steatosis (HS) to steatohepatitis (SH) stage in alcoholic liver disease (ALD) in mice is largely dependent on Large-conductance calcium-activated potassium (MaxiK) channels Tracie C. Lo, Keisaku Sato, Angela Dolganiuc

1187: Sterile and Infection-Associated SIRS Predict Multiple Organ Dysfunction in Alcoholic Hepatitis: Diagnostic Value of Procalcitonin

Javier Michelena, Jose Altamirano, Juan G. Abraldes, Silvia Affò, Oriol Morales-Ibanez, Pau Sancho-Bru, Marlene Dominguez, Vicente Arroyo, Pere Gines, Juan Caballeria, Ramon Bataller

1188: Cannabinoïd CB2 receptor protects from alcoholic liver disease via an autophagy-dependent pathway in Kupffer cells

Timothé Denaës, Jasper Lodder, Marie-Noële Chobert, Jean-Michel Pawlotsky, Sophie Lotersztajn, Fatima Teixeira-Clerc

Denotes AASLD Presidential Poster of Distinction

1189: Farnesoid X Receptor (FXR) Regulates FoxO3 Activation in Ethanol-Induced Autophagy and Liver Injury

Sharon Manley, Hong-Min Ni, Jessica A. Williams, Grace L. Guo, Wen-Xing Ding

1190: Dysbiosis-induced intestinal inflammation activates TNFR-1 and mediates alcoholic liver disease in mice

Peng Chen, Peter Starkel, Jerrold R. Turner, Samuel B. Ho, Bernd Schnabl

1191: Pharmacological activation of aldehyde dehydrogenase 2 reverses alcohol-induced hepatic steatosis and cell death in mice

Wei Zhong, Wenliang Zhang, Qiong Li, Guoxiang Xie, Qian Sun, Xiuhua Sun, Xiaobing Tan, Xinguo Sun, Zhanxiang Zhou

1192: Lipid-derived aldehyde, acrolein, is a critical mediator of alcohol-induced gut-liver injury in alcoholic liver disease

Wei-Yang Chen, Jingwen Zhang, Shirish Barve, Craig J. McClain, Swati Joshi-Barve

1193: Functional role of cellular senescence in alcoholic liver injury

Kelly McDaniel, Yuyan Han, Heather L. Francis, Haibo Bai, Julie Venter, Nan Wu, Morgan Quezada, Ying Wan, Shannon S. Glaser, Gianfranco Alpini, Fanyin Meng

1194: Alcohol stimulates release of hepatocyte derived extracellular vesicles leading to macrophage activation

Vikas K. Verma, Patrick S. Kamath, Patricia C. Contreras, Gregory J. Gores, Vijay Shah

1195: Monocyte Oxidative Burst defect is associated with susceptibility to Infection in Alcoholic Hepatitis and is restored by N-Acetylcysteine

Nikhil Vergis, Wafa Khamri, Jennifer M. Ryan, Debbie Shawcross, Yun Ma, Charalambos G. Antoniades, Mark R. Thursz

1196: Ductular bilirubinostasis predicts the evolution to acute-on-chronic liver failure in patients suspected with severe alcoholic steatohepatitis

Len D. Verbeke, Tania Roskams, Chris Verslype, David Cassiman, Schalk Van Der Merwe, Werner Van Steenbergen, Geert Maleux, Alexander Wilmer, Wim Laleman, Frederik Nevens

1197: Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways

Vikrant Rachakonda, Charles Gabbert, Amit Raina, Shahid M. Malik, Lauren N. Bell, Sara J. Cooper, Jaideep Behari

1198: Phosphodiesterase 4 (PDE4) plays a significant role in alcohol induced dysregulation of lipid metabolism and development of hepatic steatosis

Diana Avila, Jingwen Zhang, Craig J. McClain, Shirish Barve, Leila Gobejishvili




Poster Sessions 1199: Hepatic Gap Junction Inhibition Protects Against Liver Injury and Inflammation in a Murine Model of Alcoholic Steatohepatitis

Jay Luther, Kevin R. King, John Garber, Ricard Masia, Daniel L. Motola, Martin L. Yarmush, Raymond T. Chung, Suraj J. Patel

1200: NOX4 regulates CCR2 mRNA stability in hepatic stellate cells in alcoholic liver injury Yu Sasaki, Joy Jiang, Tzu-I Chao, Jijing Tian, Natalie Torok

1201: Association of Two Novel Bitter Taste Receptor 2R38 (TAS2R38) Haplotypes with Alcohol Intake among the Population of West Mexico

Oscar O. Ramos-Lopez, Sonia Roman, Claudia Ojeda-Granados, Maricruz Sepulveda-Villegas, Rafael Torres-Valadez, Maria Elena Trujillo-Trujillo, Karina Gonzalez-Aldaco, Erika Martinez-Lopez, Arturo Panduro

1202: Alcoholic Cirrhosis is Associated with NeuroInflammation and Impaired White Matter Integrity despite Controlling for MELD score and Hepatic Encephalopathy

Vishwadeep Ahluwalia, James Wade, Douglas M. Heuman, Richard K. Sterling, Scott Matherly, Mohammad S. Siddiqui, Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal, Puneet Puri, Melanie White, Nicole Noble, James Hovermale, Edith A. Gavis, Jasmohan S. Bajaj

1203: Carriage of the Ile148Met Mutation in PNPLA3 has a Detrimental Effect on Survival In Patients with Alcohol-Related Cirrhosis

Michael J. Way, Harriet M. Gordon, Jonathan C. Marshall, Andrew McQuillin, Marsha Y. Morgan

1204: Unfolded Protein Response (UPR) and calciumdependent endoplasmic reticulum stress modulate development of alcohol-induced liver disease in mice Keisaku Sato, Tracie C. Lo, Angela Dolganiuc

1205: The Worsening Profile of Acute Alcoholic Hepatitis in the United States

Tuyet A. Nguyen, Arun J. Sanyal, Jonathan P. DeShazo

1206: Fat-specific Protein 27/CIDE-C Promotes Liver Injury in Chronic Plus Binge Ethanol Fed-mice And Human Alcoholic Hepatitis

1207: Distinct Intestinal Microbiome Signature In Obese Subjects With Alcoholic Versus Nonalcoholic Fatty Liver Disease

Puneet Puri, Mohammad S. Siddiqui, Sherry L. Boyett, Carol C. Sargeant, Jolene Schlosser, Larry D. White, Richard K. Sterling, R. Todd Stravitz, Scott Matherly, Velimir A. Luketic, Faridoddin Mirshahi, Kalyani Daita, Masoumeh Sikaroodi, Andrew R. Joyce, Patrick M. Gillevet, Arun J. Sanyal

Poster Viewing: 8:00 AM – 5:30 PM

Jan Petrasek, Arvin Iracheta-Vellve, Shashi Bala, Timea Csak, Karen Kodys, Evelyn A. Kurt-Jones, Gyongyi Szabo

1209: Imaging Mass Spectrometry (IMS) Visualization of Hepatic Lipid Profiles in Experimental Steatohepatitis Induced by Chronic Ethanol, Tobacco Nitrosamine (NNK), or Both Exposures In Long Evans Rats

Emine Yalcin, Kavin M. Nunez, Ming Tong, Shannon Cornett, Suzanne M. de la Monte

1210: 9(S)-hydroxy-octadecadienoic acid (HODE) enhances interleukin-1β production of PBMCs from alcoholic liver cirrhosis patients by activation of TRPV1

Qifa Xie, Mohammad K. Mohammad, Matthew C. Cave, Shirish Barve, Irina Kirpich, Craig J. McClain

1211: Transient Receptor Potential Vanilloid 1 Gene Deficiency Ameliorates Hepatic Injury in a Mouse Model of Chronic-Binge-Induced Alcoholic Liver Disease

Irina Kirpich, Keith C. Falkner, Juliane I. Beier, Gavin E. Arteel, Christopher Ramsden, Ariel E. Feldstein, Craig J. McClain

1212: Hepatic Stellate Cell Selective Deletion of Neuropilin-1 is Protective against Alcoholic Steatohepatitis in Mice

Douglas A. Simonetto, Vikas K. Verma, Jung Hee Kwon, Usman Yaqoob, Thiago de Assuncao, Sheng Cao, Tatiana Kisseleva, David A. Brenner, Vijay Shah

1213: Nuclear receptor SHP is a key regulator of circadian clock mediated hyperhomocysteinemia induced by alcohol

Hiroyuki Tsuchiya, Yuxia Zhang, Sangmin Lee, Rana Smalling, Li Wang

1214: Calcineurin and NFAT drive the development of steatosis component of alcoholic liver disease (ALD) in mice by regulating Calcium-dependent signaling Keisaku Sato, Tracie C. Lo, Angela Dolganiuc

1215: Zinc Sulfate for Alcoholic Cirrhosis (ZAC) Clinical Trial - Interim Analysis of Clinical Parameters, Intestinal Permeability and Liver Fibrosis Biomarkers

Ming Song, Mohammad K. Mohammad, Keith C. Falkner, Craig J. McClain, Matthew C. Cave

1216: Decreased dietary fat attenuates ethanol induced oxidative stress and upregulation of antioxidant responses

Colin T. Shearn, David J. Orlicky, Rebecca Smathers-McCullough, Kenneth N. Maclean, Dennis R. Petersen

Presenters in Attendance 12:30 – 2:00 PM


Ming-Jiang Xu, Yan Cai, José T. Altamirano, Binxia Chang, Hua Wang, Adeline Bertola, Gemma Odena, Jim Lu, Kimihiko Matsusue, Shioko Kimura, Frank J. Gonzalez, Ramon Bataller, Bin Gao

1208: Interleukin-1 receptor inhibition facilitates recovery from liver inflammation and injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice



HEPATOLOGY, October, 2014

Poster Sessions 1217: Predictors of mortality and comparison of prognostic models in 220 patients with alcoholic hepatitis: a prospective study

Venu H. Aradya, Harshad Devarbhavi, Karnam Ravikiran, Keyur A. Sheth, T. R. Vijaykumar, Rajvir Singh, Adarsh Ck, Mallikarjun Patil

1218: Translational Bioenergetics: A novel biomarker in the management of patients with alcoholic liver disease

Ashwani K. Singal, Philip A. Kramer, Saranya Ravi, Toni Seay, Balu Chacko, Degui Zhi, Victor Darley-Usmar

1219: Betaine attenuates chronic ethanol-induced disruption of intestinal epithelial integrity Sarah Bligh, Kusum K. Kharbanda, Paul G. Thomes

1220: Pharmacological Restoration of WNT/β-Catenin Signaling Attenuates Alcoholic Liver Disease Progression in a Rat Model

Chiung-Kuei Huang, Tunan Yu, Zoltan Derdak, Suzanne M. de la Monte, Jack R. Wands, Miran Kim

1221: Does the Alcoholic Pancreatitis CLDN2 High-Risk Locus Predispose to Liver Disease?

Alison Jazwinski, Jyothsna Talluri, Gautam Mankaney, Jessica LaRusch, David C. Whitcomb, Jaideep Behari

1222: Kupffer cell-specific calcium signaling drives inflammation in alcoholic liver disease (ALD) in mice Tracie C. Lo, Keisaku Sato, Angela Dolganiuc

1223: The inflammasome in alchohoic hepatitis: its relationship with Mallory-Denk body formation

Cindy Peng, Barbara A. French, Brittany C. Tillman, Samuel W. French

1224: Interactions between the gut permeability, blood endotoxemia and liver injury in alcoholic patients during detoxification

Irina Kirpich, John Umhau, Vatsalya Vatsalya, Melanie Schwandt, Monte Phillips, Thomas Lionetti, Keith C. Falkner, Lucy Zhang, Catey Harwell, David George, Markus Heilig, Craig J. McClain


1225: Repeated validation of AshTest as a non-invasive alternative to liver biopsy in patients with suspicion of severe acute alcoholic hepatitis (AH)

Marika Rudler, Sarah Mouri, Frederic Charlotte, Philippe Cluzel, Yen Ngo, Mona Munteanu, Dominique Thabut, Thierry Poynard

1226: Metabolomics studies in Patients with Liver Disease Identify Novel Plasma Analytes in Alcoholic Hepatitis

Ibrahim A. Hanouneh, Stephanie Marshall, Zhen Wang, Raed Dweik, Nizar N. Zein, David Grove, Laura E. Nagy, Arthur J. McCullough, Rocio Lopez, Stanley L. Hazen, J. Mark Brown

1227: Does the Alcoholic Liver Disease/ Non-alcoholic fatty liver disease Index (ANI) predict mortality in Alcoholic Hepatitis?

Traci Murakami, Cristian E. Dominguez, Varun Takyar, Krunal Patel, Thomas D. Boyer, Shahid Habib

Denotes AASLD Presidential Poster of Distinction

1228: Alcoholic versus non-alcoholic fatty liver: Indistinguishable histology but distinct differences in function and content of proteins involved in vesicle trafficking and receptor-mediated endocytosis

Karuna Rasineni, Daniel Penrice, Edward N. Harris, Cliff I. Stains, Jon Beck, Benita L. McVicker, Mark A. McNiven, Carol A. Casey

1229: Potential Contributions of the Tobacco-Specific Nicotine-Derived Nitrosamino Ketone (NNK) in the Pathogenesis of Steatohepatitis in a Chronic-Binge Rat Model of Alcoholic Liver Disease (ALD)

Valerie Zabala, Ming Tong, Teresa Ramirez, Emine Yalcin, Silvia Balbo, Elizabeth Silbermann, Chetram Deochand, Stephen Hecht, Suzanne M. de la Monte

1230: Comparative Evaluation of Prediction Models in Severe Alcoholic Hepatitis

Gene Y. Im, Aparna Goel, Thomas D. Schiano, Scott L. Friedman

1231: Zinc Sulfate for Alcoholic Cirrhosis (ZAC) Clinical Trial - Interim Analysis of Liver Injury/Inflammation Biomarkers

Mohammad K. Mohammad, Ming Song, Keith C. Falkner, Craig J. McClain, Matthew C. Cave

1232: Serum fibroblast growth factor 19 levels are increased in subjects with alcoholic cirrhosis and positively associated with serum total bile acid levels

Cuiqing Zhao, Mohammad K. Mohammad, Liming Liu, Keith C. Falkner, Zhanxiang Zhou, Craig J. McClain, Wenke Feng, Matthew C. Cave

1233: Sarcopenia as a prognostic factor in patients with severe alcoholic hepatitis

Do Seon Song, JinMo Yang, U Im Chang, Sang Wook Choi, Se Hyun Cho, Joon-Yeol Han

1234: Hepatic cell proliferation and outcome in alcoholic hepatitis: histology, gene expression and effect of stem cell therapy

Nicolas Lanthier, Laura Rubbia-Brandt, Nathalie Lin-Marq, Sophie Clément, Jean-Louis Frossard, Nicolas Goossens, Laurent Spahr

Basic Hepatobiliary Neoplasia 1235: Genetic profiling of circulating tumor cells in hepatocellular carcinoma

Jennifer Au, Angel E. Dago, Kelly Bethel, Peter Kuhn, Randolph L. Schaffer

1236: A Cell surface β-Hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma

Arihiro Aihara, Chiung-Kuei Huang, Mark Olsen, Qiushi Lin, Waihong Chung, Qi Tang, Xiaoqun Dong, Jack R. Wands

1237: Nodular regenerative hyperplasia: expression pattern of glutamine synthetase and a potential role for hepatic progenitor cells

Marie-Christine Guilbert, Geneviève Soucy, Dominique Trudel, Bich N. Nguyen




Poster Sessions 1238: Histopathologic Features as Surrogate Markers of Molecular Classification of Hepatocellular Carcinoma

Poh Seng Tan, Anu Venkatesh, Stephen C. Ward, Claudia CanastoChibuque, Anna Koh, Venugopalan Nair, Manjeet Deshmukh, Shigeki Nakagawa, Xiaochen Sun, Masahiro Kobayashi, Hiromitsu Kumada, Yujin Hoshida

1239: TPU0114 suppresses Bcl-xl to induce apoptosis in human hepatocellular carcinoma

Tomoyuki Hayashi, Taro Yamashita, Naoki Oishi, Kouki Nio, Takehiro Hayashi, Yasumasa Hara, Yoshimoto Nomura, Mariko Yoshida, Tomomi Hashiba, Hikari Okada, Koji Miyanouchi, Shuichi Kaneko

1240: Differential EGFR regulation in metastatic and primary unresectable hepatoblastoma

Sarangarajan Ranganathan, Mylarappa Ningappa, Chethan Ashokkumar, Brandon W. Higgs, Qing Sun, Lori Schmitt, Hakon Hakonarson, Rakesh Sindhi

1241: Discovery of Novel DNA Methylation Markers for the Detection of Cholangiocarcinoma by MethylomeWide Analysis

Mohammed M. Aboelsoud, William R. Taylor, Tracy C. Yab, Patrick H. Foote, Douglas W. Mahoney, Thomas C. Smyrk, Lewis R. Roberts, David Ahlquist, John B. Kisiel

1242: Clinical significance of serum cytokeratin 19 fragment (CYFRA 21-1) in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma

Li Huang, Wei Chen, Peiwen Liang, Wenjie Hu, Kunsong Zhang, Bin Chen, Yuyan Han, Fanyin Meng, Sharon DeMorrow, Xiaoyu Yin, Jiaming Lai, Lijian Liang

1243: CD90+ and CD133+ Cancer Stem Cells Correlate with Transcription Factor FOXM1 and Glycolytic Enzyme Hexokinase II (HKII) Immunolevels, and Markers for Oxidative and Nitrosative Stress Correlate with Disease Progression in Hepatocellular Carcinoma

Lily Mei, Katherine M. Choi, Rajender Mulpuri, Dragana Kopanja, Hari Sreedhar, Michael J. Walsh, Ming Jin, Costica Aloman, Charmaine Stewart, Nissim Hay, Pradip Raychaudhuri, Grace Guzman

1246: Cartilage oligomeric matrix protein (COMP): A novel non-invasive marker for assessing liver cirrhosis and risk of progression to hepatocellular carcinoma

Gary L. Norman, Nikolaos Gatselis, Zakera Shums, Christos Liaskos, Dimitrios P. Bogdanos, George K. Koukoulis, George N. Dalekos

1247: Serum levels of advanced glycation end products and pigment epithelium derived factor in patients with hepatocellular carcinoma derived from non-alcoholic steatohepatitis

Hiromi Kan, Hideyuki Hyogo, Hiroshi Aikata, Tomoki Kobayashi, Takayuki Fukuhara, Noriaki Naeshiro, Yohji Honda, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Kazuaki Chayama

1248: Adenomatous polyposis coli-binding protein EB1 as an important predictive factor for the prognosis and recurrence in hepatocellular carcinoma

Takeshi Aiyama, Tatsuya Orimo, Hideki Yokoo, Takanori Ohata, Kanako Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Kenji Wakayama, Tatsuhiko Kakisaka, Yosuke Tsuruga, Hirofumi Kamachi, Toshiya Kamiyama, Akinobu Taketomi

1249: The expression of arginase-1, keratin (K) 8, and K18 and clinicopathologic significance of phosphorylation K8 in combined hepatocellularcholangiocarcinoma, stem cell subtypes-intermediatecell type Jun Akiba, Osamu Nakashima, Hirohisa Yano

1250: Performance of biomarkers for diagnosis of hepatocellular carcinoma –alpha fetoprotein, protein induced by vitamin K absence, osteopontin and Dickkopf-1

Jong Ho Lee, Eun Sun Jang, Yun Suk Choi, Philippe Leissner, Christian Brechot, Jung Wha Chung, Jin Wook Kim, Sook-Hyang Jeong

1251: Cancer stem cell, TGF-β gene signatures, and epithelial-mesenchymal transition are features of late rather than early hepatocarcinogenesis

Hyungjin Rhee, Jeong Eun Yoo, Ei Yong Ahn, Luca Di Tomaso, Bogdan Pintea, Massimo Roncalli, Young Nyun Park

1252: Oxidative stress in leucocytes of patients with advanced hepatocellular carcinoma

1245: Metabolomic Analysis by 1H-NMR Spectroscopy of Human Tissues reveals different metabolic biomarkers of Hepato-Cellular Carcinoma according to the underlying liver disease

1253: Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma with stem cell features

Yoriko Nomura, Sachiko Ogasawara, Jun Akiba, Hironori Kusano, Masamichi Nakayama, Osamu Nakashima, Hirohisa Yano

Camille Teilhet, Daniel Morvan, Juliette Joubert-Zakeyh, Pierre J. Déchelotte, Denis Pezet, Emmanuel Buc, Bruno Pereira, AnneSophie Biesse, Géraldine Lamblin, Sylvie Massoulier, Michel Peoc’h, Jack Porcheron, Marie-Paule Vasson, Aïcha Demidem, Armando Abergel

Poster Viewing: 8:00 AM – 5:30 PM

Paloma Lluch, Laia Navarro López, Gloria Segarra, Guadalupe Herrera, María Mora, Joan Tosca, Miguel Angel Serra, Pascual Medina

Hajime Sunagozaka, Taro Yamashita, Naoki Oishi, Takehiro Hayashi, Hajime Takatori, Tetsuro Shimakami, Kazuya Kitamura, Kuniaki Arai, Takashi Kagaya, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko

Presenters in Attendance 12:30 – 2:00 PM


1244: Identification of new tissue biomarkers to predict biologic features of hepatocellular carcinoma



HEPATOLOGY, October, 2014

Poster Sessions 1254: Fatty Acid Binding Protein 5 promotes tumor progression through epithelial-mesenchymal transition in hepatocellular carcinoma

Takanori Ohata, Hideki Yokoo, Toshiya Kamiyama, Kenji Wakayama, Tatsuya Orimo, Tatsuhiko Kakisaka, Yosuke Tsuruga, Hirofumi Kamachi, Akinobu Taketomi

1255: The Autophagy-Related Marker P62 Is Useful For Diagnosis In Human Hepatocellular Carcinoma

Changjae Hur, Byoung Kuk Jang, Jeong Min Kim, Kyung Ho Yang, Hye min Park, Sang Min Lee, Eun Sung Choi, Jung Min Lee, Woo Jin Chung, Jaeseok Hwang, Yoo Na Kang, Koo Jeong Kang

1256: A gene signature derived from sorafenib resistant liver cancer cells identifies HCC patients with poor prognosis Jeroen Dekervel, Dusan Popovic, Hannah van Malenstein, Petra Windmolders, Ashenafi S. Bulle, Bart De Moor, Frederik Nevens, Chris Verslype, Jos van Pelt

1257: Effect of metabolic syndrome on patients with viral hepatitis treated with local regional therapy for hepatocellular carcinoma Fei Wen Chen, Jacob George, Amany Zekry

1258: CUX1 downregulation causes apoptosis in HIF1alpha expressing HCC

Carmen Rothmund, Pietro Di Fazio, Heidi Griesmann, Benjamin Kuehnemuth, Thomas Gress, Patrick Michl, Thaddaeus T. Wissniowski

1259: Consecutive increment of serum alpha-feto protein level is a useful surrogate marker in predicting hepatocellular carcinoma in liver cirrhosis patients

Heechul Nam, Hae Lim Lee, Jung Suk Oh, Young Joon Lee, Ho Jong Chun, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

Biliary Atresia and Cholestasis 1260: C5aR distinguishes subsets of hepatic myeloid and lymphoid cells promoting epithelial injury in experimental biliary atresia


Pranavkumar Shivakumar, Stephanie Walters, Janet Pfister, Rachel M. Sheridan

1261: The association of tetra-hydroxylated bile acids with good prognosis in infantile intrahepatic cholestasis

Cellular and Molecular Biology 1264: The Small GTPase Rab7 as a Central Regulator of Hepatocellular Lipophagy

Barbara Schroeder, Ryan J. Schulze, Shaun Weller, Arthur C. Sletten, Carol A. Casey, Mark A. McNiven

1265: Characterization of Microtubule-based Motility of Autophagic Vesicles from Mouse Liver

Xintao Wang, Eloy Bejarano-Fernandez, John W. Murray, Ana Maria Cuervo, Allan W. Wolkoff

1266: Ca2+-depletion impairs transcytotic vesicle fusion with the apical membrane by altering the SNARE docking and fusion machinery in WIF-B cells Alfonso Lopez Coral, Pamela L. Tuma, Julia F. Omotade

1267: Dual rab17 species have distinct biochemical properties Anneliese C. Striz, Pamela L. Tuma

1268: Insulin resistance of CD56dim NK cells decrease NK killing ability in NASH patients with advanced fibrosis Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi

1269: C-Myc is a central regulator of liver regeneration in mice with chronic liver injury

Stephanie Klett, Kristin Hanak, Bruno Guigas, Robert Geffers, Jessica Endig, Laura E. Buitrago, Silke Marhenke, Michael P. Manns, Arndt Vogel

1270: TIGAR Overexpression Increases Chemosensitivity in Sorafenib-resistant Hepatocellular Carcinoma Cells Zoltan Derdak, Ragheb Harb, Jack R. Wands

1271: Mitoferrofluor – A New Approach to Determine Mitochondrial Chelatable Iron

Andaleb Kholmukhamedov, Christopher C. Lindsey, Craig C. Beeson, John J. Lemasters

1272: Concomitant loss of beta-catenin and gammacatenin in liver disrupts junctional integrity leading to cholestasis, fibrosis and mortality Lili Zhou, Kari Nejak-Bowen, Satdarshan (Paul) S. Monga

Chee-Seng Lee, Kimura Akihiko, Jia-Feng Wu, Yen-Hsuan Ni, Hong-Yuan Hsu, Mei-Hwei Chang, Huey-Ling Chen

1273: The new platelet activating receptor C-type Lectin Receptor -2 plays an essential role in the liver regeneration after partial hepatectomy in mice

1262: Portal hypertension in children; review of management in the era of non-invasive prediction markers

1274: Betaine Mitigates Acetaldehyde-Induced Gut Barrier Dysfunction

Anastasios Grammatikopoulos, Peter Witters, Dominic A. Hughes, Palaniswamy Karthikeyan, Somashekara H Ramakrishna, Mark Davenport, Anil Dhawan


Denotes AASLD Presidential Poster of Distinction

Hiroshi Kono, Hideki Fujii

Paul G. Thomes, Sandra L. Todero, Dean J. Tuma, Kusum K. Kharbanda

1275: Hepatocytes maintain their karyotype in spite of being polyploid Kristin Knouse, Angelika Amon




Poster Sessions 1276: All-in-one liver cell preparation: high quality of functional primary human hepatocytes, liver sinusoidal endothelial cells, Kupffer cells and hepatic stellate cells

Melanie Lutterbeck, Catherine I. Real, Kathrin Skibbe, Joerg Timm, Andreas Paul, Guido Gerken, Joerg F. Schlaak, Ruth Broering

1277: Nuclear receptor SHP and FOXA1 are novel modulators of homocysteine metabolism via regulating BHMT and CTH expression

Hiroyuki Tsuchiya, Kerry-Ann da Costa, Sangmin Lee, Barbara Renga, Yuxia Zhang, Rana Smalling, Hartmut Jaeschke, Steven H. Zeisel, Fiorucci Stefano, Li Wang

1285: Osteopontin isoforms are upregulated in human cholangiocarcinoma cells and modulate levels of the TGF-β repressor, SnoN

Marco A. Briones-Orta, Jason D. Coombes, Naoto Kitamura, Paul P. Manka, Roger Williams, Ali Canbay, Salvatore Papa, Wing-Kin Syn

1286: Post-translational modification of ERK mediates impaired skeletal muscle protein synthesis during hyperammonemia of cirrhosis

Gangarao Davuluri, Michela Giusto, Sathyamangla V. Naga Prasad, Srinivasan Dasarathy

1278: The role of NF-kB in inflammation-induced and obstructive cholestasis

1287: Modulation of bile acid receptor TGR5 : novel therapy for heart failure

1279: Enlarged livers in a human hepatocyte repopulated mouse model are due to aberrant bile acid signaling: potential mechanism underlying the “hepatostat”

1288: Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPAR alpha

Natarajan Balasubramaniyan, Meena Ananthanarayanan, Frederick J. Suchy

Willscott E. Naugler, Markus Grompe

1280: Yap reprograms glutamine metabolism and supports growth during liver development and tumorigenesis

Moreshwar S. Desai, Zainuer Shabier, Jorge Coss-Bu, Sundararajah Thevananther, David D. Moore, Saul J. Karpen, Daniel J. Penny

Takefumi Kimura

1289: Targeting activated Wnt/β-catenin signaling by XAV939 and its derivative WXL-8 in hepatocellular carcinoma Li Ma, Xiaolin Wang, Wei Wei, Mei-Sze Chua, Samuel K. So

Andrew G. Cox, Katie L. Hwang, Sebastian Beltz, Kimberley Evason, Keelin O’Connor, Kristin Brown, Evan C. Lien, Sagar Chhangawala, Yariv Houvras, Didier Y. Stainier, Wolfram Goessling

1290: Lysophosphatidic Acid Signaling Mediates Human Hepatoma Cell Motility

1281: Increased circulating TGFβ1 following liver failure suppresses neural IGF-1 that contributes to hepatic encephalopathy

1291: PNPLA3 (rs738409), LYPLA1 (rs12137855), and NCAN (rs2228603) are associated with elevated transaminase levels in Mexican adults

Matthew McMillin, Cheryl Galindo, Gabriel A. Frampton, Sharon DeMorrow

Yvonne N. Flores, Manuel Bañuelos, Manuel Quiterio, Hal F. Yee, Zuo-Feng Zhang, Rafael Velázquez-Cruz, Jorge Salmerón

1282: Endothelial nitric oxide synthase is a key mediator of extracellular ATP-mediated mitogenic signaling and proliferation of hepatocytes

1292: Evaluation of Yes associated protein as a therapeutic target in primary liver malignancies

Yu Mei, Sundararajah Thevananther

1283: Mechanisms of PKC-mediated enhancement of HIF-1alpha activity and its inhibition by Vitamin K2 in Hepatocellular carcinoma cells

1284: PKCδ facilitates cAMP-induced NTCP translocation and negatively regulates p38 MAPK activation in mouse hepatocytes

Se Won Park, Christopher M. Schonhoff, Cynthia R. Webster, Mohammed S. Anwer

Haibo Bai, Qing-feng Zhu, Gianfranco Alpini, Robert A. Anders

1293: Interactions between Hedgehog and inflammatory signaling reproduce aspects of biliary atresia

Zenobia Cofer, Shuang Cui, Valerie Sapp, Randolph P. Matthews

1294: Inhibition of miR-122 Mediates the Pathogenesis of Alcoholic Liver Disease

Abhishek Satishchandran, Nicita Mehta, Arvin Iracheta-Vellve, Jia Li, Shashi Bala, Donna Catalano, Li Zhong, Jun Xie, Guangping Gao, Gyongyi Szabo

1295: Expression of the Myc dominant interfering miniprotein Omomyc prevents human hepatocellular carcinoma cell growth

Barbara Barbaro, Cristiana Porcu, Gabriele Toietta, Roberta Maggio, Mauro Savino, Sergio Nasi, Clara Balsano

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Jinghe Xia, Iwata Ozaki, Sachiko Matsuhashi, Jingyan Qi, Shinji Iwane, Hirokazu Takahashi, Yuichiro Eguchi, Toshihiko Mizuta, Keizo Anzai

Valentina Zuckerman, Eugene Sokolov, Jacob H. Swet, David A. Iannitti, Iain H. McKillop



HEPATOLOGY, October, 2014

Poster Sessions 1296: Integrative role of histone lysine demethylase LSD2 in hepatic energy metabolism: possible epigenetic mechanism of nonalcoholic fatty liver disease

Katsuya Nagaoka, Shinjiro Hino, Yutaka Sasaki, Mitsuyoshi Nakao

1297: Iron-overload alters lipid metabolism and Ras signaling independent of oxidative stress in mouse liver tissue by whole RNA sequencing

Hiroki Tanaka, Takaaki Ohtake, Lynda Addo, Masayo Yamamoto, Yasumichi Toki, Koji Sawada, Shunsuke Nakajima, Takumu Hasebe, Katsuya Ikuta, Katsunori Sasaki, Yoshihiro Torimoto, Mikihiro Fujiya, Yutaka Kohgo

1298: Suppression of Dual Specificity Phosphatase I inhibits Hepatitis C Virus Replication

Jung Eun Choi, Jung Hyun Kwon, Seung Kew Yoon, Sang Wook Choi

1299: Endoplasmic reticulum stress activates the hepatic activator protein 1 complex via mitogen activated protein kinase-dependent signaling pathways Shantel Olivares, Richard Green, Anne S. Henkel

1300: The pivotal role of anti-angiogenic activity in the in vivo antitumor effects of type I interferon

Hirayuki Enomoto, Tohru Tsujimura, Masao Honda, Chikage Nakano, Kunihiro Hasegawa, Ryo Takata, Tomoko Aoki, Kenji Hashimoto, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai, Nobuhiro Aizawa, Naoto Ikeda, Yoshinori Iwata, Hironori Tanaka, Masaki Saito, Shuichi Kaneko, Hiroko Iijima, Shuhei Nishiguchi

1301: A pivotal role of KLF5 in regulation of cancer stem-like cells in hepatocellular carcinoma

Mitsuteru Natsuizaka, Osamu Maehara, Fumiyuki Sato, Yoshimasa Kubota, Goki Suda, Jun Itoh, Seiji Tsunematsu, Yoko Tsukuda, Katsumi Terashita, Masato Nakai, Takuya Sho, Koji Ogawa, Shunsuke Ohnishi, Naoya Sakamoto

1302: Characterization of Exosomal microRNA (miRNA) Content Following Hepatic Injury And Roles in Cytoprotection After Uptake of Exosomes By Injured Hepatocytes


Yogeshwar Sharma, Tatyana Tchaikovskaya, Preeti Viswanathan, David B. Rhee, Pilib Ó Broin, Tatyana Gorbacheva, Alexander Y. Maslov, Aaron Golden, Sanjeev Gupta

1303: Heat Shock Factor 1 (HSF1) Involvement In Tumour Recurrence After Radiofrequency Ablation In An Animal Model Of Secondary Liver Cancer

Francesca Zanieri, Vinicio Carloni, Sara Omenetti, Claudio Amabile, Nevio Tosoratti, Simone Cassarino, Sriram Saravanan Shanmuga Velandy, Mark Kester, Massimo Pinzani, Krista Rombouts

1304: Establishment of Liver-Targeting Delivery System Using Hepatitis E Virus-Like Particles

Jung-Hee Kim, Wonhee Hur, Eun Byul Lee, Jung Eun Choi, Seung Kew Yoon

Denotes AASLD Presidential Poster of Distinction

1305: Efficient and Safe HCC-specific Gene Therapy and Its Possible Role of Immunogenic Cell Death via Adenovirus Harboring mTERT-targeting Trans-splicing Ribozyme, Liver-specific Promoter and MicroRNA Regulation in Immunocompetent Mouse

Jin-Sook Jeong, Sang Young Han, Seong-Wook Lee, Mi Ha Ju, Kyung Sook Cho

1306: Suppression of HCV replication by exosomemediated miR-199* delivery Guohua Lou, Yanning Liu, Zhi Chen

1307: The efficiency of portal venous port-catheter system as a route of siRNA delivery for the liver metastasis Toshio Kokuryo, Yukihiro Yokoyama, Masato Nagino

Cellular Immunobiology 1308: Plasma Microparticles Modulate Vascular Inflammation and Liver Regeneration via Ectonucleotidase-Dependent Levels of MicroRNA 142-3P

Stephanie Kuhn, Katrin Splith, Ines Kämmerer, Cindy Hegewald, Linda Feldbrügge, Jan Schulte am Esch, Sven Jonas, Simon C. Robson, Moritz Schmelzle

1309: Matrix-embedded endothelial cells rescue median lobe from ischemia and switch M1 macrophages to M2 phenotype after partial hepatectomy in mice Pedro Melgar-Lesmes, Elazer R. Edelman

1310: Serum transcriptomic analysis of liver transplant recipients with hepatitis C: mild versus severe disease Obaid S. Shaikh, Yue Chen, Chengli Shen, Phalguni Gupta

1311: Effect of continuous hypothermic oxygenated machine perfusion(CHOP) on liver graft from donors after cardiac death (DCD) following liver transplantation Ling Lu, Jianhua Rao, Haoming Zhou, Xuehao Wang

1312: A novel model for reperfusion of the human liver following organ preservation

James H. Avruch, Bote G. Bruinsma, Pepijn D. Weeder, Gautham V. Sridharan, Heidi Yeh, Korkut Uygun, James F. Markmann

1313: Ischemic postconditioning (IPostC) in fibrotic livers following warm ischemia: a new strategy to protect the liver against ischemia-reperfusion injury

Julia Schewe, Ingrid Liss, Lisa Selzner, Marie-Christine Makeschin, Burkhard Göke, Alexander L. Gerbes, Christian J. Steib

1314: TLR4 activation, ER stress induction and autophagy inhibition: a tripartite synergy in interleukin 23 induction during liver ischemia and reperfusion injury Ling Lu, Jianhua Rao, Haoming Zhou, Xuehao Wang




Poster Sessions 1315: Progressive biliary fibrosis stimulates liver repopulation by either stem/progenitor cells or mature hepatocytes Mladen Yovchev, Joseph Locker, Michael Oertel

Clinical Hepatobiliary Neoplasia 1316: Analysis of Immune Responses in Patients Vaccinated with Alpha-Fetoprotein-Derived Peptides in the Treatment of Hepatocellular Carcinoma

Eishiro Mizukoshi, Tatsuya Yamashita, Kuniaki Arai, Hajime Sunagozaka, Kazumi Fushimi, Hidetoshi Nakagawa, Noriho Iida, Masaaki Kitahara, Shuichi Kaneko

1317: Prognostic Effect of Statins on Hepatocellular Carcinoma in Presence and Absence of Metformin intake

Reham Abdel-Wahab, Hesham M. Hassabo, Ahmed El Antably, Kanwal Raghav, Ahmed O. Kaseb, H. Franklin Herlong, Young Kwang Chae, Gehan Botrus, Harrys A. Torres, Ahmed S. Shalaby, Manal Hassan

1318: Hepatocellular Carcinoma: Hospitalizations and financial burden in the United States

Raxitkumar Jinjuvadia, Augustine Salami, Suthat Liangpunsakul, Reena Salgia

1319: The risk of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis is predicted by a polymorphism of MERTK gene

Vincenza Calvaruso, Stefania Grimaudo, Rosaria Maria Pipitone, Maria Grazia Bavetta, Giuseppe Cabibbo, Elisabetta Conte, Fabrizio Bronte, Antonio Craxì, Vito Di Marco

1320: Liver Transplantation for HIV-Infected Patients with Hepatocellular Carcinoma (HCC)

Heather L. Platt, Caitlin C. Citti, Beatriz Minguez, Ting-Yi Chen, Meritxell Ventura-Cots, Maria D. Hernandez, Ziba Jalali, Maaz B. Badshah, Michael Yin, Ayse Aytaman, Mark Nelson, Jürgen K. Rockstroh, Matthew B. Goetz, Myron Schwartz, Douglas Dieterich, Judith Aberg, Yujin Hoshida, Norbert Bräu

1321: The management and prognosis of patients with hepatocellular carcinoma: What has changed during 20 years?

1322: Predicting Survival of HIV-Infected Patients with Liver Cancer – the SHILCA Score and Staging Model

Ting-Yi Chen, Nicolás Merchante, Caitlin C. Citti, Heather L. Platt, Maaz B. Badshah, Meritxell Ventura-Cots, Esperanza Merino, Luciana Kikuchi, Mamta K. Jain, Francisco Rodríguez-Arrondo, Beatriz Minguez, Michael Yin, Ayse Aytaman, Cristina Tural, Myron Schwartz, Douglas Dieterich, Judith Aberg, Juan Pineda, Jorge A. Marrero, Morris Sherman, Yujin Hoshida, Norbert Bräu

Poster Viewing: 8:00 AM – 5:30 PM

Ryosuke Tateishi, Takeshi Okanoue, Kiwamu Okita, Kendo Kiyosawa, Masao Omata, Hiromitsu Kumada, Norio Hayashi, Kazuhiko Koike

1324: The Effect of HBV DNA Level on The Development of Hepatocelluar Carcinoma in Patients with Hepatitis B Virus-associated Liver Cirrhosis during Entecavir Treatment: A Multicenter Study

Oh Sang Kwon, Jong Eun Yeon, Jeong Han Kim, So Young Kwon, Sang Jun Suh, Yun Soo Kim, Ju Hyun Kim

1325: Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines Recommendation

Zahraa Alkhatib, Asmaa Gomaa, Eman A. Rewisha, Imam Waked

1326: Intrahepatic cholangiocarcinoma in patients with nonalcoholic fatty liver disease

Takayoshi Nishioka, Shogo Tanaka, Shigekazu Takemura, Takahiro Uenishi, Hiroji Shinkawa, Takatsugu Yamamoto, Masahiko Kinoshita, Genya Hamano, Sayaka Tanaka, Yuko Kuwae, Masahiko Ohsawa, Kenichi Wakasa, Shoji Kubo

1327: Validation for retreatment strategy and survival analysis after second session of transarterial chemoembolization in patient with hepatocellular carcinoma

Yang J. Yoo, Ji Hoon Kim, Ji Hye Je, Seong Hee Kang, Hae Rim Kim, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun

1328: Wnt/beta-catenin signaling activates different target genes depending on stem/maturational status and HNF4α expression in hepatocellular carcinoma Taro Yamashita, Masao Honda, Shuichi Kaneko

1329: N.I.A.C.E score: a new tool to better distribute advanced hepatocellular carcinoma (BCLC C). Results from four French cohorts comprising 703 patients

Xavier Adhoute, Guillaume Penaranda, Jean-Frédéric Blanc, Julien Edeline, Guillaume Conroy, Paul Castellani, Valerie Oules, Olivier Bayle, Olivier Monnet, Bernard L. Pol, Patrick Beaurain, Herve Perrier, Jean-Luc Raoul, Jean-Pierre Bronowicki, Marc Bourlière

1330: Specialty Care is Associated with Early Diagnosis of Hepatitis C-related Hepatocellular Carcinoma in U.S. Veterans

Janice H. Jou, Lauren A. Beste, Yin Yang, Michael F. Chang, Andrew J. Muir

1331: Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients

Maria Guarino, Giovan Giuseppe Di Costanzo, Andrea Gallotta, Giorgio Fassina, Raffaella Tortora, Concetta Tuccillo, Francesco Auriemma, Nicola Caporaso, Filomena Morisco

Presenters in Attendance 12:30 – 2:00 PM


Sun Young Yim, Yeon Seok Seo, Chang Ho Jung, Tae Hyung Kim, Jae Min Lee, Hyonggin An, Ji Hoon Kim, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um, Ho Sang Ryu

1323: Role of Occult HBV Infection in the Development of non-B, non-C Hepatocellular Carcinoma: Analysis from a Large Retrospective Multicenter Cohort Study



HEPATOLOGY, October, 2014

Poster Sessions 1332: The combined use of sorafenib and branched chain amino acids enhances antitumor effect in the treatment of hepatocellular carcinoma

Yoshiki Onishi, Tomohide Tatsumi, Satoshi Aono, Seiichi Tawara, Akira Nishio, Takatoshi Nawa, Atsuo Takigawa, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tetsuo Takehara

1333: Prospective evaluation of the performance of per ERCP bile aspiration combined to endobiliary brushing in the diagnosis of malignant strictures of the biliary tract

Roth Gael, Bichard Philippe, Fior-Gozlan Michele, Auroux Jean, Christian Letoublon, Ivan Bricault, Vincent Leroy, Thomas Decaens

1334: The outcomes of transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil compared to TACE using doxorubicin for unresectable hepatocellular carcinoma

Sung Won Lee, Jung Hyun Kwon, Soon woo Nam, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

1335: Comparison of Safety and Efficacy of Chemoembolization for unresectable Hepatocellular Carcinoma: Doxorubicin-Eluting Beads versus conventional TACE in Patients With and Without Transjugular Intrahepatic Portosystemic Shunt

Ali Faramarzalian, KV Narayanan Menon, Baljendra Kapoor, Amanjit Gill, Gordon McLennan, Amit Gupta, Benjamin Tritle, Mark J. Sands, Federico N. Aucejo, Robert J. Pelley, Bassam Estfan, Nancy Obuchowski

1336: Percutaneous thermal ablation for hepatocellular carcinoma: A systematic review and meta-analysis

Mohamed A. Chinnaratha, Anthony Chuang, Robert Fraser, Richard J. Woodman, Alan J. Wigg

1337: Serum dickkopf-1, osteopontin and midkine as novel biomarkers for the diagnosis and pre-clinical diagnosis of hepatocellular carcinoma

Roslyn Vongsuvanh, Jacob George, Tristan J. Iseli, Simone I. Strasser, Geoffrey W. McCaughan, David van der Poorten


1338: Surveillance for Hepatocellular Carcinoma with Magnetic Resonance Imaging Using a Liver-Specific Contrast Agent Gadoxetic Acid and Ultrasonography in High-Risk Patients with Cirrhosis

Young-Suk Lim, So Yeon Kim, Jae Ho Byun, Hyung Jin Won, So Jung Lee, Seungbong Han, Jihyun An, Han Chu Lee, Yung Sang Lee

1339: Epithelial to mesenchymal transition affects the stemness of primary liver cancers

Naoki Oishi, Juling Ji, Taro Yamashita, Qinghai Ye, Shuichi Kaneko, Xin W. Wang

Denotes AASLD Presidential Poster of Distinction

1340: Comparison of acute healthcare costs and effects of Trans-arterial chemo-embolization using conventional technique with drug eluting beads

Farooq A. Khan, Eleftherios Floros, Guruprasad P. Aithal, Mahal Gurpreet, Martin W. James, Zergham Zia, Stephen D. Ryder, Richard O’Neill

1341: Gross appearance of hepatocellular carcinoma reflects expression of cancer stem cells, epithelialmesenchymal transition and hypoxia related genes Hyungjin Rhee, Deuk Chae Na, Young Nyun Park

1342: Diffusion-weighted MRI is suitable to predict malignant potential in small hepatocellular carcinoma

Shusuke Okamura, Tatsuyuki Tonan, Shuji Sumie, Masahito Nakano, Manabu Satani, Ryoko Kuromatsu, Takuji Torimura

1343: Yttrium-90 radioembolization for HCC in the transplant setting: feasibility, clinical and pathological considerations. Can we give a better chance for locally advanced HCC?

Raffaella Lionetti, Andrea Laurenzi, Giovanni Vennarecci, Roberto Santoro, Marzia Montalbano, Ubaldo Visco Comandini, Elisa Busi Rizzi, Rosa Sciuto, Pierluca Piselli, Lucia Rosalba Grillo, Gianpiero D’Offizi, Giuseppe M. Ettorre

1344: Clinical characteristics of hepatocellular carcinoma in elderly patients: A retrospective, multicenter study Naota Taura, Hisamitsu Miyaaki, Kazuhiko Nakao

1345: Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virologic response (SVR) and fluctuation of Alfa feto-protein levels during antiviral treatment

Tuul Purevsambuu, Simona Bota, Florian Hucke, Harald Hofer, Peter Ferenci, Wolfgang Sieghart, Markus Peck-Radosavljevic

1346: A nationwide all-inclusive analysis demonstrates a decrease in adjusted survival of incident-cases of hepatocellular carcinoma (HCC) among HIV+ patients

Nathalie GOUTTE, Philippe Sogni, Noelle Bendersky, Bruno Falissard, Olivier Farges

1347: First generation protease inhibitor-based triple therapy and risk of hepatocellular carcinoma

Jonathan M. Fenkel, Gloria Francis, Doris H. Chan, Dina HalegouaDe Marzio, David A. Sass, Steven K. Herrine, Jesse M. Civan

1348: The Optimal Method for Measuring Intrahepatic Hepatocellular Carcinomas in Liver Transplant Candidates Undergoing Lipiodolized Transarterial Chemoembolization

Hyung-Don Kim, Ju Hyun Shim, Yeonjung Ha, Mi-Jung Jun, Young Joo Yang, Seung Bum Lee, Gi Ae Kim, Jee Eun Yang, Eui Ju Park, Jihyun An, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh




Poster Sessions 1349: Increased incidence but improved survival for biliary tract cancers in Ontario from 1994-2012: A population-based study

Jennifer A. Flemming, Senthuran Tharmalingam, Sulaiman Nanji, Jina Zhang-Salomons, Christopher Booth

1350: Surveillance for hepatocellular carcinoma is associated with better survival: Results from a large cohort in the Netherlands

Suzanne van Meer, Robert A. de Man, Minneke Coenraad, Dave Sprengers, Carin M. Van Nieuwkerk, Martijn van Oijen, HeinzJosef Klümpen, Peter L. Jansen, Peter D. Siersema, Karel J. van Erpecum

1351: Impact of advanced age on the short- and longterm postoperative outcomes in patients undergoing hepatectomy for hepatocellular carcinoma

Hiroaki Motoyama, Akira Kobayashi, Takahide Yokoyama, Akira Shimizu, Norihiko Furusawa, Hiroshi Sakai, Noriyuki Kitagawa, Takuma Arai, Tomoki Shirota, Shinichi Miyagawa

1352: Systematic Identification of Long Intergenic Noncoding RNAs expressed in Hepatocellular Carcinoma Yuji Zhang, Asha Nair, Lewis R. Roberts, Tushar Patel

1353: ω-3 Polyunsaturated Fatty Acids Regulate the Expression of 15-PGDH through miRNA26a and miRNA26b in Cholangiocarcinoma Lu Yao, Chang Han, Kyoungsub Song, Kyu Lim, Tong Wu

1354: Analytic Morphomics Improves the Prediction of Survival in Patients with Hepatocellular Carcinoma

Peng Zhang, Pratima Sharma, Pranab Barman, Neehar D. Parikh, Sampath kumar Santhanam Ethiraj, Venkat Krishnamurthy, Lu Wang, Stewart C. Wang, Grace L. Su

1355: The Effect of Demographics and Socio-Economic Factors on Survival in Metastatic Neuroendocrine Tumors: a Surveillance, Epidemiology and End Results (SEER) Population Study Minzhi Xing, Nima Kokabi, Juan C. Camacho, Hyun S. Kim

1356: Clinical outcomes of early to intermediate hepatocellular carcinoma treated with Trans-Arterial chemoembolization versus Radiofrequency ablation

1357: Inflammatory bowel disease (IBD) is a risk factor for extrahepatic cholangiocarcinoma (ECC) in subjects without underlying primary sclerosing cholangitis (PSC)

Hassan M. Ghoz, Esha Baichoo, Benyam D. Addissie, Lewis R. Roberts, Roongruedee Chaiteerakij

Hassan M. Ghoz, Esha Baichoo, Benyam D. Addissie, Lewis R. Roberts, Roongruedee Chaiteerakij

1359: Radiofrequency ablation of solid tumors in combination with bortezomib causes ER-stress

Thaddaeus T. Wissniowski, Deike Strobel, Daniel Neureiter, Thomas Gress, Patrick Michl, Pietro Di Fazio

1360: Clinical outcomes of intraoperative radiofrequency ablation for primary hepatocelluar carcinoma ineligible for percutaneous radiofrequency ablation or surgical resection

Eun Chung, Jung Hyun Kwon, Soon woo Nam, Young Woon Kim, Sung Won Lee, Young chul Yoon

1361: Ten-Year Outcomes of Cryoablation Therapy for Small Hepatocellular Carcinoma and Child–Pugh Class A or B Cirrhosis: A Single Center Large Cohort Experience

Guanghua Rong, Wenlin Bai, Zheng Dong, Chunping Wang, Yin Ying Lu, Ke-Qin Hu, Yongping Yang

1362: Prognostic factors for patients with recurrent hepatocellular carcinoma following liver transplant. A Euro-American study

Gonzalo Sapisochin, Nicolas Goldaracena, Santiago Astete, Duncan Davidson, Rafael Ehab, Lluis Castells, Charbel Sandroussi, Itxarone Bilbao, Les Lilly, Cristina Dopazo, Anand Ghanekar, Ian McGilvray, Mark Cattral, Markus Selzner, David Grant, Ramon Charco, Paul Greig

1363: Prognostic Significance of Hepatic Venous Pressure Gradient in the Prediction of Hepatocellular Carcinoma

Eun Jin Kim, Ki Tae Suk, Hyo Sun Kim, Sang Hyun Park, Chang Seok Bang, Ji Won Park, Choong Kee Park, Sung Eun Kim, Hyoung Su Kim, Myoung Kuk Jang, Sang Hoon Park, Myung Seok Lee, Dong Joon Kim

1364: Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential drug target in hepatocellular carcinoma Leona L. Pott, Henning Reis, Barbara Sitek, Hideo A. Baba

1365: A Prospective Randomized Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma

Hae Won Lee, Kyung-Suk Suh, Hyeyoung Kim, YoungRok Choi, Suk-Won Suh, Jaehong Jeong, Nam-Joon Yi, Kwang-Woong Lee

1366: Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy

Xiaodong Guo, Lingxiang Yu, Jinghui Dong, Ruisheng Li, Boan Li, Huiqiang Liu, Mei Yang, Jingmin Zhao

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Wei Rong, Benjamin Tay, Jia Chen Lim, Alfred W. Kow, Shridhar G. Iyer, Kin Yong, Stephen Stephen, Chern Hao Chong, Maureen Da Costa, Krishnakumar Madhavan, Seng Gee Lim, Yock Young Dan

1358: There are significant differences in the risk factors for perihilar cholangiocarcinoma (CCA) compared to distal CCA: Rationale for approaching them as distinct entities



HEPATOLOGY, October, 2014

Poster Sessions 1367: A retrospective review of Hepatocellular Carcinoma surveillance in 3 United Kingdom teaching hospitals Henry House, Nowlan Selvapatt, Ashley S. Brown

1368: ABSTRACT Survival of hepatocellular carcinoma in patients with normal liver versus underlying cirrhosis: Results from a large cohort in the Netherlands

Suzanne van Meer, Karel J. van Erpecum, Joanne Verheij, Minneke Coenraad, Dave Sprengers, Carin M. Van Nieuwkerk, Heinz-Josef Klümpen, Peter L. Jansen, Peter D. Siersema, Robert A. de Man

1369: A preclinical study of EpCAM-targeted therapy for human hepatocellular carcinoma with stem cell features

Shinji Tanaka, Kousuke Ogawa, Satoshi Matsumura, Arihiro Aihara, Daisuke Ban, Takanori Ochiai, Takumi Irie, Atsushi Kudo, Shigeki Arii, Minoru Tanabe

1370: Screening and Management of Hepatocellular Carcinoma. Report of a Global Survey Dalbir S. Sandhu, Antonio J. Sanchez

1371: Calculating the growth rate of small hepatocellular carcinoma: implications for surveillance and treatment

Ian A. Rowe, Debashis Haldar, Diarmaid D. Houlihan, Shishir Shetty, Hynek Mergental, Tahir Shah

1372: Subgroup Analysis of Patients with HIV+HCC Among a Cohort of 2322 Veterans Diagnosed with Hepatocellular Carcinoma (HCC) from 2008-2010

David E. Kaplan, Ayse Aytaman, Michelle Baytarian, Kathryn D’Addeo, Feng Dai, Rena K. Fox, Kristel K. Hunt, Astrid Knott, Rajni Mehta, Marcos Pedrosa, Christine Pocha, Melissa Skanderson, Adriana Valderama, Tamar H. Taddei

1373: Treatment outcome of Radiofrequency ablation as first line treatment for Hepatocellular carcinoma in Milan criteria : Analysis of 510 patients in a single center


Se Young Jang, Soo Young Park, Won Young Tak, Young Oh Kweon, Su Hyun Lee, Jung Gil Park

1374: High alpha-fetoprotein levels and presence of clinically significant portal hypertension represent risk factors for hepatocellular carcinoma development in cirrhotic patients

Simona Bota, Florian Hucke, Matthias Pinter, Mattias Mandorfer, Thomas Reiberger, Arnulf Ferlitsch, Michael Trauner, Wolfgang Sieghart, Markus Peck-Radosavljevic

1375: Impact of surveillance on the survival of patients with hepatocellular carcinoma: results from a longitudinal study in Taiwan

Diana Chirovsky, Kristen Hassmiller Lich, Alfred S. Barritt, Pei-Jer Chen, Stephanie B. Wheeler, Lucinda S. Orsini, Andrea K. Biddle

Denotes AASLD Presidential Poster of Distinction

1376: Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT)

Alberto Zanetto, Alberto Ferrarese, Kryssia I. Rodriguez, Veronica Pepe, Mariangela Fadin, Claudia M. Radu, Sabrina Gavasso, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Francesco P. Russo, Giacomo Germani, Elena Nadal, Paolo Simioni, Patrizia Burra, Marco Senzolo

1377: Clinical outcomes in patients who develop hepatocellular carcinoma after hepatitis C viral eradication by antiviral therapy

Kaoru Tsuchiya, Yutaka Yasui, Nobuharu Tamaki, Shoko Suzuki, Takanori Hosokawa, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi

1378: Absence of thrombocytopenia is correlated with decreased survival in patients with advanced liver disease and hepatocellular carcinoma

Marco Senzolo, Alessandro Vitale, Edoardo G. Giannini, Teh-Ia Huo, Franco Trevisani, Fabio Farinati

1379: Beneficial effects of oral branched-chain amino acid supplementation after local therapy for liver cancer

Shunsuke Nojiri, Kei Fujiwara, Noboru Shinkai, Etsuko Iio, Takashi Joh

1380: Doubling Time of Des-gamma-carboxy Prothrombin Can be Useful as a Prognostic Marker for Hepatocellular Carcinoma

Nobuyuki Matsumoto, Hiroki Ikeda, Yohei Noguchi, Ryuta Shigefuku, Kotaro Matsunaga, Chiaki Okuse, Michihiro Suzuki, Fumio Itoh

1381: Role of Primovist-MR Imaging on Preoperative Assessment of the Risk of Postoperative Liver Failure in Patients with Hepatocellular Carcinoma

Sin-Il Kim, Young-Joo Jin, Soon Gu Cho, Ah Rhm Woo, Jin-Woo Lee, Young Soo Kim

1382: Obesity and alfa-fetoprotein predict presence of histopathologic features associated with hepatocellular carcinoma recurrence after liver transplantation

Vinay Sundaram, Anish V. Patel, Alagappan A. Annamalai, Walid S. Ayoub, Tram T. Tran, Andrew S. Klein

1383: Tumor volume doubling time in hepatocellular carcinoma: a systematic literature review and metaanalysis

Diana Chirovsky, Andrea K. Biddle, Richard C. Semelka, Kristen Hassmiller Lich, Stephanie B. Wheeler, Lucinda S. Orsini, Alfred S. Barritt

1384: Adherence to Hepatocellular Carcinoma Diagnostic Guidelines: Single Veterans Affairs Medical Center (VAMC) Experience Thoetchai Peeraphatdit, Niyada Naksuk, Paola Ricci




Poster Sessions 1385: Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain conebeam CT Yasunori Minami, Masatoshi Kudo

1386: Phase 2 trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC)

Aiwu R. He, Narayan Shivapurkar, Anteneh A. Tesfaye, HongKun Wang, Michael J. Pishvaian, Brandon G. Smaglo, John Marshall, Karen Dorsch-Vogel, Jaydeep Kachhela

1387: WITHDRAWN 1388: Additive anti-Tumor Response to the Rabbit VX2 Hepatoma by Combined Radio Frequency Ablation and Toll like Receptor 9 Stimulation

Barbara Behm, Pietro Di Fazio, Daniel Neureiter, Thomas Gress, Patrick Michl, Detlef Schuppan, Thaddaeus T. Wissniowski

1389: Survival Benefit of Long-Term Sorafenib Treatment in Patients with Advanced Hepatocellular Carcinoma in Indonesia: Multicenter experience

Cosmas R. Lesmana, Rino A. Gani, Levina S. Pakasi, Irsan Hasan, Agus S. Waspodo, Lianda Siregar, Poernomo Budi, Laurentius A. Lesmana

1390: Trends and Patterns of Treatment for Hepatocellular carcinoma in Korea

Youngmi Hong, Mong Cho, Ki Tae Yoon, Daehwan Kang, Hyungwook Kim, Cheol Woong Choi, SuBum Park, Jeong Heo, Hyun Young Woo, Won Lim

1391: HIV Viral Load Independently Predicts Survival in HIV-Infected Patients With Hepatocellular Carcinoma (HCC)

Caitlin C. Citti, Heather L. Platt, Maaz B. Badshah, Ting-Yi Chen, Luciana Kikuchi, Meritxell Ventura-Cots, Noami Chaudhary, Sonja Marcus, Michael Yin, Ayse Aytaman, Judith Aberg, Myron Schwartz, Douglas Dieterich, Yujin Hoshida, Norbert Bräu

1392: Complete response at the first chemoembolization is still the most robust factor for favorable outcome in hepatocellular carcinoma Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han

Takayuki Fukuhara, Hiroshi Aikata, Yohji Honda, Hiromi Kan, Tomoki Kobayashi, Noriaki Naeshiro, Daisuke Miyaki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Yoshiiku Kawakami, C. Nelson Hayes, Kazuaki Chayama

Poster Viewing: 8:00 AM – 5:30 PM

Tomoko Aoki, Shuhei Nishiguchi, Chikage Nakano, Kenji Hashimoto, Akio Ishii, Tomoyuki Takashima, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Hironori Tanaka, Yoshinori Iwata, Hirayuki Enomoto, Masaki Saito, Jiro Fujimoto, Seiichi Hirota, Hiroko Iijima

1395: Prognostic value of the Barcelona Clinic Liver Cancer staging subclassification system for conventional transarterial chemoembolization

Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Koichi Gondou, Natsuko Nakakuki, Hitomi Takada, Shuya Matsuda, Yu Asano, Nobuhiro Hattori, Nobuharu Tamaki, Shoko Suzuki, Takanori Hosokawa, Hiroyuki Nakanishi, Jun Itakura, Namiki Izumi

1396: Autophagy may be an early event in the stepwise carcinogenesis via biliary intraepithelial neoplasia in cholangiocarcinoma associated with hepatolithiasis Motoko Sasaki, Takeo Nitta, Yasunori Sato, Yasuni Nakanuma

1397: In vitro validation of human glypican-3 specific chimeric antigen receptors for hepatocellular carcinoma Yonghai Li, David E. Kaplan

1398: The role of gut commensal bacteria in anti-tumor effect of chemotherapy for hepatocellular carcinoma

Noriho Iida, Eishiro Mizukoshi, Tatsuya Yamashita, Shuichi Kaneko

1399: Management of hepatocellular carcinoma in elderly patients: an Italian “in field” experience

Elena Dionigi, Mauro Borzio, Angelo Rossini, Anna Toldi, Giampiero Francica, Fabio Fornari, Andrea Salmi, Fabio Farinati, Susanna Vicari, Massimo Marignani, Giancarlo Parisi, Fulvia Terracciano, Ilario de Sio, Rodolfo Sacco

1400: Vascularization of hepatocellular adenomas and carcinomas by co-option of portal tracts Ashley E. Stueck, Masayuki Nakano, Ian R. Wanless

1401: Prognostic Assessment of Patients with Untreated Hepatocellular Carcinoma

Edoardo G. Giannini, Fabio Farinati, Francesca Ciccarese, Anna Pecorelli, Gian Ludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Franco Trevisani

1402: Clinical Impact of Additional Interferon Administration on Sorafenib-treated Patients with Recurrent Advanced Hepatocellular Carcinoma Hisakazu Doi

1403: How Is BCLC Stage C HCC Treated In Real-Word Practice And What Outcomes Are Obtained?

Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong-Won Park, Jijin Yang, Lunan Yan, Guohong Han, Francesco Izzo, Minshan Chen, Jean-Frédéric Blanc, Phillip Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman

Presenters in Attendance 12:30 – 2:00 PM


1393: Radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Compared with primary cases

1394: Retrospective Cohort study for liver carcinogenesis prediction using VF map score : Virtual Touch Quantification(VTQ), Fasting blood glucose(FBG), male, age, platelet



HEPATOLOGY, October, 2014

Poster Sessions 1404: Characteristics and prognosis of hepatocellular carcinoma after sustained virological response to interferon therapy for hepatitis C

Koichi Honda, Masataka Seike, Junya Oribe, Mizuki Endo, Mie Yoshihara, Hiroki Syo, Masao Iwao, Masanori Tokoro, Tetsu Mori, Tsutomu Yamashita, Toyokichi Muro, Kazunari Murakami

1405: The decrease of alpha-fetoprotein and/or the decrease of tumor stain on contrast enhanced CT images after 2 weeks of sorafenib treatment predict prognosis in patients with advanced hepatocellular carcinoma

Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Hidemi Goto

1406: Incidental Microscopic Bile Duct Tumor Thrombi in Hepatocellular Carcinoma after Curative Hepatectomy: A Matched Study

Jong Man Kim, Ju-Yeon Cho, Geum Youn Gwak, Choon Hyuck D. Kwon, Moon Seok Choi, Joon Hyeok Lee, Jae Won Joh, Seung Woon Paik, Cheol Keun Park, Byung Chul Yoo

1407: Staged Doxorubicin Eluting Bead Transarterial Chemoembolization Therapy for Unresectable Hepatocellular Carcinoma Confers to Survival Advantage with Preservation of Quality of Life

Minzhi Xing, Hasmukh J. Prajapati, Grant R. Webber, Hyun S. Kim

1408: Factors affecting tolerability of Yttrium-90 Radioembolization in patients with advanced hepatocellular carcinoma – A large single center analysis

Bahar Madani, Ashwini P. Mehta, Parvez S. Mantry, Carlos G. Fasola, Aden Tadelle, Islam Shahin, Alejandro Mejia, Hector Nazario, Jeffrey S. Weinstein, Maisha Barnes, Adil Habib, Abdullah Mubarak, Steve Cheng

1409: Transarterial chemoembolization (TACE) caused hypoxia may trigger a progenitor cell phenotype in hepatocellular carcinoma (HCC) Jinping Lai, Beatrice Knudsen, Maha Guindi

1410: Does Liver Regeneration Increase the Postoperative Recurrence after Curative Resection of Hepatocellular Carcinoma? MONDAY NOVEMBER 10

Jin Ho Lee, Gi Hong Choi, Dai Hoon Han, Jin Sub Choi

1411: Cancer Registries Underestimate Hepatocellular Carcinoma Incidence: An Independent Population-Based Epidemiological Study

Thai Hong, Alexander J. Thompson, Paul Gow, Michael A. Fink, Anouk T. Dev, Virginia H. Knight, Marno C. Ryan, Ian Kronborg, Niranjan J. Arachchi, Stuart K. Roberts, William W. Kemp, Amanda J. Nicoll, John Lubel, Helen Farrugia, Vicky Thursfield, Paul V. Desmond, Sally Bell

1412: Statins and metformin use improve prognosis after diagnosis of hepatocelullar carcinoma

Javier Ampuero, Raquel Calle, Blanca Figueruela, Paula Ferrero, Emilio Suarez, Manuel Romero-Gomez

Denotes AASLD Presidential Poster of Distinction

1413: Interleukin-8 level as predictive marker for treatment response after transarterial chemoembolization in hepatocellular carcinoma

Joohan Park, Soon Sun Kim, Hyo Jung Cho, Sun Young Park, Seon Joo Ahn, Jae Youn Cheong, Sung Won Cho

1414: Predisposing factors for development of hepatocellular carcinoma in chronically infected hepatitis C virus patients who underwent pegylated interferon plus ribavirin

Sin-Il Kim, Young-Joo Jin, Jihye Jang, Jin-Woo Lee, Young Soo Kim

1415: Does a Multidisciplinary Team (MDT) change management in Hepatocellular Carcinoma (HCC)? A Single Center Experience

Pierre M. Gholam, Anthony B. Post, Stanley M. Cohen, Kenneth J. Woodside, Vanessa Humphreville, Badar Muneer, Edmund Q. Sanchez, Christopher T. Siegel

1416: Selective Internal Radiation Therapy(SIRT) Using Yttrium-90 In Patients With Advanced Hepatocellular Carcinoma: A Large Single Center Experience

Bahar Madani, Ashwini P. Mehta, Parvez S. Mantry, Carlos G. Fasola, Aden Tadelle, Islam Shahin, Alejandro Mejia, Hector Nazario, Jeff Weinstein, Maisha Barnes, Adil Habib, Abdullah Mubarak, Steve Cheng

1417: Array-based gene expression analysis of M1/ M2-polarized macrophages during treatment with multikinase inhibitor Sorafenib Martin F. Sprinzl, Jens U. Marquardt, Brigitte Bartsch, Hauke Lang, Arndt Weinmann, Peter R. Galle

1418: Nuclear to Cytoplasmic Translocation of FOXO3 Determines the Sensitivity of Human Hepatocellular Carcinoma to Doxorubicin

Josiah Cox, Anusha Vittal, Maura O’Neil, Zhuan Li, Sudhakiranmayi Kuravi, Brian Bridges, Ahmad B. Abdulkarim, Steven A. Weinman

1419: Heterogeneity in risk factors and treatment allocation, but comparable clinical presentation and survival with hepatocellular carcinoma (HCC) among the three largest Asian sub-populations in California

Channa R. Jayasekera, Lily H. Kim, James M. Wantuck, Benjamin Yip, Mindie H. Nguyen

1420: Biphenotypic Tumors: Assessing Outcomes of Hepatic Directed Therapies

Kathryn Fowler, Nael Saad, Elizabeth M. Brunt, Manik Amin, Neeta Vachharajani, Maria Bernadetta Doyle, Benjamin Tan, William C. Chapman

1421: Aberrant expression of microRNA according to aging is participating in hepatocarcinogenesis

Yoshiki Murakami, Saori Itami, Hidenori Toyoda, Takashi Kumada, Toshihito Tanahashi, Etsushi Kawamura, Atsushi Hagihara, Sawako K. Uchida, Hiroyasu Morikawa, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada, Y-h Taguchi




Poster Sessions 1422: Prognostic influence of spontaneous tumor rupture on resectable hepatocellular carcinoma

Chan Albert, Ronnie T. Poon, Tan To Cheung, Kenneth S. Chok, Sheung Tat Fan, Chung Mau Lo

1423: Occurrence of Hepatocellular Carcinoma Is Comparable in Chronic HBV Infectors Treated with Different Nucleos(t)ide Analogues: A 6-year Retro- and Prospective Real World Cohort Study

Yuankai Wu, Xiangyong Li, Mingxing Huang, Guoli Lin, Shu-ru Chen, Hong Shi, Yusheng Jie, Xin-Hua Li, Fangji Yang, Min Zhang, Yunlong Ao, Yihua Pang, Yutian Chong

1424: Real-life Data of Sorafenib in Unresectable Hepatocellular Carcinoma: Retrospective Analysis of 511 Consecutive Patients Treated with Sorafenib in a Single Tertiary Referral Center

Yeonjung Ha, Hyung-Don Kim, Mi-Jung Jun, Young Joo Yang, Seung Bum Lee, Jee Eun Yang, Gi Ae Kim, Eui Ju Park, Jihyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh

1425: Etiological roles of diabetes, BMI and past hepatitis B infection in the development of non-B non-C, non-alcoholic hepatocellular carcinoma

Hae Lim Lee, Nam Ik Han, Sang Wook Choi, Joon-Yeol Han, Se Hyun Cho, Jin-Mo Yang

1426: Decreased expression of PBLD correlates with a poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma Aimin Li, Qun Yan, Side Liu, Yu Qiang Nie

1427: HBV DNA / Quantitative HBsAg Level Ratio, but Not Either Quantitative HBsAg Level or HBV DNA, Can Predict Hepatocellular Carcinoma Development in HBeAg-Negative Chronic Hepatitis Patients with HBV DNA ≥ 2000 IU/mL

Jem ma Ahn, Dong Hyun Sinn, Ju Yeon Cho, Won Sohn, GeumYoun Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo

1428: Radiofrequency ablation with or without transcatheter arterial chemoembolization for small hepatocellular carcinoma; a propensity analysis

Hee Yeon Kim, Chang Wook Kim, Yu Seung Kim, Seung Kew Yoon, Jong Young Choi, Si Hyun Bae, Chang Don Lee

Won Sohn, Yong-Han Paik, Ju Yeon Cho, Jem-Ma Ahn, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo

Won Sohn, Yong-Han Paik, Ju Yeon Cho, Jong Man Kim, Choon Hyuck D. Kwon, Jae Won Joh, Jem-Ma Ahn, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo

1431: Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma

Lei Zhuang, Tianfu Wen, Mingqing Xu, Jiayin Yang, Wentao Wang, Hong Wu, Lvnan Yan, Yonggang Wei, Bo Li

1432: Isolated Hepatitis B core Antibody positivity: a potential risk factor for liver cancer Linda L. Wong, Marina Roytman, Naoky Tsai

1433: The serum alpha-fetoprotein as predictor of tumor recurrence after liver transplantation for hepatocellular carcinoma

Luciana S. Schraiber, Angelo A. Mattos, Maria L. Zanotelli, Guido Pio G. Cantisani, Ajacio B. Brandão, Claudio A. Marroni, Guilhermo Kiss, Lucas Ernani, Livia C. Lionco

1434: Liver transplant for hepatocellular carcinoma (HCC). Are we missing some factors in the procedure’s outcomes? Single center 3-year experience

Rinjal Brahmbhatt, Lokesh K. Jha, Fedja A. Rochling, Daniel F. Schafer, Timothy M. McCashland, Diana Gomez-Martin, Marco A. Olivera-Martinez

1435: Impact of Underlying Liver Disease, Tumor Burden and Performance Status on Survival after Selective Internal Radiation Therapy: A Large Single Center Experience

Parvez S. Mantry, Bahar Madani, Ashwini P. Mehta, Aden Tadelle, Carlos Fasola, Islam Shahin, Hector Nazario, Alejandro Mejia, Jeffrey S. Weinstein, Abdullah Mubarak, Steve Cheng

1436: Relationship between the mitochondria gene abnormality in liver tissues in patients with chronic viral hepatitis C and the hepatocarcinogenesis

Nobuhiro Aizawa, Chikage Nakano, Kunihiro Hasegawa, Ryo Takata, Tomoko Aoki, Kenji Hashimoto, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai, Naoto Ikeda, Hironori Tanaka, Yoshinori Iwata, Hirayuki Enomoto, Masaki Saito, Hiroko Iijima, Yuji Iimuro, Jiro Fujimoto, Shuhei Nishiguchi

1437: Down-staging of hepatocellular carcinoma tumors at liver transplant centers in the United States She-Yan Wong, Dina Halegoua-De Marzio, Jesse M. Civan

1438: Noninvasive Fibrosis Panels are more useful than Inflammatory Markers for Prediction of Hepatocellular carcinoma Recurrence after Radiofrequency ablation Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


1429: The importance of intrahepatic tumor in hepatocellular carcinoma with extrahepatic spread in patients treated with sorafenib

1430: Effect of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load



HEPATOLOGY, October, 2014

Poster Sessions Cost-Effectiveness 1439: Modeling Cost Avoidance For Preventing Disease Progression In Hepatitis C Patients

Mary Ford, Ashly Jordan, Eric J. Rude, Nirah Johnson, Holly Hagan, Fabienne Laraque, Jay K. Varma

1440: Comorbidity and Resource Utilization in Older Liver Transplant Recipients

1449: Historical and geographical trends in hepatitis C virus (HCV) incident infection among people who inject drugs: The International Collaboration on Incident HCV and HIV Infection among PWID (InC3 Study)

Chris M. Kozma, Andrew Paris, George Wan

Nyingi M. Kemmer, Chris Albers, Edson S. Franco, Husssein Osman-Mohamed, Elizabeth Cece Fallon, Erin Parkinson, Jennifer Horkan, Angel Alsina

1441: Insurance Approval Patterns for Second Generation DAAs

Fredric D. Gordon, Amir A. Qamar, Patricia M. Hogan, Lois V. Daponte, Mary Ann Simpson

1442: Patient-Reported Outcomes (PROs) in HIV-HCV Co-infected Patients Treated with Sofosbuvir (SOF)containing Regimens

Zobair Younossi, Maria Stepanova, Mark S. Sulkowski, Susanna Naggie, Sharon L. Hunt

1443: Cost-effectiveness of Telbivudine Renoprotection in Chronic Hepatitis B Liver Cirrhosis Yock Young Dan, Seng Gee Lim

1444: Regional disparities in total hospital charges for the treatment of inpatients with alcoholic hepatitis in the United States

Folasade P. May, Vineet Syan, Ashwini Lakshmanan, Vinay Sundaram

HCV: Diagnostics, Epidemiology, and Natural History 1445: Sustained Virologic Response with Ledipasvir (LDV) and Sofosbuvir (SOF) Regimens Leads to Substantial Improvement in Patient-Reported Outcomes (PROs) Among Chronic Hepatitis C (CHC) Patients with Early Hepatic Fibrosis as Well as Those with Advanced Hepatic Fibrosis

Zobair Younossi, Maria Stepanova, Patrick Marcellin, Nezam H. Afdhal, Kris V. Kowdley, Stefan Zeuzem, Sharon L. Hunt


1448: Check Hep C: A Community-Based Approach to Hepatitis C Diagnosis in High-Risk Populations

1446: The Significance of NA5A-Y93H Mutation Evaluated by a Novel Simple Assay System Using Cycling Probe-Based Real-Time PCR in Patients with HCV Infection

Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Satoshi Mochida

1447: HCV Screening of “Baby Boomers” Increased Significantly Following 2012 CDC Call to Action, But Screening Rate Fell in Non-Baby Boomers: Results of a Nationwide Lab Test Database Analysis

Carol Smyth, Jason Bhan, Tatiana Sorokina, Ajitpal S. Dhaliwal, Nancy Reau

Denotes AASLD Presidential Poster of Distinction

Meghan D. Morris, Thomas M. Rice, Stephen Shiboski, Julie Bruneau, Andrea Cox, Gregory J. Dore, Jason Grebely, Judith A. Hahn, Arthur Y. Kim, Andrew R. Lloyd, Margaret Hellard, Lisa Maher, Barbara H. McGovern, Maria Prins, Kimberly Page

1450: Senior Center Based Hepatitis C Screening in Baltimore

Oluwaseun Falade-Nwulia, Risha Irvin, Ayesha M. McAdamsMahmoud, Shruti H. Mehta, Jackline Joy M. Lasola, Dorcas Baker, Arnold Eppel, Patrick Chaulk, Kathleen R. Page, Mark S. Sulkowski, David L. Thomas

1451: Impact of Hepatitis E Virus Seropositivity on Chronic Liver Disease of Cancer Patients with Hepatitis C Virus Infection

Andreas Kyvernitakis, Parag Mahale, Jiang Ying, Harrys A. Torres

1452: Add-on of Boceprevir in HIV-positive Patients with Genotype 1 Acute Hepatitis C at high Risk for Treatment Failure

Mattias Mandorfer, Sebastian Steiner, Philipp Schwabl, Berit A. Payer, Maximilian C. Aichelburg, Gerold Lang, Katharina Grabmeier-Pfistershammer, Michael Trauner, Markus PeckRadosavljevic, Thomas Reiberger

1453: The prevalence of naturally occurring resistance mutations against NS3 protease inhibitors, NS5A replication complex inhibitors, and NS5B polymerase inhibitors in patients with hepatitis C virus genotype 1b

Kazuhiko Hayashi, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Yoshiaki Katano, Yoshiki Hirooka, Hidemi Goto

1454: Next-generation sequencing revealed the prevalence of multi-geno/subtypic multiple infection of hepatitis C virus in hemophiliac patients in Japan

Masato Ogishi, Hiroshi Yotsuyanagi, Takeya Tsutsumi, Hiroyuki Gatanaga, Kyoji Moriya, Kazuhiko Koike

1455: Health-related quality of life (HRQOL) is not negatively impacted by therapy of MK-5172/MK-8742 during treatment of genotype (GT) 1 chronic hepatitis C in contrast to pegylated-interferon (IFN) or ribavirin (RBV)-containing therapy

Jean Marie Arduino, Boan Zhang, Chizoba Nwankwo, Shazia Khawaja, Melissa Shaughnessy, Isaias N. Gendrano, Peggy Hwang, Michael Robertson, Niloufar Mobashery, Barbara A. Haber




Poster Sessions 1456: Preliminary Assessment of Hepatitis C Antibody Testing in the United States Before and After Publication of CDC Screening Recommendations

1466: Unregulated Tattooing in an Urban Cohort: An Analysis of Age, Gender, Risk Knowledge and Risk Perception

1457: Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study

1467: Overestimate of Fibrosis by FIBROSpect II in African Americans Complicates Management of their Chronic Hepatitis C

Monina Klevens, Xiaohua Huang, Daulati Thakare, Anthony E. Yeo, Mouneer Odeh, John W. Ward

Behzad Hajarizadeh, Bart P. Grady, Kimberly Page, Arthur Y. Kim, Barbara H. McGovern, Andrea Cox, Thomas M. Rice, Rachel Sacks-Davis, Julie Bruneau, Meghan D. Morris, Janaki Amin, Janke Schinkel, Tanya L. Applegate, Lisa Maher, Margaret Hellard, Andrew R. Lloyd, Maria Prins, Gregory J. Dore, Jason Grebely

1458: Failure of Perinatal Hepatitis C Testing: Philadelphia, 2011 - 2013 Danica Kuncio, Kendra Viner, Claire Newbern

1459: If You Build It, They Will Come: Preliminary Results of the ACTonHCV Online Educational Program

Sue Currie, Joy A. Peter, HoChong Gilles, Vincent Keane, Janeil Klett, Julie A. Deal, Norah Terrault, Guadalupe Garcia-Tsao

1460: HCV Awareness, Risk Assessment, and Healthcare Utilization Among “Baby Boomers” Presenting to the Emergency Department

Derek E. Wells, Grace N. Cain, Charles T. Prickett, Ricardo A. Franco, Jordan M. Forsythe, Joel B. Rodgers, James W. Galbraith

1461: Improving HCV care cascade outcomes in a community-based testing program by providing same day confirmatory testing and patient navigation

Stacey B. Trooskin, Hwajin Lee, Joanna Poceta, Caitlin Towey, Sophie C. Feller, Annajane Yolken, Najia Luqman, Ta-Wanda Preston, Erin Smith, Amy Nunn

1462: The Different Incidences of HCV Genotypes Using Two Different Regions of Classification: 5’NC and NS5B in Vietnamese Patients at Medic Medical Center Thu Thuy Pham Thi, Tan Dat Ho, Bao Toan Nguyen

1463: Factors Associated with Hepatitis C Treatment Eligibility

Shari S. Rogal, Ada O. Youk, Michael K. Chapko, Barbara H. Hanusa, Robert A. Arnold, Galen E. Switzer, Mary Ann Sevick, Nichole K. Bayliss, Carolyn L. Zook, David S. Obrosky, Susan Zickmund

Masaya Sugiyama, Satoshi Hiramine, Norihiro Furusyo, Akio Ido, Hirohito Tsubouchi, Hisayoshi Watanabe, Yoshiyuki Ueno, Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Tatsuya Kanto, Jun Hayashi, David L. Thomas, Masashi Mizokami

1465: An Innovative, Scalable and Sustainable Model to Routinize HCV Testing and Linkage to Care in Five Federally Qualified Health Centers Catelyn Coyle

Poster Viewing: 8:00 AM – 5:30 PM

Paul Naylor, Maher Tama, Suhag Patel, Dhiraj Gulati, Johnny Altawil, Karthik Ravindran, Murray N. Ehrinpreis, Milton G. Mutchnick

1468: HCV-positive women of child-bearing age have premature ovarian senescence, associated with reproductive failure and more severe hepatic fibrosis

Aimilia Karampatou, Alessia Ciancio, Laura Turco, Enrica Baraldi, Rosina Maria Critelli, Veronica Bernabucci, Simonetta Tagliavini, Silvia Strona, Tommaso Trenti, Mario Rizzetto, Erica Villa

1469: Long-Term Impact of Hepatitis C Therapy on Liver Fibrosis and Hepatic Events in HIV-HCV Coinfected Patients

Pablo Labarga, José Vicente Fernández-Montero, Carmen de Mendoza, Pablo Barreiro, Vincent Soriano

1470: Improving predictive models of risk of disease progression among patients with chronic hepatitis C by incorporating longitudinal data

Monica Konerman, Yiwei Zhang, Ji Zhu, Peter Higgins, Anna S. Lok, Akbar K. Waljee

1471: FIB4 Score and Gender Predict the Incidence of Hepatocellular Carcinoma (HCC) among Patients with Chronic Hepatitis C Virus (HCV) Infection: Chronic Hepatitis Cohort Study (CHeCS)

Fujie Xu, Jian Xing, Anne C. Moorman, Stuart C. Gordon, Loralee B. Rupp, Mei Lu, Philip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Vinutha Vijayadeva, Mark A. Schmidt

1472: Marijuana Use Is Not Associated With Liver Fibrosis Progression in HCV/HIV Co-infected Women

Erin Kelly, Jennifer L. Dodge, Monika Sarkar, Audrey French, Phyllis Tien, Marshall Glesby, Elizabeth T. Golub, Michael Augenbraun, Michael Plankey, Marion G. Peters

1473: Performance of Cobas Taqman and Abbott Realtime HCV RNA assays during protease inhibitorbased triple therapy in patients with advanced liver fibrosis and cirrhosis

Benjamin Maasoumy, Bela Hunyady, Vincenza Calvaruso, Michael Makara, Johannes Vermehren, Attila Haragh, Simone Susser, Birgit Bremer, Gavin A. Cloherty, Michael P. Manns, Antonio Craxi, Heiner Wedemeyer, Christoph Sarrazin

1474: Spatial epidemiology and inter familial clustering of hepatitis C infection: Secondary analysis of a country wide national hepatitis survey of Pakistan Saeed S. Hamid, Bilal Ahmed, Huma Qureshi

Presenters in Attendance 12:30 – 2:00 PM


1464: Association between (TA)n dinucleotide repeat near IL28B gene and HCV spontaneous clearance in Japanese and African American

Audun Lier, Amy Nunn, Sophie C. Feller, Caitlin Towey, Joanna Poceta, Hwajin Lee, Gladys L. Thomas, Stacey B. Trooskin



HEPATOLOGY, October, 2014

Poster Sessions 1475: Hepatitis C virus network dynamics among people who inject drugs in Vancouver, Canada

Brendan Jacka, Art Poon, Tanya L. Applegate, Mel Krajden, Andrea Olmstead, Richard Harrigan, Brandon D. Marshall, Kora DeBeck, M-J Milloy, Francois Lamoury, Oliver Pybus, Viviane Lima, Gkikas Magiorkinis, Vincent Montoya, Julio Montaner, Jeffrey Joy, Gregory J. Dore, Thomas Kerr, Evan Wood, Jason Grebely

1476: A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis

Lindsay Y. King, Claudia Canasto-Chibuque, Kara B. Johnson, Shun Yip, Xintong Chen, Kensuke Kojima, Manjeet Deshmukh, Anu Venkatesh, Poh Seng Tan, Xiaochen Sun, Augusto Villanueva, Angelo Sangiovanni, Venugopalan Nair, Milind Mahajan, Masahiro Kobayashi, Hiromitsu Kumada, Massimo Iavarone, Massimo Colombo, M. Isabel Fiel, Scott L. Friedman, Josep M Llovet, Raymond Chung, Yujin Hoshida

1477: Two hepatitis C antibody chemiluminescence assays predict viremia by a different signal to cutoff ratio in asymptomatic people with hepatitis C Ana M. Contreras

1478: Birth cohort distribution and screening of viremic HCV infections in Switzerland

Francesco Negro, Florian K. Bihl, Sarah Blach, Daniel Lavanchy, Beat Mullhaupt, Homie Razavi, David Semela, Philip Bruggmann

1479: The global distribution and prevalence of HCV genotypes

Janey Messina, Isla Humphreys, Abraham D. Flaxman, Anthony C. Brown, Graham Cooke, Oliver Pybus, Eleanor Barnes

David Semela, Sarah Blach, Florian K. Bihl, Philip Bruggmann, Daniel Lavanchy, Francesco Negro, Homie Razavi, Beat Mullhaupt

1485: Identifying HCV Treatment Barriers Amongst High Risk Population of Vancouver Downtown Eastside

Brian Conway, Behroz Rashidi, Shawn Sharma, Syune Hakobyan, Osamah Alenezi, Amy Hung, Kevin Yen, Xinyang Huang, Harout Tossonian

1486: Serum Cystatin C and NGAL levels at the start of protease inhibitor antiviral therapy positively predict renal dysfunction development and anaemia severity Suman Verma, Ivana Carey, Kosh Agarwal

1487: Hepatitis C Virus (HCV) Infection in New Zealand: Burden of Chronic Disease

Edward J. Gane, Cheryl R. Brunton, Chris Estes, Charles Henderson, John Hornell, Sarah Radke, Homie Razavi, Catherine A. Stedman

1488: The global burden of viremic chronic HCV infection

Erin Gower, Chris Estes, Sarah Blach, Kathryn L. Razavi-Shearer, Homie Razavi

1489: The relationship of Wisteria floribunda agglutinin-positive human Mac-2 binding protein and hepatocellular carcinoma developed after sustained virological response against hepatitis C virus

1480: Impact of HCV Triple Therapy on Liver Stiffness

Jillian Nickerson, Kian Bichoupan, Ponni Perumalswami, Douglas Dieterich, Andrea D. Branch

Ryu Sasaki, Kazumi Yamasaki, Ayako Mine, Yuki Kugiyama, Shigemune Bekki, Satoru Hashimoto, Akira Saeki, Shinya Nagaoka, Seigo Abiru, Atsumasa Komori, Atsushi Kuno, Masaaki Korenaga, Masashi Mizokami, Hisashi Narimatsu, Hiroshi Yatsuhashi

1481: High Rates of Comorbidities and Polypharmacy in Patients with Chronic Hepatitis C (CHC) in a RealWorld Setting: a Consequence of an Aging Population

1490: Non invasive markers of liver fibrosis: which one to pick from a myriad of them! A study on 1602 liver biopsies in patients with hepatitis C

1482: Is the diagnostic accuracy of non-invasive methods better than liver biopsy ? A Latent Class Analysis on assessment of liver fibrosis in chronic hepatitis C

1491: HCV re-infection rates are low after long-term follow up of acute HCV infection: The Australian Trial of Acute Hepatitis C Recall study

Philip Vutien, Louis Brooks, Richard C. Livornese, Mindie H. Nguyen


1484: The impact of time on a scenario to minimize complications of hepatitis C infection

Flavia F. Fernandes, Maria Lucia Ferraz, Hugo Perazzo, Luis Eduardo C. Andrade, Alessandra Dellavance, Carlos Terra, Gustavo Pereira, João Luiz Pereira, Frederico F. Campos, Fátima A. Figueiredo, Renata M. Perez

1483: Impact of electronic reminder to improve hepatitis C screening in age-appropriate patients: results of a pilot quality improvement intervention

Thomas J. Byrne, Elizabeth J. Carey, Bashar Aqel, David D. Douglas, Vickie Timm, Melissa Dosmann, Patricia Whitten, Monika R. White, Jorge Rakela, Hugo E. Vargas

Denotes AASLD Presidential Poster of Distinction

Ragesh B. Thandassery, Anil John, Madiha E. Soofi, Saad R. Al Kaabi

Joseph S. Doyle, Gregory J. Dore, David Shaw, Jason Grebely, Amanda Erratt, Margaret Hellard, Gail Matthews

1492: Simple serum markers models accurately predict liver related survival, complications and HCC in chronic HCV infection

Yi Huang, Leon Adams, Gerry C. MacQuillan, Enrico Rossi, Max K. Bulsara, Gary P. Jeffrey




Poster Sessions 1493: Factors associated with hepatitis C virus RNA levels in early acute and early chronic infection: the InC3 study

Behzad Hajarizadeh, Bart P. Grady, Kimberly Page, Arthur Y. Kim, Barbara H. McGovern, Andrea Cox, Thomas M. Rice, Rachel Sacks-Davis, Julie Bruneau, Meghan D. Morris, Janaki Amin, Janke Schinkel, Tanya L. Applegate, Lisa Maher, Margaret Hellard, Andrew R. Lloyd, Maria Prins, Ronald Geskus, Gregory J. Dore, Jason Grebely

1494: NS5A variability and dynamics of resistanceassociated mutations in HCV genotype 4 patients, naive to treatment receiving triple therapy with DACLATASVIR+PEG-IFN/RBV, assessed by ultra deep sequencing

Barbara Bartolini, Raffaella Lionetti, Emanuela Giombini, Chiara Taibi, Marzia Montalbano, Gianpiero D’Offizi, Fiona McPhee, Eric A. Hughes, Giuseppe Ippolito, Anna Rosa Garbuglia, Maria R. Capobianchi

1495: The impact of genetic polymorphism in PNPLA3 gene on fibrosis progression and hepatocellular carcinoma development differs between hepatitis C and hepatitis B

Masayuki Kurosaki, Kaoru Tsuchiya, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Shoko Suzuki, Jun Itakura, Namiki Izumi

1496: Cocaine/crack use is not associated with liver fibrosis progression in HIV-HCV co-infected patients

Valerie Martel-Laferriere, Kathleen C. Rollet-Kurhajec, Joseph Cox, Curtis Cooper, Mark Tyndall, Danielle Rouleau, Sharon Walmsley, Marina B. Klein

1497: Response-guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study

Mattias Mandorfer, Sebastian Steiner, Philipp Schwabl, Berit A. Payer, Maximilian C. Aichelburg, Gerold Lang, Katharina Grabmeier-Pfistershammer, Michael Trauner, Markus PeckRadosavljevic, Thomas Reiberger

1501: Near-infrared spectroscopy for the early detection of prodromal phase of depression during interferon-based therapy for patients with chronic hepatitis C

Kazumichi Abe, Akira Wada, Sachie Oshima, Soichi Kono, Atsushi Takahashi, Yukiko Kanno, Hiromichi Imaizumi, Manabu Hayashi, Ken Okai, Shin-ichi Niwa, Hirooki Yabe, Hiromasa Ohira

1502: Identifying the disease burden of hepatitis C virus (HCV) infection and non-injection drug use: a systematic review and meta-analysis of persons who use drugs but do not inject

Rebecca L. Morgan, Natalie Blackburn, Anthony K. Yartel, Don C. Des Jarlais

1503: ABCA1 SNPs rs2230806 and rs2230808 in chronic hepatitis C are gender specific and influence cholesterol metabolism and severity of liver disease

Joana Ferreira, Cilénia B. Costa, Ricardo Andrade, Manuel Bicho, Fatima S. Serejo

1504: Time to hepatocellular carcinoma after notification of hepatitis B or C infection: a populationbased cohort study, 1992–2007

Maryam Alavi, Matthew Law, Jason Grebely, Hla-Hla Thein, Janaki Amin, Gregory J. Dore

1505: The Role Of Genetic Polymorphism Of LDL Receptor In Egyptian Population Infected With Chronic HCV, Regarding Response To Treatment

Mazen I. Naga, Mona A. Amin, Dina A. Algendy, Ahmed I. El Badry, Mai M. Fawzi, Ayman R. Foda, Serag M. Esmat, Dina Sabry, Laila A. Rashed, Samia M. Gabal, Manal Kamal

1506: Prevalence of viral hepatitis and liver fibrosis in a population of incomers in French prisons. UCSASCAN study

Julien Vergniol, Maylis Capdepont, Samy El Aouadi, Gildas Le-Port, Gilles Gatineau-Sailliant, Valéry Hédouin, Catherine Martineau, Juliette Foucher, Victor de Ledinghen

Carmi S. Punzalan, Graham F. Barnard

1507: Genetic variant of MICA in HCC development among HCV patients post anti-viral therapy- a longitudinal follow-up study

1499: Most patients with hepatitis C virus (HCV)associated lymphoma present with mild liver disease at cancer diagnosis - A call to revise indications for HCV treatment

1508: Burden of Hepatitis C Virus and Chronic Liver Disease amongst Hospitalized Inmates in Massachusetts

1498: Potential impact on mortality of HCV eradication post-liver transplant in the era of direct anti-viral agents

1500: Factors Associated with Spontaneous Resolution of HCV Infection in Untreated Individuals, Philadelphia Danica Kuncio, Amy Hueber, Claire Newbern, Kendra Viner

Poster Viewing: 8:00 AM – 5:30 PM

Alysse G. Wurcel, Michaela Superson, Kathryn Noonan, Arthur Y. Kim, Barbara H. McGovern

1509: CDC new guidelines for testing for HCV: Does one size fit all?

Mohamed G. Shoreibah, Cynthia E. Jordan, Shabnam Sarker, Mary L. McCain, Arvind Tripathi, Omar Massoud

Presenters in Attendance 12:30 – 2:00 PM


Harrys A. Torres, Parag Mahale

Ming-Lung Yu, Chung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang



HEPATOLOGY, October, 2014

Poster Sessions 1510: New Cut-off Points of Enhanced Liver Fibrosis (ELF) Panel for Chronic Hepatitis C Patients

Flavia F. Fernandes, Alessandra Dellavance, Luis Eduardo C. Andrade, Frederico F. Campos, Maria Chiara Chindamo, Joao M. Araujo-Neto, Cristiane Villela-Nogueira, Henrique Sergio M. Coelho, Carlos Terra, Gustavo Pereira, João Luiz Pereira, Fátima A. Figueiredo, Renata M. Perez, Maria Lucia Ferraz

1511: Fear of a liver biopsy is the primary barrier leading to disparities in the treatment and outcomes of hepatitis C in Somali patients in Minnesota

Esther Connor, Albert Ndzengue, Nasra H. Giama, Jeremiah Menk, Essa A. Mohamed, Saleh Elwir, Lewis R. Roberts, Mohamed A. Hassan

1512: High Rates of HCV Active Infection in a Blood Bank Study in Ghana, West Africa

Jennifer E. Layden, Richard O. Phillips, Fred S. Sarfo, Nallely Mora, Dorcas O. Owusu, Stephanie Kliethermes, Shirley P. Owusu-Ofori, Joseph Forbi, Ohene Opare-Sem, Kenrad Nelson, Richard Cooper

1513: Reduction of miR-20a, miR-92a and miR-122 in patients with chronic hepatitis C and severe fibrosis

Kevin Appourchaux, Emilie Estrabaud, Philippe Broet, Martine Lapalus, Michelle Martinot-Peignoux, Nathalie Boyer, Michel Vidaud, Pierre Bedossa, Patrick Marcellin, Tarik Asselah

1514: Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in Ireland

Colm J. Bergin, Chris Estes, Diarmaid D. Houlihan, Homie Razavi, Kathryn L. Razavi-Shearer, Lelia Thornton, Suzanne Norris

1515: A new serum biochemical model that accurately predicts liver collagen proportional area

Yi Huang, Bastiaan de Boer, Leon Adams, Gerry C. MacQuillan, Enrico Rossi, Max K. Bulsara, Gary P. Jeffrey

1516: Vitamin D binding protein gene polymorphism rs222020, CYP2R1 can predict treatment response and liver fibrosis of northern Chinese patients with chronic hepatitis C

Ruqi Mei, Yu Pan, Xiumei Chi, Xiaomei Wang, Ruihong Wu, Xiuzhu Gao, Jinglan Jin, Ge Yu, Jing Jiang, Junqi Niu


1517: Hepatitis C Virus (HCV) Infection in Argentina: Burden of Chronic Disease

Ezequiel Ridruejo, Jorge Daruich, Chris Estes, Adrian Gadano, Homie Razavi, Marcelo O. Silva, Federico G. Villamil, Fernando Bessone

1518: Treatment Patterns and Clinical Outcomes of HCV in Real World Practice in China

Huiying Rao, Hong Li, Hong Chen, Qing Xie, Shang Jia, Jun Li, ZhiLiang Gao, Yongtao Sun, Jianning Jiang, Lunli Zhang, Lai Wei

1519: Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection

David A. Sheridan, Behzad Hajarizadeh, Gail Matthews, Tanya L. Applegate, Mark W. Douglas, Beverley Askew, Dermot Neely, Margaret F. Bassendine, Gregory J. Dore, Andrew R. Lloyd, Jacob George, Jason Grebely

Denotes AASLD Presidential Poster of Distinction

1520: Assessment of noninvasive hepatic fibrosis markers among patients with chronic HCV infection and advanced liver disease

Raoel Maan, Adriaan J. van der Meer, Jordan J. Feld, Heiner Wedemeyer, Jean-Francois J. DuFour, Frank Lammert, Andres Duarte-Rojo, Michael P. Manns, Stefan Zeuzem, Wolf P. Hofmann, Harry L. Janssen, Bettina E. Hansen, Bart J. Veldt, Robert J. de Knegt

1521: Prognostic factors of survival in HIVHCV coinfected patients after a first episode of decompensation: the French prospective multicenter ANRS HC EP 25 PRETHEVIC Cohort

Moana Gelu-Simeon, Tatiana Bayan, Maria Ostos, Elina Teicher, Hélène Fontaine, Pierre Tattevin, Isabelle Poizot-Martin, Stephanie Dominguez, David Zucman, Julie Chas, Pascal P. Crenn, Anne Gervais, Karine Lacombe, Philippe Morlat, Rodolphe Anty, Faroudy Boufassa, Inga Bertucci, Georges-Philippe Pageaux, Laurence Meyer, Jean-Charles Duclos-Vallée

1522: Mutual Inhibition between Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)

Ge Yu, Yu Pan, Ruihong Wu, Xiumei Chi, Xiaomei Wang, Xiuzhu Gao, Fei Kong, Xiang-wei Feng, Jinglan Jin, Yue Qi, Junqi Niu

1523: Effect of Hemochromatosis gene mutation on HCV response to treatment in the Egyptian population

Mazen I. Naga, Mona A. Amin, Dina A. Algendy, Ahmed I. El Badry, Mai M. Fawzi, Ayman R. Foda, Serag M. Esmat, Dina Sabry, Laila A. Rashed, Samia M. Gabal, Manal Kamal

1524: Hepatitis C infection is not associated with metabolic syndrome irrespective of age, gender and fibrosis

Chien-Wei Su, Yuan-Jen Wang, Keng-Hsin Lan, Teh-Ia Huo, Yi-Hsiang Huang, Kuei-Chuan Lee, Han-Chieh Lin, Fa-Yauh Lee, Jaw-Ching Wu, Shou-Dong Lee

1525: Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in a real world HIV/HCV co-infected cohort Lauren A. Beste, Pamela Green, George N. Ioannou

1526: Low albumin is independent risk factor for postsustained virologic response hepatocellular carcinoma in chronic hepatitis C patients: A case control study

Qing-Lei Zeng, Bin Yang, Bing Li, Xue-Xiu Zhang, Fu-Sheng Wang

1527: HCV and HIV Co-Infection and Related Risks in Injecting Drug Users From A Superspeciality Centre Arun K. Sharma, Subodh Bn, Debasish Basu

1528: Audit of a universal antenatal hepatitis C virus screening programme at a London hospital

Nowlan Selvapatt, Heather Bailey, Claire Thorne, Lay-May See, Melanie Douglas, Mark R. Thursz, Gareth Tudor-Williams, Ashley S. Brown




Poster Sessions 1529: Clinical utility of the VERSANT HCV RNA 1.0 Assay (kPCR) for HCV-RNA quantification in patients with HCV genotype 1-infection

Johannes Vermehren, Simone Susser, Dany Perner, Stefan Zeuzem, Christoph Sarrazin

1530: Delay presentation to care is an independent prognostic factor for clinical outcomes in patients with chronic hepatitis C

Blaise K. Kutala, Laurent Cattan, Christine Aurière, Alexandrine Di Pumpo, Beatrice Monnier, Nathalie Giuily, Kevin Appourchaux, Corinne Castelnau, Patrick Marcellin, Nathalie Boyer

1531: VITRO-score (vWF-Ag/thrombocytes) predicting mortality in HCV cirrhosis in comparison to MELD-score

Andreas Maieron, Stephanie Hametner, Silvia I. Hametner, Monika Ferlitsch, Rainer Schöfl, Alexander Ziachehabi, Arnulf Ferlitsch

1532: Learning curve and intraobserver agreement of liver stiffness measurement in chronic hepatitis C with or without HIV co-infection

Hugo Perazzo, João Carlos Soares, Flavia F. Fernandes, Juliana Fittipaldi, Sandra W. Cardoso, Beatriz Grinsztejn, Valdilea Veloso

1533: Hepatitis C virus infection in HIV-positive men who have sex with men: Systematic review and metaanalysis Holly Hagan, Joshua Neuer, Ashly Jordan

1534: Urinary Metabolite Biomarker Panel for the Detection of Hepatocellular Carcinoma in Hepatitis C Infected Populations

Wendy S. Baker, John R. Petersen, Maen M. Masadeh, Feroze A. Hussain, Heidi Spratt

1535: Clinical outcomes of chronic hepatitis C in Korea: A prospective, multicenter cohort study

Kyeong Sam Ok, Sook-Hyang Jeong, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, Si Hyun Bae, Han Chu Lee, Mee-Kyung Kee, Sung Soon Kim, Chun Kang

1536: Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in India

1537: Characterization of Hepatitis C Patients who fail to Achieve Sustained Virologic Response with Triple Therapy (Peg-Interferon Alfa and Ribavirin with Boceprevir or Telaprevir)

Monica Konerman, Suna Yapali, Anna S. Lok

1539: Low Rates of Baby Boomer Screening for Hepatitis C in Initial Primary Care Visits at a Tertiary Care Center

Bonnie A. Ewald, Alysse G. Wurcel, Sonali Paul, Kathleen Viveiros

1540: Evidence for Multiple Transmission Pathways and Geographic Variation of HCV infection in Ghana, West Africa

Jennifer E. Layden, Richard O. Phillips, Fred S. Sarfo, Dorcas O. Owusu, Nallely Mora, Joseph Forbi, Stephanie Kliethermes, Shirley P. Owusu-Ofori, Ohene Opare-Sem, Kenrad Nelson, Richard Cooper

1541: HCV genotypes and NS3-DAAs resistant mutations in treatment naive HIV/HCV co-infected population in the South of China

Fengyu Hu, Zhiwei Liang, Yun Lan, Xiaoping Tang, Weiping Cai

1542: Treatment of Latent Tuberculosis in Patients with Hepatitis C and Advanced Fibrosis

Christini T. Emori, Silvia N. Uehara, Ana Cristina A. Feldner, Antonio Eduardo B. Silva, Roberto J. Carvalho-Filho, Ivonete Silva, Maria Lucia Ferraz

1543: Chronic Hepatitis C Infection May Be Associated With Adverse Clinical Outcomes Following Renal Transplantation Charles Gabbert, Siva Talluri, Mordechai Rabinovitz

1544: Hepatitis C virus RNA and genotype, IL28B genotype, and liver fibrosis scores in a regional cohort of HIV-HCV co-infected patients under routine HIV care in Asia

Nicolas Durier, Kiat Ruxrungtham, Anchalee Avihingsanon, Kinh Nguyen Van, Bui Vu Huy, Evy Yunihastuti, Andri S. Sulaiman, Sharifah Faridah binti Syed Omar, Ilias Adam Yee, Patricia Morgan, David Boettiger, Gail Matthews

1545: Vitamin D status and liver stiffness in chronic hepatitis C infection

Matthew T. Kitson, Paula Lewis, William W. Kemp, Adam Gordon, Eldho Paul, Stuart K. Roberts

1546: Fibroscan has a low predictive performance for hepatocellular carcinoma in HCV patients with or without a sustained virological response

Philippe Sultanik, Damien Soudan, Samir Bouam, Jean-Francois Meritet, Anaïs Vallet-Pichard, Hélène Fontaine, Laurence Bousquet, Marion Corouge, Estelle Boueyre, Philippe Sogni, Stanislas Pol, Vincent Mallet

T Craig Cheetham, Yong Yuan, Fang Niu, Anupama Kalsekar, Rulin Hechter, Kevin Chiang, Joel Hay, Lisa M. Nyberg

Poster Viewing: 8:00 AM – 5:30 PM

Presenters in Attendance 12:30 – 2:00 PM


Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Shiv K. Sarin, Radha K. Dhiman, Rakesh Aggarwal, Shivaram P. Singh, Deepak N. Amarapurkar, Anil Arora, Mohinish Chhabra, Kamal Chetri, Gourdas Choudhuri, Abhijit Chowdhury, Vinod K. Dixit, Ajay K. Duseja, Sarah Blach, Ajay K. Jain, Dharmesh Kapoor, Premashis Kar, Abraham Koshy, Ashish Kumar, Kaushal Madan, Sri P. Misra, Mohan V. Prasad, Aabha Nagral, Amarendra S. Puri, Jeyamani Ramachandran, Homie Razavi, Sanjiv Saigal, Samir R. Shah, Praveen K. Sharma, Ajit Sood, Sandeep Thareja, Manav Wadhawan

1538: Identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring: A systematic review of predictors and predictive models of disease progression



HEPATOLOGY, October, 2014

Poster Sessions Health Care Delivery 1547: A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators

Stefano Okolicsanyi, Antonio Ciaccio, Paolo A. Cortesi, Matteo Rota, Marta Gemma, Pietro Giani, Luciana Scalone, Lorenzo G. Mantovani, Stefano Fagiuoli, Maria G. Valsecchi, Giancarlo Cesana, Luca S Belli, Mario Strazzabosco

1548: Bi-Factor Item Response Theory (IRT) modeling reveals that the Chronic Liver Disease Questionnaire (CLDQ) overestimates the clinical relevance of liver disease-specific subdomain scores

Sujit V. Janardhan, Andrew Aronsohn, Jason Morris, Robert Gibbons, David G. Beiser

Jessica Yu, Amy Hosmer, Tamara Parks, Christopher J. Sonnenday, Pratima Sharma

1557: Hospice referral among veterans with cirrhosis is infrequent and primarily utilized for malignancy, not decompensated cirrhosis Mina Rakoski, Grace L. Su, Anna S. Lok, Michael Volk

1558: Sero-prevalence of Hepatitis E In Patients With Chronic Liver Disease

Niharika Samala, Elizabeth C. Wright, Joni Trenbeath, Ronald E. Engle, Nancy Fryzek, Harvey J. Alter, Jay H. Hoofnagle, Marc G. Ghany

1559: The impact of liver disease on the health-related quality of life

1549: CDC guidelines for hepatitis C screening have no impact on screening or linkage to care

Mansi Kothari, Archita P. Desai, Andrew Aronsohn, K. Gautham Reddy, Donald M. Jensen, Helen S. Te, Nancy Reau

Paolo A. Cortesi, Matteo Rota, Luciana Scalone, Paolo Cozzolino, Giancarlo Cesana, Lorenzo G. Mantovani, Stefano Okolicsanyi, Antonio Ciaccio, Marta Gemma, Stefano Fagiuoli, Maria G. Valsecchi, Luca S Belli, Mario Strazzabosco

1550: Benefit of Early Palliative Care Intervention in End-stage Liver Disease Patients Awaiting Liver Transplantation

1560: Chronic liver disease related morbidity compared to congestive heart failure and chronic obstructive pulmonary disease

Alexandra J. Baumann, David Wheeler, Marva James, Arthur Siegel, Victor J. Navarro

Sumeet K. Asrani, Maria A. Kouznetsova, Andrew Masica, Brett Stauffer, James F. Trotter, Patrick Kamath, Fasiha Kanwal

1551: Barriers to Receipt of Recommended Chronic Hepatitis B Care at a Tertiary Medical Center in Northern California

1561: Variation in Liver Disease Related Mortality in the United States

Cara Torruellas, Moon Chen, Brian Chan, Susan Stewart, Julie Dang, Tina T. Fung, Duke A. LeTran, Christopher L. Bowlus

1552: Inadequate Hepatitis B Care in Mothers After Pregnancy

Ruma Rajbhandari, Anna C. Juncadella, Anna K. Rubin, Tokunbo Ajayi, Ying Wu, Ashwin N. Ananthakrishnan, Raymond T. Chung

1553: Hospice Care Utilization Improves Outcome of Medicare Patients Diagnosed with Hepatocellular Carcinoma

Zobair Younossi, Li Zheng, Jessica Heintz, James N. Cooper, Andrei Racila, Madeline Erario, Linda Henry, Alita Mishra, Sharon L. Hunt, Gregory Trimble


1556: Predictors of 30-day Hospital Readmission after Deceased Donor Liver Transplantation

1554: A quality improvement initiative decreases 30-day readmission rates in patients admitted to a Hepatology Service

Elliot B. Tapper, Dan Finkelstein, Gail Piatkowski, Murray Mittleman, Michelle Lai

1555: Information Technology Decision Support Improves Hepatitis C Screening Rates But Not Diagnosis Rates Todd L. Burstain, Monika Ahuja, Michael D. Voigt

Archita P. Desai, Ricki Bettencourt, Rohit Loomba

1562: Severity of illness, referral patterns and specialized care are important determinants of samecenter thirty day readmissions in patients with cirrhosis

Marwan Ghabril, Samuel Hohmann, Eric S. Orman, Raj Vuppalanchi, Paul Y. Kwo, Naga P. Chalasani

1563: Healthcare Utilization Among Patients with Cirrhosis: The Role of Inflammation, Medications, Pain, and Depression

Shari S. Rogal, Klaus Bielefeldt, Susan Zickmund, Andrea DiMartini

1564: Predictors of Increased Healthcare Utilization After Liver Transplantation

Shari S. Rogal, Gautam Mankaney, Viyan Udawatta, Christopher B. Hughes, Amit D. Tevar, Mark Sturdevant, Abhinav Humar, Andrea DiMartini

1565: Pneumonia Vaccination Prevalence in Liver Cirrhosis

Tuyyab Hassan, Sulieman Abdal Raheem, Ripple Mehta, Omer J. Deen, Naim Alkhouri, Annette Kyprianou

1566: Personalized Learning: A Novel Educational Model to Prepare and Expand the Hepatitis C Workforce

Nancy Reau, Tara G. Edmonds, Jennifer Garick, Catherine C. Capparelli, Simi Hurst

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 1567: Update from an HCV Screening Program in an Emergency Department in the Southern US: Challenges to Follow-up and Linkage to Care

1576: Overestimation of Decline in Health-Related Quality of Life Occurs in a Third of Cirrhotic Patients Compared to US Norms using PROMIS tools

1568: Hepatitis B (HBV) knowledge in a large multiethnic North American cohort with chronic hepatitis B infection: Impact of ethnicity, migration status, and language fluency

1577: Paradigm Shift in Access to Adult Liver Transplantation

Anne Zinski, Ricardo A. Franco, Henry E. Wang, Michael Saag, Edgar T. Overton, Jordan M. Forsythe, Joel B. Rodgers, James W. Galbraith

Mandana Khalili, Colina Yim, Donna M. Evon, Mauricio LiskerMelman, Harry L. Janssen, Mohamed A. Hassan, Coleman Smith, Anna S. Lok

1569: Increased all-cause hospitalization among hepatitis C virus (HCV)-infected persons: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010

Eyasu H. Teshale, Jian Xing, Scott D. Holmberg, Anne C. Moorman, Stuart C. Gordon, Loralee B. Rupp, Mei Lu, Philip Spradling, Joseph A. Boscarino, Vinutha Vijayadeva, Mark A. Schmidt, Fujie Xu

1570: Assessment of Readmission rates and mortality in hospitalized Cirrhotic patients: A review of the state in patient database

Shaheryar Siddiqui, Shivang Mehta, Sachin Batra, Victor I. Machicao, Michael B. Fallon

1571: Vaccination Rates in Cirrhotic Liver Disease

Abhijeet Waghray, Nisheet Waghray, Annette Kyprianou, KV Narayanan Menon

1572: A national audit on hepatocellular carcinoma (HCC) epidemiology and management in a Western country: survival factors including healthcare organization and referral pattern

Nathalie GOUTTE, Philippe Sogni, Noelle Bendersky, Bruno Falissard, Olivier Farges

1573: Fatigue of Compensated Chronic Liver Disease is associated with Altered Sleep Pattern and Melatonin Profile

Michele M. Tana, Hawwa Alao, Nevitt Morris, Mary Walter, Jacob Hattenbach, Sarah Smyth, Robert Brychta, Xiongce Zhao, Yaron Rotman

Bevin Hearn, Rachel Chasan, Kian Bichoupan, Maria Suprun, Emilia Bagiella, Douglas Dieterich, Ponni Perumalswami, Andrea D. Branch, Shirish Huprikar

1575: Interferon (INF)-Free Regimens for Chronic Hepatitis C (CHC): Barriers to Treatment Candidacy and Insurance Coverage

Zobair Younossi, Maria Stepanova, Brian P. Lam, Manirath Srishord, Spencer Frost, Huong T. Pham, Andrei Racila, Mariam Afendy, Thomas Jeffers Poster Viewing: 8:00 AM – 5:30 PM

Nyingi M. Kemmer, Chris Albers, Edson S. Franco, Husssein Osman-Mohamed, Erin Parkinson, Elizabeth Cece Fallon, Jennifer Horkan, Angel Alsina

1578: Telehepatology improves provider satisfaction and specialty care integration among rural Veterans Affairs Primary Care Providers

Lauren A. Beste, Raimund Pichler, Maureen Germani, Michael F. Chang, Bessie Young

1579: Preventative Care Quality Indicator Adherence and Factors Affecting Quality Care Measurement in Patients with Cirrhosis: A Single-centered Study

Steven J. Scaglione, Kirk Shepard, William Adams, Elizabeth Pappano, Atif M. Ali, Amanda Cheung, Vishnu Vardhan Reddy Naravadi, Justin Mitchell, Rebecca Tsang, Shaham Mumtaz, Edward Villa, Susan Zelisko, Stephanie Kliethermes, Nina Clark, Scott Cotler

1580: Predictors of Attendance at the Gastroenterology Clinic to Discuss Treatment for Hepatitis C

Susan L. Zickmund, Michael K. Chapko, Barbara H. Hanusa, Ada O. Youk, Galen E. Switzer, Mary Ann Sevick, David S. Obrosky, Nichole K. Bayliss, Carolyn L. Zook, Robert A. Arnold

1581: Immigrant Status Influence on Chronic Hepatitis C Virus Infection Management Curtis Cooper, Kimberly Corace, Crystal D. Holly, Gary Garber

1582: Community-wide outreach and screening to reduce hepatitis B and hepatitis C disparities among Somali immigrants in Minnesota

Nasra H. Giama, Abdirashid Shire, Hassan M. Shaleh, Essa A. Mohamed, Lewis R. Roberts

1583: Burden of chronic viral hepatitis and liver cirrhosis in Brazil – The Brazilian Global Burden of Disease Study

Juliana R. de Carvalho, Flávia B. Portugal, Luísa S. Flor, Mônica R. Campos, Renata M. Perez, Cristiane Villela-Nogueira, Joyce Mendes A. Schramm

1584: Use of non-invasive markers of fibrosis for prioritizing HCV antiviral drug treatment Samuel B. Ho, Paul Thuras, Erik J. Groessl, Eric Dieperink

1585: A Universal Testing Programme for Blood Borne Viruses in an Urban Emergency Department – a call for widespread ED testing in Ireland

Sarah O’Connell, Darren Lillis, Siobhan O’Dea, Helen Tuite, Catherine Fleming, Helen Barry, Linda Dalby, Darragh Shields, Suzanne Norris, Brendan Crowley, Patrick K. Plunkett, Colm J. Bergin Presenters in Attendance 12:30 – 2:00 PM


1574: AASLD Guidelines for Chronic Hepatitis B Management: Knowledge and Adherence Among HIV Providers and Hepatologists at a Large Academic Medical Center

Jasmohan S. Bajaj, Melanie White, Nicole Noble, Richard K. Sterling, R. Todd Stravitz, Mohammad S. Siddiqui, Scott Matherly, Arun J. Sanyal, Puneet Puri, Velimir A. Luketic, Douglas M. Heuman, Michael Fuchs, James Wade



HEPATOLOGY, October, 2014

Poster Sessions 1586: Barriers to Initiating Treatment for Hepatitis C: Results of a Veteran Population

Susan L. Zickmund, Michael K. Chapko, Barbara H. Hanusa, Ada O. Youk, Galen E. Switzer, Mary Ann Sevick, Nichole K. Bayliss, Carolyn L. Zook, David S. Obrosky, Robert A. Arnold

1587: Results of a Strategy to Identify Kidney Transplant Recipients with Chronic Hepatitis C for Interferon-Free Therapies

Genevieve Huard, Anna Patel, Brian Kim, Badr Aljarallah, Ponni Perumalswami, Joseph A. Odin, Sara Geatrakas, Jawad Ahmad, Douglas Dieterich, Vinay Nair, Thomas D. Schiano, Gene Y. Im

Philippa S. Gibson, Emer Fitzpatrick, Alberto Quaglia, Anil Dhawan, Huihai Wu, Kathryn Hart, Susan Lanham-New, J Bernadette Moore

1598: Microarray analysis of laser-captured portal tracts of Jag1+/-Rfng+/- liver reveals possible subpopulation of hepatic progenitors

Lara A. Underkoffler, Emily K. McComb, John Dutton, Anthony Nelson, Kathleen M. Loomes, Matthew J. Ryan

1588: Outcomes of a HCV treatment programme in PWID over 10 years support a disease eradication strategy for all patients in the DAA era

1599: Jag1+/- Rfng+/- murine livers show aberrant differentiation of Sox9 progenitors by one week of age

1589: The Influence of Race on Patient Preferences and Access to Orthotopic Liver Transplantation and Organ Donation

Pediatric Liver Transplantation

Omar El-Sherif, Ciaran L. Bannan, Shay Keating, Susan McKiernan, Colm J. Bergin, Suzanne Norris

Omobonike O. Oloruntoba, Julius M. Wilder, Alastair D. Smith, Andrew J. Muir, Cynthia A. Moylan

1590: The burden of illness associated with cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study

Kittiyod Poovorawan, Sombat Treeprasertsuk, Kaewjai Thepsuthammarat, Bubpha -. Kitsahawong, Kamthorn Phaosawasdi

1591: Predictors of Sub-Optimal Hepatitis C Treatment Adherence: Improving Patient Outcomes

Kimberly Corace, Crystal D. Holly, Gary Garber, Mark Kaluzienski, Craig Lee, Thomas Shaw-Stiffel, Louise Balfour, Curtis Cooper

1592: High morbidity and mortality in end-stage liver disease and heart failure

Cristal L. Brown, Bradley G. Hammill, Laura G. Qualls, Lesley H. Curtis, Andrew J. Muir

1593: Symptomatic Hypogonadism in Patients listed for Liver Transplantation and Hepatocellular Carcinoma Anish V. Patel, Vinay Sundaram, Tram T. Tran

1594: Variceal Screening in Cirrhotic Patients MONDAY NOVEMBER 10

1597: Association of NADSYN1, DHCR7, GC and VDR Genotypes With Steatosis And Liver Inflammation in UK Paediatric Non-Alcoholic Fatty Liver Disease Patients

Abhijeet Waghray, Nisheet Waghray, Annette Kyprianou, KV Narayanan Menon

Pediatric Liver Disease - Basic Science 1595: Bile salt export pump and basolateral bile salt uptake transporters are down-regulated in hepatoblastoma and not in hepatocellular carcinoma

Corina G. Cotoi, Peter T. Clayton, Alberto Quaglia, A. S. Knisely

1596: Hepatic Encephalopathy in Children with Acute Liver Failure – Utility of Serum Neuromarkers

Nicole A. Toney, Robert H. Squires, Steven H. Belle, Regina M. Hardison, Michael J. Bell

Denotes AASLD Presidential Poster of Distinction

Lara A. Underkoffler, Emily K. McComb, John Dutton, Anthony Nelson, Kathleen M. Loomes, Matthew J. Ryan

1600: Data-Driven Modeling for Precision Medicine in Pediatric Acute Liver Failure

Ruben Zamora, Yoram Vodovotz, Othman Abdul-Malak, Qi Mi, Khalid Almahmoud, Rami A. Namas, Derek Barclay, Robert H. Squires

1601: Analysis of Trends in Incidence, Management, Etiology and Death [TIMED] due to Pediatric Acute Liver Failure [ALF] in the United States: Results of Analysis of the National Pediatric Health Information Systems [PHIS] Database, 2008-2013

Sakil Kulkarni, Carla Perez, Caren Pichardo, Lina I. Castillo, Michael A. Gagnon, Conseulo Beck-Sague, Erick Hernandez, Rani S. Gereige

1602: Low Rate of Recurrent Primary Sclerosing Cholangitis in Pediatric Orthotopic Liver Transplant Recipients

Sarah Taylor, Steven J. Lobritto, Mercedes Martinez, Jennifer Vittorio, Adam Griesemer, Tomoaki Kato, Jean C. Emond, Nadia Ovchinsky

1603: Intravenous pentamidine is efficacious for pneumocystis carinii/jiroveci pneumonia (PCP) prophylaxis in pediatric liver and small bowel transplant patients

Abigail Clark, Trina S. Hemmelgarn, Rohit Kohli, Lara DanzigerIsakov, Ashley Teusink

1604: Nutritional Status and Perioperative Nutritional Support in Children after Liver Transplantation

Jaime C. Silva, Stacey S. Beer, Ursula G. Kyle, Mariana Treviño Ramos, Jennifer L. Lusk, Ryan Himes, Moreshwar Desai, John A. Goss, Jorge Coss-Bu    




Poster Sessions Poster Session 4 Tuesday, November 11 POSTER VIEWING: 8:00 AM - Noon Hall C Presenters in attendance: 10:30 AM - NOON Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

HBV: Diagnostics, Epidemiology, Prevention, Natural History 1605: Prevalence of Precore and Dual Basal Core Promoter HBV Variants in a Racially Diverse Cohort of Patients with Chronic HBV Infection in North America

Daryl Lau, Lilia Ganova-Raeva, Raymond T. Chung, Geoffrey Johnson, Kyong-Mi Chang, Mauricio Lisker-Melman, Obaid S. Shaikh, Harry L. Janssen, Abdus S. Wahed, Anna S. Lok

1606: Evolution rules of hepatic fibrosis at different natural history phases of chronic HBV infection in 637 Chinese patients

Qing He, Xuejiao Liao, Shuling Ai, Qingrong Tang, Qi Yuan Tang, Feijian Ao, Zhiyu Li, Bing Bai

1607: Influence of Delta Virus Infection on the Clinical Spectrum, Serologic and Virologic Status in Chronic Hepatitis B Virus Genotype D

Rabab F. Omar, Rasha Ahmed, Dina Sabry, Mahmoud Abdel Alim, Mira Atef, Naglaa Zayed

1608: Incidence of Hepatocellular Carcinoma after HBsAg seroclearance in Chronic Hepatitis B patients: a need for Surveillance Gi-Ae Kim, Han Chu Lee, Yeonjung Ha, Eui Ju Park, Jihyun An

1609: Effect of Race on the Risk of Hepatocellular Cancer in U.S. Veterans with Chronic Hepatitis B Virus Infection

Sahil Mittal, Jennifer R. Kramer, Peter Richardson, Hashem El-Serag, Fasiha Kanwal

1610: Epidemiology of Hepatitis B Virus Infection according to Genotype in Alaska Native People

1612: Delta Hepatitis Within the Veterans Affairs Medical System Tatyana Kushner, David E. Kaplan

1613: Early on-treatment HDV RNA kinetics are not predicitve for long-term response to a PEG-IFNa therapy of hepatitis delta

Michael Wöbse, Cihan Yurdaydin, Stefanie Ernst, Svenja Hardtke, Benjamin Heidrich, Birgit Bremer, Onur Keskin, Ramazan Idilman, Armin Koch, Michael P. Manns, Heiner Wedemeyer

1614: Hepatocellular Carcinoma Risk By Genotype Among Hepatitis B Virus Infected Alaska Native Persons Who Are Below the Age For Which Guidelines Recommend HCC Surveillance. A Population-Based Retrospective Cohort Study

Prabhu P. Gounder, Lisa Bulkow, Mary Snowball, Susan Negus, Philip R. Spradling, Michael Bruce, Brian J. McMahon

1615: Serological and Molecular Epidemiological Outcomes after Two Decades of Universal Infant Hepatitis B Virus (HBV) Vaccination in Nunavut, Canada

Chris Huynh, Gerald Y. Minuk, Julia Uhanova, Maureen Baikie, Lianne Vardy, Thomas Wong, Carla Osiowy

1616: Prospective study of hepatitis B virus reactivation in rheumatoid arthritis patients on immunosuppressive therapy: Evaluation of both HBsAg-positive and -negative cohorts

Akihiro Tamori, Hitoshi Goto, Masahiro Tada, Kentaro Inui, Etsushi Kawamura, Atsushi Hagihara, Sawako Kobayashi, Hiroyasu Morikawa, Masaru Enomoto, Yoshiki Murakami, Norifumi Kawada

1617: Loss of immune tolerance is associated with HBV genotype specific patterns of accumulation of basal core promotor and precore variants, leading to decline in HBeAg and HBsAg levels

Gillian Rosenberg, Julianne Bayliss, Anuj Gaggar, Kathryn M. Kitrinos, Mani Subramanian, Patrick Marcellin, Edward J. Gane, Henry Lik-Yuen Chan, Rachel Hammond, Xin Li, Danni Colledge, Margaret Littlejohn, Lilly Yuen, Rosalind Edwards, Kathy Jackson, Sara Bonanzinga, Scott Bowden, Peter A. Revill, Stephen Locarnini, Alexander J. Thompson

1618: Analysis of dynamic parameters predicting HBsAg seroclearance in a cohort of European untreated hepatitis B (HBV) infected patients: a prospective longitudinal study (ALBATROS Study)

1611: Hepatitis B Screening and Prevalence among High-Risk Populations within the Department of Veterans Affairs

1619: Anti-HBs loss and HBV Reactivation Between Reduced Intensity versus Myeloablative Hematopoietic Stem Cell Transplant Regimens

Lisa I. Backus, Pamela S. Belperio, Timothy P. Loomis, Larry A. Mole

Poster Viewing: 8:00 AM – Noon

Hawwa Alao, Jeddeo Paul, Robert N. Reger, Elizabeth C. Wright, Kit Lu, Richard Childs, Marc G. Ghany

Presenters in Attendance 10:30 AM – Noon


Michael Bruce, Lance Ching, Prabhu P. Gounder, Lisa Bulkow, Philip R. Spradling, Mary Snowball, Susan Negus, Brian J. McMahon

Viola Knop, Johannes Vermehren, Eva Herrmann, Joerg Petersen, Peter Buggisch, Heiner Wedemeyer, Markus Cornberg, Stefan Mauss, Martin F. Sprinzl, Dietrich Hueppe, Thomas Berg, Florian van Boemmel, Michael Rausch, Tania M. Welzel, Judith Wuerzburg, Simone Susser, Stefan Zeuzem, Christoph Sarrazin



HEPATOLOGY, October, 2014

Poster Sessions 1620: Increases in APRI are Associated with LiverRelated Death in HIV-Viral Hepatitis Coinfection

Jennifer C. Price, Eric C. Seaberg, Claudia Hawkins, Susan L. Koletar, Mallory Witt, Chloe L. Thio

1621: Increased risk of developing hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis

Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

1622: Cirrhosis and its decompensation in chronic hepatitis B patients with new onset hypertension: A nationwide cohort study

Yi-Wen Huang, Szu-Chieh Fu, Ting Chuan Wang, Jui-Ting Hu, Ding-Shinn Chen, Jia-Horng Kao, Sien-Sing Yang

1623: Mapping the HBsAg immune phenotype to predict HBsAg loss or decline in chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy

Lucy Y. Lim, Lilly Yuen, Rachel Hammond, Peter W. Angus, Alexander J. Thompson, Scott Patterson, Thomas Leary, Peng Yin, Howard Thomas, Stephen Locarnini, Renae Walsh

1624: A newly developed prognosis index Improves Mortality Prediction in Patients with HBV-related Acuteon-chronic Liver Failure

Zhihong Wan, Yichen Wu, Shaoli You, HongLing Liu, Bing Zhu, ShaoJie Xin

1625: The APOBEC3B gene deletion and hepatitis B virus-associated hepatocellular carcinoma Ping An, Zheng Zeng, Victor David, Cheryl A. Winkler

1626: HBV nucleic acid quantification from liver tissue supports antiviral treatment decisions based on serum markers, but not in all phases of infection

Andrzej Taranta, Magdalena Rogalska-Taranta, Benjamin Maasoumy, Jerzy Jaroszewicz, Michael P. Manns, Robert Flisiak, Karsten Wursthorn

1627: Evaluation of liver fibrosis and prediction of hepatic carcinogenesis for patients with chronic hepatitis B by a unique glycoprotein: Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP)

Shuhei Hige, Itaru Ozeki, Mutuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takahiro Sato, Takumi Ohmura, Yoshiyasu Karino, Joji Toyota, Masashi Mizokami, Atsushi Kuno, Hisashi Narimatsu


1628: Changing Epidemiology of Hepatitis Delta Virus Infection in an HBV Hyper-endemic Area with Nationwide HBV Vaccination Program: the Need of Booster for High Risk Groups Hsi-Hsun Lin, Jaw-Ching Wu, Chien-Wei Su

1629: Prevalence and Molecular Virology of Hepatitis Delta Virus in the Western Pacific Region

Kathy Jackson, Meifang Han, Lilly Yuen, Rosalind Edwards, Uma Devi, Scott Bowden, Qin Ning, Stephen Locarnini, Margaret Littlejohn

Denotes AASLD Presidential Poster of Distinction

1630: Investigation of the efficacy of HBV DNA and HBsAg quantifications and liver stiffness measurements in identifying inactive HBV infection at a single time point evaluation

Sergio Maimone, Gaia Caccamo, Giovanni Squadrito, Angela Alibrandi, Francesca Saffioti, Rosaria Spinella, Giuseppina Raffa, Teresa Pollicino, Giovanni Raimondo

1631: Serum Caspase-Cleaved Cytokeratin 18 Fragments As A Potential Marker For Predicting Poor Outcome Of HBV Related Acute-On-Chronic Liver Failure

ZhuJun Cao, FengDI Li, Kehui Liu, Weiliang Tang, Yuhan Liu, Lanyi Lin, Hong Yu, Qing Xie, Hui Wang

1632: Efficacy of Third Trimester Maternal Tenofovir Disoproxil Fumarate Treatment in Interrupting Motherto-Infant Transmission of Hepatitis B Virus

Huey-Ling Chen, Chien-Nan Lee, Chin-Hao Chang, Yen-Hsuan Ni, Shih-Ming Chen, Jen-Jan Hu, Hans Hsienhong Lin, Shu-Chi Mu, Ming-Wei Lai, Ming-Song Tsai, Ding-Shinn Chen, K. Arnold Chan, Mei-Hwei Chang

1633: Risk of development of hepatocellular carcinoma in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase levels

Ji Hyeon Lee, Dong Hyun Sinn, Geum-Youn Gwak, Ju-Yeon Cho, Won Sohn, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo

1634: Tendency to Develop Acute Hepatitis B and its Outcome in HIV Coinfection: Comparison with HBV Infection Alone

Yuichi Nozaki, Akahito Sako, Shintaro Mikami, Yasushi Kojima, Masatoshi Imamura, Nao Nishida, Masaya Sugiyama, Masaaki Korenaga, Kazumoto Murata, Tatsuya Kanto, Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka, Mikio Yanase, Naohiko Masaki, Masashi Mizokami

1635: WITHDRAWN 1636: High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true ‘immune-tolerance’ in children and young adults with Chronic Hepatitis B

Navjyot K. Hansi, Upkar S. Gill, Amrita Banerjee, Neelan Surendraraj, Chandni Patel, Sandhia Naik, Graham R. Foster, Patrick T. Kennedy

1637: Lack of usefulness of serum makers for assessment of significant liver fibrosis in inactive carriers of hepatitis B infection

Mar Riveiro-Barciela, Francisco Rodríguez-Frías, Maria Homs, David Tabernero, Maria Buti, Rafael Esteban

1638: Patients lost to follow up: the experience of an Australian Hepatitis B Clinic

Phil Ha, Vanessa Bull, Natassia Tan, Stephanie Spring, Lukas J. Sahhar, Suong T. Le, Anouk T. Dev




Poster Sessions 1639: Diagnostic performance of transient elastography (Fibroscan ®) for the assessment of liver fibrosis in patients with chronic hepatitis B: Impact of ALT and HBV DNA serum levels

NANA Koudbi Jean, Tarik Asselah, Michael Adler, Marie Noelle Hilleret, Jean-Pierre H. Zarski, Alice Marlu, Vincent Leroy

1640: Hepatitis flares are common among patients receiving chemotherapy for cancers Jessica P. Hwang, Andrea G. Barbo, Anna S. Lok

1641: Antiviral Therapy and the Development of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB) Patients with and without Cirrhosis in a US Population

Derek Lin, Nghia H. Nguyen, Joseph Hoang, Vinh D. Vu, Huy N. Trinh, Jiayi Li, Jian Q. Zhang, Huy A. Nguyen, Khanh Nguyen, Mindie H. Nguyen

1642: A Prospective and Large Sample Study for the Long-term Safety and Clinic Outcome after Postpartum Withdrawl of Telbivudine Therapy for The Prevention of Perinatal Transmission of Hepatitis B Virus Infection

Jing Wang, Jinfeng Liu, Yingli He, Yuan Yang, Li Jin, Shulin Zhang, Yingren Zhao, Tianyan Chen

1643: Clinical Relevance of Viral Blipping During Potent Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infection

Mayur Brahmania, Willem Pieter Brouwer, Tawnya Hansen, Matt Kowgier, Jordan J. Feld, David K. Wong, Harry L. Janssen

1644: Preventing HBV reactivation: An automated prompt to remind oncologists to screen was only partially successful

Joshua Juan, Lisa K. Hicks, Lauren Lapointe-Shaw, Judy Truong, Urszula Zurawska, Kelvin Chan, Jordan J. Feld

1645: Validation of Noninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B Jieyao Cheng, Hong Ma

1646: Factors Predisposing to Development of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Spontaneous Seroclearance of Hepatitis B Surface Antigen

Eui Ju Park, Danbi Lee, Young-Hwa Chung, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Yung Sang Lee, Pyo Nyun Kim, Neung Hwa Park

1647: A ten-year follow-up of patients with dual chronic hepatitis B and C virus infections: Outcomes and determinants

1648: Hepatocellular Carcinoma Surveillance Rates in Non-Cirrhotic Patients with Chronic Hepatitis B in the United States

Kidist K. Yimam, Margaret D. Clark, Cara Torruellas, Jennifer L. Dodge, Jody L. Baron, Christopher L. Bowlus, Stewart Cooper

1650: Assessment of combined serum biomarkers and fibroscan and dynamic computed tomography in the detection of hepatic fibrosis in chronic hepatitis b patients Gurdal Yilmaz, Iftihar Koksal, Arif M. Cosar, Ugur Kostakoglu

1651: The transplacental hepatitis B core antibody correlated to the responsiveness of the hepatitis B vaccine in infants born to HBsAg-positive mothers

Taotao Yan, Jing Wang, Tianyan Chen, Jinfeng Liu, Dan Du, Li Jin, Yingli He, Yuan Yang, Yuanyuan Li, Yingren Zhao

1652: Stepwise noninvasive assessment to predict significant fibrosis in chronic hepatitis B patients who do not meet definite treatment guideline

Jin Dong Kim, Jin Yong Jung, Sun Young Yim, Yeon Seok Seo, Soon Ho Um, Ho Sang Ryu

1653: HBV Genotype, Drug Resistant Mutation & Precore/Basal Core Promoter Mutation in Acute Hepatitis B in Korea

Jong Ho Lee, Sun Pyo Hong, Eun Sun Jang, Sang Jong Park, Seong Gyu Hwang, Sook-Kyoung Kang, Jin-Wook Kim, Sook-Hyang Jeong

1654: Kinetics of Hepatitis B Surface Antigen Level During Telbivudine and Entecavir Treatment Chronic Hepatitis B Patients

Sun Young Yim, Soon Ho Um, Chang Ho Jung, Tae Hyung Kim, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Hong Sik Lee, Yoon Tae Jeen, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu

1655: LAW Index as a Novel Non-invasive Indicator for the Initiation of Antiviral Agent in Patients with Chronic Hepatitis B

Jae Min Lee, Yeon Seok Seo, Chang Ho Jung, Tae Hyung Kim, Sun Young Yim, Hyonggin An, Soon Ho Um, Ho Sang Ryu

1656: A new dynamic prognostic model for acute-onchronic hepatitis B liver failure based on the clinical and short-term changes of bio-markers

Zhonghui Duan, Li Chen, Yanmei Feng, Hong-Wei Yu, Zhen Li, Meixin Ren, Yue-Ke Zhu, Chenggang Jin, Qinghua Meng

1657: Chronic Hepatitis B in Western Europe: A Retrospective Cohort

Luis Maia, Ana Margarida S. Ribeiro, José Manuel Ferreira, Teresa Moreira, Isabel Pedroto

1658: Hepatocellular Carcinoma Replicating Hepatitis B Virus: a Clinical, Virological and Transcriptional Entity

David S. Goldberg, Adriana Valderama, Rajesh Kamalakar, Sujit S. Sansgiry, Svetlana Babajanyan, James D. Lewis

Boris Halgand, Guillaume Fallot, Lise Riviere, Christophe Desterke, Mylene Sebagh, Julien Calderaro, Paulette Bioulac-Sage, Remy Houlgatte, Marie-Annick Buendia, Didier Samuel, Christine Neuveut, Cyrille Feray

Poster Viewing: 8:00 AM – Noon

Presenters in Attendance 10:30 AM – Noon


Chun-Jen Liu, Tai-Chung Tseng, Tung-Hung Su, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao

1649: Hepatitis D: Testing Rates and Seroprevalence at Two Liver Centers in Northern California



HEPATOLOGY, October, 2014

Poster Sessions 1659: The Urgent Unmet Need to Screen for Hepatitis B virus in African born Patients within the US, and Link them to Care

Aaron M. Vanderhoff, Hari Shankar, Demetri A. Blanas, Kian Bichoupan, Daouda Ndiaye, Mulusew Bekele, Ellie Carmody, Valerie Martel-Laferriere, Saba Bekele, Andrea D. Branch, Douglas Dieterich, Kim E. Nichols, Ponni Perumalswami

1660: A risk for hepatocellular carcinoma persists longterm after hepatitis B virus DNA clearance in patients with associated advanced fibrosis

Blaise K. Kutala, Corinne Castelnau, Nathalie Boyer, Tarik Asselah, Feryel Mouri, Emilie Estrabaud, Michelle MartinotPeignoux, Dominique Valla, Patrick Marcellin

1661: Tenofovir DF prevents HBV reactivation in antiHBc positive patients with hematologic malignancies treated with Rituximab: 12-months results of a randomized study (PREBLIN study)

Maria Buti, Maria L. Manzano, Rosa María Morillas, Montserrat Garcia-Retortillo, Leticia Martin, Martin Prieto, Maria Luisa Gutierrez, Emilio Suarez, Mariano Gomez-Rubio, Javier Lopez, Francisco Gea, Manuel Rodríguez, Jose M. Zozaya, Miguel A. Simon, Albert Pardo, Luis Morano, Jose Luis Calleja, Rafael Esteban

1662: Electronic notifying system improved the coverage of HBV-related serum markers in the prevention of HBV reactivation hepatitis Toshiki Komeda, Shinji Katsushima

1663: Is HBeAg Seroconversion a Valid Surrogate Marker for Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Lamivudine or Entecavir? Jihyun An, Hwa Jung Kim, Young-Suk Lim, Dong Jin Suh

1664: Pregnancy and chronic hepatitis B – what markers change post-delivery?

Mary Horner, Matthew J. Bruce, Marie-Ange McLeod, Kath Oakes, Teresa Bowyer, Thawab Al-Chalabi, Kate E. Childs, Suman Verma, Phillip M. Harrison, Kosh Agarwal, Ivana Carey


1665: HBeAg levels predict HBeAg seroconversion during the immune clearance phase of chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy

1667: Analysis of hepatitis B surface antigen (HBsAg) levels using the Lumipulse HBsAg-HQ assay in hepatitis B virus carriers with HBsAg seroclearance according to the Abbott ARCHITECT assay

Itaru Ozeki, Tomoaki Nakajima, Shuhei Hige, Yoshiyasu Karino, Joji Toyota

1668: Associations of Adipokines with Liver Fibrosis Stages in Patients with Chronic Hepatitis B Virus Infection

Ching-Sheng Hsu, Wei-Liang Liu, Ding-Shinn Chen, Jia-Horng Kao

1669: Hepatitis B Virus Screening Rates Vary Across Specialties in Patients Receiving Immunosuppressive Therapy

Sonali Paul, Asim Shuja, Idy Tam, Sandra Kang, Leonid Kapulsky, Kathleen Viveiros, Hannah Lee

1670: Understanding the Phases of Chronic Hepatitis B; the problem and a novel solution using renamed phases, the Hepatitis B Bear and a video (see “ Understanding Hepatitis B “ on YouTube)

Heidi L. Lord, Jamee Newland, Elena Cama, Carla Treloar, Miriam T. Levy

1671: Prediction of liver disease in e antigen negative chronic hepatitis B (CHB)

Gayatri Chakrabarty, Philip Rice, Nick Tatman, Sarah J. Clark, Ken Laing, Daniel M. Forton

1672: The Neutralizing Activity of Monoclonal HBs Antibodies Separated from Hepatitis B Vaccinated Recipients and the Influence of the titers by Different Measurement Methods

Takako Inoue, Noboru Shinkai, Kumiko Ohne, Shuko Murakami, Susumu Tsutsumi, Kazuto Tajiri, Hiroyuki Kishi, Shintaro Ogawa, Masanori Isogawa, Tsunamasa Watanabe, Yasuhito Tanaka

1673: A Newly Developed High-Sensitive HBsAg Chemiluminescent Enzyme Immunoassay is a Precise Application as a pre-Transfusion Screening Test to Detect Occult HBV

Takako Inoue, Kumiko Ohne, Noriyo Ochi, Noboru Shinkai, Shuko Murakami, Sayuki Iijima, Shintaro Ogawa, Tsunamasa Watanabe, Yasuhito Tanaka

Julianne Bayliss, Alexander J. Thompson, Gillian Rosenberg, Anuj Gaggar, Kathryn M. Kitrinos, Mani Subramanian, Patrick Marcellin, Edward J. Gane, Henry Lik-Yuen Chan, Xin Li, Danni Colledge, Margaret Littlejohn, Lilly Yuen, Rosalind Edwards, Kathy Jackson, Sara Bonanzinga, Rachel Hammond, Scott Bowden, Stephen Locarnini, Peter A. Revill

1674: Biomarkers to predict the clinical outcome of hepatitis delta

1666: The Incidence Of Hepatitis B Virus (HBV) Related Hepatocellular Carcinoma (HCC) Is Reduced In North American Chronic Hepatitis B (CHB) Patients Treated With Long-Term Nucleos(t)ide Analog Therapy

1675: Switch to the second generation of nucelos(t) ide analogues from de-novo lamivudine+adefovir in sequentially treated chronic hepatitis B patients improves viral response and leads to sharper HBsAg decline

Carla S. Coffin, Maryam Rezaeeaval, Jack X. Pang, Lilibeth Alcantara, Patricia Klein, Kelly W. Burak, Robert P. Myers

Denotes AASLD Presidential Poster of Distinction

Anika Wranke, Beatriz Calle Serrano, Stefanie Ernst, Benjamin Heidrich, Janina Kirschner, Birgit Bremer, Svenja Hardtke, Markus Cornberg, Armin Koch, Michael P. Manns, Christine S. Falk, Heiner Wedemeyer

Matthew J. Bruce, Mary Horner, Thawab Al-Chalabi, Kath Oakes, Ashley Barnabas, Suman Verma, Phillip M. Harrison, Kosh Agarwal, Ivana Carey




Poster Sessions 1676: The efficacy of Telbivudine used in entire pregnancy course in blocking mother-to-child HBV transmission Wei Yi, Yao Xie, Yu-Hong Hu, Ming-hui Li

1677: Hepatitis B Core Related Antigen Levels Differ During The Natural History of Chronic Hepatitis B Infection

Willem Pieter Brouwer, Gertine van Oord, Milan J. Sonneveld, Thomas Vanwolleghem, Robert J. de Knegt, Bettina E. Hansen, Andre Boonstra, Harry L. Janssen

1678: Immunogenicity of Recombinant Hepatitis B Vaccine in Patients on Maintenance Hemodialysis and Normal Population of Pakistani Origin

Syed M. Hassan, Arzoo Saeed, Muhammad Osama Butt, Nasir Hassan Luck, Zaigham Abbas

1679: Higher rates of hepatitis B surface antigen (HBsAg) seroclearance among males and non-Asian patients with chronic hepatitis B (CHB) in a large, multicenter U.S. cohort study

Long H. Nguyen, Christina Wang, Vinh D. Vu, Huy N. Trinh, Jiayi Li, Jian Q. Zhang, Mindie H. Nguyen

1680: Are Patients with Hepatitis B Virus Infection Receiving Evaluation and Treatment?: An Analysis of A Large Insured U.S. Cohort

Loren G. Miller, Rajeshwari S. Punekar, Debra F. Eisenberg, Samantha Eells, Rakesh Luthra, Thomas Wasser, Honghu Liu

1681: Epidemiological evolution of Chronic Hepatitis Delta in Italy. An analysis of the Master-B cohort

Giuseppina Brancaccio, Tiziana Giuberti, Gabriella Verucchi, Fabio Levantesi, Daria Sacchini, Giovanna Fattovich, Salvatore Madonia, Massimo Fasano, Caius Gavrila, Alessandra Nardi, Giovanni B. Gaeta

1682: Cross-sectional study to evaluate hepatitis B virus (HBV) infection screening practices and outcomes in patients with rheumatic diseases (REBIB-I Study)

Montserrat Garcia-Retortillo, Joana Villaverde, Blanca Sampedro, Joaquin Cabezas-González, Albert Pardo, Ramon Fontova, Tarek C. Salman, Maria Pilar Lisbona, Joan Maymo, Blai Dalmau, Eduard Graell, Jose Inciarte, Raimon Sanmarti, Javier Crespo, Ricard Sola

1683: Efficacy and safety of long term tenofovir in high risk patients with hematological malignancies (HM) to prevent Hepatitis B Virus (HBV) reactivation after immunosuppressive therapies in real life

1684: Insulin resistance is associated with higher liver stiffness and increased immune response in inactive carriers of hepatitis B

Tsunamasa Watanabe, Susumu Hamada-Tsutsumi, Noboru Shinkai, Etsuko Iio, Kayoko Matsunami, Sayuki Iijima, Shuko Murakami, Katsumi Omagari, Masanori Isogawa, Wataru Sugiura, Yasuhito Tanaka

1686: Effectiveness of an Online, Tailored CME Curriculum on Chronic Hepatitis B virus (CHB) Management

Nancy Reau, Catherine C. Capparelli, Jennifer Garick, Wendy Cerenzia, Simi Hurst

1687: HBV/HIV coinfection is associated with greater mortality in hospitalized patients with HBV

Ruma Rajbhandari, Raymond T. Chung, Hamed Khalili, Ashwin N. Ananthakrishnan

1688: The landscape of pregant women with hepatitis B in a single centre

Enoka Gonsalkorala, Vi Nguyen, Carina Burns, Anne L. Glass, Miriam T. Levy

1689: HBV infection is associated with greater mortality in hospitalized patients compared to HCV infection or alcoholic liver disease Ruma Rajbhandari, Ananthakrishnan





1690: Hepatitis B core-related antigen (HBcrAg) levels in patients with chronic hepatitis B undergoing NUC therapy

Benjamin Maasoumy, Katja Deterding, Jerzy Jaroszewicz, Birgit Bremer, Patrick Lehmann, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg

1691: Dynamic of liver stiffness values by Transient Elastography in inactive HBV carriers

Milana Szilaski, Roxana Sirli, Cristian Ivascu, Oana Gradinaru Tascau, Alexandra Deleanu, Isabel Dan, Ioan Sporea

1692: Genotype A HBV-persistent infection is associated with high serum HBsAg concentration in treatmentnaïve patients

Jerzy Jaroszewicz, Malgorzata Pawlowska, Krzysztof Tomasiewicz, Wlodzimierz W. Mazur, Krzysztof Simon, Anna Piekarska, Marta Wawrzynowicz-Syczewska, Pawel Rajewski, Magdalena widerska, Elzbieta Murias-Brylowska, Ewelina Zasik, Pazgan Simon Monika, Waldemar Halota, Robert Flisiak

1693: Positive Response to Hepatitis B Virus Standard Vaccination Scheme Among Patients in an HIV Program

Francisco Fuster, Jose Ignacio Vargas, Daniela Jensen, Valeska Sarmiento, Felipe Peirano, Pedro Acuña, Sabrina Soto, Werner Jensen, Rodrigo Ahumada, Marcos Huilcaman, Mario Bruna

Mar Riveiro-Barciela, Francisco Rodriguez-Frias, Maria Homs, David Tabernero, Rafael Esteban, Maria Buti Poster Viewing: 8:00 AM – Noon


Presenters in Attendance 10:30 AM – Noon


Giuseppe Gentile, Eleonora Russo, Federico De Angelis, Alice Di Rocco, Angelo Fama, Alessandra Micozzi, Alessandro Pulsoni, Maurizio Martelli, Francesca R. Mauro, Anna P. Iori, Teresa Petrucci, Antonella Vitale, Guido Antonelli, Robin Foà

1685: Pre- and Post-Exposure Prophylaxis against Hepatitis B Virus Infection by HBV-active Antiretroviral Therapy



HEPATOLOGY, October, 2014

Poster Sessions 1694: Identification of a four-gene model to discriminate mild from moderate fibrosis in patients with chronic hepatitis B

1701: A novel TK-NOG based humanized mouse model for the study of HBV and HCV infection

Emilie Estrabaud, Roberto J. Carvalho-Filho, Olivier Lada, Cédric Laouénan, Simon Gosset, Ana Carolina F. Cardoso, Ivan Bieche, Martine Lapalus, Michel Vidaud, Tarik Asselah, Patrick Marcellin

Nobuhiko Hiraga, Michio Imamura, Takuro Uchida, Tomokazu Kawaoka, Masataka Tsuge, Hiromi Abe, C. Nelson Hayes, Hiroshi Aikata, Yuji Ishida, Chise Tateno, Katsutoshi Yoshizato, Kazuaki Chayama

1695: The prevalence of 25(OH)D3 in the patients of South China with chronic HBV infection and high 25(OH)D3 related with low HBV DNA viral load

1702: A detailed systems biology study identifies unappreciated roles for B-cells in the differentiation between HBV clinical phases

HBV: Virology and Pathogenesis

1703: Increased IL-17 producing TFh (CD4+CXCR5+ CCR6+) cells help in HBV seroconversion through TNF-α secretion

Guoli Lin, Yunlong Ao, Xin-Hua Li, Yuankai Wu, Yusheng Jie, Hong Shi, Xiangyong Li, Fangji Yang, Shu-ru Chen, Yutian Chong

1696: Associations of HLA-DPB1 with CHB infection and HBV related HCC in Asia

Nao Nishida, Hiromi Sawai, Kouichi Kashiwase, Mutsuhiko Minami, Ken Yamamoto, Takehiko Sasazuki, Masaya Sugiyama, Wai-Kay Seto, Man-Fung Yuen, Yong Poovorawan, Sang Hoon Ahn, Kwang-Hyub Han, Kentaro Matsuura, Yasuhito Tanaka, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi, Jong-Hon Kang, Shuhei Hige, Tatsuya Ide, Kazuhide Yamamoto, Isao Sakaida, Yoshikazu Murawaki, Yoshito Itoh, Akihiro Tamori, Etsuro Orito, Yoichi Hiasa, Masao Honda, Shuichi Kaneko, Eiji Mita, Kazuyuki Suzuki, Keisuke Hino, Eiji Tanaka, Satoshi Mochida, Masaaki Watanabe, Yuichiro Eguchi, Masaaki Korenaga, Minae Kawashima, Katsushi Tokunaga, Masashi Mizokami

1697: Association between the expression of aldoketo reductase family 1 member B10 and the risk of hepatitis B virus-related hepatocellular carcinoma

Masashi Mori, Takuya Genda, Takafumi Ichida, Ayato Murata, Hironori Tsuzura, Shunsuke Sato, Yutaka Narita, Yoshio Kanemitsu, Sachiko Ishikawa, Tetsu Kikuchi, Katsuharu Hirano, Katsuyori Iijima, Ryo Wada, Sumio Watanabe

Ashish Vyas, Shreya Sharma, Arshi Khanam, Ankit Bhardwaj, Nirupma Trehanpati, Shiv K. Sarin

1704: Mutational profile of HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope env183-191 in chronic HBVinfected patients and the epitopic mutation’s influence on CTL activities

Zhihui Xu, Yihui Rong, Yan Liu, Xiaodong Li, Shaoli You, Dongping Xu, ShaoJie Xin

1705: HBx interact with and modulates the expression of the DLEU2 lncRNA locus in HBV replicating cells

Francesca Guerrieri, Safaa Jeddari, Daniel D’Andrea, Anna Tramontano, Massimo Levrero

1706: Differential expression of Fc gamma receptors contributing to the diverse host immunity during HBV infection

Jinglan Jin, Ruihong Wu, Xiumei Chi, Wanyu Li, Na Wu, Junqi Niu

1698: Induction of hepatitis B virus-specific immune responses in immunologically humanized mice

1707: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients with Chronic Hepatitis B (CHB) After Eight Years of Treatment

1699: Epigenetic regulation of host immunity in HBV infection

1708: Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon–Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B

Satoshi Aono, Tomohide Tatsumi, Seiichi Tawara, Yoshiki Onishi, Akira Nishio, Tadashi Kegasawa, Atsuo Takigawa, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Hiroshi Suemizu, Takeshi Takahashi, Tetsuo Takehara

Jinglan Jin, Hongqin Xu, Xiumei Chi, Wanyu Li, Junqi Niu, Shibo Li

1700: A novel humanized cDNA-uPA/SCID mouse for the study of HBV and HCV infections


Thomas Vanwolleghem, Jun Hou, Gertine van Oord, Zwier M. Groothuismink, Kim Kreefft, Suzan D. Pas, Harry L. Janssen, Andre Boonstra

Takuro Uchida, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Hiromi Abe, C. Nelson Hayes, Hiroshi Aikata, Yuji Ishida, Chise Tateno, Katsutoshi Yoshizato, Kazunari Murakami, Kazuaki Chayama

Denotes AASLD Presidential Poster of Distinction

Amoreena C. Corsa, Yang Liu, John F. Flaherty, Patrick Marcellin, Michael D. Miller, Kathryn M. Kitrinos

Upkar S. Gill, Dimitra Peppa, Harsimran D. Singh, Lorenzo Micco, Graham R. Foster, Mala K. Maini, Patrick T. Kennedy

1709: Mice with syngeneic human liver and immune system to study cellular immunity to hepatitis B virus

Eva Billerbeck, Michiel C. Mommersteeg, Amir Shlomai, Jing W. Xiao, Linda Andrus, Ankit Bhatta, Marcus Dorner, Anuradha Krishnan, Michael Charlton, Luis Chiriboga, Charles M. Rice, Ype P. De Jong




Poster Sessions 1710: Effect of Immunosuppression and Antiviral Therapy in Persistent Intracellular Replication among Hepatitis B Virus and HIV Co-Infected Patients

Anders Boyd, Karine Lacombe, Fabien Lavocat, Sarah Maylin, Patrick Miailhes, Caroline Lascoux-combe, Constance Delaugerre, Pierre-Marie Girard, Fabien Zoulim

1711: Bile acids receptor FXR agonists repress HBV replication in HepaRG cell

Pauline Radreau, Christophe Ramière, Marine Porcherot, Vincent Lotteau, Patrice André

1712: Toll-like receptor 3-acivated non-parenchymal liver cells control hepadnaviral replication in HBVtransgenic mice lacking the surface antigen (HBsAg)

Catherine I. Real, Mengji Lu, Markus Hossbach, Kerstin JahnHofmann, Ludger M. Ickenstein, Matthias J. John, Hans-Peter Vornlocher, Reinhold Schirmbeck, Melanie Lutterbeck, Kathrin Gibbert, Ulf Dittmer, Guido Gerken, Joerg F. Schlaak, Ruth Broering

1713: Frequency and role of NKp46 and NKG2A expressing NK cells in patients with chronic hepatitis B

Teppei Yoshioka, Takuya Miyagi, Yoshinobu Yokoyama, Akira Nishio, Kaori Mukai, Satoshi Aono, Kumiko Nishio, Takatoshi Nawa, Hayato Hikita, Ryotaro Sakamori, Naoki Hiramatsu, Tomohide Tatsumi, Tetsuo Takehara

1719: Increased fucosyltransferase 2 gene expression in HBV infection enhances HBV replication

Takayuki Shiomoto, Masao Honda, Takayoshi Shirasaki, Kazuhisa Murai, Tetsuro Shimakami, Seishi Murakami, Shuichi Kaneko

1720: Extensive Hepatitis B virus (HBV) Core Antigen Mutation Associated with Massive Intrahepatic Production of Germline Anti-core IgM and IgG Suggest a Major Role of Humoral Immunity in the Pathogenesis of HBV-Associated Acute Liver Failure (ALF)

Zhaochun Chen, Ronald E. Engle, Ashley B. Tice, Zhifeng Long, Fausto Zamboni, Giacomo Diaz, Patrizia Farci

1721: Plasma Fibroblast Growth Factor 23 Concentration is Increased and Related with Liver Injury in Patients with HBV Related Acute-on-chronic Liver Failure

Fangfang Liu, ZhiHong Wan, Hong Zang, Shaoli You, HongLing Liu, ShaoJie Xin

1722: Virologic and clinical characters of hepatitis B virus mutations in basal core promoter and precore region in children with chronic hepatitis B and hepatitis B related liver cirrosis

Yanwei Zhong, Hongfei Zhang, Shishu Zhu, Yi Dong, Zhiqiang Xu, Dawei Chen, Hui Dong, Fenglin Di, Limin Wang, Yu Gan, Fuchuan Wang

1714: Hepatitis B virus enhances the endo-lysosomal pathway through the activation of the small GTPase Rab7 via an interaction between HBe and the Rab7 GAP, TBC1D15

1723: HBV genotype study by ultradeep pyrosequencing reveals complex mixtures and intergenotype recombination

1715: HBV infection in humanized chimeric mice has multiphasic viral kinetics from inoculation to steady state and an HBV half-life of 1 hr

1724: Analysis of the effect on HBV life cycle by HBV genome editing using TALEN and CRISPR/Cas9 systems

Jun Inoue, Eugene W. Krueger, Jing Chen, Hong Cao, Tooru Shimosegawa, Mark A. McNiven

Yuji Ishida, Tje Lin Chung, Michio Imamura, Nobuhiko Hiraga, Laetitia Canini, Susan L. Uprichard, Alan S. Perelson, Chise Tateno, Harel Dahari, Kazuaki Chayama

1716: Effect of bile acid on the entry of hepatitis B virus via sodium taurocholate cotransporting polypeptide

Jung Wha Chung, Eun Sun Jang, In Young Moon, Gi Hyun Kim, Kyeong Sam Ok, Jong Ho Lee, Sook-Hyang Jeong, Jin Wook Kim

1717: Distinct helper roles of dendritic cell subsets in NK cell-dependent HBV suppression in bystander infected cells

Sachiyo Yoshio, Tatsuya Kanto, Masaya Sugiyama, Hirotaka Shoji, Yohei Mano, Yoshihiko Aoki, Nao Nishida, Masaaki Korenaga, Kazumoto Murata, Masashi Mizokami

Takuro Uchida, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Hiromi Abe, C. Nelson Hayes, Hiroshi Aikata, Yuji Ishida, Chise Tateno, Katsutoshi Yoshizato, Kazuaki Chayama

Poster Viewing: 8:00 AM – Noon

Hiromi Abe, Tetsushi Sakuma, Masataka Tsuge, Nobuhiko Hiraga, Michio Imamura, C. Nelson Hayes, Hiroshi Aikata, Takashi Yamamoto, Kazuaki Chayama

1725: Serum Arginase-1 Levels Are Lower Than Expected in Hepatitis B-related Acute Liver Failure

Perry H. Dubin, Jody A. Balko, Michelle Gottfried, William M. Lee

1726: Hepatitis B virus recurrence after liver transplantation and evolution of viral quasispecies

Maria Buti, David Tabernero, Rosario Casillas, Antoni Mas, Maria Homs, Martin Prieto, Fernando Casafont, Antonio Gonzalez, Manuel Miras, Jose Ignacio Herrero, Lluis Castells, Rafael Esteban, Francisco Rodriguez-Frias

1727: Hepatitis B Virus Core Protein Amino Acids 77-78 Play Vital Roles in Capsid Foramation and Function Kai Deng, Dong Jiang, Lai Wei

1728: Cytokeratins 8 and 18 are responsible for intracellular distribution of the large hepatitis B virus surface protein

Martin Roderfeld, Dirk Schröder, Yury Churin, Dieter Glebe, Elke Roeb Presenters in Attendance 10:30 AM – Noon


1718: Establishment of a mouse model of acute hepatitis B by activation of human cytotoxic T lymphocytes

Andrea Caballero, Josep Gregori, Maria Homs, David Tabernero, Maria Blasi, Rosario Casillas, Josep Quer, Leonardo Nieto, Henar Valbuena, Rafael Esteban, Maria Buti, Francisco Rodriguez-Frias



HEPATOLOGY, October, 2014

Poster Sessions 1729: Hepatitis B virus infection efficiency and immune response decreases with cell density in primary cultured hepatocytes

C. Nelson Hayes, Hiromi Abe, Sakura Akamatsu, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Daiki Miki, Hiroshi Aikata, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama

1730: The dual immunoregulatory roles of circulating iNKT cells during chronic HBV infection Man Li, Zhen-Hua Zhou, Xue-Hua Sun, Yue-Qiu Gao

1731: Pretreatment Cirrhosis and Higher Body Mass Index Predicted Alanine Aminotransferase Abnormality in Patients Achieved Undetectable Serum HBV DNA with Nucleos(t)ide Analogs Therapy

Yuankai Wu, Yusheng Jie, Xiangyong Li, Guoli Lin, Shu-ru Chen, Xin-Hua Li, Hong Shi, Fangji Yang, Min Zhang, Mingxing Huang, Yunlong Ao, Yihua Pang, Yutian Chong

1732: Hepatitis B virus relapse after discontinuation of long-term treatment with tenofovir in chronic HBeAgnegative patients

Maria Buti, Maria Homs, Rosario Casillas, David Tabernero, Josep Gregori, Carolina Gonzalez, Mar Riveiro-Barciela, Maria Teresa Salcedo, Maria Blasi, Leonardo Nieto, Francisco Rodriguez-Frias, Rafael Esteban

1733: Clonal Hepatocyte expansion in the young adult HBV infected liver is at odds with the concept of a generic immune tolerant disease phase: can additional clinical parameters distinguish disease phase?

Patrick T. Kennedy, Upkar S. Gill, Antony Chen, Samuel Litwin, Antonio Bertoletti, William Mason

1734: Toll like Receptor Polymorphisms in Spontaneous HBsAg Seroconversion

Kamil Özdil, Levent Doganay, Adil Nigdelioglu, Seyma Katrinli, Oguzhan Ozturk, Zuhal Caliskan, Mehmet Sokmen, Gizem Dinler

1735: Phenotypic Characteristics of PD-1, CTLA-4 and FoxP3 Expression during Tenofovir therapy in Chronic Hepatitis B

Hyosun Cho, Chang Wook Kim, Yu seung Kim, Hee Yeon Kim, Jong Young Choi, Seung Kew Yoon, Chang Don Lee

1736: Hepatitis B virus (HBV) specifically induces CD4+CD25+CD127-veFoxP3+ with increased anti-tumor immunity in HBV related HCC compared to Non- HBVHCC


Shreya Sharma, Paul David, Rakhi Maiwall, Amrish Sahney, Ritu Khosla, Ashish Vyas, Shiv K. Sarin, Nirupma Trehanpati

1737: Evaluation of Serum Cytokines and Chemokines in HBeAg Negative Chronic Hepatitis B Patients Yan Cheng, Veonice Bijin Au, John E. Connolly, Seng Gee Lim

Denotes AASLD Presidential Poster of Distinction

1738: Associations of single nucleotide polymorphism rs1053004 in signal transducer and activator of transcription 3 (STAT3) for risk of hepatocellular carcinoma in Thai patients with chronic hepatitis B

Nawin Chanthra, Sunchai Payungporn, Natthaya Chuaypen, Pisit Tangkijvanich

1739: Immune system is required for HBV clearance, but not enough for explaining the difference in HBV genotype A and C clearance

Yoshinobu Yokoyama, Hayato Hikita, Teppei Yoshioka, Kaori Mukai, Satoshi Aono, Takatoshi Nawa, Ryotaro Sakamori, Takuya Miyagi, Kazuyoshi Ohkawa, Naoki Hiramatsu, Tomohide Tatsumi, Tetsuo Takehara

1740: Nucleotide analogue improves interferon responsiveness in HBV-infected human hepatocytes

Masataka Tsuge, Nobuhiko Hiraga, Eisuke Murakami, Michio Imamura, Hiromi Abe, Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Kazuaki Chayama

1741: High alpha-fetoprotein is risk factor of hepatocellular carcinoma in hepatitis B patients with good efficacy of nucleoside analogues therapy

Noboru Shinkai, Etsuko Iio, Tsunamasa Watanabe, Kentaro Matsuura, Kei Fujiwara, Shunsuke Nojiri, Yasuhito Tanaka

1742: NKP46 Is Potentially Involved in Control of Hepatitis B Virus Replication and Modulation of Liver inflammatory

Wanyu Li, Yanfang Jiang, Yanjun Cai, Yue Qi, Jinglan Jin, Xiaomei Wang, Junqi Niu

1743: Serum soluble CD40 is associated with liver injury in patients with chronic hepatitis B Hong-hui Shen, Bing-ke Bai, Panyong Mao

1744: Association study of next-generation sequencing determined HBV heterogeneity and antiviral efficacy of Lamivudine treatment Yue Han, Ling Gong, Xin-xin Zhang

1745: High-throughput hepatitis B and D virus model systems for discovery of targets for viral cure

Eloi R. VERRIER, Charlotte Bach, Laura Heydmann, Amelie Weiss, Rajeevkumar G. Tawar, Daniel Felmlee, Sarah Durand, David Durantel, Fabien Zoulim, François Habersetzer, Michel Doffoel, Catherine Schuster, Laurent Brino, Camille C. Sureau, Mirjam B. Zeisel, Thomas F. Baumert

1746: Model of HBV/HDV super-infection to study mechanisms of viral interplay and antivirals

Dulce Alfaiate, Natali A. Abeywickrama-Samarakoon, Barbara Testoni, Julie Lucifora, Fabien Zoulim, Jean-Claude Cortay, Paul Deny, David Durantel




Poster Sessions 1747: Serial Changes of Cellular, Humoral, and Innate Immune Responses following Immunosuppressive Chemotherapies Responsible for Hepatitis B Virus Reactivation

Hidetaka Matsuda, Tatsushi Naito, Takuto Nosaka, Tomoyuki Nemoto, Masahiro Ohtani, Katsushi Hiramatsu, Hiroyuki Suto, Yasunari Nakamoto

1748: The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil

1755: Sofosbuvir-Containing Regimens for Chronic Hepatitis C (CHC) Infection: Insights from a Work Productivity Economic Model

Zobair Younossi, Yushan Jiang, Nathaniel Smith, Maria Stepanova, Rachel Beckerman

1756: Cost-effectiveness of the Hepatitis C SelfManagement Program

Erik J. Groessl, Samuel B. Ho, Marisa Sklar, Ted Ganiats

Yan Liu, Xiaodong Li, ShaoJie Xin, Zhihui Xu, Rongjuan Chen, Jing Yang, Li Chen, Vincent W. Wong, Dongliang Yang, Henry LikYuen Chan, Dongping Xu

1757: Estimating the Number of Patients with Chronic Hepatitis C Infection According to Liver Fibrosis Stage in the United States

HCV: Health Economics and Cost Effectiveness

1758: Pre-transplant sofosbuvir and ribavirin for patients with advanced liver disease and chronic hepatitis C awaiting deceased donor liver transplantation: A cost-effectiveness analysis

1749: Projecting the budget impact of interferon (IFN)-free direct-acting antiviral (DAA)-based regimens for hepatitis C treatment in France: a model-based analysis (ANRS 95141)

Sylvie Deuffic-Burban, Dorothee Obach, Valerie Canva-Delcambre, Stanislas Pol, Francoise Roudot-Thoraval, Daniel Dhumeaux, Yazdan Yazdanpanah

1750: Evaluation of the Long-Term Health Outcomes of Ledipasivir/Sofosbuvir (LDV/SOF) and Sofosbuvirbased Regimens for Patients With Chronic Hepatitis C (CHC) And Liver Cirrhosis Across Genotypes 1 to 4 (GT 1-4): Results from a Decision-Analytic Markov Model Stuart C. Gordon, Aijaz Ahmed, Sammy Saab, Zobair Younossi

1751: Evaluation of the Health Outcomes for Ledipasvir/Sofosbuvir in Early vs. Delayed Treatment According to Fibrosis Stage of Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a Decision-Analytic Markov Model

Aijaz Ahmed, Stuart C. Gordon, Sammy Saab, Zobair Younossi

1752: Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits

Natasha K. Martin, Peter Vickerman, Gregory J. Dore, Jason Grebely, Graham R. Foster, Alec Miners, Sharon Hutchinson, David J. Goldberg, Thomas C. Martin

1753: Per-Protocol Subgroup Analysis of Ledipasvir and Sofosbuvir for Chronic HCV in the ION-3 Trial Thomas R. O’Brien, Krystle A. Kuhs, Ruth M. Pfeiffer

Zobair Younossi, Sammy Saab, Aijaz Ahmed, Stuart C. Gordon

Alissa J. Wright, Arthur Y. Kim, Jay A. Fishman, Benjamin P. Linas, Raymond T. Chung

1759: Demographics and Clinical Characteristics Associated with High Healthcare Resource Utilization (HRU) and Costs among Chronic Hepatitis C (CHC) Patients

Joyce LaMori, Neeta Tandon, François Laliberté, Guillaume Germain, D. Pilon, Patrick Lefebvre, Avinash Prabhakar

1760: Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in Poland

Robert Flisiak, Waldemar Halota, Krzysztof Tomasiewicz, Kaja Kostrzewska, Homie Razavi, Erin Gower

1761: Estimating projected costs and quality-adjusted life expectancy associated with daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

Philip McEwan, Thomas Ward, Yong Yuan, Anupama Kalsekar, Isao Kamae, Mariko Kobayashi, Sachie Inoue, Ann C. Tang, Hiromitsu Kumada

1762: Assessing the Health Economic Value of Each Unit of SVR Improvement in HCV Infection

Thomas Ward, Hayley Bennett Wilton, Philip McEwan, Anupama Kalsekar, Yong Yuan

1763: The impact of different strategies to reduce the burden of chronic hepatitis C infection, using new direct acting antivirals in Sweden

Ann-Sofi Duberg, Sarah Blach, Karolin Falconer, Martin Kåberg, Homie Razavi, Soo Aleman

1764: Virologic outcomes, adverse events, and healthcare costs associated with therapy of chronic HCV infection in clinical practice: results from the CMPASS study

Stefan Mauss, Maria Buti, Stephen D. Ryder, Vasily A. Isakov, Raymundo Paraná, Trong Le, Anupama Kalsekar, Gilbert J. L’Italien

Poster Viewing: 8:00 AM – Noon

Presenters in Attendance 10:30 AM – Noon


1754: A Decision- Analytic Markov Model To Evaluate The Health Outcomes of Ledipasvir/Sofosbuvir (LDV/ SOF) for Patients with Chronic Hepatitis C (HCV) Genotype 1 (GT1) Infection

Fujie Xu, Andrew J. Leidner, Xin Tong, Scott D. Holmberg



HEPATOLOGY, October, 2014

Poster Sessions HCV: Virology, Pathogenesis, and Immunology 1765: EFTUD2 alters hepatitis C virus replication by modulating the RIG-I/MDA5 pathway

Chuanlong Zhu, Jian Hong, Dahlene Fusco, Cynthia Brisac, Esperance A. Schaefer, Soung Wong Jeong, Lee F. Peng, Wenyu Lin, Raymond T. Chung

1766: Impaired inhibition of HCV IRES translation by Type I and Type III interferon in human hepatoma cell line with an unfavorable SNP rs12979860 of IL-28B gene

Pauline Ferraris, Partha K. Chandra, Rajesh Panigrahi, Fatma Aboulnasr, Ramazan Kurt, Jean-Michel Pawlotsky, Ludwig Wilkens, Tong Wu, Luis A. Balart, Srikanta Dash

1767: Identification of HCV-specific and non-specific follicular T helper cell signatures during acute and chronic HCV-infection in blood and liver

Bijan Raziorrouh, Kathrin Sacher, Rajeevkumar G. Tawar, Florian Emmerich, Thomas F. Baumert, Robert Thimme, Tobias Boettler

1768: Induction of Obesity-related Gene PLA2G16 in Acute Homologous and Heterologous HCV Infection Associated with Development of Viral Persistence Lucy Golden-Mason, Hugo R. Rosen

1769: Mipomersen, an FDA-approved anti-sense inhibitor of apoB100, has anti-HCV effect in-vitro

Esperance A. Schaefer, James Meixiong, Daniel L. Motola, Dahlene Fusco, Cynthia Brisac, Shadi Salloum, Jay Luther, Wenyu Lin, Mary P. McGowan, Lee F. Peng, Raymond T. Chung

1770: Novel in vitro models for assembly of VLDL and low-density hepatitis C virus particles

Ursula Andreo, Margaret A. Scull, Ype P. De Jong, Vyas Ramanan, Brenna Flatley, Robert E. Schwartz, Shengyong Ng, Alice A. Chen, Edward A. Fisher, Sangeeta Bhatia, Charles M. Rice

1771: HIV and HCV co-operatively increase transcriptional activation in hepatocytes and hepatic stellate cells in a novel live reporter cell co-culture model of infection

Shadi Salloum, Eoin R. Feeney, Rohit Jindal, Shyam Sundhar Bale, Cynthia Brisac, Martin L. Yarmush, Raymond T. Chung

1772: Aminoterminal Amphipathic α-Helix AH1 of HCV NS4B Possesses a Dual Role in RNA Replication and Virus Production


Jerome Gouttenoire, Roland Montserret, David Paul, Simon Meister, Rosa Castillo, Audrey Kennel, Ralf Bartenschlager, Francois Penin, Darius Moradpour

1773: Specific variation of CpG methylation in noncancerous areas of hepatocellular carcinoma after successful hepatitis C virus treatment

Masashi Nishikawa, Masao Honda, Kazunori Kawaguchi, Rika Horii, Tetsuro Shimakami, Kuniaki Arai, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko

Denotes AASLD Presidential Poster of Distinction

1774: TACSTD2 is a Novel HCV Host Cofactor that Regulates Claudin and Occludin Localization and is Downregulated in HCV-Associated Hepatocellular Carcinoma (HCC)

Vandana Sekhar, Marta Melis, Giacomo Diaz, Ronald E. Engle, Juraj Kabat, Ashley B. Tice, Nihal Altan-Bonnet, David E. Kleiner, Paolo Lusso, Suzanne U. Emerson, Fausto Zamboni, Patrizia Farci

1775: Human liver sinusoidal endothelial cell-derived exosomes augment intrinsic anti-viral pathways in HCVinfected hepatocytes: Differential Effects of Type I vs Type III Interferons

Michael Kriss, Silvia Giugliano, Michael Edwards, Evgenia Dobrinskikh, Lucy Golden-Mason, Hugo R. Rosen

1776: Regulation of Hepatitis C Virus Infection by Long Non-Coding RNAs

Tetsuro Shimakami, Masao Honda, Takayoshi Shirasaki, Fanwei Liu, Masaya Funaki, Kazuhisa Murai, Takayuki Shiomoto, Seishi Murakami, Shuichi Kaneko

1777: LECT2 specifically induced by IL28B regulates interferon response and HCV replication

Takayoshi Shirasaki, Masao Honda, Tetsuro Shimakami, Kazuhisa Murai, Takayuki Shiomoto, Hirofumi Misu, Toshinari Takamura, Stanley M. Lemon, Seishi Murakami, Shuichi Kaneko

1778: The Hepatic Group 2 Innate Lymphocyte Cell (ILC2)/IL-33 Axis is Dysregulated in Chronic HCV Infection

Lucy Golden-Mason, Christina Christianson, Linling Cheng, Rafeul Alam, Hugo R. Rosen

1779: Interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C

Jingmin Zhao, Liyuan Wu, Jin Li, Chaonan Guo, Hanwei Li, Wenshu Li, Shuhong Liu, Keming Zhang, Ping Zhao

1780: Hepatitis C Promotes Diabetes by Increasing Hepatic Insulin Resistance and Pancreatic Beta Cell Failure Via Suppression of Betatrophin a Novel Islet Cell Growth Factor

Robert K. Vincent, Sophie C. Cazanave, Hae-Ki Min, Faridoddin Mirshahi, Divya P. Kumar, Amon Asgharpour, Kalyani Daita, Karnam S. Murthy, T. Jake Liang, Arun J. Sanyal

1781: NS3, NS5A and NS5B Coevolution in Patients Experiencing Virological-Failure with First-Generation Protease Inhibitors

Velia Chiara Di Maio, Valeria Cento, Daniele Di Paolo, Francesco De Leonardis, Alessandra F. Manunta, Valeria Micheli, Monica Tontodonati, Ada Bertoli, FrancescoPaolo Antonucci, Lorenzo Nosotti, Carlo F. Magni, Jacopo Vecchiet, Maria Stella Mura, Massimo Andreoni, Filomena Morisco, Martina Spaziante, Nicola Caporaso, Giustino Parruti, Giuliano Rizzardini, Sergio Babudieri, Gloria Taliani, Mario Angelico, Carlo Federico Perno, Francesca Ceccherini-Silberstein




Poster Sessions 1782: HCV Minicores Are Heavily Secreted by Cells in Apolipoprotein Complexes

Ahmed M. Elshamy, Francis J. Eng, Erin H. Doyle, Ursula Andreo, Naga S. Veerapu, Arielle L. Klepper, Anthony S. Muerhoff, Suresh M. Desai, Ronald E. Gordon, Charles M. Rice, Andrea D. Branch

1783: Treatment Response, IFNL3 (IL28B) and IFNL4 Genotype and Hepatic Expression of Interferons and Interferon-Stimulated Genes in Patients with Chronic Hepatitis C

Mazen Noureddin, Yaron Rotman, Emmanuel Thomas, Fang Zhang, Heiyoung Park, Barbara Rehermann, T. Jake Liang

1784: Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV

Paraskevi Mandalou, Rachael Swann, Arvind H. Patel, Matthew E. Cramp

1785: HCV specificity of the activating NK cell receptor KIR2DS2

Sorcha A. Cassidy, Mengya Liu, Mohammed M. Naiyer, Arvind H. Patel, Marco Purbhoo, Salim I. Khakoo

1786: The anti-HCV gene SART1 regulates EIF4G3 and GORASP2 expression through exon splicing

Wenyu Lin, Jian Hong, Chuanlong Zhu, Dahlene Fusco, Esperance A. Schaefer, Cynthia Brisac, Lee F. Peng, Raymond T. Chung

1787: Rapid normalization of proinflammatory cytokine levels during potent antiviral therapy with sofosbuvir plus ribavirin in patients with genotype 2 and 3 HCV infection

David L. Wyles, Luisa M. Stamm, Matthew Paulson, Qinghua Song, Diana M. Brainard, Robert T. Schooley

1788: Transmitted/Founder Hepatitis C Viruses Induce Cell Type- and Genotype-Specific Differences within the Liver

Angela Mitchell, Amy Stone, Linling Cheng, Kimberly Ballinger, Michael Edwards, Mark B. Stoddard, Hui Li, Lucy Golden-Mason, George M. Shaw, Salman Khetani, Hugo R. Rosen

1789: Virology analyses of HCV isolates from genotype 4 patients treated with simeprevir in combination with peginterferon/ribavirin in the Phase III RESTORE study

Bart Fevery, Thierry Verbinnen, Monika Peeters, Mauro Zucchetto, James Witek, Wolfgang Jessner, Sandra De Meyer, Oliver Lenz

1790: Serum Lipid and Sterol Analysis in Hepatitis C (HCV) Genotype 2 and 3 Infections Treated with Sofosbuvir (SOF) and Ribavirin (RBV) Regimens

1791: Different mechanisms mediate insulin and interferon resistance in chronic hepatitis C patients with early and late stage liver fibrosis

Kazuhisa Murai, Masao Honda, Tetsuro Shimakami, Takayoshi Shirasaki, Takayuki Shiomoto, Hirofumi Misu, Toshinari Takamura, Seishi Murakami, Shuichi Kaneko

1792: Behavioral risk changes in young people who inject drugs following rapid HCV testing

Alice K. Asher, Jennifer Evans, Judith A. Hahn, Alya Briceno, Kimberly Page

1793: The HCV NS3/4A protease-helicase binds to high molecular weight telomerase holoenzyme complexes Zhaowen Zhu, M. Meleah Mathahs, Warren N. Schmidt

1794: HCV Protein Expression Induces Activation of the Akt1 Pathway In Hepatocytes, A Possible Trigger for Hepatocarcinogenesis

Mohamed R. Imache, Jacqueline Polyte, Jean-Michel Pawlotsky, Herve Lerat

1795: Cross-reactive and neutralizing E2 antibodies from a spontaneous clearer without Hepatitis C virus reinfection despite prolonged high-risk behavior

Sabrina Merat, Richard Molenkamp, Koen Wagner, Sylvie M. Koekkoek, Dorien van den Berg, Etsuko Yasuda, Bart P. Grady, Maria Prins, Arjen Q. Bakker, Menno D. de Jong, Hergen Spits, Janke Schinkel, Tim Beaumont

1796: Introduction Of a Neutralization Resistant HCV1a Variant among HIV Positive Men Who Have Sex With Men in Amsterdam

Sabrina Merat, Sylvie M. Koekkoek, Xiomara V. Thomas, Jan T. van der Meer, Marc van der Valk, Menno D. de Jong, Hergen Spits, Tim Beaumont, Richard Molenkamp, Janke Schinkel

1797: Expression of tumor suppressor PTPRD is downregulated in HCV-infected primary human hepatocytes and liver tissue of patients with chronic HCV infection

Amina Ababsa, Francois H. Duong, Claire Gondeau, Markus H. Heim, Thomas F. Baumert, Joachim Lupberger

1798: High-Level Resistance to Hepatitis C – A Possible Role for Innate Immunity

Maggie M. Ow, Doha Hegazy, Usama Warshow, Matthew E. Cramp

1799: Apolipoprotein E Functionally Obscures Hepatitis C Virus from Neutralizing Antibodies

Daniel J. Felmlee*, Catherine Fauvelle*, Mathieu Lefèvre, Laura Heydmann, Marie-Sophie Hiet, Isabel Fofana, François Habersetzer, Ross Milne, Arvind H. Patel, Koen Vercauteren, Philip Meuleman, Mirjam B. Zeisel, Ralf Bartenschlager, Catherine Schuster, Thomas F. Baumert

Poster Viewing: 8:00 AM – Noon

Presenters in Attendance 10:30 AM – Noon


Zobair Younossi, Maria Stepanova, Francesco Negro, James M. Estep, Paul J. Clark, Sharon L. Hunt, Lisa E. Kratz, Qinghua Song, Matthew Paulson, Luisa M. Stamm, Diana M. Brainard, Mani Subramanian, John G. McHutchison, Keyur Patel



HEPATOLOGY, October, 2014

Poster Sessions 1800: Expression of IFNλ4 in liver and PBMC is closely associated with higher basal expression of ISGs and impaired induction of IL28B by interferon treatment in chronic hepatitis C non-responder patients

Miyako Murakawa, Yasuhiro Asahina, Mina Nakagawa, Naoya Sakamoto, Sayuri Nitta, Fukiko Kawai-Kitahata, Miki Taniguchi, Takako Watanabe, Yasuhiro Itsui, Sei Kakinuma, Mamoru Watanabe

1801: Serum biomarker profile can predict the outcome of acute HCV infection

Verena Schlaphoff, Katja Deterding, Svenja Hardtke, Julia Hengst, Christine S. Falk, Birgit Bremer, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer

1802: Free apolipoprotein E inhibits HCV replication by inducing an ABCG1-dependent cholesterol efflux

Emilie Crouchet, Mathieu Lefèvre, Eloi R. VERRIER, Thomas F. Baumert, Catherine Schuster

1803: Impaired Insulin-Driven Gluconeogenesis ShutDown By HCV Proteins Through Uncoupling Of Foxo1/ AKT Signaling Leads To a Pre-Diabetic State In HCV Transgenic Mice

Herve Lerat, Jacqueline Polyte, Aurore Gaudin, Mohamed R. Imache, Christophe Magnan, Fabienne Foufelle, Jean-Michel Pawlotsky

1804: Identification of OCIAD1 as Cellular Substrate of the HCV NS3-4A Protease

Huong T.L. Tran, Kenichi Morikawa, Rose Zibi, Viet Loan Dao Thi, Francois Penin, Markus H. Heim, Manfredo Quadroni, Jerome Gouttenoire, Darius Moradpour

1805: Spontaneous HCV clearance in HIV-infected individuals with chronic hepatitis C bearing IL28B-CC alleles on antiretroviral therapy

Laura Benítez-Gutiérrez, Teodoro Martín, Alfonso Ángel-Moreno, María J. Cítores, Francisca Portero Azorin, Valentin Cuervas-Mons, Carmen de Mendoza

1806: A single amino acid substitution in HLA-DQB1 as well as an IFNL4 variant strongly affect susceptibility to chronic hepatitis C


Daiki Miki, Hidenori Ochi, Atsushi Takahashi, C. Nelson Hayes, Yuji Urabe, Hiromi Abe, Atsushi Ono, Sakura Akamatsu, Takashi Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro Uchida, Yohji Honda, Satoshi Yoshimi, Tomoki Kobayashi, Keiichi Masaki, Hiromi Kan, Tomokazu Kawaoka, Masataka Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Shoichi Takahashi, Norio Akuta, Fumitaka Suzuki, Kenji Ikeda, Hiromitsu Kumada, Yoshiyasu Karino, Joji Toyota, Tatsuhiko Tsunoda, Michiaki Kubo, Naoyuki Kamatani, Yusuke Nakamura, Kazuaki Chayama

1807: Replication of HCV RNA Depends on its Degradation by the Cellular RNAses and not on the Translational Efficiency of its Untranslated Regions

Patrice Bruscella, Tony Durand, Michel Ventura, Jean-Michel Pawlotsky, Cyrille Feray

Denotes AASLD Presidential Poster of Distinction

1808: Dynamics of the Virus-specific CD8 T cell Repertoire during HCV Reinfection

Mohamed S. Abdel-Hakeem, Julie Bruneau, Hugo Soudeyns, Naglaa H. Shoukry

1809: NK Cell Function Normalizes after 4 Weeks of IFN-free Therapy of Chronic Hepatitis C

Elisavet Serti, Xenia Chepa-Lotrea, Yun Ju Kim, Nancy Fryzek, T. Jake Liang, Marc G. Ghany, Barbara Rehermann

1810: Persistently infected HCV cell culture impairs RBV antiviral activity through clathrin mediated trafficking of ENT1

Rajesh Panigrahi, Partha K. Chandra, Pauline Ferraris, Ramazan Kurt, Imogen Coe, Tomami Furihata, Robert F. Garry, Tong Wu, Luis A. Balart, Srikanta Dash

1811: Vδ2 γδ T cell functional dichotomy in chronic hepatitis C virus infections Wenwei Yin, Qiongfang Zhang, Hong Ren, Dazhi Zhang

1812: Promoted liver fibrosis in hepatitis C virus transgenic mouse fed an atherogenic high-fat diet is accompanied by abnormal expression of the glycolysisrelated gene pyruvate kinase M2

Riuta Takabatake, Masao Honda, Hikari Okada, Tetsuro Shimakami, Takayoshi Shirasaki, Taro Yamashita, Yoshio Sakai, Takuji Tanaka, Shuichi Kaneko

1813: Involvement of hepatitis C virus infection in the regulation of chemo-sensitivity of hepatocellular carcinoma cells

Takatoshi Nawa, Tomohide Tatsumi, Akira Nishio, Seiichi Tawara, Yoshiki Onishi, Satoshi Aono, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tetsuo Takehara

1814: Chaperone-mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture

Ramazan Kurt, Partha K. Chandra, Fatma Aboulnasr, Rajesh Panigrahi, Pauline Ferraris, Krzysztof Reiss, Tong Wu, Luis A. Balart, Srikanta Dash

1815: Identification of a TSCM phenotype HCV-specific CD8+ T cell response with superior functionality in chronic HCV infection

Bertram Bengsch, Kristin Ladell, Bianca Martin, James E. McLaren, Katja Nitschke, Christoph Neumann-Haefelin, David A. Price, Robert Thimme

1816: Acute Hepatitis C Virus infection Induces Antihost Cell Receptor Antibodies with Virus-neutralizing Properties

Rajeevkumar G. Tawar, Michael Roggendorf, Helga Meisel, Nicolas Meyer, Francois-Loic Cosset, Thomas Berg, Mirjam B. Zeisel, Thomas F. Baumert




Poster Sessions 1817: Genetic polymorphism in interferon-λ4 gene and treatment response to peginterferon and ribavirin in Japanese chronic hepatitis C

Hisayoshi Watanabe, Ri Sho, Takafumi Saito, Kei Mizuno, Tomohiro Katsumi, Chikako Sato, Kazuo Okumoto, Yuko Nishise, Yoshiyuki Ueno

1818: Systematic identification of microRNAs functionally involved in the HCV life cycle

Sophie Pernot, Simonetta Bandiera, Erika Girardi, Amelie Weiss, Sarah Durand, Wolfgang Raffelsberger, Laurent Brino, Sebastien Pfeffer, Thomas F. Baumert, Mirjam B. Zeisel

1819: Elevated hepatic lipid and interferon stimulated gene (ISG) expression in patients infected with hepatitis C virus genotype-3 (HCVGT-3) relative to patients with non-alcoholic steatohepatitis (NASH)

Shikha Shrivastava, Eric G. Meissner, Emily K. Funk, Seerat Poonia, Virendra Shokeen, Arun Thakur, Shyam Kottilil, Shiv K. Sarin, Nirupma Trehanpati

1820: Full Length and Subgenomic HCV Infection, Endosomal TLR Stimulation, and Differentiation Increase Macrophage Immunoregulatory Galectin-9

Noah M. Harwood, Lucy Golden-Mason, Hugo R. Rosen, John A. Mengshol

1821: IFNL4- and IFNL3-associated polymorphisms strongly influence spontaneous expression of IFN-alpha receptor-1 and response to exogenous IFN-alpha in vitro in PBMC from HCV-infected patients

Eleonora Lalle, Licia Bordi, Claudia Caglioti, Anna Rosa Garbuglia, Concetta Castilletti, Gianpiero D’Offizi, Chiara Taibi, Maria R. Capobianchi

1822: Modulation of HCV infection through KHSRPDependent Regulation of miRNA 122 Maturation and Intracellular RNA Degradation Patrice Bruscella, Jean-Michel Pawlotsky, Cyrille Feray

1823: Effect of aging on fibrotic change based on sequential liver biopsy in chronic hepatitis C patient who achieved an SVR Yoshihiko Tachi

1824: NK cell anti-tumor activity was boosted by SAHA identified to induce the expression of a GWASdiscovered HCV-HCC susceptibility gene MICA

Kaku Goto, Ryosuke Muroyama, Wenwen Li, Ryo Nakagawa, Yasuo Matsubara, Naoya Kato

1825: The Scaffold Protein IQGAP2 is Essential for the Innate Control of HCV Infection in Hepatoma Cells

Daiki Miki, Hiromi Abe, C. Nelson Hayes, Hidenori Ochi, Tomokazu Kawaoka, Sakura Akamatsu, Atsushi Ono, Takashi Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro Uchida, Yohji Honda, Keiichi Masaki, Hiromi Kan, Masataka Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Michiaki Kubo, Kazuaki Chayama

1828: Pretreatment induction of ISGs in the presence of IFNL4 in hepatocytes but not in white blood cells is related with poor induction of ISGs following IFN-α therapy

Hiromi Abe, C. Nelson Hayes, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Daiki Miki, Hiroshi Aikata, Hidenori Ochi, Yuji Ishida, Chise Tateno, Katsutoshi Yoshizato, Kazuaki Chayama

1829: Quercetin inhibits both replication and assembly of hepatitis C virus by blocking the viral NS3 and the host diacylglycerol acyltransferase type 1

Angela Rojas, Sophie Clément, Matthieu Lemasson, Jose A. Del Campo, Marta García-Valdecasas, Antonio Gil-Gómez, Isidora Ranchal, Juan Bautista, Arielle R. Rosenberg, Francesco Negro, Manuel Romero-Gomez

1830: Infection and Replication of Hepatitis C Virus in Vero cells Derived from Green Monkey Kidney

Asako Murayama, Nao Sugiyama, Takaji Wakita, Takanobu Kato

1831: Impact of Donor Host Genetics on HCV Viral Evolution After Post Liver Transplantation

Sandra C. Silva Arrieta, Sandra Franco, María-Carlota Londoño, Miguel Angel Martinez, Xavier Forns, Todd M. Allen, Alberto Sanchez-Fueyo, Christian Brander

1832: Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles

Frauke Beilstein, Matthieu Lemasson, Veronique Pene, Arielle R. Rosenberg, Sylvie Demignot

1833: Increased Frequency of CD39+ HCV-Specific CD4 T cells Correlates with Progression to Chronic Hepatitis C

Diana Y. Chen, Brandon Robilotti, Lyndon K. Matsubara, Joelle Brown, Jasneet Aneja, Stephanie Kulaga, Lia Lewis-Ximenez, Eddie A. James, William W. Kwok, Arthur Y. Kim, Georg M. Lauer

1834: Impaired IFN signaling in chronic hepatitis C patients with advanced fibrosis via the TGF-β signaling pathway

Masao Honda, Takayoshi Shirasaki, Tetsuro Shimakami, Kazuhisa Murai, Takayuki Shiomoto, Hikari Okada, Riuta Takabatake, Yoshio Sakai, Taro Yamashita, Stanley M. Lemon, Seishi Murakami, Shuichi Kaneko

1826: Allosteric Heat Shock Protein Inhibitors Block Hepatitis C Virus Assembly

Ronik Khachatoorian, Ekambaram Ganapathy, Vaithilingaraja Arumugaswami, Asim Dasgupta, Samuel W. French Poster Viewing: 8:00 AM – Noon

Presenters in Attendance 10:30 AM – Noon


Cynthia Brisac, Shadi Salloum, Stephane Chevaliez, Eoin R. Feeney, Esperance A. Schaefer, Chuanlong Zhu, Jian Hong, Dahlene Fusco, Lee F. Peng, Wenyu Lin, Raymond T. Chung

1827: The IL28B SNP has a stronger regulatory effect on the expression of OAS1 than a nearby SNP located downstream of OAS1 in chronic HCV patients



HEPATOLOGY, October, 2014

Poster Sessions 1835: Interferon Lambda-4 (IFNL4) TT allele is associated with lower expression of genes associated with early inflammation after initiation of treatment

J. Michael Estep, Kellie Perry, Kameron Tavakolian, Zahra Younoszai, Maria Stepanova, Ali Noorzad, Richard Binder, Zobair Younossi

1836: Hepatitis C Proteins Interact Directly with Early Stage Autophagy Proteins

Ciara Harty, Orla M. Crosbie, Elizabeth Kenny-Walsh, Liam J. Fanning

1837: Cryoglobulins and autoantibodies:Anti-nuclear antibodies detection in cryoprecipitates of an Hepatitis C Virus-positive cohort Gian Ludovico Rapaccini, Umberto Basile, Francesca Gulli, Eleonora Torti, Luigi Colacicco, Paola Cattani

1838: Anti-viral but not anti-fibrotic activity of natural killer cells from HCV patients is significantly reduced by liver normoxic conditions

Franziska Wolter, Andreas Glässner, Benjamin Krämer, Pavlos Kokordelis, Claudia Zwank, Dominik J. Kaczmarek, Christian P. Strassburg, Ulrich Spengler, Jacob Nattermann

1839: Down regulation of hsa-miR146b-5p might affect the immunopathogenesis of chronic hepatitis C patients

Yasuteru Kondo, Masashi Ninomiya, Osamu Kimura, Takayuki Kogure, Yasuhito Tanaka, Yu Nakagome, Tomoaki Iwata, Tatsuki Morosawa, Yasuyuki Fujisaka, Tomoo Kobayashi, Tooru Shimosegawa

1840: Monocytes-derived Galectin-9 induces the cytotoxixcity of NK cells in chronic hepatitis C

Akira Nishio, Tomohide Tatsumi, Takahiro Suda, Atsuo Takigawa, Tadashi Kegasawa, Onishi Yoshiki, Seiichi Tawara, Satoshi Aono, Takatoshi Nawa, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tetsuo Takehara

1841: Characterization of a lymphotropic HCV-J6JFH1 replication in human primary B cells

Masato Nakai, Tsukasa Seya, Misako Matsumoto, Hussein H. Aly, Jun Itoh, Seiji Tsunematsu, Fumiyuki Sato, Yoko Tsukuda, Katsumi Terashita, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto

1842: Impaired expression of Type I and Type II interferon-receptors in HCV infected chronic liver disease and liver cirrhosis


Partha K. Chandra, Feyza Gunduz, Sidhartha Hazari, Ramazan Kurt, Rajesh Panigrahi, Bret Poat, David S. Bruce, Ari J. Cohen, Humberto E. Bohorquez, Ian C. Carmody, George E. Loss, Tong Wu, Luis A. Balart, Srikanta Dash

1843: The CC allele at rs12979860 IL28B is associated with higher hepatic fibrosis in HCV patients with genotype 4

Gamal E. Shiha, Waleed Samir, Seham Seif, Ayman Eldesoky, Reham Soliman

Denotes AASLD Presidential Poster of Distinction

1844: Evidence of CD8+ T cell dysfunction in chronic HCV infection with pronounced impairment of liver cells compared to circulating cells

Stephanie C. Burke, Lorna Carrasco-Medina, Curtis Cooper, Angela M. Crawley

1845: Prevalence of the NS3 protease Q80K naturally occurring variant in Hepatitis C patients in Denmark Anja Ernst, Henrik Krarup

1846: NKG2D Expression on Natural Killer T Cells, but not NK Cells, Predicts Viral Response to DAA/ PEG-IFN/ RBV Therapy in Chronic Hepatitis C

Po-sung Chu, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Shingo Usui, Hidetsugu Saito, Takanori Kanai

1847: Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment

Umberto Basile, Laura Gragnani, Francesca Gulli, Alessia Piluso, Cristina Stasi, Maria Teresa Dell’Abate, Eleonora Torti, Monica Monti, Gian Ludovico Rapaccini, Anna Linda Zignego

1848: Emergence or selection of resistant associated variant immediately after initiation of the therapy is predictive for failure of direct acting antiviral therapy: ultra-deep sequencing analyses for serial time points

Takako Watanabe, Yasuhiro Asahina, Mina Nakagawa, Sei Kakinuma, Yasuhiro Itsui, Miki Taniguchi, Miyako Murakawa, Hiroko Nagata, Mika Miura, Shinya Maekawa, Nobuyuki Enomoto, Mamoru Watanabe

1849: Aldo-keto reductase family 1 member B10 expression predicts the risk of hepatocellular carcinoma development in chronic hepatitis C patients who achieved sustained virological response to interferonbased anti-viral therapy

Ayato Murata, Takuya Genda, Takafumi Ichida, Shunsuke Sato, Hironori Tsuzura, Yutaka Narita, Yoshio Kanemitsu, Sachiko Ishikawa, Tetsu Kikuchi, Masashi Mori, Katsuharu Hirano, Katsuyori Iijima, Ryo Wada, Sumio Watanabe

1850: Markers of Intestinal Enterocyte Injury and Systemic Inflammation in HIV, HCV & HIV/HCV co-infection

Alysse G. Wurcel, Paula Grasberger, Jessica K. Paulus, Gina Masse, Christine Wanke, Tamsin A. Knox

Hepatitis B Therapy 1851: Tenofovir Disoproxil: Effective and Safe in Prevention of Mother-to-child Transmission of Hepatitis B Virus Hongfei Huang, Quanxin Wu, Yuming Wang

1852: Incidence of Hepatocellular Carcinoma (HCC) in non-cirrhotic chronic hepatitis B (CHB) patients with low ALT levels in a multicenter US Cohort

Joseph K. Hoang, Nghia H. Nguyen, Derek Lin, Vinh D. Vu, Huy N. Trinh, Jiayi Li, Jian Q. Zhang, Huy A. Nguyen, Khanh Nguyen, Mindie H. Nguyen




Poster Sessions 1853: Risk and Prediction of Hepatitis B Reactivation in Inactive Carriers Receiving Pre-emptive Antiviral Therapy During Cancer Chemotherapy

1861: Evidence for Ongoing Low-level Viremia in Patients with Chronic Hepatitis B Receiving Long-term Nucleos(t)ide Analog Therapy

Jonggi Choi, Jihyun An, Ju Hyun Shim, Hyung-Don Kim, Yeon-Jung Ha, Mi-Jung Jun, Young Joo Yang, Seung Bum Lee, Gi Ae Kim, Jee Eun Yang, Eui Ju Park, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh

Patrick Marcellin, Edward J. Gane, Robert Flisiak, Michael P. Manns, Kelly D. Kaita, Anuj Gaggar, Lanjia Lin, Kathryn M. Kitrinos, John F. Flaherty, Mani Subramanian, John G. McHutchison, Harry L. Janssen, Maria Buti

1854: Efficacy of Entecavir versus Lamivudine for Antiviral Prophylaxis in Hepatitis B Patients Receiving Cancer Chemotherapy

1862: Clinical outcomes of tenofovir disoproxil fumarate (TDF) treatment versus no treatment for pregnant women with active chronic hepatitis B (CHB) and elevated alanine aminotransaminase (ALT)

Jonggi Choi, Jihyun An, Ju Hyun Shim, Hyung-Don Kim, Yeon-Jung Ha, Mi-Jung Jun, Young Joo Yang, Seung Bum Lee, Gi Ae Kim, Jee Eun Yang, Eui Ju Park, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh

1855: Profound Reduction of HBV Covalently Closed Circular DNA with Long-term Nucleoside/tide Analogue Therapy

Ching-Lung Lai, Danny Wong, Philip Ip, Malgorzata Kopaniszen, Wai-Kay Seto, James Fung, Fung-Yu Huang, Brian P. Lee, Giuseppe Cullaro, Chi Hang Wu, Charles Cheng, Chi Hang J. Yuen, Vincent Ngai, Man-Fung Yuen

1856: Long-term Nucleos(t)ide Analogue Consolidation Therapy Reduces Risk of Relapse in Chronic Hepatitis B

Heng Chi, Bettina E. Hansen, Pauline Arends, Mahmoud AbuAmara, Colina Yim, Jordan J. Feld, Robert J. de Knegt, David K. Wong, Harry L. Janssen

1857: ALN-HBV, a GalNAc-siRNA Enhanced Stabilization Chemistry RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection

Laura Sepp-Lorenzino, Marc Abrams, Leon Carayannopoulos, Martin Koser, Steve Ludmerer, Klaus B. Charisse, Daniel Freedman, Vasant Jadhav, Kallanthottathil G. Rajeev, Greg Hinkle, Satya Kuchimanchi, Martin A. Maier, Muthiah Manoharan, Rachel Meyers, Stuart Milstein, Andrew G. Sprague

1858: On-treatment alpha-fetoprotein levels have a strong association with hepatocellular carcinoma development among chronic hepatitis B patients receiving entecavir

Ryoko Yamada, Naoki Hiramatsu, Yuki Tahata, Naoki Morishita, Naoki Harada, Tsugiko Oze, Takayuki Yakushijin, Sadaharu Iio, Yoshinori Doi, Eiji Mita, Masahide Oshita, Toshifumi Ito, Taizo Hijioka, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara

1859: Risk of Hepatocellular Carcinoma Among Treated Patients With Chronic Hepatitis B vs Chronic Hepatitis C Gi-Ae Kim, Seungbong Han, Jihyun An, Young-Suk Lim

Christopher Koh, Cihan Yurdaydin, Stewart Cooper, David Cory, Harel Dahari, Vanessa Haynes-Williams, Mark A. Winters, Matthew Bys, Ingrid C. Choong, Ramazan Idilman, Onur Keskin, Laetitia Canini, Peter Pinto, Erin F. Wolff, Rachel Bishop, David E. Kleiner, Jay H. Hoofnagle, Jeffrey Glenn, Theo Heller Poster Viewing: 8:00 AM – Noon

1863: HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg negative CHB patients on Nucleos(t) ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings

Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrié, Lawrence Serfaty, Patrick Marcellin, Noelle Pouget, Dominique Guyader, Christophe Hezode, Magali Picon, Xavier Causse, Vincent Leroy, Jean-Pierre Bronowicki, Ghassan Riachi, Isabelle Rosa, Pierre Attali, Jean-Michel Molina, Yannick Bacq, Albert Tran, Jean Didier Grange, Fabien Zoulim, Hélène Fontaine, Inga Bertucci, Magali Bouvier-Alias, Fabrice Carrat, Yves Benhamou

1864: Efficacy and Safety of Telbivudine in Preventing Mother-to-infant HBV Transmission in HBV-infected Pregnant Women in Immune Tolerant Phase

Qiuju Sheng, Yang Ding, Han Bai, Jingyan Wang, Chong Zhang, Lianrong Zhao, Xiaoguang Dou

1865: Entecavir Plus Tenofovir Combination Therapy in Patients with Multi-drug Resistant Chronic Hepatitis B: The 48-Week Results of A Multicenter, Prospective Study Jun Yong Park, Chang Wook Kim, Si Hyun Bae, Sang Hoon Ahn

1866: Entecavir reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Tetsuya Yasunaka, Fusao Ikeda, Akinobu Takaki, Tomonori Seno, Koichi Takaguchi, Kazuhide Yamamoto

1867: Altered underlying tubular function in HBV monoinfected patients receiving nucleos(t)ide analogs in a real-world setting: MENTE Study

Sonia Rodriguez Novoa, Javier García-Samaniego, Martin Prieto, Jose Luis Calleja, Juan Manuel Pascasio, Manuel B. Delgado, Javier Crespo, Maria Buti, Lucía Bonet, Juan I. Arenas, Conrado M. Fernandez Rodriguez, Ricard Sola, Enrique Fraga Rivas, Luisa González-Diéguez, Óscar Núñez, Manuel Praga, Javier del Pino, Manuel Romero-Gómez, Rosa María Morillas, Moisés Diago, Angeles Castro

1868: Hepatitis B Core Related Antigen Levels Are Associated With Response To ETV and PEG-IFN Treatment In HBeAg-Positive Chronic Hepatitis B Patients

Willem Pieter Brouwer, Milan J. Sonneveld, Qing Xie, Qing Zhang, Fehmi Tabak, Adrian Streinu-cercel, Jiyao Wang, Gertine van Oord, Thomas Vanwolleghem, Suzan D. Pas, Robert J. de Knegt, Andre Boonstra, Bettina E. Hansen, Harry L. Janssen Presenters in Attendance 10:30 AM – Noon


1860: Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans

Wei Yi, Calvin Q. Pan, Min Liu, Haodong Cai



HEPATOLOGY, October, 2014

Poster Sessions 1869: IFNL4 polymorphisms predict sustained response and HBsAg clearance in interferon treated HBeAg negative chronic hepatitis B patients

Enrico Galmozzi, Pietro Lampertico, Floriana Facchetti, Federica Invernizzi, Giampaolo Mangia, Mauro Viganò, Roberta Soffredini, Massimo Colombo

1870: Incidence of Hepatocellular Carcinoma in a National Cohort of Chronic Hepatitis B Patients on Long Term Entecavir Treatment- the ENUMERATE study

Joseph Ahn, Joseph K. Lim, Hannah Lee, Calvin Q. Pan, Mindie H. Nguyen, Huy N. Trinh, Tram T. Tran, Danny Chu, Albert Min, Son T. Do, Jocelyn Woog, Ajitha Mannalithara, Anna S. Lok, W. Ray Kim

1871: Entecavir Safety and Effectiveness in a National Cohort of Chronic Hepatitis B Patients in the United States - the ENUMERATE study

Joseph Ahn, Hannah Lee, Joseph K. Lim, Calvin Q. Pan, Mindie H. Nguyen, W. Ray Kim, Huy N. Trinh, Tram T. Tran, Danny Chu, Albert Min, Son T. Do, Jocelyn Woog, Ajitha Mannalithara, Anna S. Lok

1872: Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis

Chien-Hung Chen, Chuan-Mo Lee, Tsung-Hui Hu, Chao-Hung Hung, JIng-Houng Wang, Sheng-Nan Lu

1877: Entecavir Improves Liver Function and Fibrosis in Patients with Hepatitis B Virus-associated Liver Cirrhosis: A 2 Years-Multicenter Study

Seung Kak Shin, Oh Sang Kwon, Jong Eun Yeon, Jeong Han Kim, So Young Kwon, Sang Jun Suh, Yun Soo Kim, Ju Hyun Kim

1878: Efficacy and safety of telbivudine versus tenofovir treatment based on the Roadmap concept: Results from a randomized, controlled trial in HBeAg-negative chronic hepatitis B patients

Zahary Krastev, Iskren A. Kotzev, Mustafa K. Celen, David Mc Neeley, Kamal A. Hamed

1879: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA and Antigen Levels in Primary Human Hepatocytes

Congrong Niu, Stephane Daffis, Mei Yu, Guofeng Cheng, William E. Delaney, Simon P. Fletcher

Pauline Arends, Heng Chi, Ivana Carey, Ashley S. Brown, Massimo Fasano, David J. Mutimer, Katja Deterding, Ye H. Oo, Joerg Petersen, Florian van Bömmel, Robert J. de Knegt, Jurrien G. Reijnders, Thomas Berg, Tania M. Welzel, Stefan Zeuzem, Teresa Santantonio, Heiner Wedemeyer, Maria Buti, Pierre Pradat, Fabien Zoulim, Bettina E. Hansen, Harry L. Janssen

1880: Tenofovir Mono-rescue therapy vs. Tenofovir plus Entecavir combination-rescue therapy in chronic hepatitis B with lamivudine and entecavir resistance: a Korean multi-center study

1873: The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B is Associated with an Intrahepatic Cytotoxic T Cell Transcriptional Signature

1881: Increased HBsAg Decline in Sustained Responders After Discontinuation of Long-term Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B

Li Li, Peng Yue, Robert E. Lanford, Stephan Menne, Congrong Niu, Stephane Daffis, Daniel Tumas, Abigail Fosdick, William E. Delaney, Simon P. Fletcher

1874: Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy

Grazia A. Niro, Antonina Smedile, Rosanna Fontana, Antonella Olivero, Alessia Ciancio, Fabrizia Pittalunga, Nicola Coppola, Heiner Wedemeyer, Kalliopi Zachou, Aldo Marrone, Massimo Fasano, Teresa Santantonio, Giuseppe Lotti, Angelo Andriulli, Mario Rizzetto

1875: Decline in Quantitative Serum HBsAg Level during Consolidation Therapy Following HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir TUESDAY NOVEMBER 11

1876: The role of hepatitis B surface antigen quantification predict HBV reactivation after discontinuation of nucleos(t)ide analogs treatment in chronic hepatitis B patients with cirrhosis

Wen-Pang Su, Cheng-Yuan Peng, Hsueh-Chou Lai, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen

Sangheun Lee, Jun Yong Park, Hana Park, Moon Young Kim, Sang Hoon Ahn, Pumsoo Kim, Kwang-Hyub Han

Heng Chi, Bettina E. Hansen, Mahmoud Abu-Amara, Colina Yim, Pauline Arends, Jordan J. Feld, Annemiek A. van der Eijk, Robert J. de Knegt, David K. Wong, Harry L. Janssen

1882: Addition of Peginterferon Alfa-2b During Longterm Nucleos(t)ide Analogue Therapy Increases HBeAg Seroconversion and HBsAg Decline – Week 48 Results From a Multicenter Randomized Controlled Trial (PEGON Study)

Heng Chi, Qing Xie, Ning-Ping Zhang, Xun Qi, Chen Liang, Simin Guo, Qing Guo, Pauline Arends, Ji-yao Wang, Elke Verhey, Robert J. de Knegt, Bettina E. Hansen, Harry L. Janssen

1883: Response-guided therapy to peginterferon in chronic hepatitis B using on-treatment HBsAg quantification: a meta-analysis

Hong Peng, Fang Wei, Junying Liu, Huaidong Hu, Peng Hu, Hong Ren

1884: Prospective Observational Cohort Study For The Durability Of Oral Antiviral Treatment In Patients With Chronic Hepatitis B: Quit Study

Jun Yong Park, Kyu sik Chung, Young Eun Chon, Hyon Suk Kim, Wonseok Kang, Seung Up Kim, Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 1885: A baseline predictive tool for selecting HBeAgnegative chronic hepatitis B patients who have a high probability of achieving sustained immune control with peginterferon alfa-2a

Pietro Lampertico, Vivien Rothe, Antonietta Caputo, George V. Papatheodoridis

1886: A predictive tool for selecting HBeAg-positive chronic hepatitis B patients who have a high probability of HBV DNA suppression and HBeAg seroconversion with peginterferon alfa-2a

Henry Lik-Yuen Chan, George V. Papatheodoridis, Diethelm Messinger, George Bakalos, Pietro Lampertico

1887: Randomized Controlled Trial of Switching to Tenofovir Disoproxil Fumarate Monotherapy in Lamivudine-Resistant Chronic Hepatitis B Patients with Undetectable HBV Viral Load under Lamivudine/Adefovir Add-on Therapy: The First Interim Analysis

Yi-Hsiang Huang, Chien-Wei Su, Yuan-Jen Wang, Yi-Shin Huang, Kuei-Chuan Lee, Ming-Chih Hou, Han-Chieh Lin

1888: 24 Weeks Of Peg-Ifn Is As Good As 48 Weeks In Hbeag-Positive Genotype B Patients With An Early Hbsag Response

Milan J. Sonneveld, Henry Lik-Yuen Chan, Teerha Piratvisuth, Jidong Jia, Vincent W. Wong, Edward J. Gane, Bettina E. Hansen, Yun -Fan Liaw, Harry L. Janssen

1889: The Pattern and Predictors of Serum HBsAg Decline in Chronic Hepatitis B Patients Receiving Up to Five Years of Entecavir Therapy

Hsueh-Chou Lai, Cheng-Yuan Peng, Wen- Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen

1890: Interferon-inducible protein 10 (IP10) serum levels predict the decline of HBsAg serum levels in HBeAg-negative chronic hepatitis B (CHBe-) patients treated with tenofovir disoproxil fumarate (TDF)

George V. Papatheodoridis, Christos K. Triantos, Emilia Hadziyannis, Konstantinos Zisimopoulos, Anastasia Georgiou, Theodoros Voulgaris, Jiannis Vlachogiannakos, Vasiliki Nikolopoulou, Spilios Manolakopoulos

1891: Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon Gui-Qiang Wang, FengQin Hou, NingShao Xia

1892: Anti-HBV effectiveness and mechanisms of Chinese herbal extract-Suduxing

Weiming Yao, Yan Liu, Zhihui Xu, Lanlan Si, Penggao Li, Lvping Bo, Jinchu Lan, Dongping Xu

Rachel Wen-Juei Jeng, Yi-Cheng Chen, Ming-Ling Chang, Yun -Fan Liaw

Poster Viewing: 8:00 AM – Noon

Naoto Kawabe, Keisuke Osakabe, Senju Hashimoto, Michihito Murao, Yoshifumi Nitta, Takuji Nakano, Hiroaki Shimazaki, Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Takagawa Yuka, Takamitsu Kurashita, Emi Matsuo, Tomoki Takamura, Aiko Fukui, Toru Nishikawa, Naohiro Ichino, Kentaro Yoshioka

1895: Durability of HBeAg Seroconversion of Telbivudine as Monotherapy and as Combination Therapy with Adefovir Dipivoxil for Chronic Hepatitis B Patients with High ALT Level: A Prospective, Multicenter, Cohort Study

Yang Ding, Chong Zhang, Qiuju Sheng, Mingxiang Zhang, Feng Wu, Baojun Song, Weili Zhu, Jingyan Wang, Lilan Shi, Xiaoguang Dou

1896: Tenofovir versus Entecarvir in Antiviral-Naïve Chronic Hepatitis B Patients: Preliminary 48-Week Results

Young Joo Yang, Ju Hyun Shim, Hyung-Don Kim, Yeonjung Ha, Mi-Jung Jun, Seung Bum Lee, Jee Eun Yang, Gi-Ae Kim, Eui Ju Park, Jihyun An, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh

1897: Tenofoivr treatment in chronic hepatitis B patients with suboptimal response to adefovir with prior lamivudine resistance

Joohan Park, Hyo Jung Cho, Sun Young Park, Seon Joo Ahn, Soon Sun Kim, Jae Youn Cheong, Sung Won Cho

1898: A prospective, open-label cohort study comparing the efficacy, safety and drug resistance of entecavir monotherapy versus de novo combination of lamivudine and adefovir dipivoxil in naïve HBeAgpositive chronic hepatitis B patients with high HBV viral load (The Climber Study): a preliminary analysis

Wei Guo, Di Wu, Peng Wang, Jing-Feng Chen, Yan-hong Xu, Weiming Yan, Ke Ma, Meifang Han, Jianxin Song, Junying Qi, Jiaquan Huang, Yuancheng Huang, Xiping Zhao, Dong Xu, Qin Ning

1899: Tenofovir Montherapy in Chronic Hepatitis B Patients with Genotypic Resistance to Previous Antiviral Therapy - a Cohort Study

Jihyun An, Young-Suk Lim, Gi Ae Kim, Hyung-Don Kim, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Young-Hwa Chung, Danbi Lee, Yung Sang Lee, Dong Jin Suh

1900: Outcome of chronic hepatitis B patients who discontinued nucleos(t)ide analogue therapy Suna Yapali, Kelly Oberhelman, Anna S. Lok

1901: Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains

Yun Bin Lee, Jeong-Hoon Lee, Dong Hyeon Lee, Hyeki Cho, Hongkeun Ahn, Won-Mook Choi, Young Youn Cho, Minjong Lee, Jeong-Ju Yoo, Yuri Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Chung Yong Kim, Hyo-Suk Lee Presenters in Attendance 10:30 AM – Noon


1893: Higher AFP during hepatitis B flare is associated with greater reduction in HBsAg during Nuc therapy

1894: Effect of antiviral treatment on liver stiffness and its correlation to hepatocarcinogenesis in chronic hepatitis B



HEPATOLOGY, October, 2014

Poster Sessions 1902: Nucleoside Drug Resistance and Potential HBV Vaccine-Escape Mutation Caused by Telbivudine Treatment in a Chronic Hepatitis B Patient

Senol Comoglu, Ayten Kadanali, Behiye Dede, Gul Karagoz, Kevser K. Tatar, Murat Sayan, Nur B. Ozdemir, Zeynep S. Çakar

1903: Entecavir plus adefovir or entecavir plus tenofovir for patients with chronic hepatitis B resistant to neucleot(s)ide analogues

Jung Gil Park, Young Oh Kweon, Won Young Tak, Se Young Jang, Su Hyun Lee, Soo Young Park

1904: Estimating The Probability Of Response To Peginterferon Alfa In Hbeag-Positive Chronic Hepatitis B: The Epic-B Predictor

Milan J. Sonneveld, Vincent W. Wong, Jun Cheng, Teerha Piratvisuth, Jidong Jia, Stefan Zeuzem, Edward J. Gane, Yun -Fan Liaw, Willem Pieter Brouwer, Qing Xie, Jinlin Hou, Henry Lik-Yuen Chan, Harry L. Janssen, Bettina E. Hansen

1905: Excellent Theraputic Response to Tenofovir Dipivoxil Fumarate (TDF) in Chronic Hepatitis B Pregnant Women with Resistance to Prior Anti-viral Therapy

Hua Zhang, Calvin Q. Pan, Xin Liu, Qian Bian, Qiumei Pang, Yun X. Zhu, Qing Liu, Ruihua Tian

1906: Tenofovir versus entecavir in the treatment of chronic hepatitis B with severe acute exacerbation

Chao-Hung Hung, Chien-Hung Chen, Sheng-Nan Lu, Tsung-Hui Hu, JIng-Houng Wang, Chuan-Mo Lee

1907: Combination with Nucleoside Analogues was not Superior to Tenofovir Monotherapy in Patients with Drug-resistant Chronic Hepatitis B

Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon

1908: Tenofovir-Induced Fanconi Syndrome In Chronic Hepatitis B Monoinfected Patients Successfully Rescued By Entecavir

Mauro Viganò, Alessandra Brocchieri, Angiola Spinetti, Serena Zaltron, Giampaolo Mangia, Floriana Facchetti, Alessandro Fugazza, Francesco Castelli, Massimo Colombo, Pietro Lampertico

1909: A Comparison of the Efficacy and Safety of Entecavir Versus Lamivudine Through 240 Weeks of Treatment in Korean Patients with HBeAg-negative Chronic Hepatitis B


Kwan Sik Lee, Young-Oh Kweon, Soon Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon Ju Lee, Dong Joon Kim, Tae Hun Kim, Young Sok Lee, Kwan Soo Byun, DaeGhon Kim, Myung Seok Lee, Cyril Llamoso, Kyungha Yu, Dong Jin Suh

Denotes AASLD Presidential Poster of Distinction

1910: Does interferon treatment reduce hepatocellular carcinoma incidence in HBeAg positive chronic hepatitis B patients?

Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Taito Fukushima, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada

1911: Association between Genotype and the HBsAg Levels at HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir or Peginterferon Alfa-2a

Cheng-Yuan Peng, Hsueh-Chou Lai, Wen- Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen

1912: Durability of HBeAg Seroconversion After Treatment with Entecavir or Tenofovir in Chronic Hepatitis B Patients

Tse-Ling Fong, Edward A. Mena, Andy S. Yu, Quang-Quoc Phan, Steven-Huy B. Han, Andy Tien, Andrew J. Velasco, Vinh-Huy Leduc, Myron J. Tong

1913: Nucleoside Analogues treatment in Patients with Acute and Subacute liver failure related to hepatitis B virus

Bing Zhu, Shaoli You, HongLing Liu, Yihui Rong, Hong Zang, ZhiHong Wan, ShaoJie Xin

1914: Durability of Nucleos(t)ide Analogues Treatment in Patients with Chronic Hepatitis B: The Role of APASL Guideline

Yi-Hsiang Huang, I-Cheng Lee, Cheuk-Kay Sun, Chien-Wei Su, Yuan-Jen Wang, Han-Chieh Lin

1915: Suppression of Hepatitis B Virus Replication by Dandelion extracts and Traxasterol in Vitro

Ying Yang, Feng Chen, Jihua Xue, Jing Wang, Chaochao Qin, Yu Shi, Weixia Liu, Zhi Chen

1916: The estimated glomerular filtration rate changes in chronic hepatitis B patients during nucleos(t)ide analogues treatment

Yi-Cheng Chen, Rachel Wen-Juei Jeng, Wei Teng, Chao-Wei Hsu, Chun-Yen Lin, I-Shyan Sheen, Rong-Nan Chien, Yun -Fan Liaw

1917: Efficacy and Safety of Telbivudine in Chinese Children and Adolescents with Chronic Hepatitis B

Hongfei Zhang, Shishu Zhu, Yi Dong, Limin Wang, Zhiqiang Xu, Dawei Chen, Yu Gan, Fuchuan Wang

1918: Similar Renal Function Profile in Chronic Hepatitis B (CHB) Patients Treated with Tenofovir (TDF) vs. Entecavir (ETV) Monotherapy – A Multicenter Matched Case Cohort Study

Nghi B. Ha, Kevin Ku, Nghiem B. Ha, Kevin T. Chaung, Huy N. Trinh, Mindie H. Nguyen




Poster Sessions 1919: Effect of achieving drug-free status and HBs antigen decline in sequential therapy with Peg-IFN alfa2a on long-term nucleoside analog treated patients

Ken Nishino, Miwa Kawanaka, Jun Nakamura, Takahito Oka, Noriyo Urata, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro Yamada

1920: Entecavir monotherapy vs. lamivudine-adefovir combination therapy for chronic hepatitis B infection: a 5-year randomized controlled trial

Guan Huei Lee, Wah Wah Phyo, Yock Young Dan, Yin-Mei Lee, How Cheng Low, Kieron B. Lim, Maung Aye Thwin, Poh Seng Tan, Seng Gee Lim

1921: Long-term Follow-up and Treatment Rates of Treatment-Eligible Chronic Hepatitis B (CHB) Patients: A Multicenter Cohort Study

Vinh D. Vu, Ailinh Do, Nghia H. Nguyen, Lily H. Kim, Huy N. Trinh, Huy A. Nguyen, Khanh Nguyen, Mindie H. Nguyen

1922: 2-years impact of entecavir (ETV) on liver fibrosis and activity as assessed by FibroTest – ActiTest and Liver Stiffness Measurement (LSM) in chronic hepatitis B (CHB) patients

Fabien Zoulim, Xavier Causse, Vincent Leroy, Denis Ouzan, Nathalie Ganne-Carrié, Valerie Bourcier, Victor de Ledinghen, Philippe Mathurin, Marika Rudler, Joseph Moussalli, Dominique Thabut, Luminita Bonyhay, Vlad Ratziu, Fabienne Drane, Yen Ngo, Mona Munteanu, Thierry Poynard

1923: Efficacy of tenofovir disoproxil fumarate in chronic hepatitis B patients with genotypic resistances to other nucleos(t)ide analogues

Tae Jung Yun, Soon Ho Um, Chang Ho Jung, Tae Hyung Kim, Seok Bae Yoon, Sun Young Yim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu

1924: Factors relevant to relapse in chronic hepatitis B patients after off-therapy of telbivudine and lamivudine: focused on long-term durability

Hong-Ying Pan, Hong-Yi Pan, Li Chen, DanHong Yang, HaiJun Huang, YongXi Tong, Cui-Rong Chen, XingJiang Jian

1925: Course of partial virological response to entecavir under long-term entecavir therapy in ptatients with chronic hepatitis B

Joohan Park, Hyo Jung Cho, Sun Young Park, Seon Joo Ahn, Soon Sun Kim, Jae Youn Cheong, Sung Won Cho

Hepatitis C: New Agents (Not Approved) 1926: Baseline and Post-baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBV

Christoph Sarrazin, Hadas Dvory-Sobol, Evguenia S. Svarovskaia, Brian Doehle, Joseph F. McCarville, Phillip S. Pang, Nezam H. Afdhal, Kris V. Kowdley, Edward J. Gane, Eric Lawitz, John G. McHutchison, Michael D. Miller, Hongmei Mo

1927: CPI-431-32, a Novel Cyclophilin A Inhibitor, Simultaneously Blocks Replication of HCV and HIV-1 Viruses in a Novel in Vitro Co-Infection Model

Philippe Gallay, Michael Bobardt, Dan Trepanier, Daren Ure, Cosme Ordonez, Robert T. Foster

1928: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results

Stanislas Pol, K. Rajender Reddy, Tolga Baykal, Christophe Hezode, Tarek Hassanein, Patrick Marcellin, Marina Berenguer, Katarzyna M. Fleischer-Stepniewska, Coleen Hall, Christine Collins, Regis A. Vilchez

1929: 100% SVR4 in Japanese Patients with Chronic Genotype 1 Hepatitis C Virus Infection Receiving Ledipasvir/Sofosbuvir Fixed Dose Combination for 12 Weeks: Results from a Multicenter Phase 3 Study

Masashi Mizokami, Tetsuo Takehara, Osamu Yokosuka, Naoya Sakamoto, Masaaki Korenaga, Hitoshi Mochizuki, Kunio Nakane, Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusao Ikeda, Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatsuya Ide, Nobuo Toda, Kazushige Nirei, Yoshiyuki Ueno, Yoichi Nishigaki, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote, Phillip S. Pang, Steven J. Knox, William T. Symonds, John G. McHutchison, Namiki Izumi, Masao Omata

1930: Alisporivir Selectively Eliminates HCV-Created Double Membrane Vesicles by Disrupting CypA-NS5A interactions in Infected Hepatocytes

Udayan Chatterji, Michael Bobardt, Malcolm Wood, Philippe Gallay

1931: SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/ Ombitasvir and Dasabuvir With or Without Ribavirin

Massimo Colombo, Ola Weiland, Daniel E. Cohen, Jean-Francois J. DuFour, Hendrik Reynaert, Moises Diago, Erica Villa, Adrian Streinu-Cercel, Wangang Xie, Tolga Baykal, Jeffrey Enejosa, Eoin Coakley, Roger Trinh, Thomas Podsadecki

Tania M. Welzel, Eva Herrmann, Patrick Marcellin, Nezam H. Afdhal, Kris V. Kowdley, Luisa M. Stamm, Yanni Zhu, Phillip S. Pang, John G. McHutchison, Stefan Zeuzem

Poster Viewing: 8:00 AM – Noon

Presenters in Attendance 10:30 AM – Noon


1932: On Treatment HCV RNA as a Predictor of Virologic Response in the Ledipasvir/Sofosbuvir Phase 3 Program for HCV Genotype 1 Infection: Analysis of the ION-1, ION-2, and ION-3 Studies



HEPATOLOGY, October, 2014

Poster Sessions 1933: PEARL-IV Trial: Subgroup Analysis of Genotype 1a-Infected Patients Treated With ABT-450/r/ Ombitasvir With Dasabuvir With or Without Ribavirin

David Eric Bernstein, Yan Luo, Jacob P. Lalezari, David L. Wyles, William King, Naoky Tsai, Mitchell N. Davis, Thomas E. Sepe, Jeffrey Fessel, Martin King, Thomas Podsadecki, Curtis Cooper

1934: SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/ Ombitasvir and Dasabuvir With or Without Ribavirin

Ira M. Jacobson, Jean-Francois J. DuFour, Jeffrey Enejosa, Robert J. de Knegt, Peter Ferenci, Hendrik Reynaert, Adrian M. Di Bisceglie, Lois Larsen, Tolga Baykal, Lino Rodrigues-Jr, Thomas Podsadecki, Donald M. Jensen, Fred Poordad

1935: Early Improvement in the HepQuant® (HQ)SHUNT Function Test during Treatment with Ledipasvir/ Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation

Jacqueline G. O’Leary, James R. Burton, Steve M. Helmke, Andrea Herman, Michael W. Cookson, Shannon Lauriski, James F. Trotter, Jill M. Denning, Phillip S. Pang, John G. McHutchison, Gregory T. Everson

1936: Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials

Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Michelle Irvin, Wangang Xie, Lois Larsen, Thomas Podsadecki, Tami Pilot-Matias, Christine Collins

1937: All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Study

Kazuaki Chayama, Fumitaka Suzuki, Yoshiyuki Suzuki, Joji Toyota, Yoshiyasu Karino, Yoshiiku Kawakami, Shigetoshi Fujiyama, Takayoshi Ito, Yoshito Itoh, Etsuko Tamura, Tomoko Ueki, Hiroki Ishikawa, Misti Linaberry, Eric A. Hughes, Hiromitsu Kumada

1938: ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials

Massimo Puoti, Curtis Cooper, Mark S. Sulkowski, Graham R. Foster, Thomas Berg, Erica Villa, Federico Rodriguez-Perez, Vinod Rustgi, David L. Wyles, Martin King, Barbara H. McGovern, Heiner Wedemeyer

1939: TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Coinfected Patients Treated with ABT-450/r/Ombitasvir, Dasabuvir and Ribavirin

David L. Wyles, Mark S. Sulkowski, Joseph J. Eron, Roger Trinh, Jay Lalezari, Jihad Slim, Joseph C. Gathe, Chia C. Wang, Richard Elion, Fritz Bredeek, Robert O. Brennan, Gary Blick, Amit Khatri, Krystal Gibbons, Yiran Hu, Linda Fredrick, Tami Pilot-Matias, Barbara Da Silva-Tillmann, Barbara H. McGovern, Andrew L. Campbell, Thomas Podsadecki

1940: Pharmacokinetics of Co-Administered HCV Protease Inhibitor MK-5172 and NS5A Inhibitor MK-8742 in Volunteers with End-Stage Renal Disease on Hemodialysis or Severe Renal Impairment Not on Hemodialysis

Wendy W. Yeh, Luzelena Caro, Zifang Guo, Hwa Ping Feng, Henry U. Davis, Megan Kozisek, Daria Stypinski, Chun Feng, Carrie Mitchell, Anne Gillespie, Nita Ichhpurani, William L. Marshall, Kenneth C. Lasseter, Thomas C. Marbury, Joan R. Butterton

1941: HELIX-2, A Phase II Study of Samatasvir in Combination with Simeprevir, Low Dose Ritonavirboosted TMC647055 + Ribavirin in Treatment-naïve or Interferon/ribavirin Treated, Relapsed Genotype 1 HCVinfected Subjects

Eric Lawitz, Maribel Rodriguez-Torres, Tuan T. Nguyen, Aasim M. Sheikh, Hillel Tobias, Joseph S. Galati, John M. Hill, Anna S. Lok, David R. Nelson, Gloria Dubuc Patrick, Jie Chen, Dodie Frank, Xiao-Jian Zhou, John Sullivan-Bolyai, Leen Vijgen, Pieter Van Remoortere, René Verloes, Gaston Picchio, Douglas L. Mayers

1942: Resistance Analysis of Treatment-Naïve HCV Genotype 1-6 Infected Patients Treated with Sofosbuvir in Combination with GS-5816 for 12 Weeks

Brian Doehle, Viktoria Gontcharova, Ramakrishna K. Chodavarapu, John McNally, Raymond T. Chung, Gregory T. Everson, John G. McHutchison, Michael D. Miller, Hongmei Mo

1943: Daclatasvir in combination with asunaprevir and BMS-791325 for prior null responders with chronic HCV genotype 1 infection

Gregory T. Everson, Karen D. Sims, Paul J. Thuluvath, Howard Schwartz, Tarek Hassanein, Eric Lawitz, Lynn R. Webster, Norbert Brau, Taddese Desta, Joseph S. Galati, Reem H. Ghalib, Norman Gitlin, Steven-Huy Han, Federico Hinestrosa, Maribel RodriguezTorres, Ronald Nahass, Peter J. Ruane, Wen-Lin Luo, Fiona McPhee, David F. Gardiner

1944: Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials


Saleh Alqahtani, Nezam H. Afdhal, Stefan Zeuzem, Stuart C. Gordon, Alessandra Mangia, Paul Y. Kwo, Jenny C. Yang, Xiao Ding, Phillip S. Pang, John G. McHutchison, Patrick Marcellin, Kris V. Kowdley, Mark S. Sulkowski

Denotes AASLD Presidential Poster of Distinction




Poster Sessions 1945: Virologic Response Rates to All Oral FixedDose Combination Ledipasvir/Sofosbuvir Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors in Phase 3 Clinical Trials

Ira M. Jacobson, Paul Y. Kwo, Kris V. Kowdley, Jenny C. Yang, Yanni Zhu, Robert H. Hyland, Phillip S. Pang, John G. McHutchison, Mark S. Sulkowski, Nezam H. Afdhal

1946: A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 with High Barriers to Resistance

Teresa Ng, Tami Pilot-Matias, Liangjun Lu, Thomas Reisch, Tanya Dekhtyar, Preethi Krishnan, Jill Beyer, Rakesh Tripathi, Ron B. Pithawalla, Armen Asatryan, Andrew L. Campbell, Jens Kort, Christine Collins

1947: Concordance between SVR4, SVR12 and SVR24 in Genotype 1 HCV-Infected Patients who Received All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin in Phase 3 Clinical Trials

David Eric Bernstein, Alessandra Mangia, Norbert Brau, Jenny C. Yang, Julie Ma, Robert H. Hyland, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Michael W. Fried

1948: High Rates of SVR in Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/Sofosbuvir+Ribavirin or Ledipasvir/ Sofosbuvir+GS-9669 for 8 weeks

Eric Lawitz, Fred Poordad, Robert H. Hyland, Jing Wang, Phillip S. Pang, William T. Symonds, John G. McHutchison, Fernando E. Membreno

1949: Evaluation of the Resistance Profile of Ledipasvir (LDV), a Nonstructural Protein 5A (NS5A) Inhibitor, in Genotype (GT) 1 Chronically Infected HCV Subjects Treated with LDV-Containing Regimens without Sofosbuvir (SOF)

Kathryn M. Kitrinos, David L. Wyles, Hadas Dvory-Sobol, Angela Worth, Bin Han, Diana M. Brainard, Bittoo Kanwar, Michael D. Miller, Hongmei Mo

1950: Time to Viral Suppression is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin

Mark S. Sulkowski, Michael W. Fried, Resat Ozaras, Vasily Isakov, David L. Wyles, Peter Ferenci, Jordan J. Feld, Filipe Calinas, Michael Gschwantler, Martin King, Tolga Baykal, Edward J. Gane

1951: Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and Phase 3 Trials

Poster Viewing: 8:00 AM – Noon

Erik Mogalian, Anita Mathias, Jenny C. Yang, Phillip S. Pang, Lisa Moorehead, Maria G. Hernandez, Kenneth C. Lasseter, Daniel Ries, Richard A. Robson, Gernot Klein

1953: Adherence to Prescribed Doses of ABT-450/r/ Ombitasvir, Dasabuvir, and Ribavirin in the Phase 3 PEARL-II, PEARL-III, and PEARL-IV Trials

David Eric Bernstein, Rui T. Marinho, Daniel E. Cohen, Fritz Bredeek, Ferenc Schneider, Gunnar P. Norkrans, Manuela G. Curescu, Michael Bennett, Marina Maevskaya, Jeffrey Fessel, Wangang Xie, Yan Luo, Jeffrey Enejosa

1954: Identification and treatment of multiple subtypes of HCV genotype 4 in the PEARL-I study with ombitasvir and ABT-450/r ± ribavirin

Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Preethi Krishnan, Tolga Baykal, Coleen Hall, Regis A. Vilchez, Tami PilotMatias, Christine Collins

1955: Safety and efficacy outcomes of all-oral daclatasvir-containing regimens in patients with or without cirrhosis in phase 2 and 3 studies

Donald M. Jensen, Ira M. Jacobson, Hiromitsu Kumada, Joji Toyota, Mark S. Sulkowski, Michael P. Manns, Jia-Horng Kao, Jeong Heo, Philip Yin, Patricia Mendez, Eric A. Hughes, Stephanie Noviello

1956: Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection

Eric Lawitz, William D. O’Riordan, Bradley L. Freilich, Terry D. Box, J. Scott Overcash, Wei Liu, Andrew L. Campbell, Chih-Wei Lin, Armen Asatryan, Jens Kort

1957: Pharmacokinetics of Cyclosporine and Tacrolimus, Following Coadministration with the Direct Acting Antiviral Combination, ABT-450/r, Ombitasvir and Dasabuvir, in Liver Transplant Patients with Genotype-1 HCV Infection

Prajakta Badri, Apurvasena Parikh, Eoin Coakley, Bifeng Ding, Walid Awni, Sandeep Dutta, Rajeev Menon

1958: No Differences in the Efficacy of Fixed-Dose Combination Ledipasvir/Sofosbuvir in Patients According to Fibrosis Stage Determined by Liver Biopsy or Laboratory Biomarker in Phase 3 Clinical Trials

Stuart C. Gordon, Michael W. Fried, Paul Y. Kwo, Jenny C. Yang, Yanni Zhu, Robert H. Hyland, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Patrick Marcellin


Michael W. Fried, Adrian M. Di Bisceglie, John M. Vierling, Edward J. Gane, Frederik Nevens, Simone I. Strasser, Ola Weiland, Sorin Rugina, Sandra S. Lovell, Barbara Da SilvaTillmann, Nancy Shulman, Naoky Tsai, David R. Nelson

1952: The Pharmacokinetics of Ledipasvir, an HCV Specific NS5A Inhibitor, in HCV-Uninfected Subjects with Severe Renal Impairment

Presenters in Attendance 10:30 AM – Noon



HEPATOLOGY, October, 2014

Poster Sessions 1959: HCVerso1: A phase III study of faldaprevir (FDV) plus deleobuvir (DBV) and ribavirin (RBV) for chronic HCV genotype (GT)-1b infection in treatment-naïve patients

Christoph Sarrazin, Francesco Castelli, Massimo Puoti, Mitchell L. Shiffman, Liliana Preotescu, Xavier Forns, Maria Buti, Eric M. Yoshida, Marc Bourlière, Célia Oliveira, Jerry O. Stern, Wulf O. Boecher, George Kukolj, Carla Haefner, Richard Vinisko, Miguel Garcia, Federico J. Mensa

1960: Deep Sequencing Analysis Of Variants Resistant To Ns5a Inhibitors In Patients With Genotype 1b Hepatitis C Virus Infection

Shinya Maekawa, Mika Miura, Mitsuaki Sato, Nobutoshi Komatsu, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto, Nobuyuki Enomoto

1961: Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From PEARL II, PEARL III, and PEARL IV

Jacob P. Lalezari, Ronald Pruitt, Yan Luo, Richard J. Aspinall, Giovanni B. Gaeta, Iwona Olszok, William King, Selim Gurel, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Nancy Shulman, Velimir A. Luketic

1962: TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After Treatment With ABT450/r/Ombitasvir and Dasabuvir With Ribavirin in HCV Genotype 1-Infected Patients with Cirrhosis

Mitchell L. Shiffman, Kris V. Kowdley, Stefan Zeuzem, David J. Mutimer, Marc Bourlière, Thomas Berg, Samuel S. Lee, Sandra S. Lovell, Leticia Canizaro, Roger Trinh, Guy Neff, Paul Y. Kwo

1963: Impaired Early Viral Kinetics in Patients with Cirrhosis treated with Interferon-free Regimens - The Impact of Portal Pressure

Mattias Mandorfer, Karin Kozbial, Albert Stättermayer, Sandra Beinhardt, Philipp Schwabl, Remy Schwarzer, Michael Trauner, Arnulf Ferlitsch, Harald Hofer, Markus Peck-Radosavljevic, Peter Ferenci

1964: Resistance Analysis of Hepatitis C Virus (HCV) from Genotype 1 and 4 Treatment-naïve Subjects Receiving Samatasvir in Combination with Simeprevir and Ribavirin in a 12-week Phase II Clinical Trial

Bianca Heinrich, John P. Bilello, Eric Lawitz, Maribel RodriguezTorres, Tuan T. Nguyen, Aasim M. Sheikh, Hillel Tobias, Joseph S. Galati, John M. Hill, Anna S. Lok, David R. Nelson, Leen Vijgen, Pieter Van Remoortere, René Verloes, Gaston Picchio, Gloria Dubuc Patrick, Maria Seifer, Douglas L. Mayers


1965: Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies

K. Rajender Reddy, Stanislas Pol, Paul J. Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James M. Levin, Eric Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R. Brunetto, Cheng-Yuan Peng, Ruben Terg, Marcelo O. Silva, Simone I. Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Misti Linaberry, Eric A. Hughes, Stephanie Noviello

Denotes AASLD Presidential Poster of Distinction

1966: HCVerso2: A phase III study of faldaprevir (FDV) plus deleobuvir (DBV) and ribavirin (RBV) for chronic HCV genotype (GT)-1b infection in treatmentnaïve patients including those ineligible for pegylated interferon (PegIFN)

David R. Nelson, Pietro Andreone, Massimo Colombo, Filipe Calinas, Antonio Olveira, Jean Delwaide, Dieter Häussinger, Denis Ouzan, Simone I. Strasser, Tarik Asselah, Curtis Cooper, Jerry O. Stern, Wulf O. Boecher, George Kukolj, Stella Aslanyan, Qiqi Deng, Edward Wang, Federico J. Mensa

1967: Pharmacokinetics of asunaprevir, daclatasvir and raltegravir in HCV/HIV co infected patients, with or without cirrhosis, and previously null responders to pegylated interferon + ribavirin (ANRS HC30 QUADRIH study)

Anne-Marie Taburet, Lionel Piroth, Hubert Paniez, Mélanie Simony, Valerie Furlan, Aurélie Barrail-Tran, Corine Vincent, Eric Rosenthal, Eric Billaud, Hugues Aumaître, François Bailly, Martine Resch, Laurence Meyer, Jean-Michel Molina

1968: Efficacy by Race or Geographic Region in HCV Genotype 1-infected Patients Treated with ABT-450/ ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin

John M. Vierling, Massimo Puoti, David Eric Bernstein, Naoky Tsai, Ola Weiland, Manuel Romero Gómez, Florin A. Caruntu, JeanFrancois J. DuFour, Filipe Calinas, Lois Larsen, Fernando Tatsch, Pietro Andreone

1969: Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients ≥65 Years of Age: Results From Phase 2 and 3 Trials

Steven L. Flamm, Edward J. Gane, Jean-Francois J. DuFour, Vinod Rustgi, Vincent G. Bain, Darrell H. Crawford, Pietro Andreone, Tarek Hassanein, Wlodzimierz W. Mazur, Sandra S. Lovell, Barbara Da Silva-Tillmann, Nancy Shulman, Massimo Puoti, Terry D. Box, Ira M. Jacobson

1970: Ledipasvir/Sofosbuvir is Safe and Effective in Nosocomially Infected Patients with Advanced Age and Significant Cardiac Co-Morbidities

Raymond T. Chung, Georg M. Lauer, Luisa M. Stamm, Lin Liu, Hongmei Mo, Phillip S. Pang, Diana M. Brainard, John G. McHutchison, Arthur Y. Kim

1971: Durability of Sustained Virologic Response in Hepatitis C Infected Patients Treated with IFN-Free DAA Regimens

Sara Jones, Miriam Marti, Zayani Sims, Anita Kohli, Sarah Kattakuzhy, Tess L. Petersen, Rachel Silk, Michael A. Polis, Henry Masur, Shyam Kottilil, Anu Osinusi




Poster Sessions 1972: ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials

David R. Nelson, K. Rajender Reddy, Adrian M. Di Bisceglie, Peter Ferenci, Darrell H. Crawford, Rudolf E. Stauber, Alexey A. Yakovlev, Victor de Ledinghen, Holger Hinrichsen, David Eric Bernstein, Robert J. de Knegt, Tarek Hassanein, Suzanne Norris, Junyuan J. Xiong, Barbara H. McGovern, Kosh Agarwal

1973: Characteristics of HCV-Infected Patients with Cirrhosis Requiring Ribavirin Dose Reduction During Treatment with Direct-Acting Antivirals

Ira M. Jacobson, Xavier Forns, Stefan Zeuzem, Christophe Hezode, Mitchell L. Shiffman, Stanislas Pol, Marina Berenguer, Michael W. Fried, Kosh Agarwal, Kris V. Kowdley, Sandra S. Lovell, Manal Abunimeh, Roger Trinh, Barbara H. McGovern, Antonio Craxi

Hepatitis C: Preclinical Development 1974: A Phase I/IIa Study Assessing 7-day Dosing of IDX21437 in Subjects Infected with Hepatitis C Virus (HCV)

Edward J. Gane, Eric Sicard, Serghei Popa, Xiao-Jian Zhou, MarieFrancoise Temam, Jie Chen, Dodie Frank, Eileen F. Donovan, Keith Pietropaolo, Douglas L. Mayers

1975: A 4-N-Hydroxycytidine Ribonucleoside Phosphoramidate Delivers Intracellularly Three Distinct Active 5’-Triphosphate Nucleosides that are Potent Inhibitors of HCV Polymerase

Raymond F. Schinazi, Franck Amblard, Sijia Tao, Maryam Ehteshami, Sheida Amiralaei, Hao Li, Jadd Shelton, Tony Whitaker, Tami R. McBrayer, Steven J. Coats

1976: Drug-Drug Interaction Profile Of The FixedDose Combination Tablet Ledipasvir/Sofosbuvir

Polina German, Phillip S. Pang, Liang Fang, Diana Chung, Anita Mathias

1977: Hepatocellular carcinoma development of hepatitis C virus patients with eradication to interferon therapy: a large scale, long-term study of 2266 patients

Yuko Nagaoki, Hiroshi Aikata, Tomoki Kobayashi, Takayuki Fukuhara, Noriaki Naeshiro, Daisuke Miyaki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki Chayama

1978: ACH-3422, A Novel HCV NS5B RNA Polymerase Nucleotide Inhibitor, Demonstrates Improved Potency Over Sofosbuvir Against HCV Genotype-3 Replicons In Vitro

1979: MK-8408, A Potent and Selective NS5A Inhibitor with a High Genetic Barrier to Resistance and Activity Against HCV Genotypes 1-6

Ernest Asante-Appiah, Rong Liu, Stephanie Curry, Patricia McMonagle, Sony Agrawal, Donna Carr, Laura Rokosz, Frederick Lahser, Karin Bystol, Robert Chase, Stuart Black, Eric B. Ferrari, Paul Ingravallo, Shiying Chen, Ling Tong, Wensheng Yu, Joseph Kozlowski

1980: First Time in Human (FTIH) and Proof of Concept (POC) Studies of GSK2878175 (GSK175), a Potent PanGenotypic Non-Nucleoside NS5B Polymerase Inhibitor of HCV Replication

Stephen D. Gardner, Joseph Kim, Benjamin Van Hecke, Maribel Rodriguez-Torres, Lucinda Elko-Simms, Sharon Baptiste-Brown, Vincent Lopez, Etienne F. Dumont, Robert Hamatake, Kevin Gan, Z. Joe Zhu, Martin Leivers, Melanie T. Paff, Zhi Hong

1981: Modeling HCVcc infection reveals new insights into the dynamics that maintain the in vitro HCV steady state and the mechanisms of action of the NS5A inhibitor daclatasvir

Natasha Sansone, Harel Dahari, Gitanjali Subramanya, Alan S. Perelson, Susan L. Uprichard

1982: A Novel Approach to HCV Resistance Selection Featuring Short Treatment Duration and Reduced Interference from Host Cell Adaptation

Joanne L. Fabrycki, Yongsen Zhao, Dharaben Patel, Lingling Jia, Guangwei Yang, Steven Podos, Avinash Phadke, Mingjun Huang, Wengang Yang

1983: Preclinical Characterization of AL-516, a Potent Guanosine Based Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Hua Tan, Kenneth Shaw, Andreas Jekle, Jerome Deval, Zhinan Jin, Amy Fung, Yuen Tam, Lawrence M. Blatt, Sushmita M. Chanda, Qingling Zhang, Guangyi Wang, Natalia Dyatkina, Julian A. Symons, Leo Beigelman, David B. Smith

1984: Prevention of HCV virologic breakthrough during protease inhibitor monotherapy by addition of an SR-BI targeting monoclonal antibody

Koen Vercauteren, Ahmed A. Mesalam, Richard Brown, Fulvia Troise, Juliane Doerrbecker, Naomi Van Den Eede, Ali Farhoudi, Riccardo Cortese, Geert Leroux-Roels, Thomas Pietschmann, Alfredo Nicosia, Philip Meuleman

1985: Antiviral Activity and Resistance Emergence: Combinations of the NS5B Nucleotide Inhibitor ACH3422 with Other Antiviral Agents in Vitro

Dharaben Patel, Yongsen Zhao, Joanne L. Fabrycki, Guangwei Yang, Steven Podos, Jason Wiles, Avinash Phadke, Mingjun Huang, Wengang Yang

Poster Viewing: 8:00 AM – Noon


Yongsen Zhao, Steven Podos, Joanne L. Fabrycki, Dharaben Patel, Wengang Yang, Guangwei Yang, Jason Wiles, Avinash Phadke, Mingjun Huang

Presenters in Attendance 10:30 AM – Noon



HEPATOLOGY, October, 2014

Poster Sessions 1986: Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3 day Monotherapy in HCV Genotype-1 Infected Subjects with or without Compensated Cirrhosis

Chih-Wei Lin, Wei Liu, Armen Asatryan, Andrew L. Campbell, Sandeep Dutta

1987: Pharmacokinetics and Drug-Drug Interaction between Samatasvir, an NS5A Inhibitor, and Co-administered Simeprevir, an NS3/4A Protease Inhibitor, and Low Dose Ritonavir-Boosted TMC647055, a Non-Nucleoside NS5B Inhibitor, in Healthy Volunteers and HCV-Infected Subjects

Xiao-Jian Zhou, Keith Pietropaolo, Dodie Frank, Jie Chen, Rolf van Heeswijk, John Sullivan-Bolyai, Pieter Van Remoortere, René Verloes, Douglas L. Mayers

Ying-Huey Huang, Chih-Ming Chen, Hung-Ming Hsu, Chu-Chung Lin, Chi-Hsin R. King, Ming-Chu Hsu

1995: HCV kinetics in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

Swati DebRoy, Nobuhiko Hiraga, Michio Imamura, Laetitia Canini, Ralf T. Pohl, Stefano Persiani, Susan L. Uprichard, Alan S. Perelson, Chise Tateno, Kazuaki Chayama, Harel Dahari

1996: The Antiviral Profile of TG-2349, a novel HCV Protease Inhibitor with Pan-Genotypic Activity

Chih-Ming Chen, Yi-Fen Chen, Chu-Chung Lin, Chi-Hsin R. King, Ming-Chu Hsu

1988: The Combination of MK-5172, an NS3 inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes

1997: IDX21459, a Uridine Nucleotide Prodrug, Shows a Favorable Preclinical Profile as a Direct-acting Antiviral Agent (DAA) against HCV

Frederick Lahser, Karin Bystol, Stephanie Curry, Patricia McMonagle, Rong Liu, Ellen Xia, Robert Chase, Stuart Black, Eric B. Ferrari, Ling Tong, Wensheng Yu, Joseph Kozlowski, Ernest Asante-Appiah

Christopher D. Chapron, Kusum S. Gupta, Massimiliano La Colla, Brenda Hernandez-Santiago, Maria Seifer, Hassan Rashidzadeh, Ilaria Serra, Shouqi Luo, Xin-Ru Pan-Zhou, Christopher Brynczka, Bianca Heinrich, Jinsoo Lim, Francois-Rene Alexandre, Roger Rush

1989: AL-335, a Novel Potent anti-HCV Nucleotide Analog, Demonstrates Synergistic Activity when Given in Combination with other anti-HCV DAAs in a Subgenomic Replicon System

1998: Lack of Clinically Relevant Pharmacokinetic Drug-Drug Interaction between Norgestimate/Ethinyl Estradiol and Pangenotypic HCV NS5A Inhibitor GS-5816 in HCV-Uninfected Female Subjects

Hua Tan, Kenneth Shaw, Natalia Dyatkina, Guangyi Wang, Leo Beigelman, David B. Smith, Lawrence M. Blatt, Julian A. Symons

Erik Mogalian, Diana M. Brainard, John McNally, Gong Shen, Jennifer Cuvin, Anita Mathias

1990: Plasma microRNA-122 levels decrease significantly in chronic hepatitis C patients treated with miravirsen

Portal Hypertension - Experimental

1991: HCV Nucleoside Inhibitors can Exhibit Genotype Specific Differences in Activity

Guillermo Fernández-Varo, Denise Oró, Edward Cable, Kazimierz Wisniewski, Pere Gines, Wladimiro Jiménez

Meike van der Ree, Adriaan J. van der Meer, Adrianus C. van Nuenen, Soren Ottosen, Amy Patick, Harry L. Janssen, Neeltje A. Kootstra, Hendrik W. Reesink

Elizabeth D. Anton, Kristi Strommen, Wei Huang, Amber A. Rivera, Christos J. Petropoulos, Franck Amblard, Raymond F. Schinazi, Jacqueline D. Reeves

1992: Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide genemodified lymphocytes: an in vitro proof-of-concept

Céline Leboeuf, Joelle Roser-Schilder, Mélanie Lambotin, Sarah Durand, Tao Wu, Marina Deschamps, Christophe Ferrand, Pierre Tiberghien, Patrick Pessaux, Thomas F. Baumert, Eric Robinet


1994: Evaluation of TG-2349, a novel HCV Protease Inhibitor with Pan-Genotypic Activity, in Replicon-Mouse Models with Luciferase Reporter

1993: Comparison of Three 2’-C-Methyl Guanosine Prodrugs for Hepatitis C including a Novel β-D-2’-C-Me2,6-Diaminopurine Ribonucleoside Phosphoramidate (RS-1389): Interspecies Hepatocyte and Human Cardiomyocyte Metabolism Profiles

Sijia Tao, Zhou Longhu, Hongwang Zhang, Shaoman Zhou, Sheida Amiralaei, Jadd Shelton, Steven J. Coats, Raymond F. Schinazi

Denotes AASLD Presidential Poster of Distinction

1999: Partial Vasopressin 1α (V1α) Receptor Agonism Reduces Portal Hypertension And Hyperaldosteronism Thereby Inducing A Powerful Diuretic And Natriuretic Effect In Cirrhotic Rats With Ascites

2000: Changes in cardiac output, pulmonary dynamics and incidence of volume overload in Cirrhotics receiving 20% Albumin infusion

Saggere M. Shasthry, Manoj Kumar, Jelen K. Singh, Shiv K. Sarin

2001: Sarcopenia of cirrhosis is mediated by hyperammonemia-mediated transcriptional upregulation of myostatin due to impaired β-catenin signaling

Michela Giusto, Gangarao Davuluri, Samjhana Thapaliya, Uyen Tran, Oliver Wessely, Sathyamangla V. Naga Prasad, Srinivasan Dasarathy

2002: Hemodynamic effects of the oral non peptide compound AVE0991

Sabine Klein, Chandana B. Herath, Frank E. Uschner, Josephine A. Grace, Robert Schierwagen, Christian P. Strassburg, Tilman Sauerbruch, Peter W. Angus, Jonel Trebicka




Poster Sessions 2003: Cerium Oxide Nanoparticles Reduce Portal Hypertension and Show Antiinflammatory Properties in CCl4-Treated Rats

Denise Oró, Guillermo Fernández-Varo, Vedrana Reichenbach, Tetyana Yudina, Eudald Casals, Gregori Casals, Bernadino Gonzalez de la Presa, Víctor Puntes, Wladimiro Jiménez

2004: A Large Animal Model of Portal Hypertension and Cirrhosis in the FAH-Deficient Pig

Shennen A. Mao, Jaime Glorioso, Raymond D. Hickey, Meng Yin, Joseph Lillegard, James E. Fisher, Ronald J. Marler, Markus Grompe, Scott L. Nyberg

2005: NCX-6560, a nitric oxide-donating atorvastatin, lowers portal pressure and has a better hepatic toxicity profile than atorvastatin in cirrhotic rats

Sarai Rodríguez, Imma Raurell, Rafael Esteban, Joan Genescà, María Martell

2006: The Beneficial Effects of P2X7 Antagonism on Hepatic Fibrogenesis and Portal-Systemic Collaterals in Rats with Bile Duct Ligation Hung-Chun Tung, Teh-Ia Huo, Fa-Yauh Lee, Hui-Chun Huang

2007: In Cirrhosis, Calcium Desensitization Underlies Reduced Myogenic Tone in Small Resistance Mesenteric Arteries Ravirajsinh Jadeja, Sandeep Khurana

2008: Obliterative Portal Venopathy in subjects without portal hypertension: an unknown planet

Maria Guido, Samantha Sarcognato, Aurelio Sonzogni, Marco Senzolo, Marco Pizzi, Stefano Fagiuoli, Maria Grazia Lucà, Luciano Giacomelli, Guido Colloredo

2009: Hedgehog-signaling and angiogenesis in cirrhotic and non-cirrhotic portal hypertension

Frank E. Uschner, Ganesh Ranabhat, Michaela Granzow, Steve S. Choi, Sabine Klein, Robert Schierwagen, Esther Raskopf, Christian P. Strassburg, Kanishka Hiththetiya, Tilman Sauerbruch, Anna Mae Diehl, Jonel Trebicka

2010: Sarcopenia in alcoholic liver disease accompanied by increased malondialdehyde-aldehyde adducts and oxidative stress

Samjhana Thapaliya, Gangarao Davuluri, Megan R. McMullen, Laura E. Nagy, Geoffrey M. Thiele, Sathyamangla V. Naga Prasad, Srinivasan Dasarathy

2011: Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy in the hepatic venous pressure gradient response and propranolol dose reduction–A Pilot study

Poster Viewing: 8:00 AM – Noon

Nobuhisa Akamatsu, Yasuhiko Sugawara, Taku Aoki, Tomohiro Tanaka, Sumihito Tamura, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Junichi Kaneko, Norihiro Kokudo

2013: MicroRNA-128 is a Key Regulator of Hepatic Dimethylarginine Dimethylaminohydrolase-1 (DDAH-1) in a Rodent Model of Cirrhosis and Portal Hypertension

Gautam Mehta, Helen Jones, Vikram Sharma, Nathan Davies, Rajiv Jalan, Rajeshwar Mookerjee

2014: Fibroblastic reticular cells are the major contributors to splenomegaly and spleen stiffness in portal hypertension Chao Dong, Teruo Utsumi, Li Gong, Yasuko Iwakiri

2015: Systems Biology Analysis of Omeprazole Therapy in Cirrhosis Demonstrates Significant Shifts in Gut Microbiota Composition and Function Jasmohan S. Bajaj, I. J. Cox, Naga Betrapally, Douglas M. Heuman, Mitchell L. Schubert, Roger Williams, Melanie White, Nicole Noble, Masoumeh Sikaroodi, Simon D. Taylor-Robinson, Patrick M. Gillevet

2016: Oxidative stress plays an important role in pathogenesis of hyperdynamic circulation in portal hypertensive rats Hongqun Liu, Noura Alhassan, Samuel S. Lee

2017: Blood brain barrier permeability is increased in hepatic encephalopathy related to cirrhosis, through a hyperammonemia-dependent mechanism

Sarah Mouri, Haquima El Mourabit, Colette Rey, Romain Morichon, Dominique Wendum, Elisabeth Lasnier, Chantal Housset, Nicolas Weiss, Dominique Thabut

2018: Prognostic Significance of the Hemodynamic and Clinical Staging in the Prediction of Mortality in Patients with Chronic Liver Disease

Sang Hyun Park, Ki Tae Suk, Eun Jin Kim, Hyo Sun Kim, Chang Seok Bang, Hyoung Su Kim, Ji Won Park, Sung Eun Kim, Myoung Kuk Jang, Choong Kee Park, Myung Seok Lee, Sang Hoon Park, Dong Joon Kim

2019: Acute effect of Udenafil on portal pressure in cirrhotic rats

Frank E. Uschner, Sabine Klein, Robert Schierwagen, Bernhard Tewes, Christian P. Strassburg, Wolfgang Kreisel, Tilman Sauerbruch, Jonel Trebicka

2020: Probiotic prevents the development of Portal hypertension in a rabbit endotoxin induced portal hypertension model Nidhi Chaudhary, Rashmi Babbar, Shiv K. Sarin

Presenters in Attendance 10:30 AM – Noon


Youn zoo Cho, Moon Young Kim, Soon Koo Baik, Sang Ok Kwon, Dong Joon Kim, Ki Tae Suk, Gab Jin Cheon, Young Don Kim, Dae Hee Choi

2012: Hemodynamic changes in hepatic circulation and hepatic arterial buffer response after modulation of splenic circulation in an in-vivo human experimental model



HEPATOLOGY, October, 2014

Poster Sessions 2021: Bone Marrow Predicts Liver Regenerative Response To Growth Factors In Decompensated Cirrhosis

Lovkesh Anand, Avinash Kumar, Chhagan Bihari, Chandan K. Kedarisetty, Anupam Kumar, Sheetalnath Rooge, Rakhi Maiwall, Shiv K. Sarin

2022: Outcomes in Orthotopic Liver Transplantation; Rotational Thromboelastrography (ROTEM) versus Standard of Care: a Retrospective Study

Christopher M. Esber, Loren Brook, Nicole O’Bleness, A. James Hanje

Stem Cell Biology 2023: DNMT1 is essential for postnatal liver development

Kosuke Kaji, Valentina M. Factor, Jesper B. Andersen, Nikolay Korokhov, Marian E. Durkin, Elizabeth A. Conner, Snorri S. Thorgeirsson

2024: Matrix Metalloproteinase-14 regulates the maturation of fetal hepatic stem/progenitor cells in mice

Satoshi Otani, Sei Kakinuma, Akihide Kamiya, Fumio Goto, Shun Kaneko, Seishin Azuma, Yasuhiro Asahina, Mamoru Watanabe

2025: Targeting CD133(+) cancer stem cells by inhibiting glycolytic metabolism through miR-122

Kyoungsub Song, Hyunjoo Kwon, Chang Han, Srikanta Dash, Tong Wu

2026: Identification of a novel Wnt-responsive hepatocyte stem cell population in the normal liver Bruce M. Wang, Roel Nusse

2027: Long-term engineered cultures of iPSC-derived human hepatocytes for disease modeling and drug screening

Salman Khetani, Dustin Berger, Brenton R. Ware, Matthew Davidson

2028: Recapitulation of Human Hepato-Biliary Organogenesis in Self-assembled Liver Organoid Culture

Dipen Vyas, Pedro M. Baptista, Emma Moran, Shay Soker

2029: Generation of human hepatocyte-like cells from urine


Vanessa Sauer, Xia Wang, Krisztina Tar, Tatyana Tchaikowskaya, Yanfeng Li, Chandan Guha, Namita Roy-Chowdhury, Jayanta RoyChowdhury

2030: Human pluripotent stem cell derived hepatocytelike cells integrated in microfluidic platform for drug screening applications

Giovanni G. Giobbe, Federica Michielin, Alessandro Zambon, Stefano Giulitti, Camilla Luni, Nicola Elvassore, Annarosa Floreani

Denotes AASLD Presidential Poster of Distinction

2031: TSG-6 is involved in repair response in carbon tetrachloride-induced acute liver injury in mice Sihyung Wang, Jieun Kim, Jeongeun Hyun, Youngmi Jung

2032: Characterization and expansion mechanisms of human iPS cell-derived hepatic progenitor-like cells

Kota Tsuruya, Akihide Kamiya, Hiromi Chikada, Kazuya Anzai, Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Tetsuya Mine

2033: A Comprehensive Analysis of Gene Mutations in Liver Cancer Stem Cells

Takehiro Hayashi, Taro Yamashita, Tsuyoshi Suda, Tomomi Hashiba, Yoshirou Asahina, Mariko Yoshida, Tomoyuki Hayashi, Yoshimoto Nomura, Yasumasa Hara, Kouki Nio, Naoki Oishi, Hajime Sunagozaka, Hajime Takatori, Masao Honda, Shuichi Kaneko

2034: Human biliary tree stem cells are efficiently reprogrammed to functional β-pancreatic islet cells by a synthetic human PDX1 peptide

Vincenzo Cardinale, Gaia Scafetta, Rosa Puca, Michele De Canio, Francesca Sicilia, Guido Carpino, Domenico Casa, Rocco C. Panetta, Pasquale Bartolomeo Berloco, Giorgio Federici, Eugenio Gaudio, Marella Maroder, Domenico Alvaro

2035: Hyaluronic acid-based efficient cryopreservation of human biliary tree stem/progenitor cells (hBTSCs) demonstrated by biologic, genetic and molecular studies

Vincenzo Cardinale, Lorenzo Nevi, Raffaele Gentile, Guido Carpino, Alice Fraveto, Alessia Torrice, Alfredo Cantafora, Vincenzo Pasqualino, Giovanni Casella, Daniela Bosco, Alessandro Pintore, Giuseppe Spagnolo, Michela Nardacci, Pasquale Bartolomeo Berloco, Eugenio Gaudio, Domenico Alvaro

Varices and Bleeding 2036: Progression of hyperdynamic circulation in compensated cirrhosis with portal hypertension and response to β-blockers

Càndid Villanueva, Agustin Albillos, Joan Genescà, Juan G. Abraldes, Jose Luis Calleja, Carles Aracil, Rafael Bañares, Rosa María Morillas, Maria Poca, Beatriz Peñas, Salvador Aguustin, Juan Carlos Garcia-Pagan, Oana Pavel, Jaime Bosch

2037: Effect of Simvastatin in Portal Hypertension

Priscila P. Flores, Guilherme F. Rezende, Ubiratan Cassano, Monica Soldan

2038: Effect of Simvastatin in Portal Hypertension Priscila P. Flores, Monica Soldan, Guilherme F. Rezende

2039: Variceal bleeding at diagnosis of portal vein thrombosis does not increase mortality in patients with cirrhosis

Carlos Noronha Ferreira, Teresa Rodrigues, Patrícia Sousa, Fernando Ramalho, Paula Alexandrino, José F. Velosa




Poster Sessions 2040: Osteopontin is a new non-invasive parameter of portal hypertension in patients with liver cirrhosis

Radan Bruha, Marie Jachymova, Jaromir Petrtyl, Libor Vitek, Petr Urbanek, Karel Dvorak

2041: Embolization of splenic artery contributes to controlling elevated portal venous pressure and promoting improved hepatic function induced by occlusion of portosystemic shunts in patients with cirrhosis

Tsuyoshi Ishikawa, Shogo Shiratsuki, Takashi Matsuda, Takuya Iwamoto, Taro Takami, Shuji Terai, Isao Sakaida

2042: A simple scoring system using MELD-Na and the stage of hepatocellular carcinoma for prediction of early mortality after acute variceal bleeding in patients with liver cirrhosis Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Masatoshi Ishigami, Hidemi Goto

2043: Prognostic factors affecting treatment outcomes of acute variceal bleeding in patients with hepatocellular carcinoma: a single center prospective study

Soo Young Park, Su Hyun Lee, Se Young Jang, Jung Gil Park, Won Young Tak, Young Oh Kweon, Hyun Young Woo, Jeong Heo, Eun Jeong Kang, Yu Rim Lee

2044: VITRO-score predicting clinically significant portal hypertension

Stephanie Hametner, Alexandra Etschmaier, Arnulf Ferlitsch, Alexander Ziachehabi, Rainer Schöfl, Monika Ferlitsch, Andreas Maieron

2045: Indocyanine Green 15-min Retention test (ICGr15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis

Andrea Lisotti, Francesco Azzaroli, Buonfiglioli Federica, Marco Montagnani, Paolo Cecinato, Claudio Calvanese, Simoni Patrizia, Alberto Porro, Domenico Fiorillo, Alessandro Cucchetti, Antonio Colecchia, Rita Golfieri, Davide Festi, Giuseppe Mazzella

2046: Prospective validation of Baveno V definitions and criteria for failure to control bleeding in portal hypertension

Won Young Tak, Soo Young Park, Young Oh Kweon, Se Young Jang, Su Hyun Lee, Jung Gil Park, Jeong Heo, Hyun Young Woo

2047: Long-Term Outcome of 139 Patients with Liver Cirrhosis Receiving Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Fundal Varices

Yukinori Imai, Manabu Nakazawa, Satsuki Ando, Kayoko Sugawara, Satoshi Mochida

2049: Survival of acute peptic ulcer bleeding in cirrhosis as compared with variceal bleeding using current firstline therapies

Alba Ardèvol, Jose Castellote, Joaquim Profitos, Carles Aracil, Josep Castellvi, Oana Pavel, Gemma Ibañez Sanz, Diana Horta, Josep M M. Calafat, Barbara Gomez-Pastrana, Càndid Villanueva

2050: Hemodynamic response to non-selective betablockers is not influenced by the presence of metabolic syndrome

Simona Bota, Philipp Schwabl, Mattias Mandorfer, Petra Salzl, Arnulf Ferlitsch, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger

2051: Impact of anticoagulant and antiaggregant therapy on portal hypertension-related upper gastrointestinal bleeding in patients with liver cirrhosis. Results from a prospective multicentric observational study

Dominique Thabut, Yann Le Bricquir, Nicolas Carbonell, Xavier Causse, Jessica Coelho, Jean françois D. Cadranel, Jean Paul Cervoni, Andre Jean Remy, Isabelle Archambeaud, Khaldoun Elriz, Florent Ehrhard, Joanna Pofelski, Christophe Bureau, Bruno Bour, Florian Rostain, Francois Dewaele, Julien Vergniol, Jacques Arnaud Seyrig, Anne-Laure Pelletier, Farah Zerouala, Anne Guillygomarc’h, Arnaud Pauwels

2052: Applicability of Early TIPS in a US Based Tertiary Care Center

Swaytha Ganesh, Jyothsna Talluri, Siva Talluri, Ali Al-khafaji, Shahid M. Malik

2053: The improvement of hepatic hemodynamics and liver function before and after balloon - occluded retorograde transvenous obliteration

Ryuta Shigefuku, Hideaki Takahashi, Yoshihito Yoshida, Tomohiro Tamura, Yohei Noguchi, Hiroki Ikeda, Kotaro Matsunaga, Nobuyuki Matsumoto, Chiaki Okuse, Fumio Itoh, Shigeru Sase, Michihiro Suzuki

2054: HVPG predicting prognosis in patients with cirrhosis. Does it matters to use free hepatic vein pressure or inferior vena cava pressure?

Gilberto Silva-Junior, Anna Baiges, Fanny Turon, Karina G. Ramírez Ibarra, Vera Costa Santos, Annalisa Berzigotti, Virginia Hernandez-Gea, Jaime Bosch, Juan Carlos Garcia-Pagan

2055: Risk of esophageal varices predicted by share wave velocity

Hiroko Iijima, Tomoko Aoki, Chikage Nakano, Kenji Hashimoto, Akio Ishii, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Yoshiyuki Sakai, Hironori Tanaka, Yoshinori Iwata, Hirayuki Enomoto, Masaki Saito, Shuhei Nishiguchi

Poster Viewing: 8:00 AM – Noon



Presenters in Attendance 10:30 AM – Noon



HEPATOLOGY, October, 2014

Poster Sessions 2056: Prospective observational study of portalhypertensive bleeding in 914 cirrhotic patients in France (CHOC study) : high proportion of high-risk patients but limited access to TIPS

2061: The Child-Turcotte-Pugh (CTP) score is best at predicting 6-week mortality in patients with acute variceal hemorrhage (AVH): Analysis of a U.S. MultiCenter Prospective Study

2057: Should bleeding from gastric varices be prevented? A portuguese center experience

2062: Clinically significant hyponatremia is a rare side effect of terlipressin treatment for vericeal bleeding and hepatorenal syndrome when used as first line agent

Dominique Thabut, Andre Jean Remy, Nicolas Carbonell, Xavier Causse, Jessica Coelho, Jean françois D. Cadranel, Jean Paul Cervoni, Slim Bramli, Isabelle Archambeaud, Philippe Ah-soune, Florent Ehrhard, Alexandre Pariente, Christophe Bureau, JeanPierre Dupuychaffray, Florian Rostain, Florence Skinazi, Julien Vergniol, Rl Vitte, Anne-Laure Pelletier, Jean Henrion, Anne Guillygomarc’h, Stéphanie Combet, Arnaud Pauwels

Tiago Cúrdia Gonçalves, Joana Magalhães, Carla M. Marinho, José Cotter

2058: Correction of coagulopathy in non-bleeding cirrhotic patient undergoing Minor Invasive Procedures: A Systematic Review

Matthew J. McConnell, Ruben Hernaez, Sarah Sewaralthahab, Saleh Alqahtani

2059: The efficacy of balloon-occluded retrograde transvenous obliteration (BRTO) and coil assisted retrograde transvenous obliteration (CARTO) for the treatment of bleeding gastric varices and hepatic encepholopathy

Lisa N. Waller, Scott Schwartz, Dilip Moonka, Amir Prushani, Syed-Mohammed R. Jafri

2060: Long-term result and safety of endoscopic N-Butyl-2-cyanoacrylate injection of gastric varices : Focused on the variceal location


Wonhyeong Park, Seo Young Yang, Do Young Kim, Woong Sun Yoo, Tae Gyoon Kim, Tae Kyu Lim

Denotes AASLD Presidential Poster of Distinction

Brett E. Fortune, Guadalupe Garcia-Tsao, Maria Ciarleglio, Yanhong Deng, Michael B. Fallon, Samuel Sigal, Naga P. Chalasani, Joseph K. Lim, Adrian Reuben, Hugo E. Vargas, Gary Abrams, Michele Bishop Lewis, Tarek Hassanein, James F. Trotter, Arun J. Sanyal, Kimberly L. Beavers, Daniel Ganger, Paul J. Thuluvath, Norman D. Grace, Roberto J. Groszmann

Ruth Bolier, Bart van Hoek, Hein W. Verspaget, Minneke Coenraad

2063: Cyanoacrylate Therapy for the Treatment of Gastric Varices: A New Method Virendra Singh, Rajiv R. Singh, Navneet Sharma

2064: The long-term clinical outcome of balloonoccluded retrograde transvenous obliteration for gastric varices

Noriaki Naeshiro, Hiroshi Aikata, Hiromi Kan, Tomoki Kobayashi, Takayuki Fukuhara, Yohji Honda, Daisuke Miyaki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hideyuki Hyogo, C. Nelson Hayes, Kazuaki Chayama

2065: Safety of Endoscopy in Patients with End-stage Liver Disease Prasun K. Jalal

Poster sessions.

Poster sessions. - PDF Download Free
11MB Sizes 25 Downloads 316 Views